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Abstract 
 
Cytochrome P450 1A2 metabolizes a wide range of therapeutic drugs, including several used to 
treat  diseases  common  in  sub-Saharan  Africa.    Variation  in  the  gene  (CYP1A2)  has  been 
reported  to  be  associated  with  differential  efficacy  of  therapeutic  drugs  and  adverse  drug 
reactions.  To gain a better understanding of the extent of variation in the coding and exon-
flanking non-coding regions of CYP1A2, 762 chromosomes from members of five ethnic groups 
(Afar,  Amhara,  Anuak,  Maale  and  Oromo)  distributed  in  a  rough  north  east  to  south  west 
transect  across  Ethiopia  were  re-sequenced.    Substantial  variation  was  observed,  much  of 
which was novel.  As a consequence, a diagnostic test based on previously known variation 
cannot  predict  functional  variation  in  Ethiopians.    Evidence  of  purifying  selection  acting  on 
CYP1A2 was found and coalescent date estimates of CYP1A2 variants were old, with many 
pre-dating expansions of anatomically modern human out of Africa.   
 
Variants within the transcription factor 7-like 2 gene (TCF7L2), which are associated with an 
increased  risk  of  type  2  diabetes  (T2D),  were  common  in  multiple  Ethiopian  populations.  
TCF7L2 haplotype distribution varied among groups suggesting that T2D susceptibility may also 
vary,  with most groups likely having a West African TCF7L2 risk for the disease and some 
having more of a European TCF7L2 risk.   
 
Many CYP1A2 and TCF7L2 haplotypes can be of important predictive value in the planning and 
provision of healthcare.  These findings are not only of benefit to native Ethiopians, but are also 
of  increasing  importance  in  the  planning  of  healthcare  intervention  in  the  developed  world, 
where growing numbers of individuals with recent Ethiopian descent are living.  Comparing data 
with those from publicly available databases it appears that Ethiopian groups display a very high 
level of diversity that includes most of the common variation observed elsewhere.     iii 
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1  Introduction 
 
Studies in this thesis work towards characterising human genetic variation, with implications for 
healthcare, in Ethiopian populations.  This first chapter aims to set the scene by providing a 
brief description of past and present day Ethiopia.  The overall rationale of the thesis and an 
overview of each chapter are provided.  Chapters 2 - 5 are self contained results chapters, each 
with their own set of aims and methods. 
 
1.1  A brief history of Ethiopia 
 
Archaeology  and  paleontology  bring  Ethiopia’s  history  back  millions  of  years  with  some  of 
humankind’s oldest traces being unearthed in Ethiopia.  The most well known example is of 
‘Lucy’,  a possible ancestor of Homo sapiens found  at Hadar in south east Ethiopia,  who is 
thought to have lived in Ethiopia approximately 3.2 million years ago (Shreeve, 1994).  Fossils 
of the earliest known morphological traits associated with anatomically modern human, dated to 
150  –  190  thousand  years  ago,  have  also  been  uncovered  in  Ethiopia  (White  et  al.,  2003; 
McDougall and Fleagle, 2005; Campbell and Tishkoff, 2008).   
 
Ethiopian dynastic history (which is reviewed in Henze, 2001; Pankhurst, 2001), according to 
Ethiopian legend, traditionally begins in 1000 BC with the reign of Emperor Menelik I, whose 
lineage  is  traced  back  to  the  Queen  of  Sheba  and  King  Solomon.    According  to  historical 
records, Ethiopia’s roots date back to the Kingdom of D’mt, in the 8
th century BC,  which is 
thought to have had much contact with South Arabia.  After the fall of the Kingdom of D’mt in 
the 4
th century BC, the Kingdom of Aksum emerged as the successor state.  It was an important 
trading  nation  in  the  north  east  of  Africa  and  expanded  southwards,  achieving  great  power 
status by the 6th century AD.  Aksum was also the first major empire to convert to Christianity.  
By about 1270, the Aksumites were superseded by the Zagwes, who in turn gave way to the so-
called  'Solomonid  Restoration'.    At  its  height,  the  Ethiopian  Empire,  also  known  in Western 
literature  as  Abyssinia,  included  present  day  Northern  Somalia,  Djibouti,  Southern  Egypt, 
Eastern Sudan, Yemen and Western Saudi Arabia at different times in its history. During the 
19
th century, several migrations and conquests led to Ethiopia's borders expanding in the south, 
toward its modern borders.  With the exception of a short-lived Italian occupation from 1936-
1941, the Ethiopian Empire was the only African nation to maintain its freedom from colonial 
rule.  In 1974, a Soviet-backed military junta (the Derg) dethroned Emperor Haile Selassie (who 
had  ruled  de  facto  since  1916)  and  founded  a  single  party  socialist  state.    The  communist 
regime suffered coups, uprisings, severe drought, famine and an immense refugee problem, 
and was eventually overturned in 1991 by a coalition of rebel forces, the Ethiopian People's 
Revolutionary  Democratic  Front  (EPRDF).    An  Ethiopian  constitution  was  adopted  and 
Ethiopia's  first multiparty  elections  were  held  in  1995  (reviewed  in  Henze,  2001;  Pankhurst, 
2001).  However, the predominantly Tigrayan led Ethiopian government has been marred by   2 
allegations  of  ethno-centrism,  increasing  authoritarianism,  corruption,  serious  human  rights 
abuses and electoral fraud (Vestal, 1999).   
 
1.2  Present day Ethiopia 
 
Ethiopia  (Federal  Democratic  Republic  of  Ethiopia)  is  a  landlocked  country  (1,127,127 km² 
(www.cia.gov/library/publications/the-world-factbook/)) partly lying on the Horn of Africa in the 
north east of the African continent.  Dijibouti and Eritrea border Ethiopia to the north, Somalia to 
the East, Kenya to the south and Sudan to the west (figure 1.1).  The Great Rift Valley runs 
through the country in a rough south west to north east direction dissecting a mass of highland 
mountains and plateaus.  Lowlands, steppes and semi-desert regions boarder the Great Rift 
Valley.  The topography of Ethiopia contains a number of high mountain ranges (e.g. Semien 
Mountains and Bale Mountains) and one of the lowest African land areas (Danakil depression).  
Deserts are generally found along the eastern border whilst tropical forests are found to the 
south and extensive Afromontane forests are located in both the north and south west of the 
country.    Ethiopia’s  geographical  diversity  leads  to  high  variability  in  climate,  soils,  natural 
vegetation and patterns of population settlement. 
 
Figure 1.1  Location and relief map of Ethiopia (derived from www.worldofjah.ning.com) 
 
                                   
 
 
With  a  population  estimated  at  85,200,000  in  July  2009,  Ethiopia  is  the  world’s  15
th  most 
populous  country  (www.cia.gov/library/publications/the-world-factbook/).    Ethiopia  has  a 
plethora  of  ethnic  groups,  each  with  its  own  cultural  practices.    Some  ethnic  groups  are 
subdivided into smaller groups, some of which admix extensively with others while some do not, 
maintaining  intra-marriage  traditions  (Freeman  and  Pankhurst,  2003).    The  country  has  84 
indigenous living languages, most of them Afro-Asiatic (Semitic, Cushitic, Omotic), as well as 
some that are Nilo-Saharan.  Amhara and Oromo are Ethiopia’s main languages with the former   3 
being  the  official  language.    Ethiopia’s  main  foreign  languages  are  English  and  Arabic 
(www.ethnologue.com).  Christianity is the predominant religion but a large proportion of the 
population are Muslim and some still practice traditional beliefs (1994 census). 
 
Ethiopia is divided into nine ethnically-based administrative regions which are further divided 
into  68  zones and  two self-governing administrations, Addis Ababa (capital) and Dire Dawa 
(figure 1.2). 
 
Agriculture (primarily coffee production) is Ethiopia’s main economic activity and accounts for 
almost half of GDP, 60 % of exports,  and 80 % of  total employment.  Frequent periods of 
drought  and  poor  cultivation  practices  often  hamper  economic  growth,  and  urban  and  rural 
poverty is widespread (www.cia.gov/library/publications/the-world-factbook/). 
 
Poor sanitation and malnutrition lead to high incidences of communicable diseases which are 
worsened by a shortage of trained healthcare workers and healthcare infrastructure.  There is a 
high  risk  of  bacterial  and  protozoal  diarrhea,  hepatitis  A  and  E,  and  typhoid  fever,  malaria, 
meningococcal meningitis, rabies and schistosomiasis.  Ethiopia has a relatively low average 
life  expectancy  at  birth  (55  years)  and  infant  mortality  rates  are  relatively  high  with  8  %  of 
children not surviving the first year (www.cia.gov/library/publications/the-world-factbook/). 
 
Figure 1.2  Administrative regions (small map) and zones (large map) of Ethiopia (produced by UN emergencies 
unit for Ethiopia (2000)) 
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1.3  Rationale of thesis 
 
The Out of Africa model of human origin is a widely accepted view and postulates that modern 
humans (Homo sapiens) originated in Africa ~ 200 thousand years ago and colonised the rest of 
the world within the last ~ 100 thousand years (Stringer and Andrews, 1988; Tishkoff et al., 
1996;  Campbell  and  Tishkoff,  2008).    Support  for  the  Out  of  Africa  model  comes  from  the 
observation that African populations are more genetically diverse than non-African populations 
(Excoffier, 2002; Tishkoff and Kidd, 2004; Tishkoff et al., 2009) and that intra-population genetic 
diversity  decreases  with  distance  from  Africa  (Prugnolle  et  al.,  2005;  Handley  et  al.,  2007; 
Tishkoff et al., 2009).  Intra-population phenotypic diversity (measured by human skull size and 
shape) is also highest in African populations and is negatively correlated with distance from 
Africa  (Manica  et  al.,  2007;  Betti  et  al.,  2009).    This  pattern  of  variation  is  consistent  with 
modern human populations experiencing serial founder effects in the course of expanding out of 
Africa and across the globe (Rosenberg et al., 2002; Ramachandran et al., 2005; Rosenberg et 
al., 2006; Jakobsson et al., 2008). 
 
It is suggested that anatomically modern humans migrated out of Africa from the north east 
(possibly  via  Ethiopia)  by  crossing  the  Bab-el-Mandreb  strait  at  the  mouth  of  the  Red  Sea 
(figure 1.1) (Forster and Matsumura, 2005; Reed and Tishkoff, 2006; Campbell and Tishkoff, 
2008;  Tishkoff  et  al.,  2009).    Evidence  of  a  more  recent  migration  into  Ethiopia,  of  Semitic 
speaking  peoples  from  Arabia,  is  also  known  from  genetic  studies  (Campbell  and  Tishkoff, 
2008).  As a consequence, it is possible that more human genetic/phenotypic variation will be 
observed  in  Ethiopians  than  in  any  other  geographically  contiguous  indigenous  groups  of 
peoples of similar number. 
 
Characterising the genetic distribution among ethnically and/or geographically diverse Ethiopian 
populations  will  be  important  for  understanding  the  population  history  of  Ethiopians  and  for 
assisting  the  reconstruction  of  the  evolutionary  history  of  modern  humans  (Campbell  and 
Tishkoff, 2008).  Given that East Africa showed the greatest level of population substructure 
within  Africa  (Tishkoff  et  al.,  2009)  and  that  substructure  can  often  lead  to  false  results 
(Pritchard et al., 2000; Tishkoff et al., 2009), population genetic studies in Ethiopia will also be 
important for the better design and interpretation of disease association and pharmacogenetic 
studies, not only in Ethiopians, but also in populations across the globe. 
 
Despite  the  potential  importance  of  Ethiopian  population  genetics,  little  is  known  about  the 
distribution of human genetic variation among Ethiopian populations (Campbell and Tishkoff, 
2008).  Studies that have been undertaken have been limited to few populations and/or small 
sample sizes (e.g. Aklillu et al., 2003; Jiang et al., 2006; Tishkoff et al., 2009).  This thesis has 
contributed  to correcting this imbalance by analysing genetic variation  in  two  therapeutically 
important  genes  in  five  Ethiopian  ethnic  groups  (Afar,  Amhara,  Anuak,  Maale  and  Oromo), 
collected from a roughly north east to south west transect across the country and referred to 
hereafter as the Ethiopian ascertainment populations.   5 
1.4  Ethiopian ascertainment populations 
 
Based on pairwise Fsts from Y chromosome and mtDNA hypervariable region 1 sequences, 
evidence suggests that the majority of genetic variation is captured by sampling a north east to 
south west transect across Ethiopia (unpublished data).  In light of this, a total of 381 DNA 
samples were chosen for an ‘Ethiopian ascertainment panel’.  Samples were collected from five 
different ethnic groups inhabiting a roughly north east to south west transect across the country 
(figure 1.3) in order to provide a sample set suitable for an initial evaluation of diversity among 
the peoples of Ethiopia.  A total of 76 samples were taken from each of the following ethnic 
groups, apart from the Amhara of which there were 77:- 
 
1. Afar (Afar – North-East) 
2. Amhara (Addis Ababa) 
3. Oromo (Addis Ababa and central highlands) 
4. Anuak (Gambela – West) 
5. Maale (South Omo – South-West) 
 
Figure 1.3  Collection locations of the Ethiopian ascertainment samples 
(derived from http://www.younglives.org.uk/) 
 
 
 
1.4.1  Afar 
 
The  Afar  are  an  ethnic  group  from  the  Horn  of  Africa  who  principally  reside  in  the  eastern 
lowlands  of  the  Afar  Region  of  Ethiopia  but  are  also  found  in  eastern  parts  of  Eritrea  and 
Djibouti (Lewis, 1998).  They have preserved their own rich culture and traditions and in their 
appearance are said to be similar to the Somali (Lewis, 1998).  The total population size of the 
Afar has been estimated at 1,439,367 (http://www.ethnologue.com/), of which 979,367 live in   6 
Ethiopia (1994 census).   They speak the  Afar language  which is  a member of the Cushitic 
branch  of  the  Afro-Asiatic  language  family  and  is  further  classified  as  East,  Saho-Afar 
(http://www.ethnologue.com/).    Speakers  also  use  Arabic  as  a  second  language.    Alternate 
names for the Afar are Afaraf, Danakil, Denkel, 'Afar Af, and Adal.  (Note Danakil, an Arabic 
term, is sometimes used by non-Afar to identify the group but is considered offensive by the 
Afar  themselves).    They  are  referred  to  as  “Adal”  in  Amharic  (http://www.ethnologue.com/).  
They  are  Muslims  and  traditionally  nomadic  herders.    While  the  majority  have  remained 
nomadic pastoralists, raising goats, sheep, camels and cattle in the desert, some have migrated 
to cities and adopted urban lifestyles.  The Afar are split into clan families and divided into two 
main classes: the Adoimara (whites) and the Asaimara (reds).  The Adoimara are the dominant 
political class while the Asaimara are the commoners or working class.  The Afar appear to be 
predominantly endogamous and maintain a patriarchal society (Lewis, 1998). 
 
1.4.2  Amhara 
 
The  Amhara  are  an  ethnic  group  principally  residing  in  the  Amhara  region  in  north  central 
Ethiopia,  the  central  highlands  of  Ethiopia  and  Addis  Ababa  but  are  found  worldwide 
(http://www.ethnologue.com/).  They are arguably the most politically powerful group in Ethiopia 
and comprise an estimated 16,007,933 people, forming 30 % of the country’s population (1994 
census).  It is thought that the Amhara migrated into the central areas of Ethiopia, including 
Addis  Ababa,  in  the  last  millennium  BC.    They  are  believed  to  have  both  indigenous  and 
southwest Arabian heritage and appear to be linguistically, culturally, as well as phenotypically 
(appearance)  related  to  Arabs.    The  Amhara  have  undergone  admixture  having  assimilated 
extensively  with  local  populations,  especially  the  Oromo,  the  Afar  and  the  Tigray  (personal 
communication, Ayele Tarekegn
1).  Amharic is both the language of the Amhara and Ethiopia’s 
national language, being used in government, public media, national commerce, education and 
a  wide  variety  of  literature.    Speakers  may  also  use  English,  Arabic,  Oromo  or  Tigrinya.  
Amharic is part of the Semitic branch of the Afro-Asiatic language family and is further classified 
as  South,  Ethiopian,  South,  Transversal,  Amharic-Argobba  (http://www.ethnologue.com/).    A 
small proportion of the Amhara are Muslim but the predominant religion is Christianity, with the 
Ethiopian Orthodox Church playing a key role in the culture of the group and the country.  A 
small minority of the Amhara are Protestant.  Although many have moved to Addis Ababa, the 
vast  majority  of  the  Amhara  lead  a  rural  lifestyle  and  make  their  livelihood  through  arable 
farming, predominantly in the Ethiopian highlands.  Cattle, sheep, goats, horses and donkeys 
are also raised (personal communication, Ayele Tarekegn). 
 
                                                 
1
 Ayele Tarekegn is an Ethiopian postdoctoral research fellow at The Centre for Genetic Anthropology in UCL.  He has 
been conducting fieldwork in Ethiopia since 1997 and has collected buccal DNA and sociological background data from 
over 8000 Ethiopians from multiple ethnic groups.   7 
1.4.3  Anuak 
The Anuak are an ethnic group whose villages are scattered along river banks in the fertile 
lowlands in southeastern Sudan and western Ethiopia, in the Gambela Region.  Members of 
this ethnic group number 45,665 in Ethiopia (1994 census).  The Anuak speak Anuak which is 
part of the Nilo-Saharan language family and is further classified as Eastern Sudanic, Nilotic, 
Western,  Luo,  Northern,  Anuak  (http://www.ethnologue.com/).    They  are  believed  to  have 
migrated from the area of the Upper Nile in Sudan and are culturally, linguistically, historically 
and religiously different from most other Ethiopians.  They have traditional religious beliefs and 
are distinguished by their typically dark skin.  The Anuak have been exposed to discrimination 
and marginalisation which has affected the group’s access to education, healthcare and basic 
infrastructure.  The group also remains predominantly endogamous (personal communication, 
Ayele Tarekegn).  They are agriculturalists, growing maize and sorghum, but also earning their 
living through animal husbandry, fishing and hunting (http://www.ethnologue.com/). 
 
1.4.4  Maale 
 
The Maale  are an  ethnic  group  living in the southwest of Ethiopia in the  Southern Nations, 
Nationalities  and  Peoples  Region,  to  the  northeast  of  Jinka  town  in  the  South  Omo 
administrative Zone.   According to the 1994 census (1994 census), they  numbered 46,458.  
Maale is the group’s language which is part of the Omotic branch of the Afro-Asiatic language 
family, and further classified as North, Gonga-Gimojan, Gimojan, Ometo-Gimira then Ometo 
(http://www.ethnologue.com/).  The majority of the Maale practice their traditional religion but 
some are Protestant.  They, like the Anuak, have typically dark skin.  They are predominantly 
endogamous, maintaining intra-marriage traditions (personal communication, Ayele Tarekegn). 
 
1.4.5  Oromo 
 
The  Oromo  are  the  largest  single  ethnic  group  in  Ethiopia  constituting  over  30  %  of  the 
country’s population.  According to the 1994 Ethiopian census (1994 census), members of the 
group numbered 17,080,318.  The Oromo are found in Kenya but predominantly reside in the 
Oromo Region, west and central areas of Ethiopia, and along the Rift Valley escarpment east of 
Dessie and Woldiya.  They speak the Oromo language which is part of the Cushitic branch of 
the  Afro-Asiatic  language  family  and  further  classified  as  East,  then  Oromo.    Like  Amharic, 
Oromo is widely spoken in Ethiopia.  It is a trade language and is used in government, public 
media,  national  commerce,  education  to  eighth  grade  and  a  variety  of  literature 
(http://www.ethnologue.com/).  While further research is needed to fully understand the origin or 
origins of Oromo people, it has been postulated that they may be derived from the highlands of 
present-day Bale region in Southern Ethiopia (personal communication, Ayele Tarekegn).  Most 
of the Oromo are either Muslims or Christians but some have traditional religious beliefs.  The 
Oromo  have  a  varied  livelihood  with  some  being  agriculturalists,  growing  a  variety  of  crops   8 
including spices and coffee.  Some have livestock whilst others are miners or earn their living 
through the tourism, textile, meat packing or refinery industries (http://www.ethnologue.com/). 
 
1.5  Overview of thesis 
 
Chapters  2  –  4  focus  on  variation  observed  in  the  Cytochrome  P450  1A2  gene  (CYP1A2).  
CYP1A2 is a clinically important drug metabolising enzyme and variation in the gene has been 
reported  to  be  associated  with  differential  efficacy  of  therapeutic  drugs  and  adverse  drug 
reactions (Gunes and Dahl, 2008).  The gene was chosen for study in Ethiopians because a 
wide range of pharmaceuticals are metabolized by CYP1A2 (Gunes and Dahl, 2008), including 
several  used  to  treat  diseases  common  in  Ethiopia.    Caffeine  (an  important  component  of 
coffee)  is  a  well  known  substrate  of  CYP1A2  (Butler  et  al.,  1989),  and  coffee  was  first 
domesticated for human use in Ethiopia (Anthony et al., 2002) and is an integral part of modern 
Ethiopian culture.  Variation within CYP1A2 remains largely uncharacterised within Ethiopian 
populations.  To gain a better understanding of the extent of variation in the gene, coding and 
exon-flanking  non-coding  regions  of  CYP1A2  were  re-sequenced  in  the  Ethiopian 
ascertainment populations. 
 
Chapter  2  describes  the  variation  observed  in  CYP1A2  in  the  Ethiopian  ascertainment 
populations.  In total, 49 variable sites of different types were found, 30 of which are novel.  
Nine non-synonymous changes (seven of which are novel) and one synonymous change were 
found  in  the  coding  region.    Haplotype  analysis  of  the  entire  gene  revealed  55  different 
haplotypes, only three of which were previously reported.  When haplotypes were constructed 
using only non-synonymous polymorphisms, so as to restrict the haplotype set to those most 
likely to affect enzyme structure/function, ten haplotypes were identified, eight of which have not 
previously been reported.  Comparing these data with those from publicly available databases it 
appears that Ethiopian groups display much greater variation than do other populations (gene 
diversity using complete coding region haplotypes (non-synonymous variants only): Ethiopia = 
0.17 ± 0.02; Rest of the World combined = 0.08 ± 0.03).  Many haplotypes can be predicted to 
be of importance in the planning and provision of healthcare.  In addition, Ethiopian populations 
exhibit most of the common variation observed elsewhere. 
 
Chapter 3 focuses on extracting information about the recent evolutionary history of CYP1A2 
from  the  genetic  variation  observed  in  the  Ethiopian  ascertainment  populations.    A  rooted 
CYP1A2 haplotype network was produced which is consistent with humans evolving from non-
human primates with the chimpanzee being their closest living relative.  Of the populations used 
in  the  analysis,  which  included  non-Africans  and  those  with  a  recent  African  ancestry,  the 
Ethiopian dataset contained haplotypes most similar to the chimpanzee.  Haplotype networks 
revealed  a  varying  level  of  conservation  among  the  CYP1A2  exons  and  showed  that  all 
haplotypes predicted to code for a protein with altered activity were observed in the external 
branches  of  the  network.    Intra-population  gene  diversities  and  inter-population  genetic   9 
distances  were  generally  lowest  for  SNP  categories  expected  to  have  greatest  impact  on 
protein structure.  These results are consistent with the hypothesis that purifying selection has 
affected the allele frequencies of SNPs in CYP1A2, predicted to have greatest impact on protein 
structure, in humans.  The time to most recent common ancestor of nine CYP1A2 variants was 
estimated using variation in an AC microsatellite situated 5.6 kb downstream of the 3’ end of 
CYP1A2.  Coalescent date estimates place most variants into a period which pre-dates the 
expansion of modern humans out of Africa. 
 
Chapter 4 addressed whether it would be possible to predict CYP1A2 functional variation in 
Ethiopian  populations  using  variation  known  prior  to  this  study.    The  test  procedure  was 
constructed  utilising  CYP1A2  variant  alleles,  recorded  by  the  CYP450  Allele  Nomenclature 
Committee, which were assigned phenotypes from previously reported functional studies.  The 
test’s suitability for Ethiopia  was  investigated  by  applying  it to the  variation observed in the 
Ethiopian ascertainment populations.  The diagnostic test was found to be inappropriate for 
Ethiopia  since  it  did  not  account  for  the  plethora  of  novel  variation  observed  in  the 
ascertainment samples.  Ethiopia requires its own diagnostic test procedure initially built using 
the variation observed in the five Ethiopian ascertainment populations. 
 
Chapter  5  focuses  on  variation  within  the  transcription  factor  7-like  2  gene  (TCF7L2)  which 
plays a role in the Wnt signalling pathway (Smith, 2007).  TCF7L2 alleles are associated with an 
increased risk of type 2 diabetes (T2D) in various populations (Weedon, 2007) but little is known 
about TCF7L2 variability in Ethiopians.  Varying levels of linkage disequilibrium were observed, 
in the Ethiopian ascertainment populations, between two SNPs (rs7903146 and rs12255372) 
which have been associated with an increased risk of T2D.  Haplotypes defined by these two 
SNPs consequently captured almost all of the information on intra and inter-population diversity 
otherwise determined by analysing haplotypes defined by multiple SNPs.  Both rs7903146 and 
rs12255372  were  common  in  ~  50  Ethiopian  populations  and  haplotype  distribution  varied 
among groups suggesting that T2D susceptibility due to the effect of TCF7L2 may also vary, 
with most groups likely having a West African TCF7L2 risk for the disease and some having 
more of a European TCF7L2 risk.  The haplotypes could also effectively discriminate between 
Ethiopian  populations  in  accordance  with  geography  and  linguistics  states,  and  even  had 
enough  power  to  differentiate  caste-like  groups  covered  by  the  same  self-identifying  ethnic 
label. 
 
Chapter 6 gives a general discussion of the outcomes of studies involving both CYP1A2 and 
TCF7L2.  Details of future work are also provided. 
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2  Variation in CYP1A2 in Ethiopian populations 
2.1  Introduction 
2.1.1  Pharmacogenetics and cytochrome P450s 
 
Pharmacogenetics is the study of individual genetic variation in response to drugs (Johnson, 
2003; Weinshilboum, 2003; Wilke et al., 2007).  When a drug is administered it must undergo 
the following processes (Weinshilboum, 2003): 
 
1.  Absorption 
2.  Distribution to site of action 
3.  Interaction with targets, for example enzymes and receptors 
4.  Metabolism 
5.  Excretion 
 
Variation in each of these processes could potentially influence drug response (Weinshilboum, 
2003).  Variation in genes involved in drug transport, for example ABCB1 (ATP binding cassette 
B1), and drug targets, such as the β2- adrenoreceptor, are known (Evans and McLeod, 2003).  
However, variation in drug metabolism has received most attention.  Over the past 20 years 
there  has  been  increasing  interest  in  drug  metabolising  enzymes,  particularly  cytochrome 
P450s (CYPs), as a literature search on the subject attests; over 46, 000 CYP articles have 
been  published since 1989 (http://www.ncbi.nlm.nih.gov/pubmed/).  Contributions to the field 
include  studies  examining  functional  genomics  (Rezen  et  al.,  2007),  CYP  genomic  variation 
(Solus et al., 2004), the functional significance of mutations within CYP genes in vivo (Aklillu et 
al., 2003) and in vitro (Zhou et al., 2004), clinical implications of inter-individual CYP genomic 
variation (Kirchheiner and Seeringer, 2007), the evolutionary history of CYP genes (Heilmann et 
al., 1988; Goldstone et al., 2007), CYP roles in other species (Liang et al., 1996), links to cancer 
susceptibility (Agundez, 2004), Parkinson’s disease (Tan et al., 2007), psychosomatic disease 
(Sugahara et al., 2009) and Alzheimer's (Van Ess et al., 2002). 
 
CYP enzymes are highly potent in vivo oxidising agents, capable of catalysing the oxidative 
biotransformation  of  a  diverse  array  of  endogenous  and  exogenous  substrates  (Porter  and 
Coon, 1991).  They are a super-family of haem containing mono-oxygenases and are believed 
to have been synthesised in nature for over 3.5 billion years (Nebert and Russell, 2002).  They 
were  initially  isolated  from  rat  liver  microsomes  (Omura  and  Sato,  1964)  but  are  widely 
distributed among other organisms, including bacteria, yeast, fungi and plants.  Human CYPs 
are  primarily  membrane-associated  proteins,  located  either  in  the  inner  membrane  of 
mitochondria or in the endoplasmic reticulum of cells (Nelson, 2009).  A large proportion of 
CYPs are found within most tissues of the body (e.g. intestine and lungs), but the majority are 
present in the liver (hepatic CYPs) where they are involved in the biosynthesis of cholesterol   11 
and bile acids.  A subset of CYPs also play important roles in steroidogenesis in the adrenals 
(adrenal  CYPs)  (Nelson,  2009).    CYPs  responsible  for  the  metabolism  of  exogenous 
compounds are thought to have first evolved approximately 400-500 million years ago to allow 
animals to detoxify chemicals in plants, and excrete them from the body by making them more 
water soluble (Gonzalez and Gelboin, 1994).  As a bi-product of this process, the enzymes also 
participate in the metabolic clearance of a vast array of clinical drugs. 
 
The name P450 refers to the ‘pigment at 450 nm’ formed by absorption of light at wavelengths 
near 450 nm when the haem iron is reduced (with sodium dithionite) and complexed to carbon 
monoxide. The enzymes incorporate one molecule of oxygen into the substrate and the other 
into  water,  and  catalyse  many  types  of  reactions,  including  hydroxylation,  epoxidation,  N-
dealkylation,  O-dealkylation  and  S-oxidation,  with  hydroxylation  being  the  most  important.  
Many of the CYPs add a hydroxyl group to the substrate in Phase I of drug metabolism. In 
Phase II, this hydroxyl moiety then serves as the site for further modifications, which increase 
the  solubility  of  the  substrate  enabling  it  to  be  excreted  in  urine  (Nelson,  2009).    Some 
examples  of  Phase  II  drug  metabolising  enzymes  are  glutathione  S-transferases,  N-
acetyltransferases and sulfotransferases. 
 
The  Human  Genome  Project  has  revealed  the  presence  of  approximately  116  human  CYP 
genes,  of  which  57  are  active  and  59  are  pseudogenes 
(http://drnelson.utmem.edu/human.P450.table.html).    The  numerous  CYP  isoforms  are 
classified as follows (Nelson et al., 1996):- 
 
1.  Families - >40% amino acid sequence homology is required for members to be 
in the same family.  Families are numbered, e.g. CYP1, CYP2. 
 
2.  Subfamilies - >55% amino acid sequence homology is required for members to 
be in the same subfamily.  Subfamilies are designated by letters, e.g. CYP1A, 
CYP1B, CYP2C. 
 
3.  Individual genes – genes are numbered.  Similar function and high conservation 
is  required  for  genes  to  have  the  same  number,  e.g.  CYP1A2,  CYP1B1, 
CYP2C8. 
 
Human  CYP  enzymes  in  families  5-51  are  important  in  the  metabolism  of  endogenous 
substrates.    Generally,  they  have  high  substrate  specificity  and  have  been  relatively  well 
conserved throughout evolution.  Enzymes in CYP family 4, tend to metabolise fatty acids and 
related substrates, as well as interacting with some xenobiotics.  Those in CYP families 1-3 
have  been  conserved  less  well  throughout  evolution  and  exhibit  important  genetic 
polymorphisms.  They generally have low substrate specificity, with many having overlapping 
substrate specificities (Ingelman-Sundberg, 2004).  As a consequence of this, redundancy is 
evident  within  the  CYP  system  (Gu  et  al.,  1992).    CYPs  in  families  1-3  are  active  in  the   12 
metabolism of a vast array of xenobiotic chemicals and are involved in as much as 75 % of 
phase  I  dependent  drug  metabolism.    Approximately  40  %  of  this  is  initiated  by  genetically 
polymorphic CYP enzymes (Ingelman-Sundberg, 2004). 
 
Mutations in a gene encoding a CYP enzyme can give rise to enzyme variants with higher, lower, or no 
activity (Masimirembwa and Hasler, 1997).  Absence of enzyme activity may be caused by gene 
deletion, but can also occur when mutations lead to altered splicing, premature stop codons, 
damaged  transcriptional  initiation  sites  and  amino  acid  changes  which  alter  the 
structure/function  of  the  protein  (Pirmohamed  and  Park,  2003).    CYP  variants  can  lead  to 
reduced  enzyme  activity  (Lee  et  al.,  2002)  and  altered  activity;  mutations  in  the  active  site 
(Oscarson et al., 1997) or changes in protein folding can alter the enzyme’s substrate specificity 
(Johansson  et  al.,  1994)  for  example.    Increased  enzyme  activity  can  result  from  gene 
duplication, where individuals carry multiple copies of an active CYP gene (Johansson et al., 
1993), but has also been associated with linked amino acid changes (Sakuyama et al., 2008).  
Alternatively, a variant in a CYP gene may have no direct effect on enzyme function but may be 
in linkage disequilibrium with a functional variant (Ingelman-Sundberg, 2001). 
 
Variability in CYP activity can affect the efficacy and safety of drugs.  Whilst individuals, known as 
extensive metabolisers (EMs), demonstrate normal levels of CYP activity, those with exceptionally high 
levels of CYP activity (ultra-rapid metabolisers, URMs) metabolise standard drug doses too quickly.  As 
a result, the drug  may be absent from blood serum or present at  sub-therapeutic quantities  with the 
consequence that these individuals require correspondingly higher doses of drugs to receive therapeutic 
benefit (Bertilsson et al., 1993).  On the other hand, in individuals with exceptionally low levels of CYP 
activity (poor metabolisers, PMs), prodrugs may not be converted to the active form in sufficient quantity 
to be therapeutic or may accumulate in the body causing an adverse drug reaction (Coutts and Urichuk, 
1999).    For  example,  poor  CYP2D6  metabolisers  are  unable  to  efficiently  convert  codeine 
(prodrug)  to  morphine  (active  form)  and  as  a  consequence  may  not  experience  pain  relief 
(Desmeules  et  al.,  1991).  Ultrarapid  CYP2D6  metabolisers  may  metabolize  codeine  too 
efficiently leading to morphine intoxication (Gasche et al., 2004). 
 
Inter-individual variability in drug clearance is thought to be common (Wilkinson, 2005) and CYP 
polymorphisms  are  frequently  associated  with  adverse  drug  reactions  (Ingelman-Sundberg, 
2004).    For  instance,  59  %  of  drugs  in  adverse  drug  reaction  studies  are  metabolised  by 
polymorphic phase  I dependent enzymes,  86 % of  which are CYP enzymes (Phillips et al., 
2001).  Adverse drug reactions are a major burden on healthcare services and account for a 
great  deal  of  morbidity  and  mortality,  increased  healthcare  costs  and  pharmaceutical 
expenditure (Pirmohamed et al., 2004).  For instance, adverse drug reactions caused 5 % of 
hospital admissions worldwide between 1966 and 1989 (Einarson, 1993) and 106, 000 deaths 
in the US in 1994 (Lazarou et al., 1998).  Furthermore, it has been estimated that annual costs 
attributable to adverse drug reactions for a 700-bed hospital in the USA amount to $5.6 million 
(Bates et al., 1997). 
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2.1.2  Cytochrome P450 1A2 
 
The  human  CYP1A  subfamily,  consisting  of  CYP1A1  and  CYP1A2,  is  one  of  the  clinically 
important members of the CYP enzyme superfamily, constituting approximately 15 % of the total 
CYP  content  in  the  liver  (Shimada  et  al.,  1994).    While  CYP1A1  is  expressed  mainly  in 
extrahepatic  tissues  (lung,  skin,  larynx  and  placenta),  CYP1A2  is  expressed  in  the  liver 
(Shimada et al., 1994).  CYP1A2 detoxifies environmental xenobiotics in mammals and birds 
and  is  thought  to  have  originated  some  350  million  years  ago  by  duplication  of  CYP1A1 
(Heilmann et al., 1988; Liang et al., 1996).  As a result, both CYP1A2 and CYP1A1 have 84 % 
amino acid sequence homology. 
 
A cDNA corresponding to CYP1A2 was isolated in 1987 (Jaiswal et al., 1987).  Human CYP1A2 
is approximately 7.8 kb long with seven exons and six introns (Ikeya et al., 1989).  Exon 1 and 
the  downstream  sequence  of  exon  7  are  untranslated  regions.    The  gene  has  only  one 
transcript  which  is  translated  into  a  protein  of  515  amino  acid  residues  (NCBI36, 
http://www.ncbi.nlm.nih.gov/).  The active site is thought to incorporate amino acids C458 and 
F451 in exon 7 and T321 in exon 4 (Sansen et al., 2007).  CYP1A2 is mapped to the positive 
strand of the long arm of chromosome 15 at 15q24.1 at chromosomal location 15:72,828,237-
72,835,994  (NCBI36,  http://www.ncbi.nlm.nih.gov/).    CYP1A2  lies  approximately  25.5  kb 
upstream of the c-src tyrosine kinase (CSK) gene and is orientated head-to-head with CYP1A1, 
which is on the negative strand.  CYP1A2 and CYP1A1 are separated by a 23.3 kb spacer 
region whose role in regulating one or other of the genes, or in governing the expression of both 
genes  simultaneously,  is  not  yet  understood  (Jiang  et  al.,  2005).    A  schematic  diagram  of 
CYP1A2 on chromosome 15 is shown in figure 2.1. 
 
Figure 2.1  The location and structure of CYP1A2 
 
 
 
CYP1A2  is  responsible  for  the  oxidative  metabolism  of  a  wide  variety  of  drugs  such  as 
clozapine (Bertilsson et al., 1994; Fang et al., 1998), flutamide (Shet et al., 1997), lidocaine 
(Orlando et al., 2004) and caffeine (Butler et al., 1989).  The enzyme is also involved in the   14 
biotransformation  of  endogenous  compounds  such  as  bilirubin  (Zaccaro  et  al.,  2001)  and 
melatonin (Facciola et al., 2001; Hartter et al., 2001), as well as the metabolic activation of 
procarcinogens  such  as  aromatic,  heterocyclic  amines,  polycyclic  aromatic  hyrocarbons  and 
aflatoxin B1 (Butler et al., 1989; Boobis et al., 1994; Gallagher et al., 1994; Eaton et al., 1995).  
CYP1A2 is also induced by a number of products including cigarette smoke (Rasmussen et al., 
2002)  and  3-methylcholanthrene  (Quattrochi  et  al.,  1994).    CYP1A2  is  induced  by  3-
methylcholanthrene through binding to the aryl hydrocarbon receptor complex, which then binds 
to the xenobiotic responsive element located  in the 5’ region of the gene (Quattrochi et al., 
1994).    Several  other  transcription  factor  binding  sites,  associated  with  the  regulation  of 
CYP1A2 expression, have also been identified in the 5’ region, including AP-1, E-box proteins, 
and HNF-1 (Chung and Bresnick, 1995; Chung and Bresnick, 1997; Quattrochi et al., 1998; 
Pickwell et al., 2003).  Furthermore, GC and CCAAT boxes have been identified approximately 
940  nucleotides  upstream  of  the  translational  start  site  (Chung  and  Bresnick,  1995).    The 
enzyme also has many inhibitors including compounds found in oral contraceptives (Abernethy 
and  Todd,  1985;  Balogh  et  al.,  1995).    A  summary  of  CYP1A2  substrates,  inducers  and 
inhibitors  is  shown  in  figure  2.2.    Caffeine  is  frequently  used  as  a  substrate  in  CYP1A2 
phenotype studies (Kalow and Tang, 1993; Fuhr et al., 1996) but theophylene (Sarkar et al., 
1992) and melatonin (Hartter et al., 2001) are also used. 
 
Figure  2.2    Known  CYP1A2  substrates,  inhibitors  and  inducers  (derived  from 
http://medicine.iupui.edu/flockhart/table.htm) 
 
Substrates      Inhibitors    Inducers 
Acetaminophen      amiodarone    beta-naphthoflavone 
amitriptyline      cimetidine    broccoli 
caffeine        ciprofloxacin    brussel sprouts 
clomipramine      fluoroquinolones   char-grilled meat 
clozapine      fluvoxamine    insulin 
cyclobenzaprine      furafylline     methylcholanthrene 
estradiol       interferon    modafinil 
fluvoxamine      methoxsalen    nafcillin 
haloperidol      mibefradil    omeprazole 
imipramine            tobacco smoke 
mexiletine 
naproxen 
olanzapine 
ondansetron 
phenacetin 
propranolol 
(R)warfarin 
riluzole 
ropivacaine 
tacrine 
theophylline 
tizanidine 
verapamil 
zileuton 
zolmitriptan 
 
 
 
CYP1A2  knockout  mice  develop  normally  but  show  deficient  drug  metabolism (Liang  et  al., 
1996).  Human CYP1A2 mRNA expression varies up to 40 fold (Schweikl et al., 1993), and the 
in vivo activity of the enzyme may differ up to 60 fold (Eaton et al., 1995) among individuals.  
These  differences  may  affect  drug  efficacy  and  safety  as  well  as  susceptibilities  to  cancer 
caused by procarcinogens in humans (Gunes and Dahl, 2008).  Some of this variability may be 
due to environmental factors, such as tobacco smoke, exercise and/or diet.  On the other hand,   15 
it has been postulated that up to 75 %  of the difference  is due  to  genetic variation  among 
individuals (Kendler and Prescott, 1999; Rasmussen et al., 2002).  In addition, gender related 
differences in CYP1A2 activity have also been reported (Parkinson et al., 2004). 
 
2.1.2.1  Known CYP1A2 genomic variation prior to this study 
 
To date, excluding data reported in this study, 125 allelic variants have been reported within 
CYP1A2 (from exon 1 to exon 7) and a further 47 variants have been found within 3000 bases 
either side of the gene.  The 5’ region has 30 variants whilst the 3’ region has 17 (see table 2.1 
for a summary of the numbers and types of mutations).  A comprehensive review of all these 
CYP1A2 variants is set out in table 2.2 (please see CD); data regarding location, ancestral 
alleles,  haplotypes,  allele  frequencies  in  different  populations  and  functional  studies  are 
provided. 
 
Table  2.1    Known  CYP1A2  variants  prior  to  this  study  (data  compiled  from  NCBI  build  129 
(http://www.ncbi.nlm.nih.gov/),  CYP1A2  allele  nomenclature  web  page  (www.cypalleles.ki.se/),  NIEHS  SNPs 
programme  (www.egp.gs.washington.edu/data/CYP1A2/)  and  Pharmacogenetics  Knowledge  Base 
(www.pharmgkb.org/)). 
 
Location  Substitutions  Transitions  Transversions 
Insertion 
/Deletions  STR  Splice site  Synonymous 
Non 
synonymous 
5' end  28  17  11  2  0       
3' end  16  13  3  1  0       
3' UTR  13  9  4  4  0       
Intron 1  17  9  8  1  0  0     
Intron 2  7  6  1  0  0  0     
Intron 3  4  2  2  0  0  0     
Intron 4  6  5  1  0  0  0     
Intron 5  15  10  5  1  1  0     
Intron 6  12  8  4  2  0  1     
Exon 1 (5' UTR)  0  0  0  0  0       
Exon 2  22  13  9  0  0    6  16 
Exon 3  7  5  2  0  0    3  4 
Exon 4  1  1  0  0  0    0  1 
Exon 5  3  2  1  0  0    0  3 
Exon 6  2  2  0  0  0    1  1 
Exon 7  7  6  1  0  0    1  6 
 
The vast majority of variants are Single Nucleotide Polymorphisms (SNPs) which occur within 
the  non-coding  regions  of  the  gene  (table  2.1).    Eleven  variants  are  Deletion  Insertion 
Polymorphisms  (DIPs),  none  of  which  are  found  in  the  coding  region,  and  one  is  a  Short 
Tandem Repeat (STR) in intron 5.  A total of 67 variants lie within the introns, one of which 
causes a splicing defect in intron 6.  A total of 42 SNPs occur within the coding exons, over 70% 
of which are non-synonymous changes.  To date, no variation has been reported in exon 1 (5’ 
UTR), no more than seven variants have been found in any of exons 3, 4, 5  and 6, yet more 
than 20 variants have been found in each of exons 2 and 7 (including 3’ UTR).  Note that none 
of the variants are found in what is thought to be the active site of the protein.  In addition, no 
copy number variation or gene conversion has been reported in CYP1A2.  As far as linkage   16 
disequilibrium (LD) across CYP1A2 is concerned, patterns vary between HapMap populations 
(Yoruba, Europeans, Chinese and Japanese) and the gene is in one LD block in Europeans and 
Chinese but divided into different LD blocks in Yoruba and Japanese (http://www.hapmap.org/).  
LD was however high across CYP1A2 in another Japanese cohort (Soyama et al., 2005).  In a 
study involving Africans, Asians and Caucasians, CYP1A1 and CYP1A2 were each in their own 
block with high LD, and each block showed few historic recombination events.  A recombination 
hotspot was identified in the middle of the spacer region which separates the two genes (Jiang 
et al., 2005). 
 
Tables  2.3,  2.4  and  2.5  summarise  the  distribution  (known  prior  to  this  study)  of  allele 
frequencies of CYP1A2 variants, found above 1 % in at least one population, in the extragenic 
(5’ and 3’ regions), intronic and exonic regions respectively.  It is clear that differences in allele 
frequencies, across the entire CYP1A2 gene, exist among the study populations. 
 
To date, prior to this study, 36 CYP1A2 haplotypes (table 2.6), including 21 subtypes, have 
been  named  by  the  Human  Cytochrome  P450  Nomenclature  Committee 
(www.cypalleles.ki.se/CYP1A2.htm).  The rules for naming CYP haplotypes are as follows: The 
gene and haplotype are separated by an asterisk followed by Arabic numerals (e.g. CYP1A2*1, 
CYP1A2*2).   A  unique  haplotype  contains  nucleotide  changes  which  affect  transcription, 
splicing, translation, posttranscriptional or posttranslational modifications or result in at least one 
amino  acid  change.    Additional  nucleotide  changes  are  described  by  letters  (upper-case 
Roman) such that where silent mutations occur, or where mutations are present in regulatory 
regions  or  introns  with  an  unknown  function,  the  haplotype  name  conforms  to  the  closest 
functionally  characterised  allele  by  subgroup  allocations  e.g.  CYP1A2*1B,  *1C  and  *1D 
(www.cypalleles.ki.se/criteria.htm).  Most attention has been paid to intron 1 and the 5’ region of 
the gene, due to this region’s potential regulatory role in gene expression. A summary of the 
distribution of CYP1A2 haplotypes, in the different study populations reported so far, is set out 
in table 2.6.  Differences in haplotype frequencies among worldwide populations are evident. 
 
2.1.2.2  CYP1A2 functional variation prior to this study 
 
The associated functional status of each CYP1A2 haplotype is also summarised in table 2.6.  
CYP1A2*1J (Aklillu et al., 2003), *9, *10, *12, *13 and *14 (Murayama et al., 2004) were shown 
to have an enzyme activity similar to that of the ‘wild type’ in vitro (*1A haplotype).  This was 
replicated  in  vivo  for  CYP1A2*1J  in  the  same  study  using  caffeine  as  a  phenotyping  probe 
(substrate used to detect amount of CYP1A2 activity) (Aklillu et al., 2003).  In contrast to this 
however, CYP1A2*6 has been designated as being non-functional because the recombinant 
DNA expression (human CYP1A2 expression from non-human cells) of the *6 variant, in   17
Table 2.3  The distribution of allele frequencies of CYP1A2 variants, found above 1 % in at least one population, in the extragenic region (5’ and 3’ regions)
Population Reference
-3860A -3598T -3584G -3113A -2909T -2847C -2834T -2808C -2777A -2733T -2467- -2103A -1944A -1804G -1708C -1051C 7352A 7573T 7864A 7894A 9540A
African 0.110 0.160 Jiang et al., 2005
African American 0.035 0.167 0.000 NIEHS SNPs
1
0.110 0.109 Perlegen-AFD
2
0.396 0.042 0.146 0.000 0.000 0.021 0.021 0.563 0.021 0.021 0.146 0.146 0.000 0.167 SNP500 Cancer
3
0.336 0.092 SNP500 Cancer HDP
3
0.000 Solus et al., 2004
Asian 0.000 0.125 0.042 NIEHS SNPs
1
0.060 0.080 Jiang et al., 2005
Caucasian 0.017 0.000 0.000 0.000 CSHL HapMap
2
0.000 0.000 Perlegen-AFD
2
0.081 0.000 0.083 0.000 0.000 0.000 0.000 0.241 0.000 0.000 0.081 0.081 0.000 0.484 SNP500 Cancer
3
0.000 0.000 SNP500 Cancer HDP
3
0.030 Solus et al., 2004
0.010 0.030 Jiang et al., 2005
Chinese 0.033 ABI-AoD
2
0.091 0.089 0.023 0.000 CSHL HapMap
2
0.220 Han et al., 2002
0.120 0.146 Perlegen-AFD
2
0.000 Solus et al., 2004
European 0.000 0.595 0.000 NIEHS SNPs
1
Hispanic 0.000 0.310 0.000 NIEHS SNPs
1
0.196 0.000 0.068 0.000 0.000 0.000 0.000 0.250 0.022 0.000 0.045 0.045 0.025 0.435 SNP500 Cancer
3
Japanese 0.011 ABI-AoD
2
0.420 Chida et al., 1999
0.033 0.044 0.011 0.000 CSHL HapMap
2
0.230 Nakajima et al., 1999
0.000 Solus et al., 2004
0.236 0.032 0.170 0.026 0.032 0.016 0.438 Soyama et al., 2005
Korean 0.270 0.030 0.707 Ghotbi et al., 2007
Native American/Hispanic 0.471 0.031 SNP500 Cancer HDP
3
Pacific Rim 0.239 0.000 0.042 0.021 0.000 0.000 0.000 0.625 0.000 0.000 0.042 0.042 0.000 0.125 SNP500 Cancer
3
0.145 0.074 SNP500 Cancer HDP
3
South East Asian 0.000 Solus et al., 2004
Swedish 0.010 0.020 0.193 Ghotbi et al., 2007
Yoruba 0.100 0.125 0.000 0.067 CSHL HapMap
2
0.000 0.000 0.000 NIEHS SNPs
1
1 http://egp.gs.washington.edu/data/cyp1a2/
2 NCBI build 129
 http://www.ncbi.nlm.nih.gov/
3 http://snp500cancer.nci.nih.gov/
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Table 2.4  The distribution of allele frequencies of CYP1A2 variants, found above 1 % in at least one population, in the intronic region
Population Reference
-739G -733C -729T -662G -569A -505A -367T -349G -178A -163A -61G 850C 869C 894T 1202T 1280G 1352A 1590T 1649T 1669T 2159A 2169A 2232C 2321C 2570A 2597G 2645G 2646T 2694C 3069C 3533A 3605G 3613C 4310A 4598T 5010T
African 0.160 0.060 0.430 0.000 0.010 0.130 Jiang et al., 2005
African American 0.644 ABI-AoD
2
0.033 0.033 0.033 0.654 0.000 0.000 0.000 0.000 0.000 0.133 0.107 0.033 0.167 NIEHS SNPs
1
0.109 0.543 0.000 0.087 Perlegen-AFD
2
0.146 0.000 0.000 0.000 0.021 0.000 0.771 0.021 0.000 0.000 0.021 0.000 0.167 0.000 0.000 0.000 0.042 0.042 0.000 0.000 0.000 0.021 0.000 0.021 0.130 0.000 SNP500 Cancer
3
0.095 0.000 0.561 0.000 0.086 0.020 0.000 0.079 SNP500 Cancer HDP
3
0.060 0.000 0.000 0.000 0.380 0.000 0.130 0.000 0.000 0.060 0.000 Solus et al., 2004
0.133 0.011 0.000 PharmGKB AB-DME
4
Asian 0.000 0.000 0.000 0.625 0.000 0.000 0.021 0.021 0.000 0.130 0.021 0.000 0.229 NIEHS SNPs
1
0.067 0.000 0.000 SNP500 Cancer HapMap
3
0.080 0.000 0.440 0.080 0.180 0.080 Jiang et al., 2005
British 0.660 Sachse et al., 2003
Caucasian 0.783 ABI-AoD
2
0.000 0.000 0.692 0.000 0.644 0.033 0.000 CSHL HapMap
2
0.000 0.708 0.000 0.688 Perlegen-AFD
2
0.081 0.000 0.032 0.000 0.000 0.000 0.726 0.000 0.016 0.081 0.000 0.032 0.500 0.016 0.016 0.065 0.000 0.000 0.016 0.000 0.000 0.000 0.000 0.000 0.081 0.032 SNP500 Cancer
3
0.000 0.000 0.659 0.000 0.660 0.030 0.000 0.000 SNP500 Cancer HDP
3
0.060 0.000 0.010 0.010 0.390 0.030 0.000 0.010 0.000 0.060 0.030 Solus et al., 2004
0.005 Chevalier et al., 2001
0.000 0.000 0.000 SNP500 Cancer HapMap
3
0.056 0.000 0.000 PharmGKB AB-DME
4
0.005 Allorge et al., 2003
0.030 0.000 0.300 0.020 0.640 0.030 Jiang et al., 2005
Chinese 0.689 0.167 ABI-AoD
2
0.083 0.023 0.667 0.091 0.122 0.151 0.061 CSHL HapMap
2
0.660 Han et al., 2002
0.174 0.688 0.125 0.167 Perlegen-AFD
2
0.100 0.100 0.000 0.000 0.150 0.150 0.000 0.000 0.000 0.100 0.000 Solus et al., 2004
0.140 0.000 0.000 PharmGKB AB-DME
4
Egyptian 0.030 0.680 Hamdy et al., 2003
Ethiopian 0.075 0.030 0.496 Aklillu et al., 2003
European 0.000 0.000 0.000 0.659 0.023 0.000 0.000 0.000 0.000 0.625 0.000 0.000 0.024 NIEHS SNPs
1
0.712 SEQUENOM-CEPH
2
German 0.680 Sachse et al., 1999
Hispanic 0.000 0.000 0.000 0.857 0.000 0.023 0.023 0.000 0.000 0.325 0.023 0.023 0.095 NIEHS SNPs
1
0.043 0.000 0.000 0.043 0.023 0.000 0.696 0.000 0.000 0.000 0.000 0.000 0.435 0.000 0.000 0.022 0.000 0.000 0.000 0.022 0.000 0.000 0.000 0.000 0.022 0.065 SNP500 Cancer
3
Italian 0.670 Pavanello et al., 2005
Japanese 0.644 0.244 ABI-AoD
2
0.082 0.613 Chida et al., 1999
0.023 0.000 0.614 0.033 0.182 0.122 0.012 CSHL HapMap
2
0.000 0.050 0.000 0.000 0.250 0.200 0.000 0.000 0.000 0.000 0.000 Solus et al., 2004
0.032 0.020 0.032 0.012 0.628 0.002 0.194 0.170 0.000 0.026 Soyama et al., 2005
0.044 0.000 0.011 PharmGKB AB-DME
4
Korean 0.027 0.000 0.627 Ghotbi et al., 2007
Native American/Hispanic 0.032 0.000 0.660 0.031 0.071 0.041 0.000 0.031 SNP500 Cancer HDP
3
Pacific Rim 0.042 0.083 0.000 0.000 0.000 0.021 0.750 0.000 0.000 0.042 0.000 0.000 0.125 0.000 0.000 0.354 0.000 0.000 0.000 0.000 0.021 0.000 0.000 0.000 0.042 0.000 SNP500 Cancer
3
0.057 0.000 0.580 0.069 0.189 0.157 0.000 0.073 SNP500 Cancer HDP
3
Saudi Arabian 0.059 0.036 Aklillu et al., 2003
South East Asian 0.000 0.000 0.000 0.000 0.150 0.200 0.000 0.000 0.050 0.000 0.000 Solus et al., 2004
Spanish 0.013 0.005 Aklillu et al., 2003
Swedish 0.023 0.003 0.714 Ghotbi et al., 2007
Tanzanian 0.490 Dandara et al., 2004
Yoruba 0.125 0.000 0.567 0.000 0.008 0.025 0.059 CSHL HapMap
2
0.000 0.042 0.000 0.583 0.000 0.000 0.000 0.000 0.042 0.000 0.083 0.000 0.125 NIEHS SNPs
1
0.125 0.000 0.000 SNP500 Cancer HapMap
3
Zimbabwean 0.570 Dandara et al., 2004
1 http://egp.gs.washington.edu/data/cyp1a2/
2 NCBI build 129
 http://www.ncbi.nlm.nih.gov/
3 http://snp500cancer.nci.nih.gov/
4 http://www.pharmgkb.org/
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Table 2.5  The distribution of allele frequencies of CYP1A2 variants, found above 1 % in at least one population, in the exonic region
Population Reference
53G 217A 222T 310A 331T 393A 413A 613G 1460T 1513A 1514A 1559G 2116A 5090T 5112T 5168T 5342G 5347T 5521G 5654T 5890G 6021T 6324- 6537A 6674G 6685G
African 0.000 0.010 0.190 Jiang et al., 2005
African American 0.155 ABI-AoD
2
0.000 0.000 0.033 0.000 0.000 0.033 0.000 0.133 0.167 0.000 0.000 0.167 0.000 0.192 NIEHS SNPs
1
0.091 Perlegen-AFD
2
0.000 0.000 0.000 0.000 0.000 0.146 0.000 0.000 0.000 0.000 0.000 0.167 0.000 0.146 0.021 SNP500 Cancer
3
0.013 0.000 0.118 0.000 0.000 0.047 SNP500 Cancer HDP
3
0.000 0.130 0.000 0.000 0.370 0.070 Solus et al., 2004
0.000 0.000 0.067 0.000 0.000 0.000 PharmGKB AB-DME
4
Asian 0.000 0.000 0.000 0.000 0.000 0.000 0.028 0.125 0.229 0.000 0.000 0.000 0.000 0.222 NIEHS SNPs
1
0.000 0.000 0.000 0.000 0.000 SNP500 Cancer HapMap
3
0.080 0.150 0.250 Jiang et al., 2005
British 0.390 Sachse et al., 2003
Caucasian 0.652 ABI-AoD
2
0.642 CSHL HapMap
2
0.630 Perlegen-AFD
2
0.000 0.032 0.016 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.500 0.000 0.177 0.000 SNP500 Cancer
3
0.000 0.000 0.000 0.000 0.000 0.617 SNP500 Cancer HDP
3
0.000 0.000 0.030 0.020 0.370 0.080 Solus et al., 2004
0.010 0.005 0.330 Chevalier et al., 2001
0.000 0.000 0.000 0.000 0.000 SNP500 Cancer HapMap
3
0.000 0.022 0.000 0.000 0.000 0.000 PharmGKB AB-DME
4
0.020 0.600 0.090 Jiang et al., 2005
Chinese 0.189 ABI-AoD
2
0.122 CSHL HapMap
2
0.174 Perlegen-AFD
2
0.000 0.000 0.000 0.000 0.150 0.220 Solus et al., 2004
0.000 0.000 0.000 0.000 0.000 0.000 PharmGKB AB-DME
4
European 0.000 0.023 0.000 0.000 0.023 0.000 0.000 0.625 0.025 0.000 0.000 0.000 0.000 0.026 NIEHS SNPs
1
0.620 0.093 SEQUENOM-CEPH
2
Hispanic 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.333 0.079 0.053 0.023 0.000 0.000 0.083 NIEHS SNPs
1
0.000 0.000 0.000 0.000 0.000 0.022 0.000 0.000 0.000 0.000 0.023 0.435 0.000 0.065 0.022 SNP500 Cancer
3
Japanese 0.244 ABI-AoD
2
0.182 CSHL HapMap
2
0.000 0.000 0.000 0.000 0.250 0.200 Solus et al., 2004
0.006 0.000 0.000 0.006 0.192 0.192 Soyama et al., 2005
0.000 0.000 0.000 0.000 0.000 0.011 PharmGKB AB-DME
4
0.006 0.004 Murayama et al., 2004
Native American/Hispanic 0.000 0.000 0.000 0.000 0.000 0.043 SNP500 Cancer HDP
3
Pacific Rim 0.000 0.000 0.000 0.021 0.000 0.000 0.042 0.000 0.000 0.021 0.000 0.125 0.000 0.413 0.000 SNP500 Cancer
3
0.000 0.000 0.000 0.000 0.000 0.192 SNP500 Cancer HDP
3
South East Asian 0.000 0.000 0.000 0.000 0.150 0.200 Solus et al., 2004
Yoruba 0.000 CSHL HapMap
2
0.042 0.000 0.000 0.042 0.000 0.125 0.000 0.000 0.091 0.000 0.000 0.125 0.045 0.150 NIEHS SNPs
1
0.008 0.000 0.110 0.000 0.000 SNP500 Cancer HapMap
3
1 http://egp.gs.washington.edu/data/cyp1a2/
2 NCBI build 129
 http://www.ncbi.nlm.nih.gov/
3 http://snp500cancer.nci.nih.gov/
4 http://www.pharmgkb.org/
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Table 2.6 The distribution of CYP1A2 haplotypes in different study populations and their associated function
Ethiopian (n=346) Saudi Arabian (n=272) Spanish (n=234) Swedish (n=386) Korean (n=100) Japanese (n=500) French Caucasian (n=200)
(Soyama et al., 2005) (Chevalier et al., 2005)
*1A None (unmutated for all alleles)
Wild type function
Designated wild type 
function by Allele 
Nomenclature Committee
0.399 (only intron 1 
analysed - could be *1B for 
example)
0.244 (only intron 1 and enhancer 
region analysed - could be *1B for 
example)
0.217 (only intron 1 and 
enhancer region analysed - could 
be *1B for example) 0.635
*1B 5347T>C
N516N Undetermined
0.348 (incorrectly reported as 
*1A) 0.330
*1C -3860G>A Reduced function Nakajima et al., 1999
*1D -2467delT Undetermined 0.034 0.153
*1E -739T>G Undetermined
*1F -163C>A
Undetermined 
(controversial)
Sachse et al., 1999; Han et 
al., 2001; Han et al., 2002; 
Nordmark et al., 2002; 
Shimoda et al., 2002; 
Aklillu et al., 2003; 
Castorena-Torres et al., 
2005 0.496 0.567 0.077 0.004
*1G -739T>G; 5347T>C N516N Undetermined 0.005
*1H 1570A>C; 5347T>C A317A; N516N Undetermined 0.005
*1J -739T>G ; -163C>A  Wild type function Aklillu et al., 2003 0.075 0.059 0.013
*1K -739T>G; -729C>T; -163C>A   Reduced function Aklillu et al., 2003 0.030 0.036 0.005 0.003 0.000
*1L  -3860G>A; -2467delT;-163C>A; 
5347T>C N516N Undetermined 0.008 0.267 0.230
*1M  -163C>A; 2159G>A Undetermined 0.174
*1N 
-3594T>G; -2467delT;-163C>A; 
2321G>C; 5521A>G; 5347T>C N516N Undetermined 0.108
*1P  -3594T>G; -2467delT;-733G>C; -
163C>A; 2321G>C; 5521A>G; 
5347T>C N516N Undetermined 0.020
*1Q  -2808A>C; -163C>A; 2159G>A Undetermined 0.016
*1R  -3594T>G; -2467delT;-367C>T; -
163C>A; 2321G>C; 5521A>G; 
5347T>C N516N Undetermined 0.010
*1S  -3053A>G; 5347T>C N516N Undetermined 0.002
*1T  -2667T>G; 5347T>C N516N Undetermined 0.002
*1U  678C>T; 5347T>C F226F; N516N Undetermined 0.002
*1V  -2467delT; -163C>A Undetermined Ghotbi et al., 2007 0.123 0.260
*1W 
-3113G>A; -2467delT; -739T>G; 
-163C>A
Undetermined 
(controversial)
Chen et al., 2005; Jiang et 
al., 2006; Ghotbi et al., 
2007 0.021 0.027
*2 63C>G F21L Undetermined 0.000
*3 2116G>A; 5347T>C D348N; N516N Undetermined Zhou et al., 2004  0.000 0.010
*4 2499A>T I386F Undetermined Zhou et al., 2004  0.000 0.005
*5 3496G>A C406Y Undetermined Zhou et al., 2004  0.000 0.005
*6 5090C>T R431W Non-functional Zhou et al., 2004  0.000 0.005
*7 3533G>A Splicing defect  Reduced function Allorge et al., 2003 0.000
*8 5166G>A; 5347T>C R456H; N516N Reduced function Saito et al., 2005 0.004
*9 248C>T T83M Wild type function Murayama et al., 2004 0.004
*10 502G>C E168Q Wild type function Murayama et al., 2004 0.002
*11 558C>A  F186L Reduced function Murayama et al., 2004 0.002
*12 634A>T S212C Wild type function Murayama et al., 2004 0.004
*13 1514G>A G299S Wild type function Murayama et al., 2004 0.006
*14 5112C>T T438I Wild type function Murayama et al., 2004 0.006
*15 125C>G; 5347T>C P42R; N516N Reduced function Saito et al., 2005 0.002
*16 2473G>A; 5347T>C R377Q; N516N Reduced function Saito et al., 2005 0.002
(Aklillu et al., 2003) (Ghotbi et al., 2007)
Haplotype frequencies
CYP1A2 haplotype Nucleotide changes Amino acid change Enzyme activity
Reference for functional 
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Escherichia Coli, led to no detectable levels of CYP1A2 (Zhou et al., 2004).  CYP1A2*1C, *1K, 
*7, *8, *11, *15 and *16 all produced proteins with reduced CYP1A2 activity compared to the 
‘wild type’.  The -3860 G>A mutation in *1C caused a decrease in the inducibility of the enzyme 
in  Japanese  smokers  (Nakajima  et  al.,  1999).    CYP1A2*1K  reporter  constructs  showed 
significantly  reduced  inducibility  in  vitro  and  subjects  with  CYP1A2*1K  showed  significantly 
decreased CYP1A2 activity using caffeine as the phenotyping probe (Aklillu et al., 2003).  The -
729 C>T mutation in intron 1 was thought to be the causal variant of this reduced phenotype.  
The point mutation 3533 G>A in CYP1A2*7 caused a splicing defect in intron 6 and is likely to 
be the reason why carriers of this variant had reduced CYP1A2 activity when phenotyped with 
caffeine (Allorge et al., 2003).  The F186L amino acid substitution in CYP1A2*11 had no effect 
on  protein  expression  but  showed  a  markedly  decreased  catalytic  activity  in  vitro  in  V79 
transfected hamster cells; 12 % of the wild type’s capacity for phenacetin O-deethylation and 28 
%  for  7-ethoxyresorufin  O-deethylation  (Murayama  et  al.,  2004).    CYP1A2*8,  *15  and  *16 
showed  reduced  protein  expression  levels  and  less  than  1  %  of  the  7-ethoxyresorufin  O-
deethylation and 4 % of the phenacetin O-deethylation capacity compared with the *1A variant 
in  V79  hamster  cells  (Saito  et  al.,  2005).    None  of  these  variants  have  however  been 
functionally assessed in humans.  The recombinant DNA expression of CYP1A2 variants *3, *4 
and  *5  led  to  varying  levels  of  decreased  expression  and  catalytic  activities,  and  altered 
substrate specificity for phenacetin and heterocyclic amines (Zhou et al., 2004).  Their function 
is  still  however  classified  as  being  “undetermined”  (personal  communication,  P.  David 
Josephy
2).  CYP1A2*2 has only been found in a Chinese cohort at a frequency below 1 % (n = 
1) (Huang et al., 1999).  The functional significance of this variant has not been evaluated.  The 
-163 C>A mutation in intron 1 (CYP1A2*1F) was associated with higher enzyme inducibility by 
smoking (Sachse et al., 1999), although this association was not always replicated (Nordmark 
et al., 2002; Aklillu et al., 2003).  Likewise, the -3113 G>A variant in CYP1A2*1W was shown to 
alter CYP1A2 activity in non-smoking Chinese individuals.  However, this was not replicated in 
Caucasians, Asians or Africans (Jiang et al., 2006; Ghotbi et al., 2007).  CYP1A2*1B, *1D, *1E, 
*1G, *1H, *1L, *1M, *1N, *1P, *1Q, *1U, *1R, *1S, *1T, *1U, *1V and *1W are haplotypes whose 
functional significance remains ‘undetermined’. 
 
2.1.3  Rationale of study 
 
Little  investigation  of  CYP1A2  has  been  undertaken  in  the  Ethiopian  population  to  date.  
Researchers  at  the  Karolinska  Institute  in  Stockholm  (Aklillu  et  al.,  2003)  have  carried  out 
CYP1A2  genotype  and  phenotype  studies  in  100  Ethiopians  from  Ethiopia  and  73  living  in 
Sweden.    However  this  study  only  sequenced  the  gene  in  12  individuals,  genotyping  was 
restricted  to  intron  1  and  the  sample  set  was  of  a  mixed  Ethiopian  origin  from  the  Oromo, 
Amhara, Tigriyan and Gurage ethnic groups.  A group at the University of Cincinnati Medical 
Centre have also carried out CYP1A2 genotype studies in Ethiopians as part of a wider study 
(Jiang et al., 2006).  However, they only genotyped six SNPs in six Ethiopians, whose ethnicity 
                                                 
2 P.David Josephy is a co-author of Zhou et al., 2004   22 
is not recorded.  Despite this lack of information however, many pharmaceuticals, which may be 
metabolised  by  CYP1A2,  are  administered  in  Ethiopia.    For  example,  both  primaquine  and 
praziquantel are used as the first line of treatment for malaria and schistosomiasis respectively 
(Federal Democratic Republic of Ethiopia Ministry of Health, 2004) and CYP1A2 is thought to 
be involved in their metabolism (Li et al., 2003).  Furthermore, coffee was first domesticated for 
human use in Ethiopia (Anthony et al., 2002) and is an integral part of modern Ethiopian culture.  
The  intake  of  caffeine  (a  well  known  CYP1A2  substrate)  is  consequently  widespread  in 
Ethiopia. 
 
2.1.4  Aims 
 
1.  Characterise  the  distribution  of  genetic  variation  in  exons  and  their  flanking  intronic 
regions in CYP1A2 in the Ethiopian ascertainment populations. 
 
2.  Determine the extent of variation in comparison to what is already known. 
 
3.  Identify haplotypes common in Ethiopia and the five ethnic groups studied. 
 
4.  Analyse Ethiopian data in the context of CYP1A2 variation reported by the Institute of 
Environmental  Health  Sciences  (NIEHS)  SNPs  programme  in  African  Americans, 
Yoruba, Europeans, Hispanics and East Asians. 
 
2.2  Methods 
2.2.1  Ethiopian samples 
 
DNA  samples  were  collected  from  males,  18  years  old  or  older,  unrelated  at  the  paternal 
grandfather level.  All samples were collected anonymously with informed consent. Sociological 
data, including age, current residence, birthplace, self-declared ethnic identity and religion of the 
individual and of the individual's father, mother, paternal grandfather and maternal grandmother 
were also collected. 
 
Samples from the following ethnic groups were chosen for an ‘Ethiopian ascertainment panel’: 
Afar (n = 76), Amhara (n = 77), Anuak (n = 76), Maale (n = 76) and Oromo (n = 76).  Afar were 
collected from Dubti (11.74 ºN, 41.09 ºE) and Asayta (11.56 ºN, 41.44 ºE) in Afar, Amhara and 
Oromo from Addis Ababa (9.03 ºN, 38.70 ºE) and Jimma (7.67 ºN, 36.83 ºE), Anuak from the 
Gambela region (including Gog (7.58 ºN, 34.50 ºE), Itang (8.20 ºN, 34.27 ºE) and Akobo (7.82 
ºN, 33.03 ºE)) and Maale from Jinka (5.65 ºN, 36.65 ºE) in the Bako Gazer woreda in South 
Omo. 
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2.2.2  NIEHS samples 
 
The NIEHS in the USA have set up the Environmental Genome Project in an effort to examine 
the  relationships  between  environmental  exposures,  inter-individual  sequence  variation  in 
human  genes  and  disease  risk  in  U.S.  populations.    The  NIEHS  SNPs  Programme  at  the 
University  of  Washington  (http://egp.gs.washington.edu/)  systematically  identifies  and 
genotypes SNPs in environmental response genes as part of the wider study.  Human CYP1A2 
has been sequenced by the NIEHS SNPs Programme in a total of 95 HapMap samples from 
the following ethnicities:  12 Yoruba, 15 African American, 22 European, 22 Hispanic and 24 
East Asian (12 Japanese and 12 Han Chinese).  The genotype data is publicly available and 
was  incorporated  in  the  analyses  of  this  study  to  place  the  Ethiopian  data  in  a  worldwide 
context. 
 
2.2.3  DNA extraction from buccal swabs 
 
Buccal swabs were stored in 1 ml of preservative solution (0.05 M Ethylenediaminetetraacetic 
acid  (EDTA),  PH  8.0,  0.5  %  Sodium  Dodecyl  Sulfate  (SDS).    DNA  was  extracted  using  a 
Phenol/Chloroform DNA extraction protocol. 
 
To begin with, 40 µl of 10 mg/ml proteinase K was added to 20 ml of sterile distilled water.  0.8 
ml  of  this  solution  was  added  to  the  1.5  ml  tube  containing  the  buccal  swab  immersed  in 
EDTA/SDS solution.  Following incubation at 56 ºC for 1-3 hours, 0.8 ml of the mixture was 
added to a microfuge tube containing 0.6 ml of phenol/chloroform (1:1) mix.  The sample was 
mixed and centrifuged for 10 minutes at 2240 xg.  The resultant aqueous (upper) phase (layer) 
was transferred to a new microfuge tube containing 0.6 ml of chloroform and 30 µl of 5 M NaCl.  
The sample was mixed and centrifuged for 10 minutes at 2240 xg.  The resultant aqueous 
(upper) phase (layer) was transferred to a new microfuge tube containing 0.7 ml of chloroform, 
the  sample  was  mixed  and  centrifuged  for  10  minutes  at  2240  xg.    The  resultant  aqueous 
(upper) phase (layer) was transferred to a screw-top microfuge tube (used for long term storage 
of  DNA)  containing  0.7  ml  of  isopropanol.    The  sample  was  mixed  and  centrifuged  for  13 
minutes at 2240 xg.  The resultant supernatant was carefully (to avoid dislodging the DNA from 
the walls of the tube) discarded and the tube was inverted at 45 ˚ for one minute in order to 
drain off any remaining supernatant.  0.8ml of 70 % Ethanol was then added to the screw-top 
microfuge  tube  and  the  mixture  was  centrifuged  for  10  minutes  at  2240  xg.    The  resultant 
supernatant was carefully discarded and the tube was inverted at 45 ˚ for 20 minutes in order to 
drain off any remaining supernatant. 200 µl of TE (pH 9.0) was then added to the microfuge 
tube.    The  mixture  was  then  incubated  at  56  ºC  for  10  minutes  mixing  occasionally.    The 
resulting DNA with TE mixture was then stored upright at -20 ºC. 
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2.2.4  Amplification of CYP1A2 * 
 
All CYP1A2 exons and flanking introns were amplified in six amplicons and in two PCR rounds.  
Primer details for first and second round PCRs are shown in table 2.7.  Each DNA amplicon was 
amplified  in  a  separate  first  round  PCR  and  in  10  µl  reaction  volumes  containing  1  ng  of 
template DNA, 1 µM of each primer, 1.5 mM MgCl2, 0.2 mM dNTPs, 0.2 µl of Platinum Taq 
(Invitrogen) and MgCl2 - free buffer supplied with the Taq.  Cycling parameters were: 5 minutes 
of pre-incubation at 96 ºC, followed by 25 cycles of 30 seconds at 96 ºC, 30 seconds at 45 ºC 
and 45 seconds at 45 ºC, with a final elongation step for 7 minutes at 72 ºC.  1 µl of each of the 
purified first round PCR products was amplified in a second round PCR.  Reaction volumes and 
compositions were the same as those used in the first round PCR, with the exception of the 
DNA template and primers.  Cycling parameters were: 5 minutes of pre-incubation at 96 ºC, 
followed by 25 cycles of 30 seconds at 96 ºC, 30 seconds at 50 ºC and 45 seconds at 72 ºC, 
with a final elongation step for 7 minutes at 72 ºC.  PCR products were purified using ExoSAP-
IT (USB Corporation).  Exonuclease I (Exo) removes residual single-stranded primers and any 
extraneous single-stranded DNA produced in the  PCR. Shrimp Alkaline  Phosphatase (SAP) 
removes remaining dNTPs from the PCR mixture.  Briefly, 0.5 µl of enzyme mix was added to 1 
µl of PCR product and incubated for 15 minutes at 37 ºC, followed by 15 minutes at 80 ºC. 
 
2.2.5  Sequencing of CYP1A2 * 
 
Bidirectional sequencing was performed for each amplicon from the second round PCR with an 
overlap in the centre.  Sequencing primers were the same as the primers used in the second 
round PCRs (table 2.7).  Primers were designed to enable as much of the amplicon as possible 
to be sequenced in both directions.  DNA was sequenced in 5 µl reaction volumes containing 
1.5 µl of purified PCR template, 1 µl of BigDye termination mix v3.1 (Applied Biosystems (ABI), 
Warrington UK) and 1.5 µl of buffer supplied with the mix.  Cycling parameters were: 2 minutes 
of pre-incubation at 96 ºC, followed by 25 cycles of 15 seconds at 96 ºC, 10 seconds at 50 ºC 
and 3 minutes at 60 ºC.  Following standard ethanol precipitation, samples were then run on an 
ABI  3730  genetic  analyser  and  analysed  using  Sequencher  4.7  software  (Gene  Codes 
Corporation, USA).  All six amplicons were sequenced again in 20 samples in order to confirm 
sequencing.    Methods  highlighted  with  *  were  performed  by  Macrogen  USA  (Rockville  MD, 
USA)  (all  other  methods  were  performed  by  me).    Macrogen  USA  sequencing  was  further 
confirmed by sequencing the coding sequence (cds) of exon 7 according to a different method 
(performed by me) described below.   
 
2.2.6  Amplification of CYP1A2 exon 7 (coding sequence) 
 
A 531 bp region, containing the cds region of CYP1A2 exon 7, was amplified using primers 
CYP1A2F CCTTCATTGCTTTCAAAGTGCC and CYP1A2R CTGCACTTGGCTAAAGCTGCT.    25
Table 2.7   First (yellow) and second (green) round PCR primers for the amplification of CYP1A2.  Second round PCR primers were also used for sequencing.  
Length (bp) Amplicon location Forward primer Reverse primer Length (bp) Forward primer Reverse primer
1 730 Exon 1 and flanking regions GCTCCCTACCCTGAACCCTA TCCATATACCCAAGGGACCA 646 TGGCCTATCCCCAAAGAGTCAC AGTTCCCCCTACCCAGTGAC
2 1465 Exon 2 and flanking regions TACCCAGCATGCATGCTG CATTGCAGGACTCTGCTAGG 1315 CTACTCCAGCCCCAGAAGTG GGCTTCAAGGATGAGGAAAC
3 1648 Exons 3, 4 and 5, introns 3 and 4 and part of introns 2 and 5 CTCTGGTGTCACGTTGCTT TTAGCAAGATTGGAGGCCAA 1516 GGTGTTATTGGGAGGAAGGG ACTGGGAGGGAGGGAATATG
4 1000 Exon 6 and flanking regions CCCAAACGTTGTTCTAGTTATT ATCACCTGTAACAAACGTCT 534 TGAAATTGCCTGCTTCTTGG TGGCCATCCTAGTTGATTCC
5 1650 Part of intron 6 and the beginning of exon 7 TTAGCCGGATATGGTGCCTG CGGTGGTTCATACCTGTTAAT 1302 TTAGCCGGATATGGTGCCTG AATGTAAGTTAGGCTGGATGTG
6 1293 The end of exon 7 and part of the 3’ near gene region GAGTCACTACGCCTGGCTGA TGCCTTTTGAGAATGGGACA 1243 GAGTCACTACGCCTGGCTGA GACTGGATCCCTTTCTCCTTG
First round PCR Second round PCR and sequencing
Amplicon   26 
DNA was amplified in 96 well plates in 10 µl reaction volumes containing 1 ng of template DNA, 
0.3 µM of each primer, 2 % dimethyl sulphoxide (DMSO), 0.13 units Taq DNA polymerase (HT 
Biotech, Cambridge, UK), 9.3 nM TaqStartTM monoclonal antibody (BD Biosciences Clontech, 
Oxford, UK), 200 µM dNTPs and reaction buffer supplied with the Taq polymerase.  The cycling 
parameters were:  5 minutes of pre-incubation at 94 ºC, followed by 39 cycles of 1 minute at 94 
ºC, 1 minute at 64 ºC and 1 minute at 72 ºC, with a final elongation step for 7 minutes at 72 ºC.  
The resultant PCR product was purified by mixing 30 µl of 1/3 water 2/3 HM-MC (40 % PEG-
8000, 1 M NaCl, 2 mM Tris-HCl (pH 7.5), 0.2 mM EDTA, 3.5 mM MgCl2) to each PCR product 
and  centrifuging  the  mixture  at  2240  xg  for  45  minutes.    The  resultant  supernatant  was 
discarded by inverting the PCR plate and centrifuging for 1 minute at 13 xg.  150 µl of 70 % 
Ethanol was added to each well and the plate was centrifuged at 2240 xg for 25 minutes.  The 
resultant supernatant was discarded by inverting the PCR plate and centrifuging for 1 minute at 
13 xg.  Samples were dried for 5 minutes at 65 ºC and 30 µl of water was added to each 
purified PCR product.  The solution was mixed gently and heated at 65 ºC for 5 minutes to 
resuspend the pellet. 
 
2.2.7  Sequencing of CYP1A2 exon 7 (coding sequence) 
 
Bidirectional sequencing was performed using the same forward and reverse primers used in 
the first round PCR (CYP1A2F and CYP1A2R).  DNA was sequenced in 96 well plates in 15 µl 
reaction volumes containing 6 µl of the purified PCR product, 2.4 pm of either primer, 0.75 µl of 
BigDye  termination  mix  v1.1  (Applied  Biosystems  (ABI),  Warrington  UK)  and  5  µl  of  Better 
Buffer (Applied Biosystems (ABI), Warrington UK).  The cycling parameters were: 25 cycles of 
96 ºC for 10 seconds, 55 ºC for 5 seconds and 60 ºC for 4 minutes.  Sequencing reaction 
products  were purified by  mixing 80 µl of isopropanol  with each product and leaving for 10 
minutes at room temperature.  The mixture was centrifuged for 45 minutes at 2240 xg and the 
resultant supernatant was discarded by inverting the PCR plate and centrifuging for 1 minute at 
13 xg.  150 µl of 70 % isopropanol was added to each well and centrifuged for 15 minutes at 
2240 xg.  The resultant supernatant was discarded by inverting the PCR plate and centrifuging 
for 1 minute at 13 xg.  Samples were then dried for 5 minutes at 65 ºC.  Each sample was 
mixed with 10 µl of high purity (HiDi) formamide, heated for 4 minutes at 96 ºC and immediately 
cooled in ice.  Samples were then run on an ABI 3100 genetic analyser and analysed using 
Sequencher  4.7  software  (Gene  Codes  Corporation,  USA).    Macrogen  USA  sequencing 
(highlighted with *) was further confirmed by genotyping alleles at positions -163 (intron 1) and 
2159 (intron 4), via TaqMan technology as described below. 
 
2.2.8  Genotyping of -163 C>A 
 
Genotyping  for  -163  C>A  (rs762551)  was  performed  using  TaqMan  technology  (Applied 
Biosystems  (ABI),  Warrington  UK).    A  152  bp  region  containing  the  -163  C>A  SNP  was   27 
amplified  using  the  primers  CYP1A2-1F-M163F  CCAGCGTTCATGTTGGGAATCT  and 
CYP1A2-1F-M163R  ACTGATGCGTGTTCTGTGCTT.    The  fluorogenic  probes  VIC 
CGTCCTGGGCCCAC and FAM CGTCCTGTGCCCAC were included in the PCR to detect the 
presence of a G (C on forward strand) or T (A on forward strand) at position -163 respectively.  
The design of the probes was such that if they annealed specifically between the forward and 
reverse  primers,  the  sequence  specific  signal  was  generated  as  a  direct  result  of  probe 
degradation during PCR by the 5’ nuclease activity of the polymerase. 
 
DNA was amplified in 384 well microplates and in 4 µl reaction volumes containing 1 µl of 1 
ng/µl DNA, 2 µl of 1x TaqMan Genotyping Master Mix (Applied Biosystems (ABI), Warrington 
UK), 0.05 µl of 80x assay mix (containing primers and probes from Applied Biosystems (ABI), 
Warrington UK) and 0.95 µl of sterile water.  The thermal cycler conditions were: 10 minutes of 
pre-incubation at 95 ºC, followed by 40 cycles of 15 seconds at 92 ºC and 1 minute at 60 ºC.  
The resultant PCR product was analysed using TaqMan 7900HT software (Applied Biosystems 
(ABI), Warrington UK). 
 
2.2.9  Genotyping of 2159 G>A 
 
Genotyping of 2159 G>A (rs2472304) was performed using the ABI TaqMan SNP genotyping 
assay C__11772996_1_ (Applied Biosystems (ABI), Warrington UK).  This assay contained a 
mix of unlabeled PCR primers and TaqMan MGB probes (FAM and VIC dye-labeled) for the 
allelic discrimination of rs2472304.  Details of the oligonucleotides are not disclosed and are 
patented  by  ABI  (US  patents  and  corresponding  patent  claims  outside  the  US:  5,538,848, 
5,723,591, 5,876,930, 6,030,787, 6,258,569, and 5,804,375 (claims 1-12 only)).  The amplicon 
sequence is however made available by ABI to reviewers on request. 
 
DNA was amplified in 384 well microplates and in 4 µl reaction volumes containing 1 µl of 1 
ng/µl DNA, 2 µl of 1x TaqMan Genotyping Master Mix (Applied Biosystems (ABI), Warrington 
UK), 0.2 µl of 20x assay mix (containing primers and probes from Applied Biosystems (ABI), 
Warrington UK) and 0.8 µl of sterile water.  The thermal cycler conditions were: 10 minutes of 
pre-incubation at 95 ºC, followed by 40 cycles of 15 seconds at 92 ºC and 1 minute at 60 ºC.  
The resultant PCR product was analysed using TaqMan 7900HT software (Applied Biosystems 
(ABI), Warrington UK). 
 
2.2.10  Statistical analysis 
2.2.10.1  Hardy-Weinberg equilibrium (HWE) 
 
HWE defines the expected proportions of genotypes with respect to observed allele frequencies 
in a randomly mating population, and is given by the formula: p
2 + 2pq + q
2 = 1, where p is the 
major allele frequency and q = 1 - p.  Deviations from HWE can be observed due to non-random   28 
mating (e.g. inbreeding and assortive mating), selection, population stratification, or practical 
issues (e.g. allele drop out and small sample size).  Tests for departure of observed genotype 
frequencies  from  those  expected  under  HWE  were  performed  using  Arlequin  software 
(Schneider et al., 2000).  Arlequin uses a Fisher’s exact test analogue (Guo and Thompson, 
1992) to evaluate departures from HWE. 
 
2.2.10.2  Fisher’s exact test 
 
A  Fisher’s  exact  test  was  used  to  test  for  the  significance  of  associations  between  two 
categorical variables in a 2 x 2 contingency table (e.g. number of mutated sites versus number 
of  unmutated  sites  in  exons  2  and  3).    Under  the  null  hypothesis,  there  is  no  association 
between row and column classifications.  A 2 x 2 table of expected cell frequencies, under the 
null hypothesis, with the same row and column totals as the observed is generated.  The test 
calculates  the  difference  between  the  data  observed  and  the  data  expected  under  the  null 
hypothesis.  The probability for the test is calculated by generating all tables that are similar to, 
or more extreme than the observed table.  The p values of these tables and the p value of the 
observed table are summed to give the exact p value for the test.  Pairwise Fisher's exact tests 
were performed using GraphPad InStat version 3.00 for Windows 95, GraphPad Software, San 
Diego California USA, www.graphpad.com. 
 
2.2.10.3  Pairwise linkage disequilibrium (LD) 
 
Pairwise LD (the non-random association of alleles at two different bi-allelic loci) was measured, 
using the D' parameter (Lewontin, 1964), using GOLD software (Abecasis and Cookson, 2000).  
D is calculated according to:  D = PAB – (PA x PB), where PAB is the observed frequency of 
haplotype AB, and PA x PB is the expected frequency of haplotype AB under linkage equilibrium 
(i.e. the product of the observed allele frequencies of A and B).  Since D is dependent on the 
frequencies of alleles, it is not always comparable between loci.  To improve comparability, D is 
normalised to give the parameter D'.  The absolute value of D' is calculated by dividing D by its 
maximum possible value given the allele frequencies of the two loci.  A chi-square test is also 
performed  to  determine  whether  the  observed  haplotype  distribution  is  significantly  different 
from the expected haplotype distribution under linkage equilibrium. 
 
2.2.10.4  Haplotype inference 
 
Haplotype phase inference was estimated from unphased population genotype data using five 
different  approaches:  an  approach  implemented  in  the  programme  fastPHASE  (Scheet  and 
Stephens,  2006),  the  maximum-likelihood  approach  implemented  through  the  EM  algorithm 
(Excoffier and Slatkin, 1995) in Arlequin software, the ELB approach (Excoffier et al., 2003) also   29 
implemented  in  Arlequin  software  and  two  manual  approaches  based  on  Clark’s  algorithm 
(Clark,  1990).    One  approach  assigns  precedence  (designated  choice)  in  inferring  phase  in 
heterozygotes  to  the  ancestral  haplotype  and  is  herein  called  ‘Clark-ancestral’.    The  other 
approach  assigns  precedence  (designated  choice)  to  the  most  common  possible  haplotype 
identified from homozygotes and is herein named ‘Clark-common’.  Attempts were made to infer 
haplotypes  using  a  Bayesian  statistical  approach  implemented  through  Phase  2.0  software 
(Stephens et al., 2001), however Phase was unable to handle the quantity of data.  Details of all 
haplotype estimation approaches are described in appendix 1. 
 
Haplotype  counts  from  the  different  inference  methods  were  compared  using  Pearson’s 
correlation coefficient analyses in Microsoft Office Excel 2003.  Pearson's correlation (r) reflects 
the  degree  of  the  linear  relationship  between  two  variables  (i.e.  haplotype  counts  from  two 
haplotype inference methods).  Pearson’s r ranges from +1 to -1.   A perfect positive linear 
relationship between variables is given by +1, a perfect negative linear relationship is given by -
1.  When r = 0, the two variables are not correlated. 
 
2.2.10.5  Gene diversity ** 
 
Gene diversity (h) (probability of randomly choosing two different haplotypes from a sample 
(equivalent to heterozygosity for diploid data)) was estimated according to unbiased formulae 
of Nei (1987):  H = n(1 - ∑xi
2)/(n – 1), where n is the number of gene copies, xi is the frequency 
of the ith allele.  Standard deviation of H was the square root of the variance of H (Nei, 1987).   
 
2.2.10.6  Nucleotide diversity ** 
 
Nucleotide  diversity  (π)  (probability  that  two  randomly  chosen  homologous  nucleotides  are 
different (equivalent to gene diversity at the nucleotide level)) was estimated according to Nei 
(1987):  π = n(∑xixjπij)/(n-1), where n is the number of sequences, xi and xj the frequencies of 
the ith and jth sequences respectively and πij the proportion of different nucleotides between 
them.  Standard deviation of π was the square root of the variance of π (Nei, 1987). 
 
2.2.10.7  Exact test of pairwise population differentiation ** 
 
Genetic  differences  between  populations  were  assessed  using  an  Exact  test  of  pairwise 
population differentiation with 10,000 Markov steps (Rousset and Raymond, 1995; Goudet et 
al., 1996). This test is analogous to a Fisher’s Exact test (Lee et al., 2004) but the size of the 2 x 
2 contingency table is extended to the number of populations being compared (two in a pairwise 
population  comparison,  two  or  greater  in  a  global  test)  by  the  total  number  of  different 
haplotypes present.  All potential states of the contingency table are explored with a random   30 
walk via a Markov chain model and estimates of the probability of observing a table less or 
equally  likely  than  the  observed  data  under  the  null  hypothesis  of  panmixia  are  obtained.  
Populations  are  considered  to  be  significantly  different  if  the  p  value  is  smaller  than  the 
significance level (set at 5 %). 
 
2.2.10.8  Genetic distance (FST) ** 
 
FST measures the genetic variability within and between populations, comparing mean genetic 
diversity within sub-populations to genetic diversity in the meta-population, as follows:  FST = (HT 
- HS)/HT, where HT is the expected heterozygosity of the meta-population and HS is the mean 
expected  heterozygosity  across  sub-populations  (Hudson  et  al.,  1992).    Genetic  distance 
between two populations was analysed using population pairwise FST values (Reynolds et al., 
1983), whilst the apportionment of diversity within and between more than two populations was 
analysed using hierachical FST values (Excoffier et al., 1992). 
 
All statistically analyses denoted with ** were performed using Arlequin software (Schneider et 
al., 2000) and hypotheses were tested using permutation analysis (p values were the proportion 
of permutations giving, for example, an FST value ≥ the value obtained for the observed data), 
thus the data was not assumed to have a normal distribution. 
 
2.2.10.9  Principal coordinates analysis 
 
Principal coordinates analysis (Gower, 1966) was performed, using the R statistical package 
(www.R-project.org), on pairwise similarity matrices.  Similarity was quantified as being equal to 
the value of the genetic distance subtracted from 1 (1-Fst for example). Values along the main 
diagonal, representing the similarity of each population sample to itself, were calculated from 
the estimated genetic distance between two copies of the same sample. For Fst distances, the 
resulting similarity of a sample to itself simplifies to n/(n–1), where n = number of chromosomes.   
 
2.2.11  Prediction of functional effect of non-synonymous changes 
 
Effects of amino acid substitutions on the structure and function of CYP1A2 were predicted 
using PolyPhen software (http://genetics.bwh.harvard.edu/pph/).  PolyPhen aligns human amino 
acid sequences against orthologous amino acid sequences, and predicts whether amino acid 
changes  in  humans  will  have  the  following  effects  on  the  structure/function  of  the  protein:  
benign  (no  damage);  possibly  damaging;  probably  damaging;  presume  definite  damage.  
Predictions  consider  the  nature  of  the  amino  acid  change  and  the  degree  of  protein 
conservation across species. 
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2.3  Results 
2.3.1  Summary of variation found in Ethiopian ascertainment and NIEHS populations 
 
•  In  total,  49  CYP1A2  variants  were  found  in  the  Ethiopian  ascertainment  samples  (table 
2.8a)  whilst  22  variants  were  reported  in  the  corresponding  CYP1A2  sequence  in  the 
NIEHS samples (table 2.8d).   
 
•  All  variants,  except  one  (a  single  nucleotide  deletion  in  the  3’  UTR  reported  in  both 
Ethiopians  and  NIEHS  populations)  were  single  nucleotide  substitutions  which  together 
exhibited a transition to transversion ratio estimate of 23:25 in Ethiopians, compared to 5:2 
in the NIEHS populations.  Consequently, more than double the number of transitions than 
transversions were observed in the NIEHS sample set, whilst in Ethiopia there were slightly 
more transversions than transitions, but this difference was not significant (Fisher’s exact 
test, p > 0.1).   
 
•  The ratio of coding to non-coding variant sites was 5:19 in Ethiopians and 4:7 in the NIEHS 
populations (Fisher’s exact test, p > 0.1).   
 
•  Exons 1, 4 and 5 were monomorphic in both Ethiopians and the NIEHS populations.  In 
coding exons, all substitutions except one were non-synonymous for both Ethiopians and 
NIEHS populations (a synonymous to non-synonymous ratio estimate of 1:9 and 1:7 was 
observed in the Ethiopians and the NIEHS populations respectively).   
 
•  Notably, significantly more non-synonymous mutations were found in exon 7 compared to 
all other exons collectively, in Ethiopians (Fisher’s exact test comparing numbers of non-
synonymous mutation sites against combined numbers of not mutated and synonymous 
mutation sites, in exon 7 versus other exons collectively, p < 0.02).   
 
•  Of the 49 variants detected in Ethiopians, 19 have previously been reported (table 2.8b), 
while 30 were novel (table 2.8c).   
 
•  In both Ethiopians and NIEHS populations, variant sites were not observed within 17 bases 
either side of each intron/exon boundary and all reported catalytic residues (amino acids 
D320 and T321 in exon 4, and F451 and C458 in exon 7) were monomorphic. 
 
2.3.2  Frequencies of CYP1A2 variants 
 
CYP1A2  SNP  frequencies  are  shown  in  table  2.9.    No  SNP  frequency  for  any  population 
deviated significantly from HWE at the 1 % significance level.  Only three SNP loci were variable  32
Table 2.8 CYP1A2 variants a) observed in, b) confirmed by, c) added by the Ethiopian ascertainment samples and d) observed in the NIEHS populations
a b c d a b c d a b c d a b c d a b c d a b c d a b c d a b c d
5' end 2 0 2 0 1 0 1 0 1 0 1 0 0 0 0 0 0 0 0 0
3' end 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
3' UTR 12 5 7 4 5 3 2 3 7 2 5 1 1 1 0 1 0 0 0 0
Intron 1 7 4 3 4 3 2 1 3 4 2 2 1 0 0 0 0 0 0 0 0 0 0 0 0
Intron 2 3 1 2 1 3 1 2 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
Intron 3 2 0 2 2 1 0 1 1 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0
Intron 4 2 2 0 1 1 1 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Intron 5 1 0 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Intron 6 9 3 6 1 4 3 1 1 5 0 5 0 0 0 0 0 0 0 0 0 0 0 0 0
Exon 1 (5' UTR) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Exon 2 1 1 0 4 0 0 0 3 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 4
Exon 3 1 1 0 2 0 0 0 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 2
Exon 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Exon 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Exon 6 2 0 2 0 1 0 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 2 0
Exon 7 6 1 5 2 4 1 3 2 2 0 2 0 0 0 0 0 0 0 0 0 1 1 0 1 5 0 5 1
Location
Substitutions Transitions Transversions Non synonymous Insertion/Deletions Short tandem repeat Splice site SynonymousTable 2.9  CYP1A2 allele frequencies in the Ethiopian ascertainment and NIEHS populations
Yellow = novel mutations, green = known mutations, italics = private to one population
f = frequency, n = chromosome number
f n f n f n f n f n f n f n f n f n f n
-1014 C>A 72828121 5' upstream 0.00 0 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
-1008 G>A 72828127 5' upstream 0.00 0 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
-739 T>G rs2069526 72828396 Intron 1 0.05 8 0.07 11 0.03 5 0.08 12 0.09 14 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
-729 C>T rs12720461 72828406 Intron 1 0.00 0 0.01 1 0.00 0 0.01 2 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
-661 T>A 72828474 Intron 1 0.00 0 0.00 0 0.00 0 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
-592 C>T 72828543 Intron 1 0.00 0 0.00 0 0.00 0 0.00 0 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
-569 G>A rs45518531 72828566 Intron 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.03 1 0.00 0 0.00 0 0.00 0 0.00 0
-505 G>A rs45607039 72828630 Intron 1 0.00 0 0.00 0 0.07 11 0.00 0 0.00 0 0.03 1 0.04 1 0.00 0 0.00 0 0.00 0
-163 C>A rs762551 72828972 Intron 1 0.57 86 0.58 89 0.38 57 0.43 65 0.62 94 0.65 17 0.58 14 0.66 29 0.86 36 0.63 30
-151 G>T  72828984 Intron 1 0.00 0 0.01 2 0.00 0 0.01 2 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
-61 A>G  rs41279194 72829074 Intron 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.02 1 0.00 0 0.00 0
53 C>G  rs17861152 72829187 Exon 2 S18C 0.00 0 0.01 1 0.01 1 0.00 0 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
217 G>A  rs45565238 72829351 Exon 2 G73R 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.04 1 0.00 0 0.00 0 0.00 0
310 G>A  rs34067076 72829444 Exon 2 D104N 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.02 1 0.00 0 0.00 0
331 C>T  rs45442197 72829465 Exon 2 L111F 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.03 1 0.00 0 0.00 0 0.00 0 0.00 0
613 T>G  rs45540640 72829747 Exon 2 F205V 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.04 1 0.00 0 0.00 0 0.00 0
869 G>C  rs45533242 72830003 Intron 2 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.02 1 0.00 0
1352 G>A  rs34264399 72830486 Intron 2 0.01 2 0.01 1 0.00 0 0.02 3 0.01 2 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
1353 G>A  72830487 Intron 2 0.00 0 0.00 0 0.00 0 0.00 0 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
1370 G>A  72830504 Intron 2 0.00 0 0.00 0 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
1460 C>T  rs45468096 72830594 Exon 3 R281W 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.02 1 0.00 0 0.00 0
1513 C>A  rs17861157 72830647 Exon 3 S298R 0.03 4 0.01 1 0.11 16 0.05 8 0.05 7 0.03 1 0.13 3 0.00 0 0.00 0 0.00 0
1589 G>T  72830723 Intron 3 0.01 1 0.04 6 0.00 0 0.06 9 0.05 7 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
1611 G>A  72830745 Intron 3 0.00 0 0.01 2 0.00 0 0.00 0 0.02 3 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
1649 G>T  rs45484991 72830783 Intron 3 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.02 1
1669 C>T  rs45445793 72830803 Intron 3 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.04 1 0.00 0 0.00 0 0.00 0
2159 G>A  rs2472304 72831293 Intron 4 0.38 58 0.43 66 0.07 10 0.23 35 0.36 54 0.13 4 0.00 0 0.63 25 0.33 13 0.13 6
2321 G>C  rs3743484 72831455 Intron 4 0.03 4 0.02 3 0.02 3 0.01 2 0.02 3 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
2534 C>T  72831668 Intron 5 0.00 0 0.00 0 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
3463 C>T  72832597 Exon 6 T395M 0.01 2 0.01 1 0.01 2 0.01 1 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
3468 A>C  72832602 Exon 6 N397H 0.01 2 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
3588 G>T  72832722 Intron 6 0.00 0 0.00 0 0.00 0 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
3605 A>G  rs34356615 72832739 Intron 6 0.01 1 0.00 0 0.00 0 0.00 0 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
3613 T>C  rs4646427 72832747 Intron 6 0.06 9 0.07 11 0.03 5 0.07 11 0.09 13 0.11 3 0.08 2 0.00 0 0.02 1 0.02 1
4957 C>G  72834091 Intron 6 0.00 0 0.01 2 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
4961 C>T  72834095 Intron 6 0.00 0 0.00 0 0.00 0 0.00 0 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
4984 C>G  72834118 Intron 6 0.00 0 0.00 0 0.00 0 0.00 0 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
5010 C>T  rs28399423 72834144 Intron 6 0.01 2 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
5015 C>G  72834149 Intron 6 0.00 0 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
5029 C>G  72834163 Intron 6 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
5094 T>C  72834228 Exon 7 F432S 0.00 0 0.01 1 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
5105 G>A  72834239 Exon 7 D436N 0.01 1 0.01 1 0.01 1 0.07 10 0.02 3 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
5112 C>T  rs45486893 72834246 Exon 7 T438I 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.03 1
5253 C>G  72834387 Exon 7 P485R 0.00 0 0.00 0 0.00 0 0.00 0 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
5284 C>A  72834418 Exon 7 Y495Ter 0.00 0 0.00 0 0.03 4 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
5328 G>A  72834462 Exon 7 R510Q 0.01 2 0.00 0 0.00 0 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
5347 C>T  rs2470890 72834481 Exon 7 Synonymous 0.29 44 0.33 51 0.04 6 0.13 20 0.25 38 0.13 4 0.00 0 0.63 25 0.33 12 0.12 6
5355 G>C  72834489 3' UTR 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
5521 A>G  rs11636419 72834655 3' UTR 0.10 15 0.09 13 0.07 10 0.09 14 0.11 16 0.17 5 0.09 2 0.03 1 0.08 3 0.23 11
5620 A>C  rs58661304 72834754 3' UTR 0.05 8 0.03 4 0.12 17 0.20 30 0.06 9 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
5987 G>T  72835121 3' UTR 0.01 1 0.00 0 0.00 0 0.04 6 0.02 3 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
6021 C>T  rs45485796 72835155 3' UTR 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.02 1 0.00 0
6233 C>T  72835367 3' UTR 0.00 0 0.00 0 0.00 0 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
6324 Gdel  rs45564134 72835458 3' UTR 0.04 6 0.01 2 0.06 9 0.00 0 0.02 2 0.17 5 0.13 3 0.00 0 0.00 0 0.00 0
6388 T>G  72835522 3' UTR 0.01 1 0.00 0 0.00 0 0.01 1 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
6537 G>A  rs45599945 72835671 3' UTR 0.00 0 0.00 0 0.03 4 0.00 0 0.00 0 0.00 0 0.04 1 0.00 0 0.00 0 0.00 0
6562 T>A  72835696 3' UTR 0.01 1 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
6674 C>G  rs17861162 72835808 3' UTR 0.08 12 0.09 14 0.09 14 0.09 14 0.11 16 0.19 5 0.15 3 0.03 1 0.08 3 0.22 8
6685 A>G  rs17861163 72835819 3' UTR 0.03 5 0.01 1 0.00 0 0.00 0 0.02 3 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
6714 A>T  72835848 3' UTR 0.00 0 0.01 1 0.00 0 0.00 0 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
6765 C>T  72835899 3' UTR 0.00 0 0.00 0 0.00 0 0.01 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0
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in all populations and these were:  -163 C>A (intron 1), 5521 A>G and 6674 C>G (both in the 3’ 
UTR).  Half of the SNPs were private to populations (highlighted in italics in table 2.9).  Notably, 
all variants found more than once in any one NIEHS population, were detected in the Ethiopian 
ascertainment  population.    It  is  also  relevant  to  note  that  no  non-synonymous  mutation 
exceeded 13 % in any one population with many being observed at frequencies of 1 - 3 %.  In 
addition,  a  previously  unreported  premature  stop  codon  in  exon  7  (5384  C>A  resulting  in 
Y495Ter) was observed in Anuak at 3 %. 
 
2.3.3  LD across CYP1A2 
 
Pairwise LD (D´) was measured across CYP1A2 both by pooling all the Ethiopian ascertainment 
and NIEHS populations data together (world dataset) and by analysing each group separately.  
Monomorphic loci and rare variants (where frequency < 0.01) were removed from the datasets 
prior to the analysis.  In the world dataset (figure 2.3), the majority of CYP1A2 loci are in total 
LD (D´ = 1) but several cases where D´ was less than 1 were observed across the gene.  The 
majority of lower D´ values were evident between pairs of loci including at least one marker 
towards the 3’ end of the gene, and loci from intron 1 up to and including 5521 in the 3’ UTR 
constituted an LD block as defined by other investigators (figure 2.3).  When independently 
analysing pairwise LD in each population, D´ values of less than 1 were observed in all groups 
except Yoruba, Europeans and East Asians (figure 2.4). 
 
2.3.4  CYP1A2 haplotype inference 
 
Given that rare CYP1A2 variants were observed in this study, and that CYP1A2 could not be 
analysed as one LD block (figure 2.3), haplotype inference for the entire CYP1A2 gene (61 
variants)  was  not  straight  forward.    CYP1A2  haplotype  estimates  were  compared  from  the 
following  haplotype  inference  approaches:  ELB  (Excoffier  et  al.,  2003),  EM  (Excoffier  and 
Slatkin,  1995),  fastPHASE  (Scheet  and  Stephens,  2006)  and  two  extensions  of  the  Clark 
algorithm (Clark, 1990), Clark-ancestral and Clark-common, which were performed by hand.  
Attempts were made to estimate haplotypes via Phase (Stephens et al., 2001) but the software 
was  unable  to  handle  the  large  quantity  of  data.    The  Ethiopian  ascertainment  and  NIEHS 
population genotype data were pooled (world dataset) and haplotype inference was performed 
using this dataset in the first instance.  Haplotypes were then inferred from the pooled Ethiopian 
ascertainment dataset and from each of the individual populations.  Note that only samples with 
full genotype data were included in the analysis. 
 
Pearson’s  correlation  coefficient  analysis  was  performed  to  compare  the  haplotype  counts 
generated from the different haplotype inference approaches.  Haplotype counts and Pearson’s 
correlation  coefficients  are  shown  in  supplementary  tables  S1-S12  (please  see  CD).    In 
summary, a strong positive correlation (r ≥ 0.8) was observed among all approaches, except   35
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Figure 2.4  Pair wise LD (D´) across CYP1A2 in the various populations.  CYP1A2 variants and their relative locations within the gene are highlighted in grey, D' values of 1 are highlighted in pink, significant Chi square associations are in bold (p < 0.05).   
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Clark-ancestral, for haplotype counts from all datasets and the fastPHASE and EM approaches 
were often in complete agreement (r = 1).  The majority of the weaker haplotype correlations 
stemmed  from  the  Clark-common  approach.    These  were  however  likely  to  be  due  to  the 
method  not  resolving  rare  variants  into  haplotypes  and  producing  more  orphan  alleles 
(unresolved  haplotypes)  compared  to  other  approaches.    Haplotype  counts  from  the  Clark-
ancestral  approach  showed  the  weakest  correlations  of  all  and  Pearson’s  correlation 
coefficients  dropped  to  0.2  in  some  comparisons  in  African  Americans  and  Yoruba 
(supplementary tables S8 and S9 respectively).  Weak correlations such as these are likely to 
result  from  differences  (in  haplotype  counts)  being  inflated  in  and  information  (from  which 
haplotypes are resolved) being lost in small datasets.  Andres et al. (2007) demonstrated that, 
in populations of mixed ancestry, the most accurate haplotypes are probably resolved from the 
largest  pooled  sample,  despite  theoretical  problems  associated  with  pooling  across 
heterogeneous population samples.  In this study, a strong positive correlation (r ≥ 0.94) was 
observed among haplotype counts from all approaches, including the Clark-ancestral approach, 
when  the  world  dataset  was  analysed  (supplementary  table  S1).    In  light  of  these  findings, 
subsequent analyses in this study used haplotypes (for the entire CYP1A2 gene) estimated 
from the world dataset and from one haplotype inference approach.  The ELB approach was 
chosen because it is particularly well suited to problems involving many loci and/or relatively 
large genomic regions, including those with variable recombination rates (Excoffier et al., 2003). 
 
2.3.5  CYP1A2 haplotypes in the Ethiopians and NIEHS populations 
2.3.5.1  CYP1A2 (entire gene) haplotypes 
 
A total of 64 CYP1A2 (entire gene) haplotypes were determined/inferred in the world dataset 
(table 2.10).  Haplotypes 1, 5 and 61 are CYP1A2*1B, *1M and *1F respectively, which are 
associated with an unknown CYP1A2 activity (table 2.6).  It should be noted however, that the 
enhancer  region  (thought  to  be  -3990  to  -2118  nucleotides  from  the  translational  start  site 
(Soyama et al., 2005)) was not sequenced in the Ethiopians nor the NIEHS populations and the 
following SNPs, reported in a number of CYP1A2* alleles by the Human CYP450 Nomenclature 
Committee, were not genotyped in this study:  -3860G>A, -3594T>G, -3113A>G, -3053A>G, -
2467delT,  -2808A>C  and  -2667T>G.    As  a  consequence  of  this,  any  CYP1A2*  haplotype 
assignments  in  this  study  should  be  considered  preliminary  until  the  enhancer  region  is 
sequenced.  All haplotypes shown in table 2.10, except haplotypes 1, 5 and 61, are not reported 
by  the  Human  CYP450  Nomenclature  Committee,  with  the  consequence  that  61  novel 
haplotypes have been generated in this study.  Many of these novel haplotypes are however 
closely related to those previously reported.  For example, CYP1A2*1K, with -729C>T, -739T>G 
and -163C>A, and coding for a protein with a reduced function (table 2.6), was not observed in 
this study.  All three nucleotide changes were however identified in haplotype 49 (table 2.10) 
which consequently may also have a reduced function.  Notably, 19 novel haplotypes, with non-
synonymous mutations, were identified in this study (highlighted in pink in table 2.10).   -1014 -1008 -739 -729 -592 -569 -505 -163 -151 -61 53 217 331 613 869 1352 1370 1513 1589 1611 1649 2159 2321 2534 3463 3468 3588 3605 3613 4957 4961 5010 5015 5029 5094 5105 5253 5284 5328 5347 5355 5521 5620 5987 6021 6233 6324 6388 6537 6562 6674 6685 6714 6765
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Predicted associated phenotype (refer to section 2.1.2.2):  *1B, *1F and *1M = undetermined CYP1A2 activity, haplotype 49 = reduced CYP1A2 activity due to -729 C>T (Aklillu et al., 2003)
2 White cell, allele observed in CYP1A2*1A, grey cell, derived allele. A total of 21 haplotypes (shown in bold) were unambiguously resolved from homozygous genotypes at all loci or from a single site heterozygote.
Depending on variation in the enhancer region (which was not sequenced in this study), haplotypes 1, 5 and 61 may be Human CYP Allele Nomenclature Committee CYP1A2*1B, *1F and *1M respectively.  
Table 2.10   Haplotype inference across the entire CYP1A2 gene in the Ethiopian ascertainment and NIEHS populations.  Frequencies are shown in figure 2.5.  Within the world dataset (352 individuals), 
which only included samples with full genotype data, 54 polymorphic CYP1A2 loci and 231 ambiguous individuals (where phase is not inferred with high confidence) were observed.  The ELB haplotype inference 
approach estimated 64 CYP1A2 haplotypes from this sample.  
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1 Position from base A in the initiation codon (A in ATG is +1, base prior to A is -1) from the CYP1A2 genomic reference sequence (NC_000015.8)
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Figure 2.5  CYP1A2 (entire gene) haplotype frequencies in the Ethiopian ascertainment and NIEHS populations.  Asians are East Asians. 
   40 
An  extensive  analysis  of  the  cds  exons  is  described  in  the  next  section.    The  evolution  of 
CYP1A2 in the context of the chimpanzee and other primates is discussed in chapter 3. 
 
2.3.5.2  CYP1A2 (entire gene) haplotype frequencies 
 
CYP1A2  (entire  gene)  haplotype  frequencies  are  shown  in  figure  2.5.    Considerably  more 
haplotypes were found in Ethiopians compared to NIEHS populations, however this may be a 
reflection of the relative sizes of the datasets (shown in brackets in figure 2.5).  Haplotype 1 
(CYP1A2*1B) was the modal haplotype (≥ 30 %) in all groups with an African Ancestry whilst 
both haplotypes 1 and 7 were found at equal frequencies (27 %) in East Asians and haplotype 5 
(CYP1A2*1M), which was observed in all groups except Yoruba, was identified as the modal 
type in Europeans (67 %) and Hispanics (50 %).  Haplotype 49, which is related to CYP1A2*1K 
with a reduced function, was identified as singletons in Maale and Oromo, and haplotype 61 
(CYP1A2*1F) was only found as a singleton in Oromo.  Notably, 49 haplotypes (13 – 61) were 
specific to Ethiopia while nine haplotypes (2, 4, 6, 9, 11, 12, 62 - 64) were only observed outside 
Ethiopia, all of which, except haplotype 6, were observed as singletons in any one group. 
 
2.3.5.3  Recombined CYP1A2 (entire gene) haplotypes 
 
No recombination was observed in any of the CYP1A2 (entire gene) haplotypes found in NIEHS 
populations,  Afar  and  Amhara.    Four  haplotypes,  and  hence  recombination,  were  however 
observed between pairs of SNPs in Anuak, Maale and Oromo (figure 2.6). 
 
Figure 2.6  CYP1A2 (entire gene) haplotype and SNP combinations from which recombination was observed in 
Anuak, Maale and Oromo.  White cell = allele observed in CYP1A2*1A, grey cell = derived allele 
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2.3.5.4  CYP1A2 cds haplotypes 
 
In order to restrict the haplotype set to those most likely to affect the structure/function of the 
enzyme,  haplotypes  were  constructed  using  only  non-synonymous  polymorphisms  from 
samples with full genotypes.  A total of 13 CYP1A2 cds haplotypes were determined/inferred in 
the  Ethiopian  ascertainment  and  NIEHS  populations,  none  of  which  had  recombined  (table 
2.11).    Haplotype  cds  8,  characterised  by  no  mutations,  was  the  haplotype  reported  in  the 
chimpanzee.  Four haplotypes (cds 1, 2, 4 and 13) were compound haplotypes with two non-
synonymous alterations, except cds 1 which had three.  Only 1513C>A in exon 3 (S298R) was 
observed in multiple haplotypes, one of which contained the premature stop codon (Y495Ter) in 
exon 7. 
 
2.3.5.5  Predicted effect of amino acid substitutions on CYP1A2 structure/function 
 
The possible impact of each of the amino acid substitutions on the structure and function of 
CYP1A2 was performed using PolyPhen software.  The predicted effect of each amino acid 
change is shown in table 2.11 whilst the predicted effect of each cds haplotype, based upon the 
single amino acid alterations, is shown in table 2.12 (310 G>A in exon 2 (D104N) and 1460 C>T 
in  exon  3  (R281W)  could  not  be  incorporated  into  haplotypes  because  they  were  not 
polymorphic in samples without missing genotypes).  Haplotypes cds 3, 6, 7, and 9 - 12 were 
predicted to have no effect on the structure/function of the protein, and consequently may not 
differ from the ancestral haplotype (cds 8).  Haplotype cds 9, harbouring T438I and previously 
reported by the CYP450 Allele Nomenclature Committee as CYP1A2*14, has been shown to 
have a CYP1A2*1A-like function (Murayama et al., 2004).  No functional studies have however 
been reported concerning the effects of the other amino acid changes.  Haplotypes cds 1, 2, 4, 
5 and 13 were predicted to be damaging in some way. 
 
Table 2.11  The predicted effect of the non-synonymous CYP1A2 variants on the structure and function of the 
protein using PolyPhen software 
 
CYP1A2 variant  Location  Amino acid change  Amino acids  Predicted effect on CYP1A2 structure/function 
53C>G  Exon 2  S18C  Serine > Cysteine  Possibly damaging 
217G>A  Exon 2  G73R  Glycine > Arginine  Probably damaging 
310G>A  Exon 2  D104N 
Aspartic  Acid  > 
Asparagine  Benign 
331C>T  Exon 2  L111F  Leucine > Phenylalanine  Benign 
613T>G  Exon 2  F205V  Phenylalanine > Valine  Probably damaging 
1460C>T  Exon 3  R281W  Arginine > Tryptophan  Probably damaging 
1513C>A  Exon 3  S298R  Serine > Arginine  Benign 
3463C>T  Exon 6  T395M  Threonine > Methionine  Benign 
3468A>C  Exon 6  N397H  Asparagine > Histidine  Benign 
5094T>C  Exon 7  F432S  Phenylalanine > Serine  Probably damaging 
5105G>A  Exon 7  D436N 
Aspartic  Acid  > 
Asparagine  Benign 
5112C>T  Exon 7  T438I  Threonine > Isoleucine  Benign 
5253C>G  Exon 7  P485R  Proline > Arginine  Possibly damaging 
5284C>A  Exon 7  Y495Ter  Tyrosine > STOP  Presume definite damage 
5328G>A  Exon 7  R510Q  Arginine > Glutamine  Benign 
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Table 2.12   Haplotype inference across the cds exons (only non-synonymous changes) in the Ethiopian ascertainment and NIEHS populations.  Frequencies are shown in figure 2.7.  
53 217 331 613 1513 3463 3468 5094 5105 5112 5253 5284 5328
C>G G>A C>T T>G C>A C>T A>C T>C G>A C>T C>G C>A G>A
Exon 2 Exon 2 Exon 2 Exon 2 Exon 3 Exon 6 Exon 6 Exon 7 Exon 7 Exon 7 Exon 7 Exon 7 Exon 7
S18C G73R L111F F205V S298R T395M N397H F432S D436N T438I P485R Y495Ter R510Q
cds 1 Probably damaging
cds 2 Presume definite damage
cds 3 Undamaged
cds 4 Possibly damaging
cds 5 Probably damaging
Haplotype id 
2 cds 6 Undamaged
cds 7 Undamaged
cds 8 CYP1A2*1A - like function
cds 9 (*14) Undamaged
cds 10 Undamaged
cds 11 Undamaged
cds 12 Undamaged
cds 13 Possibly damaging
1 Position from base A in the initiation codon (A in ATG is +1, base prior to A is -1) from the CYP1A2 genomic reference sequence (NC_000015.8)
3 Predictions made using PolyPhen software.  Predicted effects of each cds haplotype are based upon the single amino acid alterations
2 White cell, allele observed in CYP1A2*1A, grey cell, derived allele.  Ten haplotypes (shown in bold) were unambiguously resolved from homozygous genotypes at all loci or from a single site heterozygote
Haplotype cds 9 was reported in CYP1A2*14 (CYP1A2*1A-like function) by the Human CYP450 Nomenclature Committee.  5112 C>T (T438I) was observed in an East Asian sample but was excluded 
from CYP1A2 (entire gene) analysis due to missing data at other SNP loci in that individual.  
Nucleotide change 
1
Location
Amino acid change
Predicted effect on CYP1A2 
structure/function
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2.3.5.6  CYP1A2 cds haplotype frequencies 
 
CYP1A2 cds haplotype frequencies are shown in figure 2.7.  The modal haplotype (≥ 83 %) in 
all populations was cds 8 (ancestral).  In fact, this was the only haplotype in Europeans and 
Hispanics.    Notably,  potentially  damaging  cds  haplotypes  were  only  observed  in  Amhara, 
Anuak, Oromo and Yoruba, and their frequencies never exceeded 8 % in any one group.  All 
chromosomes  found  more  than  once  in  any  one  NIEHS  population,  were  detected  in  the 
Ethiopian ascertainment population. 
 
2.3.5.7  CYP1A2 cds diplotype frequencies 
 
Diplotype  configurations  of  CYP1A2  cds  haplotypes  are  shown  in  figure  2.8.    All  diplotypes 
included at least one cds haplotype which was predicted to have an undamaged protein and the 
majority had a copy of cds 8 (ancestral).  The modal diplotype (≥ 67 %) was 8/8 (ancestral) in all 
populations.  This was the only diplotype in Europeans and Hispanics. 
 
2.3.6  CYP1A2 diversity in the Ethiopian ascertainment and NIEHS populations 
 
Gene diversity for the entire gene (figure 2.9) was highest in African Americans (0.91 ± 0.06) 
and lowest in Europeans (0.49 ± 0.08).  African Americans, Yoruba, Maale and Oromo were all 
more heterozygous than the world dataset.   
 
Gene diversity for the cds region (figure 2.9) was lower than that for the entire gene.  Europeans 
and Hispanics (0.00) were the least diverse whilst Yoruba (0.32 ± 0.16) were the most diverse.  
Again,  Yoruba,  Maale  and  African  Americans  were  all  more  heterozygous  than  the  world 
dataset, but Anuak and the combined Ethiopian dataset were now more heterozygous than the 
world combined. 
 
Nucleotide diversity for the entire gene (figure 2.10) was highest in Oromo (0.05 ± 0.03) and 
lowest  in  Europeans  (0.03  ±  0.02).    Oromo,  Maale,  African  Americans  and  the  combined 
Ethiopian ascertainment population were all more diverse than the world dataset.   
 
Consistent with gene diversity, nucleotide diversity for the cds region (figure 2.10) was lower 
than that for the entire gene, and was lowest in Europeans and Hispanics (0.00) and highest in 
Yoruba (0.04 ± 0.0398).   Yoruba, Anuak, Maale  and the combined Ethiopian ascertainment 
population were all more heterozygous than the world dataset. 
 
Notably however, both gene and nucleotide diversity values for NIEHS populations should be 
treated with caution given their small sample sizes and large variances. 
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Figure 2.7  CYP1A2 cds haplotype frequencies in the Ethiopian ascertainment and NIEHS populations.  Asians are East Asians. 
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Figure 2.8  CYP1A2 cds diplotype frequencies in the Ethiopian ascertainment and NIEHS populations.  Diplotype numbers correspond to those previously assigned to each cds haplotype.  Asians are 
East Asians. 
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Figure 2.9  Gene diversity (h) based on the CYP1A2 entire gene (above) and cds region (below).  Error bars 
indicate standard deviation. 
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Figure 2.10  Nucleotide diversity (π or pi) based on the CYP1A2 entire gene (above) and cds region (below).  
Error bars indicate standard deviation. 
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2.3.7  How similar are the Ethiopian ascertainment and NIEHS populations in terms of 
their CYP1A2 haplotype frequencies? 
 
The majority of populations were significantly different (p < 0.05) when entire gene haplotypes 
were considered (figure 2.11a).  When the haplotype set was restricted to markers which are 
most likely to affect the structure/function of the protein (i.e. the cds region), considerably less 
pairwise differentiation was observed (figure 2.11b).  Notably, significant differences were only 
observed amongst Ethiopian populations when the cds region was analysed (figure 2.11b). 
 
Figure 2.11  Exact test of population differentiation p values (lower triangle) and significant/not significant (+/-) 
differences at the 5 % threshold (upper triangle) for CYP1A2 entire gene (a) and cds (b) haplotypes 
 
  (a) CYP1A2 (entire gene) haplotypes 
  Afar  Amhara  Anuak  Maale  Oromo  African American  Yoruba  European  Hispanic  East Asian 
Afar    -  +  +  -  +  +  -  -  + 
Amhara  0.11    +  +  +  +  +  -  +  + 
Anuak  < 0.01  < 0.01    +  +  +  -  +  +  + 
Maale  < 0.01  < 0.01  < 0.01    +  +  +  +  +  + 
Oromo  0.13  0.01  < 0.01  < 0.01    +  +  -  -  - 
African American  < 0.01  < 0.01  0.02  < 0.01  0.02    -  +  -  - 
Yoruba  < 0.01  < 0.01  0.18  < 0.01  0.05  0.96    +  +  - 
European  0.48  0.61  < 0.01  0.01  0.46  < 0.01  < 0.01    -  + 
Hispanic  0.16  0.03  < 0.01  0.01  0.46  0.12  0.04  0.06    - 
East Asian  0.01  < 0.01  < 0.01  < 0.01  0.07  0.06  0.09  < 0.01  0.1   
                     
  (b) CYP1A2 cds haplotypes (non-synonymous variants) 
  Afar  Amhara  Anuak  Maale  Oromo  African American  Yoruba  European  Hispanic  East Asian 
Afar    +  -  +  -  -  -  -  -  - 
Amhara  0.01    +  +  -  -  -  -  -  - 
Anuak  0.07  < 0.01    +  -  -  -  -  -  - 
Maale  < 0.01  < 0.01  < 0.01    -  -  -  -  -  - 
Oromo  0.33  0.19  0.23  0.09    -  -  -  -  - 
African American  0.4  0.21  0.54  0.26  0.35    -  -  -  - 
Yoruba  0.16  0.07  0.35  0.18  0.19  0.64    -  -  - 
European  0.89  1.00  0.66  0.44  0.86  0.18  0.07    -  - 
Hispanic  1.00  1.00  0.76  0.53  1.00  0.48  0.11  1.00    - 
East Asian  0.39  0.67  0.29  0.13  0.56  0.31  0.16  1.00  1.00   
 
 
To establish the pattern of CYP1A2 genetic structuring within and among populations in this 
study,  hierarchical  Fsts  were  calculated  for  various  datasets  (table  2.13).    The  majority  of 
variation occurred within populations, but notably, of all the datasets, most variation (1.7 %) was 
observed among Ethiopians when cds haplotypes were analysed. 
 
Table 2.13  Hierarchical Fsts based on CYP1A2 entire gene (black) and cds (red) haplotypes 
 
Dataset  FST  Variation among 
populations (%) 
Variation within 
populations (%)  p value 
Individual  Ethiopian  ascertainment  &  NIEHS 
populations  0.04  0.02  4.5  1.6  95.5  98.4  p < 0.00001  p < 0.00001 
Combined Ethiopian ascertainment population & 
individual NIEHS populations  0.07  0.005  6.7  0.5  93.3  99.5  p < 0.00001  p > 0.1 
Ethiopian ascertainment populations  0.03  0.02  3.1  1.7  96.9  98.3  p < 0.00001  p < 0.00001   48 
PCO plots of genetic distances are shown in figure 2.12.  Concerning CYP1A2 (entire gene) 
haplotypes  (figure  2.12a),  Yoruba  and  Europeans  were  most  dissimilar,  with  Anuak  being 
closest to Yoruba and Hispanics being closest to Europeans.  Consistent with their assumed 
similar  mixed  ancestry,  Afar,  Amhara  and  Oromo  formed  a  tight  cluster  which  was  almost 
equidistant between Yoruba and Europeans.  Maale were observed between the Afar, Amhara 
and Oromo cluster and Anuak, whilst African Americans and East Asians clustered together 
between the Afar, Amhara and Oromo cluster and Yoruba.  The closeness of East Asians to 
African Americans was surprising and required further investigation with more samples.  When 
another  East  Asian  cohort  (Japanese)  (Soyama  et  al.,  2005)  was  included  in  the  analysis, 
African Americans were not tightly clustered with this group (data not shown). 
 
When cds haplotypes were analysed (figure 2.12b), Yoruba were considerably differentiated 
from all other populations.  This observation should however be treated with caution since the 
NIEHS  Yoruba  population  included  only  12  subjects.    Similar  to  CYP1A2  (entire  gene) 
haplotype data, Yoruba and Europeans were most dissimilar while Afar and Oromo, and East 
Asians and African Americans were respectively close to each other.  In stark contrast however, 
Amhara were no longer tightly clustered with Afar and Oromo but were close to Europeans, and 
Anuak and Maale were firmly clustered together. 
 
Figure 2.12  PCO plots of genetic distance (Fst) among the Ethiopian ascertainment and NIEHS populations for 
CYP1A2 entire gene (a) and cds (b) haplotypes.  Pairwise Fsts are shown in supplementary figure S1. 
 
 
 
2.3.8  Imputation of missing genotype data 
 
A total of 26 % of individuals had at least one of the polymorphic nucleotides not characterised 
due  to  failed  sequencing.    Missing  genotypes  were  imputed  using  fastPHASE  software.  
Samples with missing data were then included in the analysis to determine whether inclusion of   49 
imputed data would significantly affect analysis at the population level.  Results were largely 
consistent with those from data without missing genotypes (data not shown). 
 
2.4  Discussion 
 
All seven exons and flanking regions of the adjacent introns of CYP1A2 were sequenced in five 
Ethiopian populations: Afar, Amhara, Anuak, Maale and Oromo.  This is the first detailed report 
of human CYP1A2 genetic variation in Ethiopian populations.  Unlike previous studies, which 
have  only  sequenced  twelve  Ethiopians  of  a  mixed  ethnic  origin  (Aklillu  et  al.,  2003)  or 
genotyped six SNPs in just six Ethiopians with unknown ethnicities (Jiang et al., 2006), this 
study resequenced the entire CYP1A2 gene in five different Ethiopian ethnic groups.  Each 
sample set comprised at least 76 individuals.  Corresponding sequence data from an additional 
five  populations,  (African  Americans,  Yoruba,  Europeans,  Hispanics  and  East  Asians), 
generated by the NIEHS SNPs programme was also included in the analysis.  Sequence data 
was available from a Japanese population (n = 250) (Soyama et al., 2005) but was not used 
throughout the whole of the analysis because subjects were either patients with arrhythmia or 
patients with epilepsy. 
 
The combined NIEHS sample amounted to only 95 individuals with just 15, 12, 22, 22 and 24 
subjects  included  in  African  American,  Yoruba,  European,  Hispanic  and  East  Asian  sample 
sets, respectively.  Given the following equation: (1 - p)
n = significance threshold (where n = the 
number of chromosomes and p = the proportion of the minor allele), the minimum number of 
chromosomes required to identify the proportion of the minor allele with 95 % confidence when 
the  minor  allele  frequency  is  1  %,  2  %,  3  %,  4  %  and  5  %  is  298,  148,  98,  73  and  58 
respectively.    Hence,  the  minimum  number  of  individuals  required  to  identify  alleles  at 
frequencies of 1 %, 2 %, 3 %, 4 % and 5 % with 95 % confidence is 149, 74, 49, 36 and 29 
respectively.    The  Ethiopian  ascertainment  sample  sets  are  consequently  large  enough  to 
identify variants at frequencies of 2 % or above in each of the populations with 95 % confidence.  
However, the largest sample set used in the NIEHS study was 24 individuals (East Asians).  
Consequently, none of the NIEHS sample sets are large enough to detect variants present at 5 
% in the population with 95 % confidence.  Small sample sizes such as these, which have been 
used in the majority of CYP1A2 sequencing studies reported to date, lack power and prevent 
reliable conclusions being reached.  In spite of this however, the NIEHS data proved to be 
useful in placing the Ethiopian data, albeit tentatively, into a worldwide context.  Future studies 
designed to analyse genetic sequences at the population level should include a minimum of 74 
people,  or  148  chromosomes,  in  the  sample  population  for  a  chance  of  capturing 
polymorphisms ≥ 2 % with 95 % confidence.  This number also allows the data to be analysed 
in terms of both chromosomes and people which increases its usefulness. 
 
The main finding of this study is that it is clear that there was a substantial amount of previously 
unreported CYP1A2 genetic variation present in the Ethiopian sample sets.  A total of 30 novel   50 
CYP1A2 mutations were identified in the Ethiopian ascertainment populations alone.  Haplotype 
analysis, where missing data was not imputed, revealed no less than 64 haplotypes covering 
the  entire  CYP1A2  gene  in  the  combined  Ethiopian  ascertainment  and  NIEHS  populations.  
Only three of these have been reported by the Human CYP450 Nomenclature Committee as 
CYP1A2*1B, *1F and *1M meaning that a total of 61 novel haplotypes, many of them rare, were 
identified in this study.  Notably, 48 of these novel haplotypes were specific to Ethiopia. 
 
When haplotypes were constructed using only non-synonymous polymorphisms so as to restrict 
the haplotype set to those most likely to affect the protein (although it is accepted that variation 
in splice sites could also affect the protein’s structure and variation in the promoter could affect 
gene expression), 13 haplotypes were identified.  Only two of these had been reported by the 
Human  CYP450  Nomenclature  Committee  (the  ancestral  haplotype  and  CYP1A2*14  with 
T438I).    Consequently  eleven  haplotypes  with  novel  amino  acid  changes  (eight  specific  to 
Ethiopia) were identified by this study. 
 
When  missing  data  was  imputed,  85  haplotypes  (covering  the  entire  CYP1A2  gene)  were 
identified.  With the exception of CYP1A2*1B, *1F and *1M, none of these haplotypes have 
previously been reported.  Again the majority (61) were only identified in Ethiopians, all of which 
were novel.   Analysing only  non-synonymous variants, two  additional  haplotypes, compared 
with  the  unimputed  data  analysis,  were  identified.    These  were  identified  in  the  NIEHS 
European  population  but  have  not  been  reported  by  the  Human  CYP450  Nomenclature 
Committee.  It is thus evident that not only has variation revealed by resequencing in Ethiopian 
populations yielded additional information, but that not all variation recorded in publicly available 
databases has yet been reported to the Human CYP450 Nomenclature Committee.  Prior to this 
study most resequencing of the entire CYP1A2 gene has been of Japanese samples.  Of all the 
haplotypes with novel amino acid changes identified in this study, only one has been previously 
documented by the Human CYP450 Nomenclature Committee (cds haplotype 9 (CYP1A2*14) 
identified  only  in  the  NIEHS  East  Asian  population).    It  is  clear  that  CYP1A2  Allele 
Nomenclature  must  be  updated  regularly  if  it  is  to  fully  deliver  its  potential  utility  for 
pharmacogenetic prediction. 
 
Consistent with the hypothesis that there is more human genetic variation in sub-Saharan Africa 
than in the rest of the world combined, CYP1A2 gene diversity and nucleotide diversity were 
always observed to be highest in African populations in this study.  Furthermore, Maale (1994 
census population 46,458), Oromo (1994 census population, 17,080,318), Anuak (1994 census 
population  45,665),  and  the  combined  Ethiopian  ascertainment  population  were  often  more 
diverse  than  the  world  dataset.    Gene  diversity  and  nucleotide  diversity  values  were  also 
comparatively high in both the NIEHS African American and Yoruba data sets. 
 
Exact  tests  of  population  differentiation  revealed  considerably  fewer  differences  among 
CYP1A2 cds haplotypes than among CYP1A2 entire gene haplotypes.  This finding supports 
evolutionary conservation of the CYP1A2 coding region and emphasizes the importance of the   51 
gene  in  nature  (refer  to  chapter  3  for  analyses  regarding  selection).    Consistent  with  other 
studies  which  show  Ethiopia’s  marked  variability  relative  to  other  global  populations,  the 
Ethiopian ascertainment populations were the only ethnic groups to be differentiated when cds 
haplotypes  (only  non-synonymous  changes)  were  considered.    In  light  of  this,  the  general 
Ethiopian  population  should  perhaps  not  be  treated,  at  the  CYP1A2  protein  level,  as  one 
homogenous  group,  a  finding  which  undoubtedly  has  implications  for  future  therapeutic 
intervention in Ethiopia.  In this study, about 3 % of CYP1A2 genetic variation was evident 
among  populations.    This  finding  is  also  of  therapeutic  importance  because  statistically 
significant variation exists among indigenous groups living in close geographical proximity. 
 
Consistent with anatomically modern humans migrating out of Africa via Ethiopia, and a more 
recent migration of Semitic speaking peoples from Arabia into Ethiopia, much of the CYP1A2 
variation found outside Ethiopia remains present within Ethiopian groups.  Furthermore, all of 
the  common  variation  observed  in  the  NIEHS  populations  (in  the  regions  sequenced  in  the 
Ethiopians  in  this  study)  was  detected  in  the  Ethiopian  ascertainment  population.  
Consequently, the Ethiopians could perhaps serve  not  only  as  a suitable population for the 
development  of  CYP1A2  diagnostic  markers/tests  useful  in  pharmacogenetic  prediction  in 
populations worldwide but also to ensure that such tests were suitable not only for developed 
countries.  These findings also highlight the need to conduct population genetic research in 
Ethiopians  if  conclusions  reached  concerning  populations  outside  of  Ethiopia  are  to  be 
interpreted in context. 
 
Several  of  the  CYP1A2  alleles  identified  in  this  study  were  predicted  to  change  the 
structure/function of the protein.  At the cds level (only non-synonymous variants), six novel 
haplotypes were predicted to alter the functional activity of the protein.  At the entire CYP1A2 
gene level, novel haplotypes 49 and 66, which stem from CYP1A2*1K, are predicted to have a 
reduced  function.    Since  all  variants  predicted  to  change  the  function  of  the  protein  were 
observed in individuals who were at least 18 years old (the age of the Yoruba individual (DY10) 
with cds haplotype 1 (predicted to be damaging) is not reported but the subject has a biological 
child), it is clear that these variants are compatible with maintenance of life to reproductive age.  
Tolerance of functional variation within CYP1A2 is consequently evident.  Haplotype cds 2 (with 
S298R and the premature stop codon Y495Ter) was identified in Anuak at 3 % (with a 95 % 
confidence interval of 0.007 to 0.066 (exact Pearson-Klopper method)), hence in a population 
numbering 45, 655 (the 1994 census record for Anuak), it is expected that 2657 people would 
carry  one  copy  of  the  premature  stop  codon  whilst  41  people  would  carry  two  copies  and 
potentially  have  a  non-functional  CYP1A2  protein  (providing  such  a  condition  is  not 
homozygous lethal).  In light of this, it is evident that future studies are warranted regarding the 
functional significance of the premature stop codon in exon 7. 
 
All of the other haplotypes that were predicted to have a damaging effect on the protein were 
very rare and never exceeded more than a single observation in any one ethnic group.  It is 
obvious that unrecognised variation cannot be studied in vivo, and paucity of such knowledge   52 
may  lead  to  inappropriate  therapeutic  intervention  and  increase  the  risk  of  adverse  drug 
reactions.  However, should public health workers be concerned about how the non-modal ~ 3 
% in a population react to a drug given that at least 67 % of each population in this study did not 
carry a non-synonymous mutation?  Similarly is it appropriate to utilise resources to investigate 
the impact of haplotype 61 (CYP1A2*1F), which may have a higher inducibility compared to 
CYP1A2*1A, given its rarity in Oromo and Hispanics?  Answers to these questions fall within 
the realm of pharmacoeconomics and pharmacoethics and are therefore outside the confines of 
this study. 
 
Of  considerable  practical  relevance  in  healthcare,  only  these  haplotypes:  haplotype  1 
(CYP1A2*1B), haplotype 5 (CYP1A2*1M) and haplotype 7 were modal in any population and 
together never fell below 46 %.  Of even more relevance, the three haplotypes did not vary so 
far as non-synonymous mutations are concerned and consequently are not likely to differ from 
the CYP1A2*1A in terms of protein function.  This finding is important for public health policy 
formers since most people in all populations in this study may be expected to have normal 
CYP1A2 function.  Moreover, all cds diplotypes included at least one cds haplotype which was 
predicted to code for a normal protein and the vast majority of people carried at least one copy 
of the unmutated haplotype (cds 8).  Nevertheless, given the frequency of the non ‘wild type’ 
cds haplotypes there will be individuals, in different proportions in different ethnic groups, that 
may be expected to have two copies of non ‘wild type’ cds haplotypes.  But in this study in no 
case is this predicted to be > 2 %.  In view of this, perhaps a large proportion of the populations 
have a normal, or ‘wild type’-like, CYP1A2 function  overall, even if individuals do carry one 
damaged copy of the protein. 
 
In  terms  of  non-synonymous  variants,  Europeans,  Hispanics  and  East  Asians  were 
considerably less variable than Ethiopians, African Americans and Yoruba.  As a consequence, 
public health policy makers may not have to be concerned about variable drug response, due to 
variation in the protein, in non-African populations.  However given that currently most drug 
testing is undertaken on non-African populations and that Yoruba and Europeans were always 
most  dissimilar  in  terms  of  CYP1A2  haplotypes,  more  testing  on  non  European/Asian 
populations is warranted.   With increasing numbers of people having a recent African descent 
living  in  Europe  and  the  Americas  their  pharmacogenetic  profiles  should  be  represented  in 
clinical  trials.    In  addition,  there  should  be  close  attention  paid  to  them  in  post-marketing 
surveillance and greater awareness of variability amongst them. 
 
Studies of the range of CYP1A2 variants observed in the Ethiopian ascertainment populations 
will  undoubtedly  prove  useful  across  different  scientific  disciplines.    The  vast  majority  of 
mutations  were  found  in  the  non-coding  regions  of  the  gene.    Although  it  is  important  to 
consider  functional  markers,  particularly  for  healthcare  utility,  non-functional  markers  are 
important  in  population  studies  including  association  studies  investigating  pharmacokinetic 
variation due to the cis promoter region, not least in CYP1A2 where it has not yet been fully 
characterised.    Similarly,  non-functional  markers  should  prove  useful  in  investigating  copy   53 
number  variation  and  variability  due  to  mutations  in  non-coding  regions  e.g.  splice  sites, 
initiation sites. 
 
From this study, it is evident that varying the choice of markers can reveal different levels of 
inter-population  differentiation  and  intra-population  structure.    For  example,  when  the  cds 
haplotypes were considered, in stark contrast to the entire gene haplotypes, Amhara were no 
longer tightly clustered with Afar and Oromo but were close to Europeans.  Similarly, Anuak and 
Maale were placed close together.  Variants confined to Ethiopia may be particularly useful in 
the study of migration and ethnic group relationships in Ethiopia.  Among the non-synonymous 
variants 5284C>A in exon 7 is particularly interesting since this is the first report of a premature 
stop codon in this gene.  Apart from the splice site variant in intron 6, identified as a singleton in 
Caucasian (Allorge et al., 2003) and Japanese subjects (http://www.pharmgkb.org/), there have 
been no other reports of mutations altering the primary structure of the protein and leading to a 
truncated non-functional enzyme.  This observation prompts the question of whether mutations 
causing  the  protein  to  be  truncated  are  simply  not  recognised  at  appreciable  levels  in  the 
population, because if they do occur in a homozygous form, foetuses do not survive.  The data 
generated in this study is now being analysed to assess the probability that truncated proteins 
due  to  stop  codons,  or  altered  splice  sites  in  introns  1-6  are  not  observed  because  their 
presence would be lethal in utero.  More samples should also be sequenced to try and establish 
whether the absence of mutations  in splice sites in  this study  was a consequence of small 
sample size.  Functional studies should also be able to determine whether the premature stop 
codon  in  exon  7  does  actually  lead  to  a  non-functional  enzyme  or  a  protein  with  reduced 
function.  If non functionality is the case and if homozygotes do exist, then such individuals 
would be living human CYP1A2 knock outs whose existence would open interesting possibilities 
for research into P450 mediated metabolic activity. 
 
In this study, as in others, 1879C>A in exon 3, resulting in S298R, and the deletion in the 3’ 
UTR (4714Gdel) were only observed in African populations or populations with recent African 
ancestry.    With  the  exception  of  1879C>A  observed  as  a  singleton  in  a  Hispanic  sample 
(http://snp500cancer.nci.nih.gov/),  there  have  been  no  reports  of  these  mutations  in  non-
Africans.  Both SNPs may therefore be of practical use in anthropological research. 
 
Several recombination events were inferred in CYP1A2, particularly towards the 3’ end of the 
gene  (from  intron  6  onwards).    Considering  this,  and  given  that  the  premature  stop  codon,  
splice site variant and several potentially damaging amino acid substitutions have also been 
found in exon 7, perhaps this region, particularly the 3’ UTR, is not as functionally important as 
is the rest of the gene.  In turn, this finding questions whether two of the enzyme’s catalytic 
residues  are  in  fact  located  in  exon  7,  as  a  recent  study  suggests  (Sansen  et  al.,  2007).  
Consistent with this possibility, prior to this study variation has not been reported in exon 1 and 
very few non-synonymous variants have been identified in exons 4 and 5.  This is not surprising 
given that exon 1 contains the leader sequence of the mRNA, thus playing a crucial role in 
protein expression, and exon 4 is thought to contain part of the enzyme’s active site (Sansen et   54 
al., 2007).  Variation was also not observed in exons 1, 4 and 5 in this study, further suggesting 
that the beginning and middle of the gene may be more functionally significant than the end.  
However,  is  what  appears  to  be  recombination,  in  fact  a  result  of  gene  conversion?  
Distinguishing between the two phenomena is not currently possible with the data generated in 
this study.  The plethora of variation identified in this study should prove of considerable utility in 
designing association studies to elucidate the effects of non-coding sequence variation on the 
activity of CYP1A2. 
 
2.5  Conclusion 
 
Drugs thought to be metabolised by CYP1A2 are widely administered to Ethiopians.  However 
in comparison with other countries, particularly Japan, studies investigating the distribution of 
human CYP1A2 genetic variation have been scarce. Those that have been undertaken have 
been  limited  to  few  populations  and  small  sample  sizes.    This  study  has  contributed  to 
correcting  this  imbalance  and  found  that  Ethiopia  has  more  CYP1A2  variation  than  other 
populations characterised to date and, in some respects, the rest of the world combined.   It 
also evidences much of the variation found on a global scale.  Not only does this serve as 
further support for the proposition that anatomically modern humans migrated out of Africa from 
Ethiopia,  but  also  emphasizes  the  value  of  conducting  population  genetic  research  with 
Ethiopians if appropriate conclusions are to be formulated concerning populations outside of 
Ethiopia.    This  study  found  a  substantial  amount  of  uncharacterised  variation  in  Ethiopia.  
Unrecognised  variation  can  lead  to  unsuitable  therapeutic,  prophylactic  and  diagnostic 
intervention and can increase the risk of an adverse drug reaction.  Investigations such as this 
are not only of benefit to  the  indigenous  populations of Ethiopia, but are also of increasing 
importance in directing public healthcare policies in the developed world, where the number of 
individuals of recent Ethiopian descent is growing. 
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3  The recent evolutionary history of CYP1A2 
 
3.1  Introduction 
 
Diversity  in  the  human  CYP1A2  gene,  which  was  described  in  chapter  2,  could  have  been 
shaped  by  several  different  evolutionary  forces.    These  processes  include  mutation  and 
recombination  which  generate  new  genetic  variation,  selection  which  shapes  pre-existing 
variation and genetic drift which serves to remove variation.  The interplay of these different 
forces, within the framework of the demographic histories of various population groups, in the 
evolutionary history of CYP genes is likely to have been very complex.  CYP1A2 detoxifies 
environmental xenobiotics in mammals and birds and is thought to have evolved 350 million 
years ago as the result of a duplication of CYP1A1 (Heilmann et al., 1988; Liang et al., 1996).  
Exons 2, 4, 6 and especially 5 are strikingly conserved between CYP1A2 and CYP1A1 in both 
nucleotide types and total number of bases (Ikeya et al., 1989).  Little is known however about 
the preservation of CYP1A2 among human populations.  This chapter attempts to redress this 
imbalance and focuses on extracting information about the evolutionary history of CYP1A2 from 
the genetic variation observed in the Ethiopian ascertainment and NIEHS populations. 
 
A substantial amount of CYP1A2 genetic variation was observed in the Ethiopian ascertainment 
populations (see chapter 2).  The depth of this unique data set allows a detailed investigation 
into the evolution of CYP1A2 in humans.  Network analysis of CYP1A2 haplotypes will provide 
insight  into  CYP1A2  evolution  in  human  populations.    Furthermore,  comparisons  between 
CYP1A2 sequences in humans and some of their closest living relatives (other ape species) will 
root the network, thus providing further insights into the evolutionary history of the gene.  A 
rooted  network  can  be  used  to  construct  a  relative  chronology  for  genetic  changes  within 
CYP1A2.    For  example,  changes  within  the  external  branches  of  the  network  must  have 
occurred  after  those  found  closer  to  the  root  within  the  same  clade.    A  rough  absolute 
chronology can also be produced by dating of the CYP1A2 variants.  Such contextualisation of 
CYP1A2  genetic  data  may  prove  useful  in  the  reconstruction  of  human  pre-history.    Time 
estimates can place genetic changes in a wider context and can be integrated with evidence 
from other disciplines attempting to examine human evolution.  For instance, dates of mutations 
may be related to periods in human history (Thomas et al., 1998). 
 
Positive, balancing and purifying (negative) selection can shape genetic diversity in a number of 
ways and whilst it can be directly detected in both intragenic and extragenic sequences, its 
signature  can  also  be  observed  in  markers  linked  to  the  locus  under  selection.    Detecting 
selection is however inherently difficult and many studies lack power due to the lack of diversity 
observed.    The  Ethiopian  ascertainment  data  set  may  be  rich  enough  to  detect  possible 
signatures of selection. 
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3.1.1  Aims 
 
1.  Construct a rooted CYP1A2 network for the combined cds region and, to the extent that it 
has a single genealogy, the entire gene. 
 
2.  Determine to what extent the combined cds region and the entire CYP1A2 gene have been 
conserved among human populations and throughout primate evolution. 
 
3.  Apply tests to see if the gene is under selection, and of what type. 
 
4.  Estimate when various polymorphisms arose in CYP1A2. 
 
 
3.2  Methods 
3.2.1  CYP1A2 sequence data 
 
The Ethiopian ascertainment and NIEHS CYP1A2 sequences described in chapter 2 were used 
in this study.  Missing data was excluded from the analysis and haplotypes were inferred by the 
ELB approach (Excoffier et al., 2003) from the combined Ethiopian ascertainment and NIEHS 
population.  The imputed dataset was not used in this study.  Refer to the methods section in 
chapter 2 for details regarding sample collection, DNA extraction, sequencing and haplotype 
inference. 
 
CYP1A2 sequences from the chimpanzee (Pan troglodytes), orangutan (Pongo pygmeus) and 
Rhesus macaque (Macaca mulata) were obtained from Ensembl (52: Dec 2008).   CYP1A2 in 
the  chimpanzee  was  referred  to  as  Q9N256_PANTR,  whilst  CYP1A2  in  the  orangutan  and 
macaque was referred to as CP1A2_PONPY and Q9N253_MACMU respectively. 
 
3.2.2  CYP1A2 mutation networks 
 
Mutation  networks  were  constructed  using  Network  software,  version  4.510  (fluxus-
engineering.com).    Median  joining  networks  were  constructed  to  limit  levels  of  reticulation 
(Bandelt et al., 1999).  The algorithm used to construct these median joining networks is based 
on the limited introduction of likely ancestral sequences/haplotypes into a minimum spanning 
network of the observed sequences.  These likely ancestral sequences are identified through 
the  calculation  of  median  haplotypes.    The  resultant  networks  were  drawn  using  Network 
publisher, version 1.1.0.7 (Fluxus Technology Ltd). 
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3.2.3  Testing for selection in CYP1A2 
3.2.3.1  Tajima’s test of neutrality * 
 
This test calculated the D test statistic proposed by Tajima (1989), equation 38, for testing the 
null  hypothesis  that  all  mutations  were  selectively  neutral  (Kimura,  1983).    The  D  test  was 
based on the differences between two estimates of theta (θ), one  based on  the  number of 
segregating sites (θs), and the other based on the average number of nucleotide differences 
between pairs for CYP1A2 sequences (θπ).  The confidence limits of D (two tailed test) were 
obtained from table 2 of Tajima (1989).  These confidence limits assumed that D followed a 
beta distribution described by equation 47 in Tajima (1989). 
 
3.2.3.2  McDonald-Kreitman test of neutrality * 
 
This is a test of the neutral hypothesis (Kimura, 1983) proposed by McDonald and Kreitman 
(1991).  The test was based on a comparison of synonymous and non-synonymous variation 
within and between species.  Under neutrality, the ratio of non-synonymous to synonymous 
fixed  substitutions  (differences)  between  species  should  be  the  same  as  the  ratio  of  non-
synonymous to synonymous polymorphisms within species.  The selected non-human species 
was the chimpanzee.  P values were obtained from two-tailed Fisher's exact tests. 
 
3.2.3.3  Fu and Li’s tests of neutrality (with an outgroup) * 
 
This test calculated the statistical tests D and F which were proposed by Fu and Li (1993) for 
testing  the  null  hypothesis  that  all  mutations  were  selectively  neutral  (Kimura  1983).  
Interspecific difference was obtained by comparison with the chimpanzee. 
 
The D test statistic was based on the differences between the total number of mutations in 
external branches of the genealogy and the total number of mutations (equation 32 from Fu and 
Li  (1993)).    The  F  test  statistic  is  based  on  the  differences  between  the  total  number  of 
mutations  in  external  branches  of  the  genealogy  and  the  average  number  of  nucleotide 
differences between pairs of CYP1A2 sequences (page 702 of Fu and Li (1993)). 
 
The critical values (two-tailed test) shown in tables 2 and 4 from Fu and Li (1993) were used to 
determine the statistical significance of the D and F test statistics. 
 
Statistical tests of neutrality marked with * were performed on data from each population using 
DNAsp software (http://www.ub.edu/dnasp/). 
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3.2.3.4  Testing  for  evidence  of  purifying  selection  at  radical  non-synonymous  SNP 
sites 
 
For  a  given  SNP  site,  gene  diversity  (heterozygosity)  was  estimated  according  to  unbiased 
formulae of Nei (1987) (see methods in chapter 2). 
 
For a given SNP site, genetic distance between each pair of populations was estimated by the 
formula:  d = 1-((x1y1)
1/2+(x2y2)
1/2), where x1 and y1 are the frequencies of the first allele in each 
of the two populations respectively, and x2 and y2 are the frequencies of the second allele in 
each of the two populations respectively.  The average of d over all loci is the average genetic 
distance (Nei, 1987). 
 
SNPs were classified with respect to location and predicted effect on protein function as follows: 
(1) SNPs located in the 5’ non-coding region outside the 5’ UTR (exon 1*), (2) SNPs located in 
the  introns,  (3)  SNPs  located  in  the  3’  UTR,  (4)  synonymous  SNPs  in  exons,  (5)  non-
synonymous SNPs in exons causing a conservative amino acid change, (6) non-synonymous 
SNPs in exons causing a radical amino acid change and (7) nonsense SNPs in exons causing 
premature stop codons.    Radical  non-synonymous  changes  included two  SNPs (217G>A in 
exon 2 causing G73R, and 5094T>C in exon 7 causing F432S), each of which caused an amino 
acid replacement involving two  amino acids  with a pairwise stereochemical difference > 3.0 
according to the scale described by Miyata et al. (1979) (figure 3.1).  All other non-synonymous 
SNPs were categorised as conservative non-synonymous SNPs since they resulted in an amino 
acid replacement involving two amino acids with a pairwise stereochemical difference < 3.0.  
 
* Exon 1 was monomorphic in Ethiopian ascertainment and NIEHS populations (see chapter 2).   
 
Figure 3.1  Pairwise amino acid stereochemical differences based on amino acid residue and volume (Miyata et 
al., 1979) 
 
   C  P  A  G  S  T  Q  E  N  D  H  K  R  V  L  I  M  F  Y 
P  1.33                                                       
A  1.39  0.06                                                    
G  2.22  0.97  0.91                                                 
S  1.84  0.56  0.51  0.85                                              
T  1.45  0.87  0.9  1.7  0.89                                           
Q  2.48  1.92  1.92  2.48  1.65  1.02                                        
E  3.26  2.48  2.46  2.78  2.06  1.83  0.84                                     
N  2.83  1.8  1.78  1.96  1.31  1.4  0.99  0.85                                  
D  3.48  2.4  2.37  2.37  1.87  2.05  1.47  0.9  0.65                               
H  2.66  2.15  2.17  2.78  1.94  1.32  0.32  0.96  1.29  1.72                            
K  3.27  2.94  2.96  3.54  2.71  2.1  1.06  1.14  1.84  2.05  0.79                         
R  3.06  2.9  2.92  3.58  2.74  2.03  1.13  1.45  2.04  2.34  0.82  0.4                      
V  0.86  1.79  1.85  2.75  2.15  1.42  2.13  2.97  2.75  3.4  2.11  0.7  2.43                   
L  1.65  2.7  2.76  3.67  3.04  2.25  2.7  3.53  3.49  4.1  2.59  2.98  2.62  0.91                
I  1.63  2.62  2.69  3.6  2.95  2.14  2.57  3.39  3.37  3.93  2.45  2.84  2.49  0.85  0.14             
M  1.46  2.36  2.42  3.34  2.67  1.86  2.3  3.13  3.08  3.69  2.19  2.63  2.29  0.62  0.41  0.29          
F  2.24  3.17  3.23  4.14  3.45  2.6  2.81  3.59  3.7  4.27  2.63  2.85  2.47  1.43  0.63  0.61  0.82       
Y  2.36  3.12  3.18  4.08  3.33  2.45  2.4  3.22  3.42  3.95  2.27  2.42  2.02  1.52  0.94  0.86  0.93  0.48    
W  3.34  4.17  4.23  5.23  4.3  3.5  3.42  4.08  4.39  4.88  3.16  3.11  2.32  2.51  1.73  1.72  1.89  1.11  1.04   59 
 
Significance  tests  (t-test,  Kruskal-Wallis  test  and  Wilcoxon  matched-pairs  signed-ranks  test) 
were performed using GraphPad InStat version 3.00 for Windows 95, GraphPad Software, San 
Diego California USA, www.graphpad.com. 
 
3.2.3.5  Testing  for  evidence  of  purifying  selection  at  conservative  non-synonymous 
SNP sites 
 
CYP1A2  pairwise  alignments  between  human  and  mouse (Mus  musculus),  and  human  and 
chimpanzee (Pan troglodytes) DNA sequences were obtained from Ensembl (52: Dec 2008).  
Since the possibility of variability at each of the conservative non-synonymous SNP sites in the 
mouse and chimpanzee could not be addressed given the available data, it was assumed that 
the mouse and chimpanzee sequences represented the more common allele in these species.  
In  accordance  with  maximum  parsimony  (Fitch,  1971),  it  was  also  assumed  that  a  residue 
representing the more common allele in human, mouse and chimpanzee has been conserved 
since the most recent common ancestor of the three species. 
 
3.2.4  Genohaplotyping of an AC microsatellite and a G>C SNP (rs11072507) using a 
SNPstr system 
 
The  AC  microsatellite  was  situated  5.6  kb  downstream  of  the  3’  end  of  CYP1A2  and 
rs11072507 was a G>C SNP situated 218 bases downstream of the AC microsatellite. 
 
3.2.4.1  SNPstr assay design 
 
A 384 bp region containing the AC microsatellite and G>C SNP (rs11072507) was amplified 
using  the  forward  primer  TCTCATCTCGCAACTGGGGA  and  the  reverse  primer 
GGGTTGGGGGCCCATTGTCS (see figure 3.2). 
 
Figure 3.2  Primers (blue) used in the SNPstr system which incorporated an AC microsatellite (green) and the 
rs11072507 G>C SNP (S) 
 
CCTTGGGCCTGTGACATAAACTTTCTGAGTCTAGACTTTCTCATCTCGCAACTGGGGATGATAATCTTAT
CTTACAGGTTGGGTGGGAGGTTTAATGAGATAATGTGTGTAAAGTGCCAAATTACAGGTCAGGGTACAAC
ACACACACACACACACACACACACACACACACACACACACACACCAGAAATCCTGAGAAAGGTGGACTCA
GGGCAAGATGGACCCCCGACACACGTGTGGCATGTGCAGCTGTGCACACACCAGGCCCACACGTGAGCCA
GCATTTCCCCAAACCCTGCGCTCTCTCACTGGGGTCTTGCCAGGGCCTGGGCTCAGCCCACTTCCTTCCA
CTGCTCCCCCCACCCAGAAGCTGGGGAGGGCTGGGGGTGGTAGCGTGCCAGG(S)AACAATGGGCCCCCA
ACCCCTTCCCGCCCATTGCGTGAGAAGGAGCTGCCGGAAGGAAACTCACCTCCCAGTGGGAC 
 
 
Since the 3’ end of the reverse primer annealed to the site of the G>C SNP, each allele was 
independently amplified.  The fragment ending with the C allele was specifically amplified using   60 
the  fluorescently  labelled  FAM-  GGGTTGGGGGCCCATTGTCG  reverse  primer  whilst  the 
fragment  ending  with  the  mutated  G  allele  was  specifically  labelled  with  the  HEX- 
GGGTTGGGGGCCCATTGTCC reverse primer.  A 3’ mismatch (at the penultimate base) was 
incorporated into both reverse primers to increase specificity of the assay.  Each fluorescently 
labelled PCR product encompassed the SNP at one end and the microsatellite at the other and 
the length of the PCR product varied among chromosomes, depending solely on the number of 
microsatellite repeats.  Consequently, the gametic phase for the SNP and microsatellite could 
be empirically determined by electrophoresis on a genetic analyser using fluorescent detection. 
 
3.2.4.2  SNPstr assay protocol 
 
Individual  sample  DNAs  were  amplified  separately  with  each  allele-specific,  fluorescently 
labelled  reverse  primer  and  the  same  forward  primer.    Two  separate  PCR  reactions  per 
individual were carried out in order to increase the reliability of the results.  DNA was amplified 
in 96 well plates in 10 µl reaction volumes containing 1 ng of template DNA, 0.3 µM of each 
primer (forward and reverse), 0.13 units Taq DNA polymerase (HT Biotech, Cambridge, UK), 
9.3  nM  TaqStartTM  monoclonal  antibody  (BD  Biosciences  Clontech,  Oxford,  UK),  200  µM 
dNTPs and reaction buffer supplied with the Taq polymerase.  The cycling parameters were: 4 
minutes of pre-incubation at 94 ºC, followed by 35 cycles of 30 seconds at 94 ºC, 30 seconds at 
56 ºC and 30 seconds at 72 ºC , with a final elongation step for 7 minutes at 72 ºC.  A 2 µl 
aliquot of the diluted PCR product (1 in 5 dilution) was mixed with 9.89 ul of high purity (HiDi) 
formamide and 0.11 ul of ROX size standard (Applied Biosystems).  The mixture was heated for 
4 minutes at 96 ºC and immediately cooled in ice.  Samples were run on an ABI 3100 genetic 
analyser and analysed using GeneMapper software v4.0 (Applied Biosystems (ABI), Warrington 
UK).    Genohaplotypes  (rs11072507  genotypes  and  AC  microsatellite  haplotypes)  were  then 
recorded for each sample. 
 
3.2.4.3  Assessing the reliability of the SNPstr assay 
 
In order to ensure that the SNPstr assay was accurately determining microsatellite lengths (by 
fragment  mobility),  a  sample  of  rs11072507  heterozygous  individuals  also  had  their 
microsatellite lengths determined by sequencing.  PCR conditions were the same as previously 
described except that the reverse primers were not labelled.  Uni-directional sequencing was 
performed on each allele using the unlabelled reverse primers.  The fragment ending with the C 
allele was sequenced using primer GGGTTGGGGGCCCATTGTCG whilst the fragment ending 
with  the  G  allele  was  sequenced  with  primer  GGGTTGGGGGCCCATTGTCC.    DNA  was 
sequenced  in  96  well  plates  in  15  µl  reaction  volumes  containing  6  µl  of  the  purified  PCR 
product, 2.4 pm of either primer, 0.75 µl of BigDye termination mix v1.1 (Applied Biosystems 
(ABI), Warrington UK) and 5 µl of Better Buffer (Applied Biosystems (ABI), Warrington UK).  The 
cycling parameters were: 25 cycles of 96 ºC for 10 seconds, 55 ºC for 5 seconds and 60 ºC for   61 
4 minutes.  Sequencing reaction products were purified by mixing 80 µl of isopropanol with each 
product and leaving for 10 minutes at room temperature.  The mixture was centrifuged for 45 
minutes at 2240 x g and the resultant supernatant was discarded by inverting the PCR plate 
and centrifuging for 1 minute at 13 x g.  150 µl of 70 % isopropanol was added to each well and 
centrifuged for 15 minutes at 2240 x g.  The resultant supernatant was discarded by inverting 
the PCR plate and centrifuging for 1 minute at 13 x g.  Samples were then dried for 5 minutes at 
65 ºC.  Each sample was mixed with 10 µl of high purity (HiDi) formamide, heated for 4 minutes 
at  96  ºC  and  immediately  cooled  in  ice.    Samples  were  then  run  on  an  ABI  3100  genetic 
analyser  and  analysed  using  Sequencher  4.7  software  (Gene  Codes  Corporation,  USA).  
Microsatellite lengths were confirmed by counting the number of AC repeats observed in the 
sequence chromatograms. 
 
3.2.5  Estimating  the  time  to  most  recent  common  ancestor  (TMRCA)  for  CYP1A2 
variants 
 
Under the stepwise mutation model, the average square distance (ASD) in microsatellite allele 
size  among  all  sampled  chromosomes  from  the  most  recent  common  ancestral  haplotype, 
averaged over loci, has been shown to be linearly related to µt, where µ is the mutation rate and 
t  the  coalescence  time  in  generations  (Goldstein  et  al.,  1995;  Slatkin,  1995).    The  AC 
microsatellite alleles obtained from the SNPstr assay were used to date CYP1A2 variants in this 
study.    Since  the  gametic  phase  for  the  SNP  (rs11072507)  and  AC  microsatellite  was 
empirically determined from the SNPstr assay for each sample, the  SNP (rs11072507)  was 
used  to  determine  to  which microsatellite  haplotype  the  allele,  which  was  being  dated,  was 
linked.  Phase was inferred for all CYP1A2 variant alleles and rs11072507 from the pooled 
Ethiopian ascertainment population (excluding missing genotype data) by the ELB approach 
(Excoffier et al., 2003) implemented in Arlequin software, version 3.01 (Schneider et al., 2000).  
When both CYP1A2 SNP alleles were on the background of both the G and C of rs11072507, 
recombination was inferred.  Since recombination initiates a new distribution of microsatellite 
alleles  in  the  evolutionary  history  of  the  gene  (overlaid  on  the  previous  distribution),  these 
variants were dated using microsatellites on the background of each of rs11072507 C and G 
separately  and  together  (where  possible).    Of  the  date  estimates  produced  from  only 
rs11072507 G or C alleles, the older dates were assumed to indicate the coalescent date of the 
SNP being dated, whilst the younger was taken as the coalescent date of the recombination 
event.    Since  recombination  between  identical  haplotypes  would  not  affect  coalescent  date 
estimates, recombination between identical CYP1A2 haplotypes was not accounted for in the 
method. 
 
ASD  and  t  were  calculated  using  Ytime  software,  version  2.08  (Behar  et  al.,  2003).    The 
software includes a set of functions written for the MATLAB programming environment.  The 
functions are designed to infer the TMRCA of a clade on a single-locus genealogy for which 
microsatellite haplotype information is available.  The microsatellite haplotype of the MRCA is   62 
assumed  to  be  known.    In  this  study,  the  modal  haplotype  was  assumed  to  be  ancestral 
because of its high frequency.  The TMRCA (unbiased estimate plus confidence interval) was 
inferred under the Simple Stepwise Mutation Model (S-SMM) of microsatellite evolution.  The 
AC microsatellite mutation rate per generation was assumed to be 0.0005 (Farrall and Weeks, 
2007).  Confidence intervals were obtained on the distance between the ancestral and sampled 
chromosomes  (ignoring  uncertainty  in  mutation  rate)  from  simulations  involving  a  star-
genealogy model.  This model was used because most non-ancestral haplotypes were rare (in 
some  cases  most  were  singletons)  and  negative  Tajima  D  values  were  observed  for  all 
Ethiopian ascertainment populations (see table 3.5), indicating that the genealogy linking the 
CYP1A2 chromosomes was more like the star genealogy characteristic of rapid growth than the 
genealogy associated with no growth.  For each generation, a time period of 32  years was 
assumed based on data from Tremblay and Vezina (2000). 
 
3.3  Results 
3.3.1  Network analysis of CYP1A2 haplotypes 
 
In order to establish the relationship between CYP1A2 haplotypes observed in the Ethiopian 
ascertainment  and  NIEHS  populations,  mutation  networks  of  these  haplotypes  were 
constructed.  Haplotypes from the chimpanzee, orangutan and Rhesus macaque were included 
to determine the extent to which CYP1A2 has been conserved throughout primate evolution.  
Since  it  was  established  in  chapter  2  that  CYP1A2  can  be  divided  into  two  LD  blocks 
constituting the cds region and the 3’ end of the gene, networks of the entire cds region (exons 
2-7) were constructed in addition to networks of the entire gene.  Cds haplotype networks will 
provide a clear insight into the conservation of the protein, whilst entire gene networks will place 
coding variation into the context of variation within the entire gene.   
 
3.3.1.1  CYP1A2 cds networks 
 
The  network  of  the  cds  region  (exons  2-7)  can  be  seen  in  figure  3.3.    A  total  of  14  cds 
haplotypes were included in the network (see tables 3.1 and 3.2 for details regarding haplotype 
types  and  frequencies  respectively).    The  chimpanzee  was  the  most  similar  species  to  the 
human  clade,  followed  by  the  orangutan  and  then  by  the  macaque.    The  modal  human 
haplotype (8), which was observed in all Ethiopian and NIEHS populations (table 3.2), was the 
most  similar  of  the  human  haplotypes  to  the  chimpanzee.    The  chimpanzee,  macaque  and 
orangutan  haplotypes  were  linked  to  the  human  clade  via  a  single  common  branch.  
Recombination was not observed in the network and all haplotypes, with one exception, within 
the human clade were separated by a single mutation.  Most haplotypes stemmed from the 
modal  haplotype,  and  as  is  evident  from  figure  table  3.2,  the  vast  majority  of  non-modal   63 
haplotypes  were  African.    Moreover,  the  vast  majority  of  these  were  confined  to  Ethiopia, 
however this may be a reflection of the relative sizes of the datasets.   
 
Figure 3.3  Mutation network of CYP1A2 cds haplotypes observed in the Ethiopian ascertainment and NIEHS 
populations.  Haplotypes from the chimpanzee (Pan troglodytes), orangutan (Pongo pygmaeus) and Rhesus macaque 
(Macaca mulatta) are shown.  Nodes represent haplotypes (shown in table 3.1) and are proportional to haplotype 
frequencies in the combined Ethiopian ascertainment and NIEHS population (shown in table 3.2).  Mutated positions are 
shown in red along the grey links.  All links, except those connecting the chimpanzee, orangutan and Rhesus macaque, 
are to scale.  Haplotypes denoted with * contain amino acid alterations which are predicted to be damaging to the 
structure/function of the protein in some way (table 3.1).   
 
 
 
 
 
 
For each  of the individual exons, the chimpanzee  was the most similar relative  to  humans, 
followed by the orangutan, and then the macaque (data not shown).   
 
Exons 1, 4 and 5 were not variable in the Ethiopian ascertainment and NIEHS populations and 
whilst  exon  1  differed  from  the  chimpanzee  by  two mutations  and  exon  4  differed  from  the 
chimpanzee by one mutation, no variation was observed between the human and chimpanzee 
in exon 5.  Consequently, exon 5 was the most conserved CYP1A2 exon throughout primate 
evolution, followed by exon 4 and then by exon 1.   
 
Of the exons which were variable in the Ethiopian ascertainment and NIEHS populations, exon 
2 appeared to be the least conserved throughout primate evolution.  A total of nine mutations 
separated the chimpanzee from the closest human node for exon 2, whilst only two, one and 
three mutations differentiated the chimpanzee from the closest human node for exons 3, 6 and 
7 respectively.  On the other hand however, exon 7 was the most variable of the exons and was 
therefore the least conserved exon among human populations.     64
Table 3.1  CYP1A2 cds haplotypes used in the mutation networks shown in figure 3.3
53 217 331 613 1513 3463 3468 5094 5105 5112 5253 5284 5328 5347
C>G G>A C>T T>G C>A C>T A>C T>C G>A C>T C>G C>A G>A T>C
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Exon 2 Exon 2 Exon 2 Exon 2 Exon 3 Exon 6 Exon 6 Exon 7 Exon 7 Exon 7 Exon 7 Exon 7 Exon 7 Exon 7
S18C G73R L111F F205V S298R T395M N397H F432S D436N T438I P485R Y495Ter R510Q N516N
1 Probably damaging
2
Presume definite 
damage
3 Undamaged
4 Possibly damaging
5 Probably damaging
6 Possibly damaging
7 Undamaged
8
No amino acid 
alteration
9
No amino acid 
alteration
10 Undamaged
11 Undamaged
12 Undamaged
13 Undamaged
14 Undamaged
1 Position from base A in the initiation codon (A in ATG is +1, base prior to A is -1) from the CYP1A2 genomic reference sequence (NC_000015.8)
2 White cell, non-derived allele, grey cell, derived allele
3 Predictions made using PolyPhen software.  Predicted effects of each cds haplotype are based upon the singular amino acid alterations
Nucleotide change 
1
Haplotype id 
2
Predicted effect on 
CYP1A2 
structure/function 
3
Mutated position in cds 
phylogenetic network
Location
Amino acid change 65
Table 3.2 CYP1A2 cds haplotype frequencies in the world dataset and their distribution among the Ethiopian ascertainment and NIEHS populations
n f n f n f n f n f n f n f n f n f n f n f
1 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.08 0 0.00 0 0.00 0 0.00 1 0.001
2 0 0.00 0 0.00 4 0.03 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 4 0.005
3 4 3.28 0 0.00 11 0.07 8 0.06 4 0.03 1 0.05 1 0.08 0 0.00 0 0.00 0 0.00 29 0.036
4 0 0.00 0 0.00 0 0.00 0 0.00 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.001
5 0 0.00 1 0.01 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 2 0.002
6 0 0.00 1 0.01 1 0.01 0 0.00 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 3 0.004
7 2 1.64 0 0.00 0 0.00 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 3 0.004
8 77 63.11 90 0.63 127 0.84 106 0.74 87 0.69 17 0.77 10 0.83 11 0.37 12 0.55 29 0.81 566 0.700
9 35 28.69 48 0.34 5 0.03 18 0.13 30 0.24 3 0.14 0 0.00 19 0.63 10 0.45 6 0.17 174 0.215
10 0 0.00 1 0.01 1 0.01 10 0.07 2 0.02 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 14 0.017
11 2 1.64 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 2 0.002
12 2 1.64 1 0.01 2 0.01 1 0.01 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 7 0.009
13 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.05 0 0.00 0 0.00 0 0.00 0 0.00 1 0.001
14 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.03 1 0.001
Grand Total 122 100.00 142 1.00 152 1.00 144 1.00 126 1.00 22 1.00 12 1.00 30 1.00 22 1.00 36 1.00 808 1.000
n = number of chromosomes, f = frequency
Haplotype id
Afar Amhara Anuak Maale Oromo African American World dataset Yoruba European Hispanic East Asian  66 
3.3.1.2  CYP1A2 entire gene networks 
 
The network of the whole CYP1A2 gene is shown in figure 3.4.  A total of 37 haplotypes were 
included in the network (see tables 3.3 and 3.4 for details regarding the types and frequencies 
of haplotypes respectively).   
 
Recombination was inferred between loci 20 (2159G>A in intron 4and 34 (5347C>T in exon 7 
(non-synonymous))  which  manifested  itself  in  haplotypes  16,  17,  23  and  24  (table  3.3).  
Recombination was also evident between loci 21 (2321G>A in intron 4) and 34, manifesting 
itself in haplotypes 21, 22, 23 and 24 (table 3.3).  Recombined haplotypes 22 and 24, which 
were only observed as singletons in Afar and Oromo respectively (table 3.4), were excluded to 
prevent reticulations within the network shown in figure 3.4.  Given their appreciable frequencies 
within  some  of  the  Ethiopian  ascertainment  and  NIEHS  populations  (table  3.4),  the  other 
recombined haplotypes mentioned above were not excluded from the network shown in figure 
3.4.   
 
The chimpanzee, macaque and orangutan haplotypes were again linked to the human clade via 
a single common branch (figure 3.4).  The chimpanzee was also the most similar relative to 
humans, but the orangutan was now the most dissimilar species to humans (figure 3.4).   
 
Contrary to the combined cds region network, the most frequent human haplotype (33), which 
was observed in all Ethiopian ascertainment and NIEHS populations (table 3.4), was not the 
most similar human node to the chimpanzee.  In this instance, haplotype 3 was the most similar 
and was only observed in Ethiopia in Afar, Amhara, Anuak and Oromo (table 3.4).  Furthermore, 
the majority of haplotypes linked to haplotype 3 were only found in Ethiopian populations (table 
3.4), however this may be a reflection of the relative sizes of the datasets.   
 
Within the human clade, single mutations separated all haplotypes, with three exceptions (figure 
3.4).  Similar to the cds region network, the majority of entire gene haplotypes stemmed from 
the  modal  haplotype  and  the  vast  majority  of  non-modal  haplotypes  were  only  observed  in 
samples with a recent African ancestry, the majority of which were confined to Ethiopia (table 
3.4).  Again however, this may be a reflection of the relative sizes of the datasets.   
 
Cds  haplotype  8  was  observed  on  the  background  of  most  of  the  entire  gene  haplotypes, 
including  the  modal  haplotype  and  haplotype  3  which  was  most  similar  to  the  chimpanzee 
(figure 3.4).  Cds haplotype 9 (characterised by no mutations in table 3.1) was found on the 
background of the recombined entire gene haplotypes 22 and 24 (figure 3.4).  Notably, most of 
the cds haplotype backgrounds which were predicted to be damaging in some way (see table 
3.1 for phenotype predictions) were directly linked to entire gene haplotype 12 (figure 3.4). 
    67 
Figure 3.4  Mutation network of CYP1A2 (entire gene) haplotypes observed in the Ethiopian ascertainment and NIEHS populations.  Haplotypes from the chimpanzee (Pan troglodytes), orangutan 
(Pongo pygmaeus) and Rhesus macaque (Macaca mulatta) are shown.  Nodes represent haplotypes (shown in table 3.3) and are proportional to haplotype frequencies in the combined Ethiopian 
ascertainment and NIEHS population (shown in table 3.4).  Mutated positions are shown in red along the grey links.  All links, except those connecting the chimpanzee, orangutan and Rhesus macaque, are 
to scale.  Recombined haplotypes 22 and 24 were removed from the network to prevent reticulations and are shown in the top right hand corner.  Haplotypes are coloured according to their cds haplotype 
background.   
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Table 3.3   CYP1A2 (entire gene) haplotypes used in the mutation networks shown in figure 3.4
Nucleotide change 
1 -1014 -1008 -739 -729 -592 -569 -505 -163 -151 -61 53 217 331 613 869 1352 1370 1513 1589 2159 2321 3463 3468 4957 4961 5010 5015 5029 5094 5105 5253 5284 5328 5347 5355 6765
C>A G>A T>G C>T C>T G>A G>A C>A G>T A>G C>G G>A C>T T>G G>C G>A G>A C>A G>T G>A G>C C>T A>C C>G C>T C>T C>G C>G T>C G>A C>G C>A G>A T>C G>C C>T
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
Location 5' upstream 5' upstream Intron 1 Intron 1 Intron 1 Intron 1 Intron 1 Intron 1 Intron 1 Intron 1 Exon 2 Exon 2 Exon 2 Exon 2 Intron 2 Intron 2 Intron 2 Exon 3 Intron 3 Intron 4 Intron 4 Exon 6 Exon 6 Intron 6 Intron 6 Intron 6 Intron 6 Intron 6 Exon 7 Exon 7 Exon 7 Exon 7 Exon 7 Exon 7 3' UTR 3' UTR
Amino acid change S18C G73R L111F F205V S298R T395M N397H F432S D436N P485R Y495Ter R510Q N516N
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16 A C
17 A T
Haplotype id 
2 18
19
20
21 G C
22 G T
23 G C
24 G T
25
26
27
28
29
30
31
32
33
34
35
36
37
1 Position from base A in the initiation codon (A in ATG is +1, base prior to A is -1) from the CYP1A2 genomic reference sequence (NC_000015.8)
2 White cell, non-derived allele, grey cell, derived allele, nucleotides are also shown to highlight incidences where recombination is inferred
Mutated position in entire 
gene phylogenetic network
Recombination was inferred between loci 2159 and 5347 in haplotypes 16, 17, 21 and 24 (highlighted in red letters) and between loci 2321 and 5347 in haplotypes 21, 22, 23 and 24 (highlighted in 
yellow fill) 69
Table 3.4  CYP1A2 haplotype (entire gene) frequencies in the world dataset and their distribution among the Ethiopian ascertainment and NIEHS populations.   
n f n f n f n f n f n f n f n f n f n f n f
1 0 0.00 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.001
2 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.001
3 3 0.03 2 0.02 5 0.04 0 0.00 4 0.04 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 14 0.020
4 1 0.01 4 0.03 0 0.00 9 0.07 6 0.06 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 20 0.028
5 0 0.00 0 0.00 0 0.00 1 0.01 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 2 0.003
6 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.07 0 0.00 0 0.00 0 0.00 0 0.00 1 0.001
7 0 0.00 0 0.00 11 0.08 0 0.00 0 0.00 1 0.07 1 0.10 0 0.00 0 0.00 0 0.00 13 0.018
8 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.10 0 0.00 0 0.00 0 0.00 1 0.001
9 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.07 0 0.00 1 0.001
10 0 0.00 0 0.00 0 0.00 0 0.00 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.001
11 0 0.00 0 0.00 4 0.03 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 4 0.006
12 3 0.03 0 0.00 9 0.06 7 0.05 3 0.03 0 0.00 1 0.10 0 0.00 0 0.00 0 0.00 23 0.033
13 0 0.00 0 0.00 0 0.00 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.001
14 0 0.00 0 0.00 0 0.00 0 0.00 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.001
15 0 0.00 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.001
16 8 0.07 10 0.08 2 0.01 13 0.10 9 0.09 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 42 0.060
17 32 0.27 42 0.34 5 0.04 16 0.12 24 0.24 1 0.07 0 0.00 16 0.67 8 0.57 5 0.19 149 0.212
18 0 0.00 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.001
19 2 0.02 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 2 0.003
20 2 0.02 1 0.01 2 0.01 1 0.01 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 7 0.010
21 1 0.01 1 0.01 3 0.02 2 0.02 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 7 0.010
22 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.001
23 11 0.09 4 0.03 21 0.15 5 0.04 12 0.12 6 0.43 4 0.40 0 0.00 3 0.21 13 0.50 79 0.112
24 0 0.00 0 0.00 0 0.00 0 0.00 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.001
25 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.001
26 0 0.00 1 0.01 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 2 0.003
27 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.04 0 0.00 0 0.00 1 0.001
28 0 0.00 2 0.02 0 0.00 2 0.02 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 4 0.006
29 1 0.01 1 0.01 0 0.00 2 0.02 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 4 0.006
30 0 0.00 0 0.00 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.001
31 0 0.00 1 0.01 1 0.01 9 0.07 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 12 0.017
32 2 0.02 0 0.00 0 0.00 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 3 0.004
33 47 0.40 51 0.41 74 0.53 63 0.48 37 0.36 4 0.29 3 0.30 7 0.29 2 0.14 8 0.31 296 0.420
34 0 0.00 1 0.01 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 2 0.003
35 2 0.02 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 2 0.003
36 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.07 0 0.00 0 0.00 0 0.00 0 0.00 1 0.001
37 0 0.00 0 0.00 0 0.00 0 0.00 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.001
Grand Total 118 1.00 124 1.00 140 1.00 132 1.00 102 1.00 14 1.00 10 1.00 24 1.00 14 1.00 26 1.00 704 1.000
n = number of chromosomes, f = frequency
Hispanic East Asian World dataset
Recombination was inferred between loci 2159 and 5347 in haplotypes 16, 17, 21 and 24 (highlighted in red letters) and between loci 2321 and 5347 in haplotypes 21, 22, 23 and 24 (highlighted in yellow fill) (table 3.3)
Haplotype id
Afar Amhara Anuak Maale Oromo African American Yoruba European  70 
3.3.2  Testing for selection in CYP1A2 
3.3.2.1  Analysis using statistical tests of neutrality 
 
In  order  to  test  the  hypothesis  that  all  CYP1A2  mutations  were  selectively  neutral  (Kimura, 
1983), three neutrality tests were performed.  To control for the effects of different demographic 
histories,  each  test  was  performed  on  each  of  the  individual  Ethiopian  ascertainment  and 
NIEHS populations.  Since Amhara and Oromo were similar throughout population analyses 
(see chapter 2), both samples were also combined in an attempt to increase power. 
 
Table  3.5    Results  of  neutrality  tests  performed  on  CYP1A2  in  the  Ethiopian  ascertainment  and  NIEHS 
populations.  n = number of chromosomes. 
 
Tajima's test  McDonald-Kreitman test  Fu and Li's test with an outgroup 
Population  n  Tajima's D (p value)  Fisher's exact test p value  D test (p value)  F test (p value) 
Afar  118  -0.88 (p > 0.10)  0.34  -0.84 (p > 0.10)  -1.02 (p > 0.10) 
Amhara  124  -1.16 (p > 0.10)  0.32  -4.24 (0.01 < p < 0.02)  -3.68 (0.01 < p < 0.02) 
Anuak  140  -1.24 (p > 0.10)  0.32  -1.07 (p > 0.10)  -1.35 (p > 0.10) 
Maale  132  -0.86 (p > 0.10)  0.34  -0.88 (p > 0.10)  -1.05 (p > 0.10) 
Oromo  102  -0.85 (p > 0.10)  0.34  -2.55 (0.02 < p < 0.05)  -2.30 (0.02 < p < 0.05) 
Amhara & Oromo  226  -1.26 (p > 0.10)  0.17  -3.36 (p < 0.02)  -3.03 (p < 0.02) 
African American  14  -0.77 (p > 0.10)  1.00  -0.81 (p > 0.10)  -0.95 (p > 0.10) 
Yoruba  10  -0.63 (p > 0.10)  0.23  -0.95 (p > 0.10)  -1.03 (p > 0.10) 
European  24  0.78 (p > 0.10)  1.00  0.07 (p > 0.10)  0.33 (p > 0.10) 
Hispanic  14  -0.53 (p > 0.10)  1.00  0.24 (p > 0.10)  0.38 (p > 0.10) 
East Asian  26  0.95 (p > 0.10)  1.00  0.97 (p > 0.10)  1.13 (p > 0.10) 
 
 
Results of the neutrality tests are shown in table 3.5.  Tajima’s D was not significantly different 
from zero in any population (p > 0.10 in all cases) and Fisher’s exact test p values (two tailed) 
for  each  of  the  McDonald-Kreitman  tests  were  above  0.05.    Consequently,  the  neutral 
hypothesis was not rejected in each case.   
 
Fu  and  Li’s  D  and  F  statistics  were  not  significant  at  the  5  %  significance  threshold  for  all 
populations except Amhara and Oromo.  The negative D and F statistics for Amhara and Oromo 
were  indicative  of  an  excess  of  recent  mutations  in  the  genealogy  which  is  consistent  with 
purifying or positive (not balancing) selection acting on CYP1A2 (Fu and Li, 1992).  Although a 
Bonferroni correction for multiple tests (11 in this case) suggests that a p value of less than 
0.005 would be considered significant, negative D and F test statistics were observed for all 
Ethiopian ascertainment populations, and Amhara and Oromo were consistent with selection at 
5 % significance when analysed separately and together.  As a consequence, further analysis 
was performed in order to try and determine the type of selection.  Since CYP1A2 is highly 
conserved between species e.g. humans, mice and rats (Aklillu et al., 2003), and non-coding 
variation is tolerated more than coding variation in humans (see chapter 2), the prior hypothesis 
was that purifying selection, not positive selection, has been operating on CYP1A2.     71 
3.3.2.2  Testing for evidence of purifying selection 
 
Reduction of both intra-population gene diversity and inter-population genetic distance for non-
synonymous SNPs (predicted to cause radical changes to protein structure) in comparison to 
SNPs in the same genes which have no effect on protein structure is evidence that purifying 
selection has acted at these non-synonymous SNP sites (Hughes et al., 2003; Hughes et al., 
2005).  To establish whether purifying selection could be evidenced in CYP1A2 according to 
this method, mean gene diversities and genetic distances were computed for variation observed 
in the Ethiopian ascertainment and NIEHS populations. 
 
3.3.2.2.1  Analysis of intra-population gene diversity 
3.3.2.2.1.1  Are  reduced  gene  diversities  consistently  observed  for  radical  non-
synonymous SNPs? 
 
With the exception of the 5’ non-coding SNPs, the lowest mean gene diversity (figure 3.5) was 
observed for radical non-synonymous SNPs.  Mean gene diversity was low for nonsense and 
conservative non-synonymous SNPs, at intermediate levels for intron and 3’ UTR SNPs, and 
highest for the synonymous SNP.  In instances where data was sufficiently informative to permit 
significance tests to be carried out, the difference in mean gene diversity between intron SNPs 
and radical non-synonymous SNPs was significant as was the difference in mean gene diversity 
between 3’ UTR and radical non-synonymous SNPs (figure 3.5). 
 
Figure  3.5    Mean  gene  diversity  (heterozygosity)  at  non-synonymous  SNP  sites  (nonsense,  radical  or 
conservative) and synonymous or non-coding sites in CYP1A2 in the combined Ethiopian ascertainment and 
NIEHS population.  Error bars indicate variance from the mean.  Numbers of SNP sites in each category are shown in 
brackets.  One tail p values from t-tests of the hypothesis that mean gene diversity of each SNP category equals that for 
radical non-synonymous SNP loci are shown in red.   n/a = t - test not applicable due to small sample number. 
 
 
 
3.3.2.2.1.2  Further analysis in the context of haplotype networks 
 
Particularly low gene diversity values for SNPs occurring on the same haplotype background as 
non-synonymous  SNPs  (genetic  hitchhikers)  might  be  observed  as  a  result  of  them  being   72 
Figure 3.6  Identifying hitchhikers of non-synonymous SNPs from a network of CYP1A2 haplotypes observed in the Ethiopian ascertainment and NIEHS populations.  Nodes represent 
haplotypes and mutated positions are shown in red along the links.  All links are drawn to scale.  All 3’ UTR SNPs and the single synonymous SNP (5347 C>T in exon 7) were excluded from the analysis to 
prevent reticulation in the network so that hitchhikers could be easily identified.  Non-synonymous SNPs (conservative, radical and nonsense) and their hitchhikers are indicated.  Although marker 13 
occurred on the background of marker 22, marker 13 was not classified as a hitchhiker (which would have its gene diversity reduced even further as a consequence of being closely linked to a non-
synonymous SNP) since it was predicted to be more deleterious than marker 22 (see chapter 2).  Intronic markers 6, 26 and 29 were removed from the analysis along with the conservative non-synonymous 
SNP (16). 
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closely linked to a non-synonymous SNP.  To control for this effect, only loci which were not 
‘hitchhikers of non-synonymous SNPs’ were included in the analysis.  A network of CYP1A2 
haplotypes was drawn to identify which SNPs were hitchhikers of non-synonymous SNPs (see 
figure  3.6  for  further  details).    Results  were  consistent  with  those  observed  in  the  previous 
analysis except that mean gene diversity values were now higher for SNP categories where 
genetic hitchhikers of non-synonymous SNPs had been removed (i.e. conservative and intron 
SNP categories) (figure 3.7). 
 
Figure  3.7    Mean  gene  diversity  (heterozygosity)  at  various  CYP1A2  SNP  sites  in  the  combined  Ethiopian 
ascertainment  and  NIEHS  population  once  hitchhikers  of  non-synonymous  SNPs  were  excluded  from  the 
analysis.  Light and dark blue bars indicate datasets with and without genetic hitchhikers of non-synonymous SNPs, 
respectively.  Error bars indicate variance from the mean.  Numbers of SNP sites in each category are shown in 
brackets.  One tail p values from t-tests of the hypothesis that mean gene diversity of each SNP category equals that for 
radical non-synonymous SNP loci are shown in red.   n/a = t - test not applicable due to small sample number. 
 
 
 
3.3.2.2.2  Analysis of inter-population genetic distance 
3.3.2.2.2.1  Are  reduced  genetic  distances  consistently  observed  for  radical  non-
synonymous SNPs? 
 
Consistent  with  analyses  regarding  intra-population  gene  diversity,  differences  were  found 
among SNP categories with respect to inter-population genetic distance (figure 3.8).   With the 
exception of 5’ non-coding SNPs, mean genetic distance was lowest for nonsense SNPs and 
radical non-synonymous SNPs.  Mean genetic distances for conservative, intron, 3’ UTR and 
synonymous SNPs were significantly higher than that for radical non-synonymous SNPs.  With 
the exception of 5’ non-coding SNPs, mean genetic distances were higher for SNP categories 
with no amino acid change than for conservative non-synonymous SNPs.  Consistent with the 
pattern from gene diversity, once non-synonymous hitchhikers were removed from intron and 
conservative SNP categories (dark green bars in figure 3.8), mean genetic distances between 
populations increased for these groups. 
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Figure 3.8  Mean genetic distance values at various CYP1A2 SNP sites for all inter-population comparisons 
using individual Ethiopian ascertainment and NIEHS populations.  Light green bars indicate datasets using all 
CYP1A2 variation.  Dark green bars indicate conservative and intron SNP categories from which hitchhikers of non-
synonymous SNPs have been removed.  Numbers of population comparisons in each SNP category are shown in 
brackets.  One tail p values from t-tests of the hypothesis that mean genetic distance for each SNP category equals that 
for radical non-synonymous SNP loci are represented as follows:  ns = p > 0.05, ** = p < 0.01, *** = p < 0.001 
 
 
 
 
3.3.2.2.3  Evidence  of  purifying  selection  acting  upon  conservative  non-synonymous 
SNPs 
 
To  test  for  evidence  of  purifying  selection  on  non-synonymous  SNPs  causing  conservative 
amino acid changes, the CYP1A2 genomic human reference sequence was compared with the 
mouse  and  chimpanzee  CYP1A2  sequences.    A  mouse  and  chimpanzee  orthologue  was 
available for all twelve of the conservative non-synonymous SNPs observed in the Ethiopian 
ascertainment and NIEHS populations.  At seven (58 %) of these SNP sites, one of the two 
human alleles encoded an amino acid residue identical to that of the mouse, whereas at five (42 
%) of these SNP sites, both human alleles encoded different amino acids to the mouse.  At all 
twelve SNP sites, one of the two human alleles encoded an amino acid residue identical to that 
of the chimpanzee. 
 
Differences in mean gene diversity were observed among SNP sites in which both amino acids 
were different from that observed in the mouse, sites at which only the higher frequency residue 
was different from that observed in the mouse, and sites at which only the lower frequency 
residue  was identical to  that observed  in the mouse (figure 3.9).  Mean gene diversity  was 
lowest  (0.003)  when  the  higher  frequency  amino  acid  was  identical  to  that  observed  in  the 
mouse, at an intermediate level (0.021) when neither amino acid was identical to that observed 
in the mouse, and highest (0.033) when the lower frequency amino acid was identical to that 
observed  in  the  mouse.    Mean  (unpaired  t  test)  and  median  (Kruskal-Wallis  test)  gene 
diversities were not however significantly different at the 5 % significance threshold, possibly   75 
because of the small sample number.  These results were in accordance with the hypothesis 
that, given the functional constraints on evolutionary conserved amino acids, purifying selection 
acts against mutations which introduce amino acids not observed in the mouse (Hughes et al., 
2003). 
 
Figure 3.9  Mean gene diversity at non-synonymous SNP sites causing conservative amino acid changes in the 
combined Ethiopian ascertainment and NIEHS population.  Error bars indicate variances and red horizontal lines 
indicate median values. 
 
 
 
In instances when one of the two human alleles encoded the same amino acid as the mouse, 
while the other encoded a different amino acid, the mean allele frequency of the former allele 
(0.802)  was  four  times  the  mean  frequency  of  the  latter  allele  (0.198)  (figure  3.10).    The 
difference between the two mean allele frequencies was not significant (p > 0.05 for Wilcoxon 
matched-pairs signed-ranks test). 
 
Figure 3.10  Mean allele frequency at 12 conservative non-synonymous SNP sites (in the combined Ethiopian 
ascertainment and NIEHS population) for which a mouse orthologue was available and one SNP encoded a 
residue identical to the mouse.  Error bars indicate variances and red horizontal lines indicate median values. 
 
 
 
The mean allele frequency of the allele which encoded a different amino acid to the chimpanzee 
was less than 1 % (figure 3.11).  The difference between the two mean allele frequencies was 
significant (p < 0.05 for Wilcoxon matched-pairs signed-ranks test).  Since the higher frequency 
alleles  encode  residues  which  have  been  conserved  within  mammals,  these  results  provide 
further evidence of purifying selection at these conservative non-synonymous SNP sites. 
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Figure 3.11  Mean allele frequency at 12 conservative non-synonymous SNP sites (in the combined Ethiopian 
ascertainment and NIEHS population) for which a chimpanzee orthologue was available and one SNP encoded 
a residue identical to the chimpanzee.  Error bars indicate variances and red horizontal lines indicate medians. 
 
 
 
3.3.3  CYP1A2 chronology 
3.3.3.1  Estimating the TMRCA of CYP1A2 allelic variants 
 
The  CYP1A2  sequences  and  SNPstr  genohaplotypes  (which  incorporated  the  rs11072507 
genotypes with the AC microsatellite haplotypes) were informative enough to date nine CYP1A2 
variants, in addition to the G>C SNP (rs11072507) in the SNPstr, in the Ethiopian ascertainment 
populations.    The  majority  of  variants  observed  in  the  Ethiopian  ascertainment  populations 
could not be dated because variants were either a) singletons, b) associated with microsatellites 
which were not variable in size or c) less than eight microsatellite chromosomes were available 
per  variant  with  the  consequence  that  confidence  intervals  were  so  large  that  dates  were 
uninformative. 
 
3.3.3.2  Coalescent date estimates for CYP1A2 variants 
 
The unbiased time estimates and associated 95 % confidence intervals for each variant which 
was dated is shown in table 3.6.  Both 2159 G>A and 5347 C>T could not be dated on the 
background of only the rs11072507 G allele due to small sample numbers.  Coalescent date 
estimates would not however have been significantly different between the rs11072507 G and C 
background in any case because no more than two G linked chromosomes were available for 
each variant.  In both cases, coalescent dates from rs11072507 G and C combined were used 
in subsequent analysis. 
 
Consistent with rs11072507 C being the derived allele and rs11072507 G being the ancestral 
allele (status in the chimpanzee), the coalescent date of rs11072507 C was estimated to be 
younger than rs11072507 G (table 3.6).  The distribution of microsatellite alleles for rs11072507 
C and G and for each CYP1A2 variant dated is shown in figure 3.12.  Microsatellite alleles 
ranged from 16 – 27 and 14 – 25 AC repeat units on the background of rs11072507 C and G   77 
Table 3.6  Inference of the TMRCA (unbiased estimate plus confidence interval) for CYP1A2 variants and rs11072507.  n = chromosome number, G = generations, Y = years, n/a = not applicable.  
Variants in yellow were assumed to have recombined with rs11072507 (table 3.7) and were consequently dated using microsatellites on the background of each of rs11072507 C and G separately and 
together (C always produced the younger dates (in blue) which were assumed to be the coalescent dates of the recombination events).  All other CYP1A2 variants (in purple) only occurred on the 
background of rs11072507 G (table 3.7).  Date estimates in green were used in the subsequent analyses.   CYP1A2 variants are arranged in order of increasing TMRCA.   
 
 
 
Equal-tailed 95 % confidence intervals with a star-genealogy model  Time to most common recent ancestor 
Lower  Upper  CYP1A2 variant  Location  Allele dated  rs11072507 background  n  Average Square Distance (ASD) 
G  Y  G  Y  G  Y 
1589 G>T  Intron 3  T  G  13  0.077  154  4922  22  719  865  27688 
C  53  0.925  1849  59168  1160  37133  2999  95955 
G  2  Undetermined                    2159 G>A  Intron 4  A 
G+C combined  55  1.491  2982  95437  1998  63933  4662  149178 
C  139  1.626  3252  104058  2493  79773  4253  136109 
G  1  Undetermined                    5347 C>T  Exon 7  T 
G+C combined  140  1.729  3457  110630  2673  85546  4556  145782 
rs11072507  SNPstr  C  n/a  270  1.778  3556  113779  2950  94390  4295  137440 
C  15  1.533  3067  98131  1414  45245  7262  232394 
G  11  2.182  4364  139635  1906  60992  12693  406176  5620 A>C  3' UTR  C 
G+C combined  26  2  4000  128000  2250  71994  7885  252320 
3613 T>C  Intron 6  C  G  24  3.5  7000  224000  4106  131392  14081  450592 
1513 C>A  Exon 3  A  G  23  3.826  7652  244870  4403  140896  14785  473120 
6324 G>del  3' UTR  -  G  32  5.594  11188  358003  6812  217984  19578  626496 
C  23  5.044  10087  322784  5865  187680  19542  625344 
G  184  5.647  11293  361389  9223  295136  14074  450368  -163 A>C  Intron 1  C 
G+C combined  207  5.58  11159  357101  9201  294432  13764  440448 
C  250  1.812  3624  115968  2995  95824  4424  141565 
G  380  5.771  11542  369350  9983  319456  13395  428640  -739 G>T  Intron 1  T 
G+C combined  630  4.2  8400  268800  7517  240541  9439  302048 
rs11072507  SNPstr  G  n/a  450  5.982  11964  382861  10450  334400  13793  441376 
  Younger 
Older   78 
respectively.  The modal microsatellite allele size was 23 AC repeats for both rs11072507 C 
and G, and for the majority of CYP1A2 variants (figure 3.12).   
 
Figure 3.12  Distributions of AC microsatellite alleles which were used to date rs11072507 (SNPstr SNP) and 
various CYP1A2 variants observed in the Ethiopian ascertainment populations 
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Figure 3.12 continued 
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Distribution of microsatellite alleles associated with 
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Figure 3.12 continued 
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3.3.3.3  Are the dates consistent with each other? 
 
Of all the coalescent dates, the date for rs11072507 G was estimated to be the oldest (table 
3.6).  This was expected given that rs11072507 G was observed in the chimpanzee (ancestral 
allele) whereas all of the dated CYP1A2 variants were not (i.e. they were derived alleles) and 
would have post-dated rs11072507 G.   
 
All coalescent dates estimated on the background of either rs11072507 C or G did not pre-date 
the rs11072507 C or G allele respectively, with one exception.  The coalescent date of -163 
A>C, dated on the background of rs11072507 C, was estimated to be older than rs11072507 C 
(table 3.6).  This can however be due to the recombination event involving both -163 A>C and 
rs11072507 (table 3.7). 
 
In order to establish whether the date estimates were consistent with the evolution of CYP1A2 
in  humans,  a  rooted  network  of  haplotypes  (CYP1A2  entire  gene  plus  rs11072507  SNP) 
observed in the Ethiopian ascertainment population was produced.  The network is shown in 
figure 3.13 whilst the haplotypes are shown in table 3.7.  All SNP coalescence date estimates 
(table  3.6)  were  consistent  with  the  relative  positions  of  the  SNPs  in  the  mutation  network 
(figure 3.13), i.e. SNPs on internal branches were older than SNPs on external branches.   
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Table 3.7   CYP1A2 plus rs11072507 haplotypes.  Haplotype network is shown in figure 3.13.
Nucleotide change 
1 -1014 -1008 -739 -729 -592 -505 -163 -151 53 1352 1370 1513 1589 2159 2321 3463 3468 4957 4961 5010 5015 5094 5105 5253 5284 5328 5347 5355 6765 rs11072507
C>A G>A G>T C>T C>T G>A A>C G>T C>G G>A G>A C>A G>T G>A G>C C>T A>C C>G C>T C>T C>G T>C G>A C>G C>A G>A C>T G>C C>T G>C
1 2 3 4 5 7 8 9 11 16 17 18 19 20 21 22 23 24 25 26 27 29 30 31 32 33 34 35 36 37
Location 5' upstream 5' upstream Intron 1 Intron 1 Intron 1 Intron 1 Intron 1 Intron 1 Exon 2 Intron 2 Intron 2 Exon 3 Intron 3 Intron 4 Intron 4 Exon 6 Exon 6 Intron 6 Intron 6 Intron 6 Intron 6 Exon 7 Exon 7 Exon 7 Exon 7 Exon 7 Exon 7 3' UTR 3' UTR SNPstr
Amino acid change S18C S298R T395M N397H F432S D436N P485R Y495Ter R510Q N516N
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
Haplotype id 
2 18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
1 Position from base A in the initiation codon (A in ATG is +1, base prior to A is -1) from the CYP1A2 genomic reference sequence (NC_000015.8)
2 White cell, non-derived allele, grey cell, derived allele.  
SNPs highlighted in purple only occurred on the background of rs11072507 G.  
SNPs highlighted in yellow were observed on the background of both rs11072507 G and C.  
Although recombination was not observed between -739 G>T (highlighted in green) and rs11072507 (only three haplotypes observed between the two SNPs), since -163 A>C only occurred on background of -739 T and since 
recombination was observed between -163 A>C and rs11072507 (four haplotypes observed between the two SNPs) and -739 T and -163 C are located close to each other, recombination was assumed to have occurred on the 
background of -739 T.  
Mutated position in mutation 
network
Nucleotide changes in bold were dated.  3613 T>C (intron 6), 5620 A>C (3' UTR) and 6324 G>del (3' UTR) were also dated but are not shown here because their allelic status in the chimpanzee and macaque is not known and 
haplotypes shown here were used to construct a mutation network (figure 3.13).  Haplotype analysis did however reveal that 3613 T>C and 6324 G>del only occurred on the background of rs11072507 G, whilst 5620 A>C occurred 
on the background of both rs11072507 G and C (data not shown).    82 
Figure  3.13    Mutation  network  of  haplotypes  (CYP1A2  entire  gene  plus  rs11072507  SNP)  observed  in  the 
Ethiopian ascertainment populations.  Nodes represent haplotypes (table 3.7) and mutated positions are shown in 
red along the grey links.  All links are drawn to scale.  The network was rooted using haplotypes from the chimpanzee 
and macaque.  Dated SNPs are highlighted in blue.  Alleles at positions 3613, 5620 and 6324 (which have been dated) 
could not be included in the network since their status in the chimpanzee and macaque was not known.  The network is 
consistent with the network shown in figure 3.4.   
 
 
 
3.3.3.4  Approximate dates for non-synonymous CYP1A2 variants 
 
Dates could not be estimated from microsatellite data for many of the non-synonymous variants 
observed in the Ethiopian ascertainment populations. The positions of these variants within the 
network (figure 3.13), relative to dated variants, were however used to estimate their coalescent 
dates as follows: 
 
•  Since 53 C>G (S18C at mutated position 11), 5253 C>G (P485R at mutated position 31) 
and 5284 C>A (Y495Ter at mutated position 32) occurred on the background of 1513 C>A 
(at mutated position 18), all three variants were expected to be younger than 1513 C>A 
(245,000 years). 
 
•  Since  3468  A>C,  (N397H  at  mutated  position  23)  and  5105  G>A  (D436N  at  mutated 
position 30) occurred on the background of rs11072507 G>C (at mutated position 37), both 
variants were expected to be younger than rs11072507 G>C (114,000 years).   83 
 
•  Since 3463 C>T (T395M at mutated position 22) and 5094 T>C (F432S at mutated position 
29) were on the background of 2159 G>A (at mutated position 20), both variants were also 
expected to be younger than 2159 G>A (95,400 years). 
 
3.4  Discussion 
3.4.1  Network analysis of CYP1A2 haplotypes 
 
This  study  has  unveiled  a  network  of  CYP1A2  haplotypes  observed  in  the  Ethiopian 
ascertainment and NIEHS populations and has compared human CYP1A2 DNA sequences to 
those found in chimpanzee, orangutan and Rhesus macaque genomes.  Of all the CYP1A2 
exons, exon 5 was the most conserved throughout primate evolution showing 100 % similarity 
to the chimpanzee’s sequence.  Exons 4 and 1 were also highly conserved among the primates.  
These results are unsurprising since exon 1 is the 5’ UTR and contains the leader sequence of 
the gene (Ikeya et al., 1989), thus playing a crucial role in protein expression, and exon 4 is 
thought to contain part of the enzyme’s active site (Sansen et al., 2007).  Situated in the middle 
of the gene and in close proximity to exon 4, exon 5 is likely to play a pivotal role in the structure 
and functioning of the protein.  Exon 2 on the other hand was the least conserved exon.  This 
too is expected given its distance from the location of the presumed active site. 
 
Consistent with other studies investigating relationships between primates (e.g. Bailey et al., 
1991), the chimpanzee, orangutan and macaque were generally linked to the human clade via a 
single  common  branch  with  the  chimpanzee  being  the  most  similar  to  the  humans,  usually 
followed by the orangutan, then the macaque.  In some networks, the orangutan was the most 
dissimilar to the humans, however this may be explained by missing data since the orangutan 
CYP1A2 sequence has yet to be fully characterised. 
 
Contrary to the combined cds region, the modal human haplotype for the entire CYP1A2 gene, 
which was observed in all Ethiopian ascertainment and NIEHS populations, was not the most 
similar human node to the chimpanzee.  Consequently, it appears that non-coding CYP1A2 
variants have been tolerated more than coding CYP1A2 variants throughout evolution, a finding 
which is to be expected if purifying selection has been taking place.  A haplotype confined to 
Ethiopia, and which was connected to many other haplotypes specific to Ethiopia, was most 
similar to the chimpanzee in the CYP1A2 entire gene network.  In light of this, it appears that 
out of the populations included  in this analysis, the  Ethiopians may  have retained ancestral 
forms of CYP1A2. 
 
In the vast majority of cases, single mutations (single steps) linked human CYP1A2 haplotypes 
together.  Retention of almost all the steps between haplotypes is consistent with population 
expansion.    In  some  instances,  intermediate  haplotypes  were  missing  in  the  networks.    84 
Potentially  common  intermediate  haplotypes  were  missing  in  the  NIEHS  sample  sets  (since 
intermediate  haplotypes  linking  common  haplotypes  together  were  not  observed),  whilst 
potentially  rare  intermediate  haplotypes  were  missing  in  the  Ethiopians  (since  intermediate 
haplotypes connecting two singletons to their respective progenitor haplotypes were not found).  
These findings are likely to reflect the power of the sample sizes used in this study to detect 
variants within the actual populations (refer to the discussion in chapter 2 for further information 
regarding sample sizes and power calculations). 
 
All of the CYP1A2 haplotypes predicted to code for a protein with altered activity were observed 
in the external branches of the networks, and may consequently be recent (coalescent dates 
are discussed towards the end of this chapter).  They appeared to evolve from two haplotypes 
and the vast majority evolved from just one (which is characterised as entire gene haplotype 12 
in this chapter).   In view of this, perhaps entire gene haplotype 12 is more mutable than others.  
The haplotype itself is predicted to code for an undamaged CYP1A2 protein, but could be in 
linkage  disequilibrium  with  a  variant  outside  of  the  gene  that  increases  its  susceptibility  to 
mutations likely to alter the structure/function of the protein. 
 
3.4.2  Testing for selection in CYP1A2 
 
Fu and Li’s tests pointed towards selection (purifying or positive) in CYP1A2 in Amhara and 
Oromo but Tajima’s D and the McDonald-Kreitman test did not detect selection in any of the 
populations analysed in this study.  These neutrality test statistics do not have the ability to 
distinguish between demographic effects and selection, and lack power to detect very recent 
selection pressures when the selected lineage may be in the minority.  The methods also have 
little  power  to  detect  selection  when  intragenic  recombination  (Wall,  1999)  and  population 
structuring are evident (Przeworski, 2002).  Given that all of the CYP1A2 haplotypes predicted 
to code for a protein with altered activity may be recent, and recombination was inferred in the 
Ethiopian ascertainment populations, and since it is common place for Ethiopian populations to 
form hierarchical societies (Freeman & Pankhurst, 2003), it is therefore possible that selective 
pressures  operating  on  CYP1A2  would  not  be  detected  by  these  commonly  used  neutrality 
tests. 
 
A study involving 2784  SNPs, in  396 protein coding genes, in  an  ethnically  diverse sample 
showed  that  reduction  of  both  intra-population  gene  diversity  and  inter-population  genetic 
distance for non-synonymous SNPs (predicted to cause radical changes to protein structure) in 
comparison to SNPs in the same genes which have no effect on protein structure is evidence 
that purifying selection has acted at these non-synonymous SNP sites (Hughes et al., 2003; 
Hughes et al., 2005).  When this approach was applied to the variation observed in CYP1A2 in 
the Ethiopian ascertainment and NIEHS populations, intra-population gene diversities and inter-
population genetic distances were generally lowest for SNPs expected to have greatest impact 
on protein structure (radical  non-synonymous  SNPs and the nonsense mutation  in  exon  7).    85 
These results are consistent with the hypothesis that purifying selection has affected the allele 
frequencies  of  SNPs,  predicted  to  have  greatest  impact  on  protein  structure,  in  CYP1A2  in 
humans.  Evidence of purifying selection at these SNP sites was strengthened when genetic 
hitchhikers  of  non-synonymous  SNPs  (which  may  affect  differences  in  gene  diversity  and 
genetic distance) were taken into account.  This variable was not considered by Hughes et al. 
(2003) and Hughes et al. (2005), possibly due to the nature of the dataset studied. 
 
Purifying selection was also evidenced in the case of conservative non-synonymous SNPs, as it 
was in Hughes et al. (2003), through comparison of human sequences with orthologous mouse 
sequences  at  conservative  non-synonymous  SNP  sites.    Comparisons  with  chimpanzee 
sequences  were  also  performed  to  increase  the  depth  of  the  analysis.    Results  were  in 
accordance with the hypothesis that, given the functional constraints on evolutionary conserved 
amino  acids,  purifying  selection  acts  against  mutations  which  introduce  amino  acids  not 
observed  in  the  mouse  or  chimpanzee.    Further  evidence  of  purifying  selection  at  these 
conservative non-synonymous SNP sites was also provided by the observation that the higher 
frequency human alleles, at all conservative SNP sites, encoded residues which have been 
conserved throughout mammalian evolution. 
 
Contrary to our expectations, gene diversity and genetic distance for 5’ non-coding SNPs was 
often  lower  than  that  for  radical  non-synonymous  SNPs.    This  may  be  explained  by  small 
sample size since there were only two SNPs in the 5’ non-coding category.  It is possible that 
the results would be different if the numbers were increased.  It is noteworthy to mention that 
variability in only one gene was analysed in this study, as opposed to 396 in Hughes et al. 
(2005).  Although this study may have lacked power in the number of genes analysed, it has 
shown that Ethiopians are a good population for detecting signatures of purifying selection in 
humans because, through being an old population and maintaining a relatively large population 
size, they have retained a number of mutations likely to be under purifying selection. 
 
Contrary to expectations for a SNP which introduces a premature stop codon into the gene, 
mean gene diversites and genetic distances for the nonsense SNP were never lower than those 
for radical non-synonymous SNPs.  In view of this, it is possible that this nonsense SNP may 
not be too important to the structure/function of the enzyme given its proximity to the end of the 
gene (exon 7). 
 
Population frequencies of the minor allele at SNP sites which showed evidence of purifying 
selection were generally in the range of 1-10 %.  Other studies (Hughes et al., 2003; Hughes et 
al., 2005; Wong et al., 2003) have also reported numerous non-synonymous SNPs with similar 
minor  allele  frequencies  in  human  genes.    These  frequencies  are  substantially  higher  than 
those of genes causing severe Mendelian disease phenotypes such as Huntington’s Chorea 
and cystic fibrosis (McKusick and Francomano, 1997), suggesting that these non-synonymous 
SNPs are not as deleterious as those causative of severe disease types.  This in turn suggests 
that the selective forces acting against these non-synonymous SNPs are modest in comparison   86 
to those at SNP sites causative of severe disease (Hughes et al., 2003; Hughes et al., 2005).  
Since mutations associated with complex diseases are expected to be individually only slightly 
deleterious,  as  opposed  to  highly  deleterious  variants  associated  with  Mendelian  diseases, 
evidence  of  mild  purifying  selection  may  be  used  to  identify  candidate  alleles  for  complex 
disease-association studies (Hughes et al., 2003). 
 
As reviewed in Hughes et al. (2003) and Hughes et al. (2005), the observation of purifying 
selection  acting  against  slightly  deleterious  alleles  which  are  present  at  relatively  high 
frequencies in the human population is in accordance with the nearly neutral theory of molecular 
evolution (Ohta, 1973; Ohta, 1976; Ohta, 2002).  This theory predicts that slightly deleterious 
mutations can reach high frequencies (effectively acting as if they were selectively neutral) due 
to  genetic  drift  when  population  size  is  small.    As  effective  population  size  increases  and 
purifying selection becomes more effective, it is predicted that slightly deleterious alleles, which 
reached high frequencies in bottlenecked populations due to drift, will decrease gradually over 
time.  It is a widely accepted view that the human population has expanded since the origin of 
anatomically modern human 100,000 – 250,000 years ago and has experienced a number of 
bottlenecks  (Harpending  et  al.,  1998;  Watkins  et  al.,  2003;  Zhitovsky  et  al.,  2003).    The 
mutations evidenced to be under purifying selection in this study may be recent in origin, but 
may also include variants which drifted to high frequencies in smaller ancestral populations. 
 
3.4.3  CYP1A2 chronology 
 
Human and chimpanzee lineages are generally assumed to have diverged approximately 5-7 
million years ago (Chen and Li, 2001; Carroll, 2003) with the human genus (Homo) originating 
in  Africa  (Horai  et  al.,  1995;  Ingman  et  al.,  2000;  Thomson  et  al.,  2000;  Ke  et  al.,  2001).  
Morphological traits from fossils support the idea of a recent origin for modern humans in Africa 
less than 200,000 years ago (White et al., 2003; McDougall and Fleagle, 2005; Campbell and 
Tishkoff, 2008).  According to the ‘Out of Africa’ model of human evolution, modern humans 
originated in Africa and colonised the rest of the globe in the last ~ 100,000 years (Tishkoff and 
Verrelli, 2003).  Evidence suggests that humans may have migrated out of Africa, reaching the 
Middle East and Europe, Asia and Australia by 30 – 50,000 years ago, and the Americas some 
15 – 30,000 years ago (Campbell and Tishkoff, 2008). 
 
The coalescent date estimates of the CYP1A2 variants in this study were old in terms of the 
emergence  of  anatomically  modern  human  and  all,  except  for  1589  G>T,  pre-dated  the 
expansion of humans out of Africa, less than ~ 100,000 years ago.  In fact, five variants (-739 
G>T and -163 A>C, both of which are in intron 1, 1513 C>A in exon 3 causing S298R, 3613 
T>C in intron 6 and 6324 G>del in the 3’ UTR) were estimated to have arisen prior to the 
emergence of modern humans in Africa.  We saw from chapter 2 that whilst 1589 G>T (the 
youngest CYP1A2 variant in this study) was confined to Ethiopia, -163 C>A and -739 T in intron 
1, 2159 G>A (intron 4) and 3613 T>C (intron 6) were found in populations worldwide.  This is   87 
not unexpected given their relative coalescent date estimates.  On the other hand however, 
1513 C>A (S298R) and 6324 G>del (3’ UTR) were only found at appreciable frequencies in 
populations with a recent African ancestry and may belong to a subset of alleles which did not 
leave Africa.  Likewise, 5620 A>C (3’ UTR) was only observed in Ethiopian populations and 
despite  its  age  may  also  belong  to  a  subset  of  alleles  which  did  not  leave  Ethiopia.  
Interestingly, non-synonymous 5347 C>T (exon 7) was observed on a global scale but was not 
found in Yoruba and may have not therefore been transferred from East to West Africa during 
the early expansion of African populations.  The G>C SNP (rs11072507) in the SNPstr has 
been  reported  in  the  Japanese  (14.6  %)  and  Chinese  (10.5  %)  HapMap  populations 
(http://www.hapmap.org/)  but  was  also  not  observed  in  Yoruba.    Perhaps  this  allele  also 
followed a similar route to 5347 C>T. 
 
Although many of the coalescent dates for non-synonymous variants could not be estimated 
using microsatellite data, they could be placed within a time frame because the positions of 
these non-synonymous variants in the CYP1A2 network, relative to variants which were dated, 
were known.  The approximate time frame of these alleles was consistent with the hypothesis 
that the mutations evidenced to be under purifying selection in the Ethiopian ascertainment and 
NIEHS populations may include variants which drifted to high frequencies in smaller ancestral 
populations. 
 
Although  the  coalescent  date  estimates  appear  to  be  consistent  with  the  human  CYP1A2 
mutation network, they should be treated cautiously.  Their confidence intervals are large and 
more samples and/or microsatellites are needed to improve time point estimates and reduce the 
confidence intervals.  Furthermore, a novel A>C SNP was observed in the Amhara (8.3 %) at 
the penultimate base of the AC microsatellite which was used to date CYP1A2 alleles in this 
study.    This  variant  may  affect  the  mutation  rate  of  the  microsatellite  which  is  important  in 
determining estimates of the time to the most recent common ancestor. 
 
3.5  Conclusion 
 
This study has produced a rooted CYP1A2 haplotype network which is consistent with humans 
evolving from non-human primates with the chimpanzee being their closest living relative.  Of 
the  populations  used  in  the  network,  which  included  those  with  a  recent  African  ancestry, 
Europeans, Hispanics (partial African ancestry) and East Asians, a CYP1A2 haplotype in the 
Ethiopian dataset was most similar to that of the chimpanzee.  Haplotype networks revealed a 
varying  level  of  conservation  among  the  CYP1A2  exons  and  showed  that  all  haplotypes 
predicted to code for a protein with altered activity were observed in the external branches of 
the network.  Furthermore, most of these potentially damaging haplotypes evolved from a single 
haplotype which may be susceptible to non-synonymous mutations.  Commonly used neutrality 
tests  lacked  power  in  detecting  signatures  of  selective  processes  in  this  study.    Purifying 
selection was however evidenced in CYP1A2 in the human population through an approach   88 
which takes into account intra-population gene diversity and inter-population genetic distance.  
The time to most common recent ancestor of nine CYP1A2 variants was estimated using an AC 
microsatellite situated 5.6 kb downstream of the end of CYP1A2.  Coalescent date estimates 
place most variants into a period which pre-dates the expansion of anatomically modern human 
out of Africa and into the New World, e.g. -739 G>T in intron 1 is estimated to be ~369,000 
years old with a 95 % confidence interval of 319,000 – 429,000 years.   
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4  Can  data  reported  by  the  CYP450  Allele 
Nomenclature  Committee  be  used  to  design  a 
diagnostic  test  to  predict  CYP1A2  functional 
variation in Ethiopian populations? 
 
4.1  Introduction 
 
Individualised medicine is a concept in which healthcare intervention utilises information about a 
patient’s  specific  characteristics  (including  genes,  phenotype  and  lifestyle)  to  better  match 
intervention to an individual's needs (Kawamoto et al., 2009).  Such information could be used 
to  help  distinguish  disease  status,  choose  between  different  medications  and/or  tailor  their 
dosage, provide a specific therapy, or initiate a preventative measure at an appropriate time.  
Individualised medicine is not in widespread clinical use, but some aspects of the approach 
have been established in medical practice (Arnett et al., 2009).  As an example, knowledge of 
polymorphisms  in  CYP2C9  and  vitamin  K  epoxide  reductase  (VKORC1),  has  led  to 
commercially  available  tests  which  enable  more  accurate  dosing  of  the  anticoagulant  drug 
warfarin (http://www.fda.gov/bbs/topics/NEWS/2007/NEW01701.html).  The tests are based on 
algorithms  that  take  into  account  the  age,  gender,  weight,  and  CYP2C9  and  VKORC1 
genotypes of an individual.   
Individualised medicine may be unrealistic in Africa for the foreseeable future due to sparse 
funds and rudimentary healthcare infrastructure.  Since CYP450 allelic variants are known to be 
distributed  differently  among  ethnic  groups  and/or  geographic  regions  (see  chapter  2  with 
respect  to  CYP1A2),  it  may  be  feasible  to  decide  between  alternative  medical  intervention 
options using group derived pharmacogenetic profiles when individual characterisation is not 
possible.    An  aim  of  the  research  programme  of  which  this  project  is  part,  is  to  develop  a 
diagnostic test (based on genetic markers) to predict the functional variation of CYP1A2 among 
different Ethiopian populations, with a view to seeing if ethnic identity, or geographic location, is 
useful in  predicting efficacy  and safety of therapeutic interventions.  The use of ethnicity  or 
geographic location as a proxy for the prediction of drug response could potentially be beneficial 
to  medical  practice  and  public  health  policy  makers  in  Ethiopia.    For  instance,  medical 
professionals may be able to prescribe drugs most likely to be most effective in the group being 
treated, when the genetic profiles of individuals are not known.   
The diagnostic test will be based on genetic markers, within CYP1A2,  which  should offer a 
higher throughput, more practical and efficient approach than phenotype testing would (e.g. with 
caffeine).   
The importance of predicting CYP1A2 functional variation in Ethiopian populations is highlighted 
by  the  fact  that  many  pharmaceuticals,  which  may  be  metabolised  by  CYP1A2,  are   90 
administered in Ethiopia.  Examples include primaquine and praziquantel (Li et al., 2003) which 
are used as the first line  of treatment for malaria and schistosomiasis respectively (Federal 
Democratic Republic of Ethiopia Ministry of Health, 2004).  Other examples of pharmaceuticals 
metabolised by CYP1A2 are shown in table 4.1.   
Table 4.1  Pharmaceuticals metabolised by CYP1A2 (derived from http://medicine.iupui.edu/flockhart/table.htm) 
 
Drug  Treatment 
Phenacetin 
Naproxen 
Acetaminophen 
Pain relief 
Mexiletine  Antiarrhythmic 
Warfarin  Anticoagulant 
Amitriptyline 
Clomipramine 
Fluvoxamine 
Imipramine N-DeMe 
Antidepressant 
Ondansetron  Antiemetic 
Clozapine 
Haloperidol 
Olanzapine 
Antipsychotic 
Propranolol  Hypertension 
Verapamil  Hypertension, angina, certain heart rhythm disorders 
Zileuton  Respiratory disease 
Ropivacaine  Local anaesthetic 
Theophylline  Respiratory disease 
Cyclobenzaprine 
Tizanidine 
Muscle relaxant 
Tacrine  Alzheimer's disease 
Zolmitriptan  Migraine 
Estradiol  Menopause or prostate cancer, ovarian failure, hypogonadism 
Riluzole  Motor neuron disease 
 
4.1.1  Aim 
The aim of this project is to establish whether it is possible to predict population level CYP1A2 
functional variation in Ethiopia on the basis of known variants.  The following steps are required 
in order to do this: 
Step 1:  Design a typing strategy, based on previously reported sequence and functional data, 
to  predict  CYP1A2  functional  variation  among  populations.    Begin  by  identifying  all  known 
CYP1A2 allelic variants reported by the CYP450 Allele Nomenclature Committee and assign 
each  variant  with  an  associated  phenotype  from  previously  reported  functional  data.    The 
predicted phenotype categories may be: non-functional, reduced metabolic activity, increased 
metabolic activity, normal (CYP1A2*1A-like) metabolic activity or unknown function.  Generate a 
network of these CYP1A2 alleles to help select the minimum number of polymorphisms which 
need to be typed in order to predict CYP1A2 phenotypes.  Compile an algorithm to determine 
the predicted CYP1A2 phenotype based on CYP1A2 polymorphic states.   
   91 
Step  2:    Establish  what  CYP1A2  functional  variation  is  predicted  to  exist  in  Ethiopia  by 
sequencing  all  seven  CYP1A2  exons  and  flanking  introns  in  the  Ethiopian  ascertainment 
populations.  
 
Step 3:  Apply the algorithm from step 1 to variation observed from step 2 to establish the extent 
to which the algorithm, based on known variation, predicts functional variation predicted from 
CYP1A2 sequences in the Ethiopian ascertainment populations.   
 
Step  4:    If  the  algorithm  based  on  known  variation  fails  to  predict,  or  incorrectly  predicts 
CYP1A2  functional  variation  predicted  from  sequencing  the  Ethiopian  ascertainment 
populations,  establish  how  much  genotype/phenotype  testing  is  required  to  improve  the 
diagnostic test for Ethiopia.   
 
4.2  Methods 
 
The  Ethiopian  ascertainment  sequences  described  in  chapter  2  were  used  in  this  study  in 
addition to genotype  data from -3860 G>A  and -2467 delT (see below).   Missing  data  was 
excluded from the analysis and haplotypes were inferred by the ELB approach (Excoffier et al., 
2003).  Refer to the methods section in chapter 2 for details regarding sample collection, DNA 
extraction,  sequencing,  testing  for  deviation  from  Hardy  Weinberg  equilibrium,  haplotype 
inference and CYP1A2 phenotype predictions.   
 
Mutation  networks  were  constructed  using  Network  software,  version  4.510  (fluxus-
engineering.com).    Median  joining  networks  were  constructed  to  limit  levels  of  reticulation 
(Bandelt et al., 1999).  The algorithm used to construct these median joining networks is based 
on the limited introduction of likely ancestral sequences/haplotypes into a minimum spanning 
network  of  the  observed  sequences.    The  resultant  networks  were  drawn  using  Network 
publisher, version 1.1.0.7 (Fluxus Technology Ltd).   
 
4.2.1  Genotyping of -3860 G>A and -2467 T>- 
 
Genotyping of -3860 G>A (rs35694136) and -2467 T>- (rs2069514) was performed using the 
ABI  TaqMan  SNP  genotyping  assay  C__60142977_10  and  C__15859191_30  respectively 
(Applied Biosystems (ABI), Warrington UK).  Each assay contained a mix of unlabeled PCR 
primers and TaqMan MGB probes (FAM and VIC dye-labeled) for the allelic discrimination of 
each  SNP.    Details  of  the  oligonucleotides  are  not  disclosed  and  are  patented  by  ABI  (US 
patents  and  corresponding  patent  claims  outside  the  US:  5,538,848,  5,723,591,  5,876,930, 
6,030,787, 6,258,569, and 5,804,375 (claims 1-12 only)).  The amplicon sequence for each 
assay is however made available by ABI to reviewers on request.   
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DNA was amplified in 384 well microplates and in 4 µl reaction volumes containing 1 µl of 1 
ng/µl DNA, 2 µl of 1x TaqMan Genotyping Master Mix (Applied Biosystems (ABI), Warrington 
UK), 0.2 µl of 20x assay mix (containing primers and probes from Applied Biosystems (ABI), 
Warrington UK) and 0.8 µl of sterile water.  The thermal cycler conditions were: 10 minutes of 
pre-incubation at 95 ºC, followed by 40 cycles of 15 seconds at 92 ºC and 1 minute at 60 ºC.  
The resultant PCR product was analysed using TaqMan 7900HT software (Applied Biosystems 
(ABI), Warrington UK).   
 
4.3  Results 
4.3.1  Step  1:    Diagnostic  test  to  predict  CYP1A2  functional  variation  among 
populations:  test built from known CYP1A2 variation 
 
A  mutation  network  was  drawn  using  the  CYP1A2*  alleles  reported  by  the  CYP450  Allele 
Nomenclature Committee (figure 4.1) in order to choose the minimum number of polymorphisms 
which  need to  be typed to distinguish  between each of the  independently  evolved  CYP1A2 
allele phenotypes.  A total of 15 polymorphisms were selected (highlighted with * in figure 4.1). 
 
The algorithm which will determine the predicted CYP1A2 phenotype based on the particular 
combination of alleles observed is shown in figure 4.2.  As examples, chromosomes with -3860 
G>A or -729 C>T are predicted to code for a slow functioning protein, whilst chromosomes with 
-2467 delT, or with -163 C>A but not -739 T>G and -729 C>T, are predicted to code for a 
protein whose function is not known.   
 
Figure 4.2   Algorithm (based on known variation) for predicting CYP1A2 metabolic activity.  White columns 
represent different chromosomes.  √ = mutation must be present, x = mutation must be absent.  Chromosomes which 
cannot be assigned to one of the predicted functions shown in the table are predicted to have a normal (CYP1A2*1A-
like) functioning CYP1A2 allele.   
 
Predicted CYP1A2 metabolic activity  Marker 
in 
figure 
4.1 
Mutation 
Slow  Non-functional  Undetermined  Normal  
1  -3860G>A  √                                              
7  -2467delT                                   √             
8  -739T>G                                      x  √     √ 
10  -729C>T     √                                x  x     x 
12  -163C>A                                      √  x     √ 
13  63C>G                          √                      
14  125C>G        √                                   x    
17  558C>A           √                                     
25  2473G>A              √                             x    
26  2499A>T                             √                   
27  3496G>A                                √                
28  3533G>A                 √                               
29  5090C>T                       √                         
31  5166G>A                    √                       x    
32  5347T>C                                            √      93 
Figure 4.1  Mutation network of CYP1A2* alleles.  Nodes represent CYP1A2* alleles reported by the CYP450 Allele Nomenclature Committee (http://www.cypalleles.ki.se/cyp1a2.htm (04/06/09).  See 
table 2.6 (chapter 2) for references concerning allele phenotypes.  Mutated positions are shown in red along the grey links.  All links are drawn to scale.  The network was used to help select the minimum 
number of polymorphisms (*) which need to be typed in order to predict CYP1A2 phenotypes.  Reticulations are observed in the network with the consequence that some markers appear more than once.   
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4.3.2  Step 2: CYP1A2 functional variation predicted from sequencing CYP1A2 in the 
Ethiopian ascertainment populations 
 
The enhancer region was not sequenced (see chapter 2) with the consequence that -3860 G>A 
and -2467 delT were not characterised via sequencing.  Since -3860 G>A and -2467 delT were 
included in the algorithm and were needed to differentiate chromosomes into undetermined or 
reduced  metabolic  activity  phenotypes,  in  this  study,  both  SNPs  were  genotyped  in  the 
Ethiopian ascertainment populations.  For each SNP, no population deviated significantly from 
Hardy  Weinberg  equilibrium  at  5  %  significance.    Both  SNPs  were  polymorphic  in  all 
populations (table 4.2).   
 
Table 4.2  -3860 G>A and -2467 T>- frequencies in the Ethiopian ascertainment populations 
 
Afar  Amhara  Anuak  Maale  Oromo  Ethiopia  
SNP  n  f  n  f  n  f  n  f  n  f  n  f 
-3860 G>A  26  0.19  21  0.14  43  0.29  24  0.17  28  0.21  142  0.20 
-2467 T>-  7  0.05  6  0.04  30  0.21  11  0.08  12  0.08  66  0.09 
  
n = number of chromosomes, f = frequency of the minor allele 
 
A total of 60 CYP1A2 haplotypes (including alleles at positions -3860 and -2467) were observed 
in the combined Ethiopian ascertainment population (table 4.3), 52 % of which were assigned a 
reduced CYP1A2 predicted metabolic activity, 3 % of which were predicted to code for a non-
functional enzyme and 45 % of which were assigned an unknown CYP1A2 function.  Haplotype 
distribution  (table  4.4)  varied  among  populations  but  haplotype  3  (CYP1A2*1B),  which  was 
assigned an unknown function, was the most frequent haplotype in all groups (≥ 28 %).   
 
4.3.3  Step 3:  Application of the CYP1A2 diagnostic test (based on known data) to the 
Ethiopian ascertainment population, and the extent to which it predicts functional 
variation predicted from sequencing CYP1A2 
 
Of  the  15  CYP1A2  SNPs  included  in  the  algorithm  (from  step  1),  six  were  observed  to  be 
polymorphic in the Ethiopian ascertainment populations.  These were:  -3860 G>A, -2467 delT, -
739 T>G, -729 C>T, -163 C>A and 5347 T>C.   
 
Figure  4.3a  shows  the  outcome  of  the  diagnostic  test  once  it  was  applied  to  the  variation 
observed in the Ethiopian ascertainment populations in this study.  Over 38 % of chromosomes 
in  each  population  were  predicted  to  code  for  a  protein  with  a  normal  CYP1A2  function.  
Between 14 – 29 % of chromosomes in each group were predicted to code for proteins which 
function slowly but no non-functional alleles were predicted in any one group.   
 
Figure 4.3b shows the CYP1A2 functional variation predicted from sequencing CYP1A2 in the 
Ethiopian ascertainment populations. Similar to predictions from the diagnostic test (figure 4.3a) Table 4.3  CYP1A2 haplotypes observed in the Ethiopian ascertainment populations and their predicted CYP1A2 metabolic activities (frequencies are shown in table 4.4)
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Predicted phenotypes: Haplotypes 38 and 42 were predicted to code for a truncated protein owing to the premature stop codon (P495Ter) in exon 7 (chapter 2). The -3860 G>A SNP in the enhancer region, which was reported as being
causative of reduced CYP1A2 inducibility in Japanese smokers, most probably owing to reduced protein expression (Nakajima et al., 1999), was observed in just over half (52 %) of the haplotypes, which were assigned a reduced CYP1A2
metabolic activity as a result. Some of the haplotypes with -3860 G>A also included other variants associated with a reduced CYP1A2 metabolic activity: Haplotype 54 included -729 C>T which was reported to code for a reduced functional
allele (Aklillu et al., 2003); haplotypes 27 and 53 included amino acid substitutions S18C (exon 2) and P485R (exon 7) respectively, both of which were predicted to have a damaging effect on the structure/function of the protein by PolyPhen
software (chapter 2). Haplotype 31 was assigned a reduced CYP1A2 metabolic activity since it included the amino acid change F432S in exon 7 which was also predicted to have a damaging effect on the structure/function of the protein by
PolyPhen software (chapter 2).  
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1 Position from base A in the initiation codon (A in ATG is +1, base prior to A is -1) from the CYP1A2 genomic reference sequence (NC_000015.8)
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Table 4.4  CYP1A2 haplotype distribution among the combined and individual Ethiopian ascertainment populations
n f n f n f n f n f n f
1 27 0.28 40 0.34 5 0.04 16 0.13 22 0.24 110 0.197
2 1 0.01 0 0.00 2 0.01 1 0.01 1 0.01 5 0.009
3 35 0.36 50 0.42 63 0.47 34 0.28 27 0.30 209 0.375
4 5 0.05 9 0.08 1 0.01 13 0.11 6 0.07 34 0.061
5 2 0.02 0 0.00 0 0.00 0 0.00 0 0.00 2 0.004
6 2 0.02 0 0.00 2 0.01 0 0.00 1 0.01 5 0.009
7 2 0.02 1 0.01 5 0.04 0 0.00 1 0.01 9 0.016
8 2 0.02 0 0.00 0 0.00 0 0.00 0 0.00 2 0.004
9 4 0.04 2 0.02 8 0.06 0 0.00 1 0.01 15 0.027
10 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 1 0.002
11 2 0.02 0 0.00 0 0.00 1 0.01 0 0.00 3 0.005
12 1 0.01 0 0.00 4 0.03 0 0.00 2 0.02 7 0.013
13 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 1 0.002
14 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 1 0.002
15 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 1 0.002
16 1 0.01 0 0.00 5 0.04 19 0.16 3 0.03 28 0.050
17 1 0.01 1 0.01 3 0.02 3 0.03 4 0.04 12 0.022
18 1 0.01 1 0.01 0 0.00 2 0.02 1 0.01 5 0.009
19 1 0.01 1 0.01 2 0.01 2 0.02 0 0.00 6 0.011
20 1 0.01 0 0.00 0 0.00 1 0.01 0 0.00 2 0.004
21 1 0.01 4 0.03 0 0.00 7 0.06 3 0.03 15 0.027
22 2 0.02 0 0.00 0 0.00 0 0.00 2 0.02 4 0.007
23 1 0.01 0 0.00 0 0.00 0 0.00 0 0.00 1 0.002
24 0 0.00 1 0.01 0 0.00 0 0.00 0 0.00 1 0.002
25 0 0.00 2 0.02 0 0.00 0 0.00 0 0.00 2 0.004
26 0 0.00 1 0.01 0 0.00 0 0.00 2 0.02 3 0.005
27 0 0.00 1 0.01 1 0.01 0 0.00 0 0.00 2 0.004
28 0 0.00 1 0.01 1 0.01 7 0.06 1 0.01 10 0.018
29 0 0.00 1 0.01 0 0.00 0 0.00 0 0.00 1 0.002
30 0 0.00 1 0.01 0 0.00 0 0.00 0 0.00 1 0.002
31 0 0.00 1 0.01 0 0.00 0 0.00 0 0.00 1 0.002
32 0 0.00 0 0.00 8 0.06 1 0.01 2 0.02 11 0.020
33 0 0.00 0 0.00 10 0.07 0 0.00 0 0.00 10 0.018
34 0 0.00 0 0.00 1 0.01 0 0.00 0 0.00 1 0.002
35 0 0.00 0 0.00 1 0.01 0 0.00 0 0.00 1 0.002
36 0 0.00 0 0.00 3 0.02 0 0.00 0 0.00 3 0.005
37 0 0.00 0 0.00 1 0.01 0 0.00 0 0.00 1 0.002
38 0 0.00 0 0.00 3 0.02 0 0.00 0 0.00 3 0.005
39 0 0.00 0 0.00 1 0.01 0 0.00 0 0.00 1 0.002
40 0 0.00 0 0.00 1 0.01 1 0.01 0 0.00 2 0.004
41 0 0.00 0 0.00 1 0.01 1 0.01 0 0.00 2 0.004
42 0 0.00 0 0.00 1 0.01 0 0.00 0 0.00 1 0.002
43 0 0.00 0 0.00 1 0.01 0 0.00 0 0.00 1 0.002
44 0 0.00 0 0.00 0 0.00 4 0.03 1 0.01 5 0.009
45 0 0.00 0 0.00 0 0.00 1 0.01 0 0.00 1 0.002
46 0 0.00 0 0.00 0 0.00 1 0.01 0 0.00 1 0.002
47 0 0.00 0 0.00 0 0.00 1 0.01 0 0.00 1 0.002
48 0 0.00 0 0.00 0 0.00 1 0.01 0 0.00 1 0.002
49 0 0.00 0 0.00 0 0.00 1 0.01 0 0.00 1 0.002
50 0 0.00 0 0.00 0 0.00 1 0.01 0 0.00 1 0.002
51 0 0.00 0 0.00 0 0.00 1 0.01 0 0.00 1 0.002
52 0 0.00 0 0.00 0 0.00 0 0.00 1 0.01 1 0.002
53 0 0.00 0 0.00 0 0.00 0 0.00 1 0.01 1 0.002
54 0 0.00 0 0.00 0 0.00 0 0.00 1 0.01 1 0.002
55 0 0.00 0 0.00 0 0.00 0 0.00 2 0.02 2 0.004
56 0 0.00 0 0.00 0 0.00 0 0.00 1 0.01 1 0.002
57 0 0.00 0 0.00 0 0.00 0 0.00 1 0.01 1 0.002
58 0 0.00 0 0.00 0 0.00 0 0.00 1 0.01 1 0.002
59 0 0.00 0 0.00 0 0.00 0 0.00 1 0.01 1 0.002
60 0 0.00 0 0.00 0 0.00 0 0.00 1 0.01 1 0.002
Grand Total 96 1.00 118 1.00 134 1.00 120 1.00 90 1.00 558 1.000
n = number of chromosomes, f = frequency
Predicted CYP1A2 metabolic activity:
Reduced
Non-functional
Unknown
Maale Oromo Ethiopia
Haplotype id
Afar Amhara Anuak  97 
Figure 4.3  Comparison of predicted CYP1A2 functional variation among the Ethiopian ascertainment populations.  Pie charts represent the proportions of chromosomes in each population 
predicted to code for proteins with one of four CYP1A2 metabolic activities. 
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between 12 – 25 % of chromosomes in each population were predicted to code for a protein 
with  reduced  metabolic  activity,  with  most  (25  %)  being  observed  in  Anuak  (figure  4.3b).  
Contrary to predictions from the diagnostic test however, normal functioning alleles were not 
predicted from CYP1A2 sequences in any group, and 3 % of sequenced Anuak chromosomes 
were  predicted  to  be  non-functional  (figure  4.3b).    In  addition,  at  least  72  %  of  sequenced 
chromosomes in each population were assigned an unknown CYP1A2 function.   
 
Predictions from application of the diagnostic test (figure 4.3a) were consequently not consistent 
with the functional variation predicted from sequencing CYP1A2 in the Ethiopian ascertainment 
populations  (figure  4.3b).    This  is  likely  to  be  due  to  the  plethora  of  previously  unknown 
haplotypes identified from sequencing CYP1A2 in the Ethiopian ascertainment populations (see 
chapter 2).   
 
4.3.4  Step 4:  Diagnostic test to predict CYP1A2 functional variation among Ethiopian 
populations:  test built from Ethiopian sequence data from this study 
 
A  mutation  network  of  the  CYP1A2  haplotypes  observed  in  the  Ethiopian  ascertainment 
populations is shown in figure 4.4.  Three polymorphisms need to be typed (-3860 G>A (1), 
5094  T>C  (29)  and  5284  C>A  (32))  in  order  to  distinguish  the  alleles  predicted  to  be  poor 
functioning  (highlighted  in  red)  from  the  alleles  which  have  an  undetermined  function 
(highlighted in green).   
 
Since haplotypes 1 and 3 were observed at frequencies over 10 % in the combined Ethiopian 
ascertainment population (table 4.4) and were assigned an unknown function, these haplotypes 
should  also  be  recognised  by  the  diagnostic  test  for  Ethiopia.    Future  genotype/phenotype 
studies should be performed using Ethiopian individuals with either haplotype.  An additional 15 
polymorphisms need to be typed to characterise haplotypes 1 and 3.  These, together with -
3860 G>A, 5094 T>C and 5284 C>A, are highlighted with * in figure 4.4.   
 
The algorithm which will determine the predicted phenotype based on the particular combination 
of alleles observed is shown in figure 4.5.  As examples, a chromosome with 5284 C>A  is 
predicted to code for a protein with no function, whilst a chromosome with -3860 G>A but not 
5284 C>A is predicted to code for a slow functioning protein.   
 
4.4  Discussion 
 
This  study  clearly  established  that  it  is  not  possible  to  predict  functional  CYP1A2  variation 
among  Ethiopian  populations  using  a  diagnostic  test  built  from  variation  recorded  by  the 
CYP450  Allele  Nomenclature  Committee  (http://www.cypalleles.ki.se/cyp1a2.htm).    Although 
the diagnostic test was derived from data from peoples of different ancestry (including Africans    99 
Figure 4.4  Mutation network of CYP1A2 alleles observed from sequencing CYP1A2 in the Ethiopian ascertainment populations.  See chapter 2 for references concerning allele phenotypes.  Nodes 
represent CYP1A2 alleles.  Mutated positions are shown in red along the grey links.  All links are drawn to scale.  The network was used to help select the minimum number of polymorphisms (*) which need 
to be typed in order to predict CYP1A2 phenotypes.  Reticulations are observed in the network with the consequence that some markers appear more than once.   
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Figure 4.5  Algorithm (based on CYP1A2 sequence variation in the Ethiopian ascertainment populations) for 
predicting CYP1A2 metabolic activity.  White columns represent different chromosomes.  √ = mutation must be 
present, x = mutation must be absent.  Chromosomes which cannot be assigned to one of the predicted functions 
shown in the table are predicted to have a CYP1A2 allele whose associated function is not known.   
 
Predicted CYP1A2 metabolic activity 
Undetermined  Marker in 
figure 4.4  Mutation 
Non-functional  Slow 
Haplotype 1  Haplotype 3 
1  -3860G>A     √     x    
2  -2467T>-              x 
8  -505G>A              x 
9  -163C>A              x 
12  1352G>A              x 
13  1370G>A              x 
17  2159G>A           √    
21  3468A>C              x 
27  5010C>T           x    
29  5094T>C        √  x    
30  5105G>A              x 
32  5284C>A  √  x          
33  5328G>A              x 
34  5347T>C           x    
37  5620A>C              x 
42  6537G>A              x 
44  6674C>G              x 
45  6685A>G              x 
 
 
and non-Africans), it  was  particularly biased  towards the Japanese (Murayama et al., 2004; 
Soyama  et  al.,  2005)  and  may  consequently  be  suitable  for  predicting  CYP1A2  functional 
variation in Japanese populations.  The diagnostic test was found to be unsuitable for Ethiopia 
since  it  did  not  account  for  much  of  the  diversity  observed  in  the  Ethiopian  ascertainment 
populations.  Ethiopia requires its own diagnostic test designed initially by using the variation 
observed in the five Ethiopian ascertainment populations.   
 
Since  it is not possible  to confidently  predict the likely  phenotypes of many  of the CYP1A2 
haplotypes  identified  in  the  Ethiopian  ascertainment  populations,  functional  studies  will  be 
necessary before a robust predictive algorithm can be formulated.  The functional effect of the 
amino acid substitutions predicted to have a damaging effect on the structure/function of the 
protein should be established initially in in vitro studies.  These are:  53C>G in exon 2 (S18C) 
and 5094T>C (F432S), 5253C>G (P485R) and 5284C>A (Y495Ter) in exon 7.  Protein models 
could also be constructed in silico to establish whether SNPs alter protein shape/structure in 
any  way  (Karchin  et  al.,  2005).    Genotype/phenotype  tests  (using  caffeine)  investigating 
whether -3860 G>A (enhancer region) leads to reduced enzyme inducibility in Ethiopians should 
also be undertaken.  Genotype/phenotype association studies should also be performed using 
haplotypes observed at appreciable frequencies.  It may be appropriate, as a first milestone, to 
take into account haplotypes observed in the combined Ethiopian ascertainment population at 
frequencies  ≥  10  %.    The  functional  significance  of  lower  frequency  haplotypes  should  be 
established in due course.  It is also necessary to bear in mind that an overall frequency of less 
than 10 % might be significantly higher in one or more ethnic groups.     101 
Haplotype 1 (CYP1A2*1M) and haplotype 3 (CYP1A2*1B) were the most frequent haplotypes in 
the combined Ethiopian ascertainment populations.  Haplotype 1 has -163C>A in intron 1 and 
2159G>A  intron  4,  whilst  haplotype  3  has  the  synonymous  mutation  5347T>C  in  exon  7 
(N516N).  Since these three mutations do not result in amino acid changes, both haplotypes 
may consequently code for a protein with a normal (CYP1A2*1A-like) function.  On the other 
hand -163C>A has been associated with higher enzyme inducibility by smoking (Sachse et al., 
1999), although this association has not always been replicated (Nordmark et al., 2002; Aklillu 
et al., 2003), and haplotype 1 may code for an enzyme with an altered activity as a result.  
Genotype/phenotype association studies involving haplotypes 1 and 3  will establish  whether 
functional variation exists because of variation within regulatory elements such as the promoter 
or enhancer region.   
 
Future  studies  should  conduct  genotype/phenotype  testing  on  approximately  100  individuals 
from the same ethnic group.  A sample population of at least 100 individuals would be large 
enough  to  identify  variants  at  frequencies  of  2  %  or  above  in  a  population  at  the  5  % 
significance  threshold  (refer  to  the  discussion  in  chapter  2  for  power  calculation  details).  
Ethiopians living in Ethiopia or the Ethiopian diaspora population in London could be involved in 
the study.   
 
This study mainly focussed on variation within the gene since the enhancer region was not 
sequenced.    Given  that  variation  in  the  enhancer  region  may  affect  the  quantity  of  active 
protein,  future  studies  should  also  attempt  to  characterise  its  variation  in  the  Ethiopian 
ascertainment  populations  and  should  incorporate  this  information  into  the  design  of  the 
diagnostic  test  if  it  is  to  fully  deliver  its  potential  utility  for  group  based  pharmacogenetic 
prediction.   
 
Table 4.5  Common African diseases, drugs used in their treatment in Ethiopia, and CYPs involved in the drugs' 
metabolism 
 
Disease 
Drug used to 
prevent/cure disease  Reference  Metabolised by  Reference 
Malaria  Artemeter-lumefantrine  1, Ethiopia, MOH (2004) 
CYP3A4, CYP2B6, 
CYP2D6 
Giao and de Vries (2001); Li et 
al., 2003 
Malaria  Chloroquine  1, Ethiopia, MOH (2004) 
CYP3A4, CYP3A5, 
CYP2D6, CYP2C8 
Kim et al., 2003; Li et al., 2003; 
Projean et al., 2003 
Malaria  Primaquine  1, Ethiopia, MOH (2004)   CYP1A2, CYP2D6  Li et al., 2003 
Malaria  Quinine  1, Ethiopia, MOH (2004)  CYP3A4, CYP2C19 
Li et al., 2003, Mirghani et al., 
2003 
Malaria  Mefloquine  Ethiopia, MOH (2004)  CYP3A  Fontaine et al., 2000 
Onchocerciaisis  Ivermectin  1  CYP3A4  Zeng et al., 1998 
Schistosomiasis  Praziquantel  1 
CYP1A2, CYP2C19, 
CYP2D6, CYP3A4, 
CYP3A5  Li et al., 2003 
 
1  Information provided by Dr. Senbeta Guteta (medical faculty of Addis Ababa University) and Dr. Diriba Agegnehu 
(Benishangul-Gumz national regional state HIV secretariat Head) 
 
Since many CYP enzymes have overlapping substrate specificities and enzymatic redundancy 
is evident in the CYP450 system (Gu et al., 1992), multiple CYPs would have to be included in 
the study in years to come, to fully predict the metabolic effect of the enzyme variants.  As an   102 
example, CYP1A2 and CYP2D6 enzymes both metabolise the anti-Malarial drug Primaquine (Li 
et al., 2003).  As a consequence, the presence of a normally functioning CYP2D6 protein in an 
individual, may compensate for the absence or defective form of a CYP1A2 protein, and vice 
versa.    Furthermore,  true  poor  metaboliser  phenotypes  may  arise  from  the  presence  of 
defective  genes  for  both  enzymes.    Performing  combined  genotype  analysis  for  defective 
CYP1A2 and CYP2D6 polymorphisms is thus important in determining the contribution of CYP 
genotypes to phenotype.  Since CYP2B6, CYP2C8, CYP2C19, CYP2D6, CYP3A4 and CYP3A5 
are thought to be involved in the metabolism of various anti-malarials and drugs used to treat 
Onchocerciasis and Schistosomiasis in Ethiopia (table 4.5), it would be appropriate to extend 
this study to these enzymes in the first instance.   
 
4.5  Conclusion 
 
This study examined the design of a diagnostic test procedure to predict CYP1A2 functional 
variation among Ethiopian populations.  The test procedure was constructed utilising CYP1A2 
variant alleles, recorded by the CYP450 Allele Nomenclature Committee, which were assigned 
phenotypes from previously reported functional studies.  The test procedure was derived from 
data from peoples of different ancestry, with a particular bias towards Japanese.  The test’s 
suitability for Ethiopia was investigated by applying it to the variation observed in the Ethiopian 
ascertainment populations.  The diagnostic test was found to be inappropriate for Ethiopia since 
it did not account for the plethora of novel variation observed in the ascertainment samples.  
Ethiopia requires its own diagnostic test procedure initially built using the variation observed in 
the five Ethiopian ascertainment populations.  The functional significance of all of the Ethiopian 
ascertainment haplotypes is currently not known and a robust diagnostic test procedure cannot 
be designed at present.  Future studies should attempt to establish the function of potentially 
deleterious amino acid substitutions and high frequency haplotypes observed in the Ethiopian 
ascertainment  populations.    Future  studies  should  also  incorporate  any  variation  in  the 
enhancer region into the design of the diagnostic test procedure to improve its utility in group 
based pharmacogenetic prediction.  The use of group based pharmacogenetic profiles for drug 
response prediction may be both a practical and beneficial approach in the pursuit of improved 
healthcare in Ethiopia and elsewhere.   
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5  The distribution of  TCF7L2 alleles, associated with 
an  increased  risk  of  type  2  diabetes,  among  Afro-
Caribbeans with the disease, HapMap and Ethiopian 
populations 
 
5.1  Introduction 
5.1.1  Type 2 diabetes 
 
Type 2 diabetes (T2D), otherwise known as diabetes mellitus ("sugar diabetes"), is a long-term 
condition characterised by hyperglycemia which is caused by impaired insulin secretion, insulin 
resistance in peripheral tissues and increased glucose output by the liver (Grant et al., 2006).  
The  majority  of  type  2  diabetics  suffer  from  chronic  hyperglycemia  which  can  lead  to 
nephropathy, neuropathy, retinopathy and an increased risk of cardiovascular dieasease (Grant 
et al., 2006).  T2D often occurs later in life and is known as late-onset diabetes or non-insulin-
dependent diabetes mellitus (NIDDM), because insulin treatment is not always necessary and 
the disease can often be managed by exercise and diet (Burnet et al., 2006).  T2D is a complex 
disease  and many genes, in  addition to environmental factors, are thought  to determine an 
individual’s risk to developing the disease (Weedon, 2007).  The global prevalence of all types 
of diabetes for all age groups was estimated to be 2.8 % in 2000, with T2D being accountable 
for at least 90 % of this figure (Oldroyd et al., 2005).  The prevalence of diabetes is set to 
substantially increase in the near future, largely because people are living longer (Wild et al., 
2004) but also because of diet and lifestyle changes leading to obesity (Singh et al., 2004; 
Wiegand et al., 2004).   
 
5.1.2  A genetic element to T2D 
 
Despite  having  a  strong  environmental  component,  evidence  from  twin  and  family  studies 
suggests that T2D risk also has an underlying genetic element (Gloyn and McCarthy, 2001).  
Furthermore,  the  prevalence  of  T2D  varies  widely  amongst  different  ethnic  groups,  being 
particularly  common  among  people  of  Afro-Caribbean  or  South  Asian  origin  (Oldroyd  et  al., 
2005).  For example, by comparison to UK European whites with an estimated T2D prevalence 
of 2.4 %, the rate in those of Indian and Afro-Caribbean descent living in the UK is three- to 
sixfold higher (Riste et al., 2001).  African Americans are also twice as likely to develop T2D 
compared to non-Hispanic white populations in the US (Harris et al., 1998). 
 
5.1.3  The thrifty gene hypothesis 
 
African and Asian diasporas are more likely to develop T2D than their respective source    104 
populations, e.g. the prevalence of T2D is higher (~ 11-13 %) among people of recent African 
descent in developed countries than in Africa (~ 1-2 %) (Rotimi et al., 2004).  It is however 
necessary to bear in mind that the possibility of T2D under diagnosis in developing countries 
cannot be ruled out.  This phenomenon is suggested to be due to changes in environmental 
conditions  acting  on  thrifty  genes  (genes  promoting  the  efficient  absorption,  storage,  or 
utilization of nutrients in periods of food abundance) (Neel, 1962).  Prior to the development of 
farming roughly 10,000 years ago (Mithen, 2007), anatomically modern humans lived as hunter-
gatherers  and  were  likely  to  experience  frequent  cycles  of  food  abundance  and  famine 
(Campbell and Tishkoff, 2008).  According to the thrifty gene hypothesis (Neel, 1962), ancestral 
genetic variants that were historically advantageous in enabling individuals to efficiently process 
food to deposit fat during periods of food abundance, are now maladaptive to more modern 
environments with a constant abundance of food.  The ‘thrifty’ genotype effectively prepares 
individuals for a famine that never comes, resulting in obesity and an increased risk of T2D (Di 
Rienzo and Hudson, 2005; Paradies et al., 2007).   
 
5.1.4  Genes implicated in T2D aetiology 
 
Recent  genome-wide  association  studies  in  large  sample  sizes  (tens  of  thousands  of 
individuals) have identified several common variants (allele frequencies ranging from 10-90 %) 
associated with an increased susceptibility to T2D (Weedon, 2007).  Variants include rs4402960 
(IGF2BP2)  and  rs1801282  (PPARG)  on  chromosome  3,  rs10946398  (CDKAL1)  and 
rs10010131 (WFS1) on chromosome 6, rs13266634 (SLC30A8) on chromosome 8, rs10811661 
(CDKN2B) and rs564398 (CDKN2B) on chromosome 9, rs5015480 (HHEX) on chromosome 10, 
rs5215 (KCNJ11) on chromosome 11, and rs8050136 (FTO) on chromosome 16 (Zeggini et al., 
2007).   With  particular  relevance  to  populations  with  a  recent  African  ancestry,  the  porcine 
agouti-related protein (AGRP) (Bonilla et al., 2006) and proprotein convertase subtilisin/kexin-
type 2 (PCSK2) (Leak et al., 2007) genes have been identified as candidate loci associated with 
diabetes.  Genome-wide association studies in West Africans have also suggested association 
of regions of chromosomes 12, 19 and 20 to diabetes susceptibility (Rotimi et al., 2004).  There 
have also been other reports of strong association with chromosomes 4, 6, 8, 10 and 15-18 for 
a number of traits that contribute to the disease (Chen et al., 2007; Chen et al., 2007; Rotimi et 
al., 2006).   
 
5.1.4.1  The transcription factor 7-like 2 gene (TCF7L2) 
 
TCF7L2, also known as TCF-4, is found on the long arm of chromosome 10 (figure 5.1).  The 
gene is ~ 217.43 kb in length and has 10 transcripts which range from 7 exons (620 bp) to 16 
exons (2838 bp) in length (Ensembl release 55, July 2009).  TCF7L2 is a high mobility group 
(HMG)  box-containing  transcription  factor  which  plays  a  role  in  the Wnt  signalling  pathway, 
acting as a nuclear receptor for CTNNB1 (β-catenin) (Smith, 2007).  Wnt proteins form a family   105 
of highly conserved secreted signalling molecules that are important in cell-to-cell interactions 
during  cell  proliferation,  motility  and  normal  embryogenesis  (Etheridge  et  al.,  2004).    Wnt 
signalling has also been shown to regulate myogenesis and adipogenesis (Ross et al., 2000) 
and,  with  particular  importance  to  glucose  homeostasis,  is  critical  for  the  development  of 
pancreatic tissue and islets of Langerhans during embryonic development (Papadopoulou et al., 
2005).  Further support for the importance of Wnt signalling in glucose homeostasis stems from 
the recent finding that common variants within HHEX (target of Wnt signalling) also correlate 
with T2D risk (Weedon, 2007).   
 
Figure 5.1  Location and structure of TCF7L2 
 
 
 
5.1.4.2  Alleles of TCF7L2 associate with an increased risk of T2D 
 
In 2006, Decode Genetics demonstrated that the microsatellite marker, DG10S478, in exon 3 of 
TCF7L2, was significantly associated with T2D in Icelandic subjects (Grant et al., 2006).  The 
association  was  also  replicated  in  American  and  Danish  cohorts.    The  strong  link  between 
DG10S478 and T2D risk was then replicated with other markers within TCF7L2 including two 
intronic SNPs (rs7903146 C>T intron 5 and rs12255372 G>T in intron 6).  The alleles were all 
strongly  associated  with  each  other  and  represented  one  risk  allele  present  in  ~  36  %  of 
individuals  with  T2D  and  ~  28  %  of  control  subjects.    The  increased  risk  of  T2D  was 
considerable, with each extra copy of the risk allele increasing the odds of the disease by 1.5-
fold (p ~ 10
-18) (Grant et al., 2006).   
 
Humphries  et  al.,  (2006)  confirmed  the  association  between  rs7903146  and  rs12255372  in 
European whites, Indians and Afro-Caribbeans, and found weaker associations for rs12255372 
compared  to  rs7903146.    LD  between  the  two  SNPs  was  high  in  Indians  (D’  =  0.94)  and 
European whites (D’ = 0.88), but considerably lower in Afro-Caribbeans (D’ = 0.17).  Haplotype 
frequencies also differed considerably in Afro-Caribbeans (e.g. both CT and TG were observed 
at  frequencies  of  ~  20  %  in  Afro-Caribbeans  compared  to  <  6  %  in  European  whites  and   106 
Indians.  TT was the rarest haplotype in Afro-Caribbeans (9 %) yet observed at frequencies of ≥ 
27  %  in  European  whites  and  Indians).    Only  the  TG  haplotype  was  associated  with  an 
increased risk of T2D in Afro-Caribbeans (albeit not at 5 % significance, p = 0.24) whilst TG and 
TT were associated with a significantly increased risk of the disease in European whites and 
Indians.  The study recommended further investigation into the TT and TG haplotypes.   
 
The association of TCF7L2 alleles with an increased risk of T2D has also been observed in 
other  populations including Indians (Chandak et  al., 2007), Japanese (Hayashi  et al.,  2007; 
Horikoshi et al., 2007), Mexican-Americans (Lehman et al., 2007), West Africans (Helgason et 
al., 2007), Moroccans (Cauchi et al., 2007), French (Sladek et al., 2007), Amish (Damcott et al., 
2006) and Finnish (Scott et al., 2006).  Of the known T2D candidate genes identified to date, 
TCF7L2 makes the strongest contribution to T2D susceptibility and might consequently be the 
most important gene contributing to T2D risk (Weedon, 2007).   
 
5.1.5  Aetiology of T2D 
 
The causal variant of the association of TCF7L2 and an increased risk of T2D is not known.  
Extensive  sequencing  of  TCF7L2  in  Icelandic,  Danish  and  American  cohorts  revealed  no 
functional sequence change on the TCF7L2 risk haplotype (Grant et al., 2006) and no functional 
candidates have been reported by other studies (Weedon, 2007).  The SNP in intron 5 of the 
gene, rs7903146, which shows the strongest association (Humphries et al., 2006; Helgason et 
al., 2007), remains the most likely candidate.  Since this variant occurs in an intron and has not 
been linked to any coding variation to date (Weedon, 2007), the causal variant is likely to act by 
altering protein expression, as opposed to protein structure.  The causal variant’s effect on T2D 
risk  may  act  through  an  impairment  of  insulin  secretion  (Weedon,  2007).    Individuals  with 
rs7903146 T had significantly reduced levels of insulin secretion compared to the ancestral C 
allele (Florez et al., 2006) and TT homozygotes had ~ 50 % lower insulinogenic and insulin 
deposition  indexes  (Saxena  et  al.,  2006).    Further  support  for  a  role  of  TCF7L2  in  insulin 
regulation stems from a birth weight study.  Correcting for foetal genotype, each maternal copy 
of rs7903146 T allele was associated with a 31 g increase in offspring birth weight (Freathy et 
al., 2007).  The increase in offspring birth weight is thought to have resulted from the rs7903146 
T allele reducing maternal insulin secretion, thereby elevating maternal blood glucose levels 
during pregnancy (Freathy et al., 2007).   
 
The mechanism by which a reduced or non-functional allele of TCF7L2 should impair insulin 
secretion remains unclear. Given that TCF7L2 is part of the Wnt signalling which is critical for 
the development of the pancreas and islets during embryonic growth, impairment of beta-cell 
mass, pancreatic beta-cell development and/or beta-cell function is possible (Weedon, 2007).  
However, since TCF7L2 has been linked to the development of colorectal cancer (Wong and 
Pignatelli,  2002),  and  TCF7L2  homozygous  knockout  mice  lack  an  epithelial  stem-cell 
compartment, and die ~ 24 hours after birth (Korinek et al., 1998), it has been hypothesised that   107 
the defect may result from a decrease in glucagon-likepeptide-1 secretion from enteroendocrine 
cells  (Grant  et  al.,  2006).    (GLP1  is  an  insulinotropic  hormone  which  is  transcriptionally 
regulated by TCF7L2 (Yi et al., 2005)).   
 
Identifying the causal genetic variant of the association of TCF7L2 with an increased risk of 
T2D, and being able to specifically target treatments to carriers of this defect, would lead to 
improved  management  and  treatment  of  people  with  or  at  risk  of  developing  this  complex 
disease (Weedon, 2007). 
 
5.1.6  TCF7L2 in HapMap European and Yoruba populations 
 
LD was analysed across the entire TCF7L2 gene in HapMap European and Yoruba populations 
using Haploview (figure 5.2).  SNPs rs7903146 and rs12255372 were found in the same LD 
block in Europeans, where the LD between the two SNPs was high (D´ = 0.95).  The SNPs 
were  found  in  separate  LD  blocks  in  Yoruba;  rs7903146  was  located  in  LD  block  5  and 
rs12255372 in LD block 6.  This was not surprising given the low LD value between the two 
markers (D´ = 0.14).   
 
Figure 5.2  LD across TCF7L2 in HapMap populations (red = high LD, white = low LD) 
 
HapMap Europeans        HapMap Yoruba  
     
   
 
 
5.1.7  Aims 
 
1.  Analyse variation in TCF7L2 in an Afro-Caribbean cohort with T2D 
 
•  Refine the search for a potentially causal polymorphism of T2D in Afro-Caribbeans from 
55053 bases (distance between rs7903146 and rs12255372) to a smaller area in TCF7L2.  
Since Afro-Caribbeans may have a predominantly West African ancestry (Miljovic-Gacic et 
al., 2005), use HapMap West African Yoruba data to help narrow the search.  Given that 
rs7903146 and rs12255372 are in separate LD blocks in HapMap Yoruba (figure 5.2), and 
rs7903146  C>T  was  more  strongly  associated  with  an  increased  risk  of  T2D  than 
LD Block 5 
rs7903146 & 
rs12255372 
LD Block 5 
rs7903146  LD Block 6 
rs12255372   108 
rs12255372 G>T (Humphries et al., 2006), limit the search to LD block 5 of HapMap Yoruba 
(figure 5.3).   
 
Figure 5.3  LD block 5 of TCF7L2 in HapMap Yoruba (red = high LD) 
 
 
 
•  Analyse  the  distribution  of  haplotypes  (consisting  of  SNPs  in  LD  block  5  of  the  Yoruba 
(figure  5.3)  and  rs12255372)  in  a  type  2  diabetic  cohort  from  Humphries  et  al.  (2006).  
Using HapMap data (Yoruba, Europeans, Chinese and Japanese) as a control, establish 
whether  a  potential  T2D  risk  haplotype,  on  the  background  of  the  TG 
rs7903146/rs12255372 haplotype, can be identified in Afro-Caribbeans with T2D.   
 
2.  Analyse variation in TCF7L2 in the Ethiopian ascertainment populations 
 
•  Type  rs7901695,  rs4132115,  rs4506565,  rs7068741  and  rs7069007,  in  addition  to 
rs7903146 and rs12255372 in the Ethiopian ascertainment populations.  Estimate allele and 
haplotype frequencies in each population. 
 
•  Calculate LD between SNPs in each population. 
 
•  Characterise variation within and among populations, and in the context of Afro-Caribbeans 
with T2D and HapMap data (from aim 1).   
 
•  Establish whether variation in TCF7L2 can be used to effectively differentiate ethnic groups.  
 
3.  Analyse variation in TCF7L2 in multiple Ethiopian populations 
 
In the course of this study it was established that rs7903146 and rs12255372 haplotypes could 
effectively differentiate populations (see results).  As a consequence, both SNPs were typed in 
multiple Ethiopian populations.  The aims of this section are to: 
 
•  Estimate allele and haplotype frequencies in each population. 
 
•  Calculate LD between SNPs in each population.   109 
 
•  Characterise variation within and among populations, and in the context of Afro-Caribbeans 
with T2D and HapMap data (from aim 1).   
 
5.2  Methods 
5.2.1  Samples 
 
DNA samples (n = 81) from Afro-Caribbeans with T2D are described in Humphries et al., (2006) 
whilst DNA samples from the Ethiopian ascertainment populations (Afar, Amhara, Anuak, Maale 
and Oromo) are described in chapter 2.  Samples from other Ethiopian populations (including 
the Ethiopian ascertainment samples plus more individuals from Afar, Amhara, Anuak, Maale 
and Oromo) were collected according to the methods outlined in chapter 2 for the Ethiopian 
ascertainment populations.   
 
5.2.2  Multiple Ethiopian populations 
 
A  total  of  6350  Ethiopian  individuals  were  genotyped  for  rs7903146  and  rs12255372.    This 
dataset included samples from multiple Ethiopian populations collected from various locations in 
a rough south west to north east transect across Ethiopia (figure 5.4).  Whilst all samples were 
analysed in terms of Ethiopia overall, at the ethnic group level, only populations with at least 15 
individuals were included in the analyses (47 ethnic groups analysed).   
 
5.2.2.1  Marginalised groups study 
 
Manja (n = 344) and Dawuro (n = 634), and Ari cultivators (n = 464), Ari potters (n = 262) and 
Ari smiths (n = 106) form part of a wider study which researches the genetic relationships of 
groups living in hierarchical societies (groups highlighted with * in figure 5.4).  In this particular 
case, Manja and Dawuro are different ethnic groups living side by side in the Dawuro zone.  
Dawuro  (farmers)  are  considered  to  be  the  dominant  social  group  whilst  Manja  are  the 
subordinate ethnic minority involved with artisanal production and hunting.  Manja are heavily 
discriminated  against  and  it  is  custom  for  the  two  groups  not  to  interact  with  each  other 
(Freeman and Pankhurst, 2003).  Ari cultivators, Ari potters and Ari smiths are all from the Ari 
ethnic group living near Jinka town in South Omo.  They are separate from the Ari dataset (n = 
232) which does not consider social structure evident in Ari.  Ari cultivators (farmers) are the 
dominant  social  group  whilst,  as  a  consequence  of  their  trade,  Ari  potters  (potters)  and  Ari 
smiths  (blacksmiths)  are  the  subordinate  ethnic  minorities.    The  potters  and  smiths  are 
marginalised groups who, despite making important economic and social contributions to the 
local community, are subjected to various forms of discrimination.  As with Manja and Dawuro, it  
   110 
Figure 5.4  Multiple Ethiopian populations:  sample size (chromosomes), collection location and first languages 
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is  also  customary  for  Ari  farmers  not  to  interact  with  Ari  potters  and  smiths  (Freeman  and 
Pankhurst, 2003).   
 
5.2.2.2  Language 
 
In total, 62 first languages (mother tongue), from four linguistic groups, were reported when all 
ethnic groups  were  pooled (figure 5.4).  The majority (40 %) of languages belonged to the 
Omotic family, whilst 34 % belonged to the Cushitic family and 18 % and 8 % belonged to the 
Semitic and Nilo-Saharan families respectively.  Each ethnic group spoke their own language 
with most individuals in each group having their group’s language as their mother tongue.  For 
the  majority  of  groups,  several  first  languages  were  reported  with  many  speaking  Amharic.  
Semitic, Omotic and Nilo-Saharan languages were generally spoken more towards the north 
east, south west and west of Ethiopia respectively whilst Cushitic languages were generally 
spoken more in the south west and north east of the country (figure 5.5).   
 
Figure 5.5  Distribution of first spoken languages (categorized by linguistic group) among multiple Ethiopian 
populations 
 
 
 
5.2.2.3  Religion 
 
In terms of the pooled Ethiopian dataset, the majority (88 %) were Christian, whilst 8 % were 
Muslim and 4 % had traditional religious beliefs.  Christianity was observed in all ethnic groups 
except Afar who were all Muslim (figure 5.6).  Islam was reported to be more widespread among 
groups towards the north east of Ethiopia and Traditional religions were observed more widely 
in marginalised groups (Manja, Ari potters and Ari smiths).   
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Figure 5.6  Distribution of religions among multiple Ethiopian populations 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Gewada 
Dizi 
Mejenger 
Nuer 
Anuak 
Ari 
Ari Cultivator 
Ari Potter 
Ari Smith 
Bena 
Basketo/Masketo 
Bume/Nyangagtom 
Busa 
Dime 
Dirasha 
Dasenech 
Gobeze 
Gofa 
Ganjule 
Gamo 
Genta 
Hamer 
Konso 
Mashile 
Maale 
Wolayta 
Zayse 
Bench 
Kefa 
Shekecho 
Sheko 
Burji 
Dorze 
Gedeo 
Kore
Dawuro 
Konta 
Manja 
Alaba 
Kembata 
Sidama 
Oromo 
Gurage 
Hadiya 
Yem 
Tigrayan 
Amhara 
Agew, Eastern 
Somali 
Afar 
Population (arranged in a rough south west to north east transect)
R
e
l
i
g
i
o
n
Christian Muslim Traditional  
 
5.2.3  Genotyping of TCF7L2 SNPs 
 
Genotyping  for  all  TCF7L2  SNPs  was  performed  using  TaqMan  technology  (Applied 
Biosystems (ABI), Warrington UK).  Forward and reverse primers, and fluorogenic probes are 
provided in table 5.1.  For each assay, the design of the probes was such that if they annealed 
specifically between the forward and reverse primers, a sequence specific signal was generated 
as a direct result of probe degradation during PCR by the 5’ nuclease activity of the polymerase.   
 
DNA was amplified in 384 well microplates and in 4 µl reaction volumes containing 1 µl of 1 
ng/µl DNA, 2 µl of 1x TaqMan Genotyping Master Mix (Applied Biosystems (ABI), Warrington 
UK), 0.01 µl of 40x assay mix (containing primers and probes from Applied Biosystems (ABI), 
Warrington UK) and 0.90 µl of sterile water.  The thermal cycler conditions were: 10 minutes of 
pre-incubation at 95 ºC, followed by 40 cycles of 15 seconds at 92 ºC and 1 minute at 60 ºC.  
The resultant PCR product was analysed using TaqMan 7900HT software (Applied Biosystems 
(ABI), Warrington UK).   
 
5.2.4  Statistical analyses 
 
Haplotypes were inferred from unphased genotype data using Phase 2.0 software (Stephens et 
al., 2001).  Mantel tests and partial mantel tests were performed using vegan libraries within the 
R  statistical  package  (www.R-project.org).    Population  pairwise  geographic  distances  were 
calculated based on great-circle differences.  Population pairwise language, linguistic group and 
religious distances (Fsts) (Reynolds et al., 1983) were calculated from counts of languages,   113
Table 5.1 TaqMan primers and probes for TCF7L2 genotyping
SNP SNP alleles
Location in 
TCF7L2
Assay designed on forward or 
reverse strand
Forward primer Reverse primer VIC labelled probe FAM labelled probe
rs7901695 C>T Intron 5 Reverse TGGATTTGCCTGTTCTTGACATTTC TGAGAACCGTATGCTAAGTGAAAGC AAAAGCCCGTAGATTT CAAAAGCCCATAGATTT
rs4132115 C>A Intron 5 Reverse AGGCGCCAGCAAGCA AGGCCCTCTGGGAAACCT CCTTTCCTGATAGTCAC CTTTCCTGAGAGTCAC
rs4506565 T>A Intron 5 Reverse TGACTCTCGGAGGAGGATGAG GATGCCATAATAGAGACCCTTGACAA CCCCATATCACTTCGG CCCAAATCACTTCGG
rs7068741 C>T Intron 5 Forward ACCCCAGGATCCAGATGGTT AGCTTATGCTATTGGTTCCAACACT ACTCTCAAACCAGGGCC ACTCTCAAATCAGGGCC
rs7069007 G>C Intron 5 Forward GATCCAGATGGTTGCACTCTCAA GTCCTGACCAAAGCTTATGCTATTG CCTTCAGCATTTAGTG CCTTCACCATTTAGTG
rs7903146 C>T Intron 5  Forward  CCTCAAAACCTAGCACAGCTGTTAT TGAAAACTAAGGGTGCCTCATACG CTAAGCACTTTTTAGATACTATAT TAAGCACTTTTTAGATATTATAT
rs12255372 G>T Intron 6  Forward GCTGAGCTGCCCAGGAATAT GCAGAGGCCTGAGTAATTATCAGAA CAGGCAAGAATGACCATA CCAGGCAAGAATTACCATA  114 
linguistic groups and religions, respectively, in Arlequin software 3.01 (Schneider et al., 2000).  
In this case, languages, linguistic groups and religions were treated as if they were haplotypes.  
All other statistical analyses were performed according to methods outlined in chapter 2.   
 
5.3  Results 
5.3.1  Variation in TCF7L2 in Afro-Caribbeans with T2D 
 
In  order  to  establish  whether  a  potential  T2D  risk  haplotype  could  be  identified  on  the 
background of the TG rs7903146/rs12255372 haplotype in Afro-Caribbeans with T2D, SNPs 
within  LD  block  5  of  HapMap  Yoruba  (rs7901695,  rs4132115,  rs4506565,  rs7068741  and 
rs7069007  and  rs7903146)  together  with  rs12255372,  were  analysed.    HapMap  Yoruba, 
European, Chinese and Japanese populations were used as controls, and were assumed to be 
representative of their respective general populations (some may be susceptible to T2D, some 
may not).  If this region of TCF7L2 is associated with an increased risk of T2D, expectations 
were  that  a  different  distribution  of  SNP  alleles  or  haplotypes  would  be  observed  in  Afro-
Caribbeans with the disease compared to the HapMap populations.   
 
5.3.1.1  TCF7L2  allele  frequencies  in  Afro-Caribbeans  with  T2D  and  HapMap 
populations 
 
For each SNP, no population deviated significantly from Hardy Weinberg equilibrium at 5 % 
significance.  All seven SNPs were common (≥ 15 %) in Afro-Caribbeans with T2D, and were 
observed at frequencies most similar to Yoruba (figure 5.7).   
 
5.3.1.2  TCF7L2 haplotypes in Afro-Caribbeans with T2D and HapMap populations 
 
Of the HapMap populations, Yoruba were the most similar to Afro-Caribbeans with T2D in terms 
of their haplotype distribution (figure 5.8a).  All populations were significantly different (at 5 % 
significance) in terms of their haplotype frequencies, except for Afro-Caribbeans and Yoruba, 
and  Chinese  and  Japanese  (figure  5.8c).    Furthermore,  no  haplotype  appeared  to  be  over-
represented  in  Afro-Caribbeans  compared  to  Yoruba.    Only  two  Afro-Caribbean  haplotypes 
(TCATGCG and CATCGTG) were not observed in Yoruba and both of these haplotypes were 
only  observed  in  Afro-Caribbeans  at  a  frequency  of  1  %  (figure  5.8a).    The  distribution  of 
haplotypes  on  the  background  of  rs7903146  T/rs12255372  G  (named  TG  at  risk  allele 
hereafter) was also similar between Afro-Caribbeans with T2D and Yoruba (figures 5.8b and 
5.8d).   
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Figure 5.7  TCF7L2 SNP allele frequencies in Afro-Caribbeans with T2D and HapMap populations (derived alleles 
are always shown in purple) 
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Figure  5.8    Comparison  of  TCF7L2  haplotypes  among  Afro-Caribbeans  with  T2D  and  each  of  the  HapMap 
populations.  Frequencies of haplotypes (rs7901695, rs4132115, rs4506565, rs7068741, rs7069007, rs7903146 and 
rs12255372)  are  shown  in  figure  5.8a.    Proportions  of  haplotypes  ending  with  rs7903146/rs12255372  TG  (those 
associated with an increased risk of T2D in Afro-Caribbeans (Humphries et al., 2006)) are shown in figure 5.8b.   
 
                      
 
c   Exact test of population differentiation significant/not significant (+/-) differences at the 5 % threshold for 
TCF7L2 haplotypes shown above (a) 
 
  Afro-Caribbeans with T2D  Yoruba  European  Chinese  Japanese 
Afro-Caribbeans with T2D            
Yoruba  -          
European  +  +        
Chinese  +  +  +      
Japanese  +  +  +  -    
 
d  Pairwise Fisher’s exact tests comparing numbers of haplotypes ‘ending with TG’ versus those ‘not ending 
with TG’ shown above in (b)                                                                                          - = p > 0.05, +++ = p < 0.0005 
 
  Yoruba  European  Chinese  Japanese 
Afro-Caribbbeans with T2D  -  +++  +++  +++ 
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5.3.1.3  TCF7L2 genetic structure in Afro-Caribbeans with T2D and HapMap populations 
 
Hierarchical Fst (based on TCF7L2 haplotypes) for Afro-Caribbeans and HapMap populations 
was 0.198 (p < 0.00001), with 19.8 % of the variation occurring among populations and 80.2 % 
occurring within populations.   
 
A PCO plot of genetic distances (population pairwise Fsts are shown in supplementary figure 
S2) based on TCF7L2 haplotypes is shown in figure 5.9.  PCO 1 and 2 captured 100 % of the 
variation.  Afro-Caribbeans with T2D lay between Yoruba and Europeans but were closest to 
Yoruba.  East Asians formed a tight cluster furthest away from Afro-Caribbeans with T2D, and 
Europeans were almost equidistant between East Asians and Yoruba. 
 
Figure 5.9  PCO plot of genetic distance (Fst) among Afro-Caribbeans with T2D and HapMap populations for 
TCF7L2 haplotypes.  Population pairwise Fsts are shown in supplementary figure S2.   
 
 
 
 
5.3.1.4  Summary of results from Afro-Caribbeans with T2D and HapMap populations 
 
In  summary,  these  results  show  that  whilst  the  distribution  of  TCF7L2  haplotypes  differed 
between  Afro-Caribbeans  with  T2D  and  Europeans,  Chinese  and  Japanese,  against 
expectations, Yoruba were surprisingly similar to Afro-Caribbeans, even in terms of their TG at 
risk  alleles.    In  accordance  with  their  geographic  proximity  and  recent  East  Asian  ancestry, 
Chinese  and  Japanese  groups  were  similar  throughout  the  analysis.    Consistent  with  their 
assumed mixed ancestry, Afro-Caribbeans were more similar to Yoruba and Europeans than 
East Asians.  The TCF7L2 haplotypes considered in this study were consequently capable of 
differentiating populations according to their recent ancestry and should prove useful data for   118 
the  study  of  inter-relationships  and  demographic  history  of  Ethiopian  populations.    For  this 
reason, and to place the results of this analysis into the context of Ethiopia, this study was 
extended to the Ethiopian ascertainment populations.   
 
5.3.2  Variation in TCF7L2 in the Ethiopian ascertainment populations 
5.3.2.1  TCF7L2 allele frequencies in the Ethiopian ascertainment populations 
 
For each SNP, no population deviated significantly from Hardy Weinberg equilibrium at 5 % 
significance, except rs12255372 in Maale (p = 0.004).  Following a Bonferroni correction for five 
tests, genotype distribution for Maale was not consistent with Hardy Weinberg equilibrium at the 
reduced  p  value  threshold  of  0.01.    On  closer  inspection  of  rs12255372  genotypes,  this 
deviation  from  Hardy  Weinberg  equilibrium  was  caused  by  an  over  representation  of  GG 
homozygotes in this group.  All seven SNPs were common (≥ 8 %) in all groups, with many 
reaching frequencies > 20 % (figure 5.11).   
 
5.3.2.2  LD in the Ethiopian ascertainment populations 
 
Whilst the following intron 5 SNPs were in complete LD (D´ = 1) with each other in all groups: 
rs7901695, rs4132115, rs4506565, rs7068741, rs7069007, rs7069007 and rs7903146, many of 
the SNPs were not in complete LD with rs12255372 (intron 6).  Varying levels of LD between 
rs7903146 and rs12255372 were observed in the Ethiopian ascertainment populations (figure 
5.10).  Similar to Europeans, LD was high in Amhara and Oromo.  Similar to Yoruba, LD was 
low in Anuak.   
 
Figure  5.10    LD  between  rs7903146  and  rs12255372  in  the  Ethiopian  ascertainment  populations,  Afro-
Caribbeans with T2D and HapMap Yoruba, European and Japanese populations (data was uninformative with 
respect to LD in HapMap Chinese, as all samples were homozygous G for rs12255372) 
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Figure  5.11    TCF7L2  SNP  allele  frequencies  in  the  Ethiopian  ascertainment  populations  (derived  alleles  are 
always shown in purple) 
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Figure 5.12  TCF7L2 haplotypes among the Ethiopian ascertainment populations.  Frequencies of haplotypes 
(rs7901695, rs4132115, rs4506565, rs7068741, rs7069007, rs7903146 and rs12255372) are shown in figure 5.12a.  
Proportions of haplotypes ending with rs7903146/rs12255372 TG (those associated with an increased risk of T2D in 
Afro-Caribbeans (Humphries et al., 2006)) are shown in figure 5.12b.   
 
                  
 
 
 
c  Pairwise Fisher’s exact tests comparing numbers of haplotypes ‘ending with TG’ versus those ‘not ending 
with TG’ shown above in (b)                                                                                                                            - = p > 0.05 
 
 
  Afar  Amhara  Anuak  Maale  Oromo 
Afro-Caribbeans with T2D  -  -  -  -  - 
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5.3.2.3  TCF7L2 haplotypes in the Ethiopian ascertainment populations 
 
A  total  of  13  haplotypes  were  observed  in  the  Ethiopian  ascertainment  populations  (figure 
5.12a).  Consistent with Afro-Caribbeans with T2D and HapMap populations (figure 5.8a), the 
most frequent haplotype for all populations was TCACGCG (≥ 38 % in any one group).  Notably, 
all of the common variation observed in Afro-Caribbeans and HapMap populations (≥ 2 % in any 
one  group)  (figure  5.8a)  was  observed  in  the  Ethiopian  ascertainment  populations  (figure 
5.12a).    Consistent  with  Yoruba,  none  of  the  Ethiopian  ascertainment  populations  were 
significantly different from Afro-Caribbeans with T2D in terms of their TG at risk alleles (figures 
5.12b and 5.12c).   
 
5.3.2.4  How diverse are the Ethiopian ascertainment populations? 
 
Consistent with there being more human genetic diversity in Africans than in non-Africans, all 
African populations were more diverse than East Asians and Europeans (figure 5.13).  Amongst 
the Africans, gene diversity was highest in Yoruba and Afro-Caribbeans with T2D and lowest in 
Amhara.   
 
Figure 5.13  Gene diversity (h) based on TCF7L2 haplotypes in various datasets (error bars represent standard 
deviation) 
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5.3.2.5  Can variation in TCF7L2 differentiate populations? 
 
For  each  SNP,  Chinese  and  Japanese,  and  in  some  cases  Europeans,  were  significantly 
different (p < 0.05) from most populations in terms of their genotypes (figure 5.14).  Consistent 
with their recent African ancestry, the majority of African groups were not differentiated at 5 % 
significance (figure 5.14).     122 
Figure 5.14  Exact test of population differentiation p values (lower triangle) and significant/not significant (+/-) 
differences at the 5 % threshold (upper triangle) for TCF7L2 genotypes.  All Afro-Caribbeans were type 2 diabetics. 
 
rs7901695 
  Afar  Amhara  Anuak  Maale  Oromo  Afro-Caribbeans  Yoruba  European  Chinese  Japanese 
Afar     -  +  -  -  +  +  -  +  + 
Amhara  1.00     +  -  -  +  +  -  +  + 
Anuak  0.01  0.02     -  -  -  -  +  +  + 
Maale  0.25  0.35  0.29     -  -  -  +  +  + 
Oromo  0.48  0.59  0.19  0.90     -  -  +  +  + 
Afro-Caribbeans  0.02  0.02  0.35  0.52  0.21     -  +  +  + 
Yoruba  0.01  0.01  0.08  0.18  0.08  0.68     +  +  + 
European  0.30  0.25  p<0.01  0.02  0.04  p<0.01  p<0.01     +  + 
Chinese  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01     - 
Japanese  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  1.00    
 
rs4132115 
  Afar  Amhara  Anuak  Maale  Oromo  Afro-Caribbeans  Yoruba  European  Chinese  Japanese 
Afar     -  +  +  -  +  -  +  +  + 
Amhara  0.26     +  +  -  -  -  +  +  + 
Anuak  p<0.01  0.02     -  -  -  +  +  +  + 
Maale  p<0.01  0.01  0.88     +  -  +  +  +  + 
Oromo  0.18  1.00  0.08  0.03     -  -  +  +  + 
Afro-Caribbeans  p<0.01  0.19  0.27  0.32  0.28     -  +  +  + 
Yoruba  0.05  0.54  0.03  0.04  0.47  0.48     +  +  + 
European  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01     -  - 
Chinese  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  1.00     - 
Japanese  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  1.00  1.00    
 
rs4506565 
 
  Afar  Amhara  Anuak  Maale  Oromo  Afro-Caribbeans  Yoruba  European  Chinese  Japanese 
Afar     -  +  -  -  +  +  -  +  + 
Amhara  1.00     +  -  -  +  +  -  +  + 
Anuak  0.01  0.02     -  -  -  -  +  +  + 
Maale  0.24  0.34  0.31     -  -  -  +  +  + 
Oromo  0.48  0.59  0.18  0.91     -  -  +  +  + 
Afro-Caribbeans  0.01  0.01  0.12  0.27  0.11     -  +  +  + 
Yoruba  0.01  0.03  0.07  0.23  0.11  0.97     +  +  + 
European  0.28  0.20  p<0.01  p<0.01  0.02  p<0.01  p<0.01     +  + 
Chinese  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01     - 
Japanese  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  1.00    
 
rs7068741 
 
  Afar  Amhara  Anuak  Maale  Oromo  Afro-Caribbeans  Yoruba  European  Chinese  Japanese 
Afar     -  +  +  -  +  -  +  +  + 
Amhara  0.25     +  +  -  -  -  +  +  + 
Anuak  p<0.01  0.02     -  -  -  -  +  +  + 
Maale  p<0.01  p<0.01  0.73     +  -  -  +  +  + 
Oromo  0.19  1.00  0.07  0.01     -  -  +  +  + 
Afro-Caribbeans  0.02  0.47  0.20  0.07  0.48     -  +  +  + 
Yoruba  0.09  0.62  0.19  0.06  0.89  0.81     +  +  + 
European  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01     -  - 
Chinese  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  1.00     - 
Japanese  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  1.00  1.00    
 
rs7069007 
 
  Afar  Amhara  Anuak  Maale  Oromo  Afro-Caribbeans  Yoruba  European  Chinese  Japanese 
Afar     -  +  +  -  -  -  +  +  + 
Amhara  0.70     +  +  -  -  -  +  +  + 
Anuak  p<0.01  p<0.01     -  +  -  -  +  +  + 
Maale  p<0.01  p<0.01  1.00     +  -  -  +  +  + 
Oromo  0.32  0.69  0.03  0.02     -  -  +  +  + 
Afro-Caribbeans  0.10  0.29  0.12  0.09  0.80     -  +  +  + 
Yoruba  0.14  0.41  0.10  0.06  0.83  1.00     +  +  + 
European  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01     -  - 
Chinese  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  1.00     - 
Japanese  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  1.00  1.00    
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Figure 5.14 continued 
 
rs7603146 
 
  Afar  Amhara  Anuak  Maale  Oromo  Afro-Caribbeans  Yoruba  European  Chinese  Japanese 
Afar     -  -  -  -  -  -  -  +  + 
Amhara  0.24     -  -  -  -  -  -  +  + 
Anuak  0.51  0.85     -  -  -  -  -  +  + 
Maale  0.24  1.00  0.90     -  -  -  -  +  + 
Oromo  0.09  0.88  0.60  0.80     -  +  +  +  + 
Afro-Caribbeans  0.46  0.82  0.92  0.83  0.52     -  -  +  + 
Yoruba  0.28  0.09  0.12  0.08  0.04  0.25     -  +  + 
European  0.81  0.09  0.25  0.12  0.04  0.18  0.09     +  + 
Chinese  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01     - 
Japanese  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  1.00    
 
 
rs12255372 
 
  Afar  Amhara  Anuak  Maale  Oromo  Afro-Caribbeans  Yoruba  European  Chinese  Japanese 
Afar     -  -  +  -  -  -  -  +  + 
Amhara  0.32     -  +  -  -  -  -  +  + 
Anuak  0.71  0.19     +  -  -  -  -  +  + 
Maale  p<0.01  p<0.01  p<0.01     +  +  +  +  +  - 
Oromo  0.37  0.48  0.10  p<0.01     -  -  -  +  + 
Afro-Caribbeans  0.27  0.79  0.08  p<0.01  0.82     -  -  +  + 
Yoruba  0.44  0.07  0.12  p<0.01  0.33  0.10     +  +  + 
European  0.38  0.88  0.31  0.02  0.31  0.56  0.04     +  + 
Chinese  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01     - 
Japanese  p<0.01  p<0.01  p<0.01  0.13  p<0.01  p<0.01  p<0.01  p<0.01  0.24    
 
 
When  haplotypes  using  all  seven  SNPs  (named  seven  SNP  haplotypes  hereafter)  were 
analysed  (figure  5.15a),  the  majority  of  populations  were  significantly  different  at  5  % 
significance.  Consistent with language similarity, Afar and Oromo, both speaking languages in 
the Cushitic family, were not significantly different.   
 
Figure 5.15  Exact test of population differentiation p values (lower triangle) and significant/not significant (+/-) 
differences  at  the  5  %  threshold  (upper  triangle)  for  TCF7L2  haplotypes.    All  Afro-Caribbeans  were  type  2 
diabetics. 
 
a)  Based on haplotypes from all seven SNPs 
 
  Afar  Amhara  Anuak  Maale  Oromo  Afro-Caribbeans  Yoruba  European  Chinese  Japanese 
Afar     +  +  +  +  +  +  +  +  + 
Amhara  p<0.01     +  +  -  +  +  +  +  + 
Anuak  p<0.01  p<0.01     +  +  +  +  +  +  + 
Maale  p<0.01  p<0.01  p<0.01     +  +  +  +  +  + 
Oromo  p<0.01  0.47  p<0.01  p<0.01     +  +  +  +  + 
Afro-Caribbeans  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01     -  +  +  + 
Yoruba  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  0.46     +  +  + 
European  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01     +  + 
Chinese  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01     - 
Japanese  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  0.63    
 
 
b)  Based on haplotypes from rs7903146 (intron 5) and rs12255372 (intron 6) 
 
  Afar  Amhara  Anuak  Maale  Oromo  Afro-Caribbeans  Yoruba  European  Chinese  Japanese 
Afar     +  -  +  +  +  +  +  +  + 
Amhara  0.02     +  +  -  +  +  +  +  + 
Anuak  0.12  p<0.01     -  +  -  -  +  +  + 
Maale  p<0.01  p<0.01  0.26     +  +  +  +  +  + 
Oromo  0.03  0.90  p<0.01  p<0.01     +  +  +  +  + 
Afro-Caribbeans  0.03  p<0.01  0.22  p<0.01  p<0.01     -  +  +  + 
Yoruba  p<0.01  p<0.01  0.17  p<0.01  p<0.01  0.68     +  +  + 
European  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01     +  + 
Chinese  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01     - 
Japanese  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  0.62    
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When haplotypes using only two SNPs (rs7903146 in intron 5 and rs12255372 in intron 6 and 
named two SNP haplotypes hereafter) were analysed (figure 5.15b), the majority of information 
observed from seven SNP haplotypes was captured.  Only four population pairs were no longer 
differentiated at 5 % significance.  Consistent with Anuak having Y chromosome types similar to 
those  prevalent  in  West  Africa  but  not  widely  observed  elsewhere  in  Ethiopia  (unpublished 
data), Anuak were not significantly different from Yoruba or Afro-Caribbeans.  In accordance 
with their geographical proximity, Anuak and Maale, both residing to the west of Ethiopia, were 
not significantly different.  Despite living in very different areas of the country, Afar (NE) and 
Anuak (W) were also not significantly different.   
 
When  the  pattern  of  TCF7L2  genetic  structuring  within  and  among  various  populations  in 
different  datasets  was  analysed  (table  5.2),  similar  results  were  observed  from  seven  SNP 
haplotypes and two SNP haplotypes.  In all datasets, the vast majority (≥ 90 %) of variation was 
observed within populations.   
 
Table 5.2  Hierarchical Fst based on seven SNP haplotypes (7) and two SNP haplotypes (2) in various datasets.  
All Fsts were significant (p < 0.00001). 
 
Fst  Variation among populations (%)  Variation within populations (%) 
Dataset 
7  2  7  2  7  2 
Individual Ethiopian 
ascertainment populations, Afro-
Caribbeans and individual 
HapMap populations  0.09  0.08  9.28  7.81  90.72  92.19 
Pooled Ethiopian ascertainment 
population, Afro-Caribbeans and 
individual HapMap populations  0.11  0.29  10.59  9.65  89.41  90.35 
Individual Ethiopian 
ascertainment populations  0.03  0.01  2.74  1.29  97.26  98.71 
 
 
A similar pattern was observed when population pairwise genetic distances (Fsts) based on 
seven SNP and two SNP haplotypes were analysed (figure 5.16).  Afro-Caribbeans lay between 
Yoruba and Europeans but were closest to Yoruba.  Notably, of all the groups, Yoruba were 
always closest to Afro-Caribbeans with T2D.  East Asians formed a tight cluster furthest away 
from the other groups.  Anuak lay closest to Yoruba and Afro-Caribbeans.  Consistent with their 
assumed  mixed  ancestry,  Afar,  Amhara  and  Oromo  clustered  almost  equidistantly  between 
Yoruba and Europeans, and Amhara were the closest Ethiopian group to Europeans. 
 
Given their capacity to differentiate the Ethiopian ascertainment populations, rs7903146 and 
rs12255372 genotypes were obtained for over 6000 individuals from multiple Ethiopian ethnic 
groups.  In addition to providing insight into T2D susceptibility in Ethiopians, this data should 
prove  useful  for  the  study  of  inter-relationships  and  demographic  history  of  Ethiopian 
populations.   
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Figure 5.16  PCO plots of genetic distance (Fst) among various populations for TCF7L2 haplotypes.  Population 
pairwise Fsts are shown in supplementary figure S3.  Both plots are largely similar. 
 
a) Based on seven SNP haplotypes                                      b) Based on two SNP haplotypes 
 
 
 
 
 
5.3.3  Variation in TCF7L2 in multiple Ethiopian populations 
5.3.3.1  rs7903146 and rs12255372 allele frequencies in multiple Ethiopian populations 
 
For each SNP, no population deviated significantly from Hardy Weinberg equilibrium at 5 % 
significance, except rs7903146 in Mashile (p = 0.01) and rs12255372 in Dasenech (p = 0.02), 
Maale (p = 0.04) and Yem (p = 0.01).  In view of multiple testing however, a p value of 0.05 
indicated no significant deviation from Hardy Weinberg; with a Bonferroni correction for 50 tests, 
a p value of less than 0.001 was considered significant.  Genotype distributions for the above 
groups  were  therefore  consistent  with  Hardy  Weinberg  equilibrium  at  this  reduced  p  value 
threshold.   
 
rs7903146 T allele frequencies were very common in all populations (figure 5.17) ranging from 
0.24 (n = 13) in Dasenech to 0.56 (n = 259) in Ari cultivators, and reaching ≥ 0.40 in most 
groups.  For the pooled Ethiopian dataset, rs7903146 T was observed at a frequency of 0.41 (n 
= 5246).   
 
rs12255372 T allele frequencies were also observed in all populations (figure 5.18) but were 
less common than rs7903146 T.  Allele frequencies ranged from 0.01 (n = 1) in Ari smiths to 
0.26 (n = 76) in Oromo, and reached ≥ 0.10 in most groups.  For the pooled Ethiopian dataset, 
rs12255372 T was observed at a frequency of 0.14 (n = 1821).   
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Figure 5.17  rs7903146 allele frequencies in multiple Ethiopian populations 
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Figure 5.18  rs12255372 allele frequencies in multiple Ethiopian populations 
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5.3.3.2  LD between rs7903146 and rs12255372 in multiple Ethiopian populations 
 
LD between both SNPs was moderately high for the pooled Ethiopian dataset (D´ = 0.44, Chi 
square association p < 0.01).  LD varied among the different Ethiopian populations (figure 5.19).  
Complete LD (D´ = 1) was only observed in Ari smiths.  Where D´ was not equal to 1, LD 
ranged from 0.02 in Mejenger to 0.77 in Dasenech, and was ≥ 0.40 in most groups.  LD was 
generally higher in groups towards the north east of Ethiopia and lower in groups to the south 
west.     127 
Figure 5.19  LD between rs7903146 and rs12255372 in multiple Ethiopian populations.  P values are for Chi 
square associations.   
 
 
 
5.3.3.3  rs7903146/rs12255372 haplotype frequencies in multiple Ethiopian populations 
 
For the pooled Ethiopian dataset, CG was the modal haplotype (55 %, n = 7009).  The T2D at 
risk haplotypes (TG and TT (Humphries et al., 2006)) were common (30 %, n = 3831 and 11 %, 
n = 1400 respectively) and CT was observed at a frequency of 3 % (n = 412).  Consistent with 
D´ values, all four haplotypes were reported in all populations but one (CT was not observed in 
Ari smiths) (figure 5.20).  CG was the modal haplotype (≥ 47 %) in most groups.  TG was 
generally  the  next  most  frequent  haplotype  and  reached  ≥  30  %  in  most  groups.    TT  was 
generally the third most frequent haplotype, reaching ≥ 10 % in most groups.  CT was generally 
the least frequent haplotype, reaching ≥ 3 % in most groups.   
 
Figure 5.20  rs7903146/rs12255372 haplotype frequencies in multiple Ethiopian populations 
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5.3.3.4  Gene  diversity  for  rs7903146/rs12255372  haplotypes  in  multiple  Ethiopian 
populations 
 
Gene diversity for the Ethiopian populations (light blue bars in figure 5.21) was moderately high 
in  all  groups  (≥  0.43)  and  ranged  from  0.43  ±  0.07  in  Dasenech  to  0.66  ±  0.05  in 
Bume/Nyangagtom,  with  a  mean  of  0.57  and  a  variance  of  0.002.    In  the  context  of  gene 
diversity in other populations (dark blue bars in figure 5.21), all Ethiopian groups lay between 
Europeans and both Yoruba and Afro-Caribbeans with T2D, and Dasenech were most similar to 
Europeans.   
 
Figure 5.21  Gene diversity for rs7903146/rs12255372 haplotypes in multiple Ethiopian populations.  Error bars 
represent standard deviation. 
 
 
 
5.3.3.5  How  different  are  the  Ethiopian  populations  in  terms  of  their 
rs7903146/rs12255372 haplotype frequencies? 
5.3.3.5.1  Population differentiation 
 
In  accordance  with  their  recent  non-African  ancestries,  HapMap  Europeans,  Chinese  and 
Japanese populations were significantly different (p > 0.05) from all African groups (figure 5.22).  
Consistent with geography, Hamer, Bena and Bume/Nyangagtom, who live in the south west of 
Ethiopia,  were  not  different  from  Yoruba  at  5  %  significance.    Notably,  Hamer,  Bena  and 
Bume/Nyangagtom were the only Ethiopian populations to not significantly differ (p < 0.05) from 
Afro-Caribbeans with T2D.  Consistent with there being substantial human genetic variation in 
Ethiopia,  53  %  (n  =  646)  of  pairwise  comparisons  among  Ethiopian  populations  were 
significantly different (p < 0.05).  In accordance with their marginalised societies, Manja and  Figure 5.22 Exact test of population differentiation significant/not significant (+/-) differences at the 5% threshold for rs7903146/rs12255372 haplotypes.  Afro-Caribbeans have T2D.  Bume are also known as Nyangagtom, and Basketo are also known as Masketo.
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Afro-
Caribbean
Yoruba European Chinese
Ari Cultivator  -
Afar  + +
Agew, Eastern  + + -
Alaba  + + + +
Amhara  + + + - -
Anuak  + + - + + +
Ari Potter  - + + + + + +
Ari Smith  + + + + + + + +
Bena  - - + + - + - - +
Basketo  - + + + + + + - + -
Bume + + - - + + - + + - +
Bench  - - + + + + + - + - - +
Burji  - + + + + + + - - - - + -
Busa  - + + + + + + - + - - + - -
Dizi  - + + + + + + - + - - + - - -
Dime  - + + + - + + - + - - - - - - -
Dirasha  - + + + + + + - + - - + - - - - -
Dasenech  + + - - - - - + + + + - + + + + + +
Dawuro  + + + + - + + + + - + - + + + + - + -
Dorze  - + + + + + + - + - - + - - - - - - + +
Gobeze  + + + + - + + - + - - + + + - - - - - + -
Gedeo  - + + + + + + - + - - + - - - - - - + + - +
Gofa  + + + + - + + - + - - + + + - - - - + + - - +
Ganjule  - + + + + + + - + - - + - - - - - - + + - - - -
Gamo  + + - + - + - + + - + - + + + + - + - - + - + - +
Genta  + + + + - + + - + - - + + - - - - - + + - - - - - -
Gurage  + + - - - - + + + + + - + + + + + + - - + + + + + - +
Gewada  - + + + + + + - + - - + - - - - - - + + - - - - - + - +
Hadiya  + + - + - + - + + - + - + + + + - + - - + - + - + - - - +
Hamer  - + - + - + - - + - - - - - - - - - - - - - - - - - - - - -
Kefa  + + + + - - + + + - + + + + + + - + + - + - + - + + + - + + -
Kembata  + + - + - + - + + - + - + + + + - + - - + - + - + - - - + - - +
Konta  + + + + + + + + + - - - + + + + - + + + - - + - + + - + - + - - +
Kore  - + + + + + + - + - - + - - - - - - + + - - - - - + - + - + - + + +
Konso  + + + + - + - + + - + - + + + - - - - - - - + - - - - - - - - + - - +
Manja  - + + + + + + - + - - + - - - - - - + + - - - - - + - + - + - + + - - +
Mejenger  + + + + + + - + + - + + + - + - - + - + + - - + + + + + - - - + - + + - +
Mashile  + + + + + + + + + - + + + + - - - - - + + - + - - - - + - - - + - + - - + -
Maale  + + + + + + + - + - - + + - - - - - + + - - - - - - - + - - - + - + - - - - -
Nuer  + + - + + + - + + + + - + + + + + + - + + + + + + - + + + - - + - + + - + - - +
Oromo  + + - - - - + + + + + - + + + + + + - + + + + + + + + - + + + + + + + + + + + + +
Shekecho  + + + + - + + + + - + - + + + + - + + - - - + - + - - + + - - - - - + - + + + + + +
Sidama  + + + + - + + + + - + + + + + + - - - - - - + - + - - - + - - - - - + - + + - + + + -
Sheko  - - + + + + + - + - - + - - - + - + + + - + - + + + + + + + - + + + + + - + + + + + + +
Somali  + + - + - + - + + - + - + + + - - - - - + - + - + - - - - - - + - + + - + - - - - + - - +
Tigrayan  + + - - - - - + + + + - + + + + + + - - + + + + + - + - + - + + - + + + + + + + - - + + + -
Wolayta  + + + + - + + - + - - + + - - - - - + + - - - - - - - + - - - + - - - - - + - - + + - - + - +
Yem  - + + + + + + - + - - + - - - - - - + + - - - - - + - + - + - + + - - - - + - - + + - - + - + -
Zayse  - + + + + + + - + - - + - - - - - - + + - - - - - + - + - + - + + - - - - + - - + + + - - + + - -
Afro-Caribbean + + + + + + + + + - + - + + + + + + + + + + + + + + + + + + - + + + + + + + + + + + + + + + + + + +
Yoruba + + + + + + + + + - + - + + + + + + + + + + + + + + + + + + - + + + + + + + + + + + + + + + + + + + -
European + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Chinese + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Japanese + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + -
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Dawuro were significantly different (p < 0.05) and Ari cultivators differed from Ari potters and 
smiths at 5 % significance.  Ari potters and smiths were also significantly different (p < 0.05).  
Notably, Ari (dataset not considering Ari social structure and collected prior to the collection of 
the  Ari  cultivators,  potters  and  smiths)  were  not  significantly  different  from  Ari  cultivators  or 
potters but were different from the Ari smiths at 5 % significance.   
 
5.3.3.5.2  Genetic structure 
 
Hierarchical  Fst  values  (table  5.3)  showed  that,  whilst  most  variation  was  observed  within 
populations, inter-population variation was evident, with 2 % of variation being observed among 
Ethiopian populations.   
 
Table  5.3    Hierarchical  Fst  based  on  rs7903146/rs12255372  haplotypes  in  various  datasets.    All  Fsts  were 
significant (p < 0.00001). 
 
Dataset  Fst  Variation among populations (%)  Variation within populations (%) 
Individual Ethiopian populations  0.02  1.98  98.03 
Ethiopian populations plus 
HapMap Yoruba, Europeans, 
Chinese and Japanese  0.03  2.78  97.22 
Pooled Ethiopian population plus 
HapMap Yoruba, Europeans, 
Chinese and Japanese   0.32  8.89  91.11 
 
5.3.3.5.3  Genetic distance 
 
A  PCO  plot  of  population  pairwise  Fsts  (figure  5.23a)  showed  that  the  vast  majority  of 
Ethiopians cluster together.  Afro-Caribbeans with T2D tightly cluster with Yoruba and lie close 
to the Ethiopian cluster.  Chinese and Japanese are close but furthest away from the other 
populations.    Europeans  are  not  tightly  clustered  with  any  population  but  are  closest  to 
Dasenech.  At closer resolution (figure 5.23b), Yoruba remain close to Afro-Caribbeans with 
T2D.   
 
5.3.3.5.4  Is genetic distance correlated with geography, language and/or religion? 
 
Pairwise genetic distances (Fst), based on rs7903146/rs12255372 haplotypes in the Ethiopian 
populations  (supplementary  figure  S4),  were  correlated  with  pairwise  average  geographic 
distances  (supplementary  figure  S5)  (mantel  z  statistic  =  6443.91,  p  <  0.01).    Given  the 
correlation between genetic distance and geographic distance: 
 
•  Pairwise language distances (Fst), based on donor’s first language (supplementary figure 
S6), were not correlated with pairwise genetic distances (partial mantel statistic r = 0.06, p > 
0.1). 
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Figure 5.23  PCO plots of pairwise genetic distances (Fst) based on rs7903146/rs12255372 haplotypes.  Pairwise Fsts are shown in supplementary figure S4 (the majority (57 %) of pairwise Fst values 
were significant at the 5 % significance threshold).  For each plot, PCOs 1 and 2 capture > 98 % of the variation.   
 
a)  All populations:  The majority of Ethiopian populations cluster together away from Europeans    b)     At closer resolution:  Yoruba remain closest to Afro-Caribbeans with T2D. 
& East Asians.  Yoruba are closest to Afro-Caribbeans with T2D.   
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•  Pairwise language distances (Fst), based on linguistic group in which donor’s first language 
falls  (supplementary  figure  S7),  were  weakly  correlated  with  pairwise  genetic  distances 
(partial mantel statistic r = 0.20, p < 0.001). 
 
•  Pairwise  religious  distances  (Fst)  (supplementary  figure  S8)  were  not  correlated  with 
pairwise genetic distances (partial mantel statistic r = -0.11, p > 0.1). 
 
5.4  Discussion 
5.4.1  Variation in TCF7L2 in Afro-Caribbeans with T2D 
 
Since the causative variant of the association of TCF7L2 with an increased risk of T2D is not 
known,  it  was  important  to  further  analyse  TG  rs7903146/rs12255372  haplotypes  which  are 
thought to be associated with T2D susceptibility in a type 2 diabetic Afro-Caribbean cohort from 
Humphries  et  al.  (2006).    By  extending  the  TG  rs7903146/rs12255372  haplotype  to  include 
SNPs found in LD block 5 of HapMap Yoruba (rs7901695, rs4132115, rs4506565, rs7068741 
and rs7069007), this study aimed to investigate whether a specific TG haplotype might be a 
potential  T2D  risk  haplotype  in  Afro-Caribbeans  with  T2D.    Ethnically  matched  non-diabetic 
controls  were  not  available  for  this  study,  and  as  a  consequence,  variability  in  haplotype 
distribution due to differential demographic histories was not controlled.  HapMap populations 
were used as controls, and it was assumed that each control population was representative of 
their respective general populations, with some individuals being prone to T2D and some not.  
Since Afro-Caribbeans are thought to be an admixed population with recent European and West 
African  ancestry  (Miljovic-Gacic  et  al.,  2005),  HapMap  European  and  Yoruba  (West  African 
ethnic group) populations were useful as controls in this respect.   
 
Results showed that whilst haplotype distribution differed between Afro-Caribbeans with T2D 
and Europeans, Chinese and Japanese groups, Yoruba were always strikingly similar to Afro-
Caribbeans, even in terms of their ‘TG at risk’ alleles.  Of the rs7903146/rs12255372 haplotypes 
in Afro-Caribbeans with T2D, Humphries et al. (2006) only reported an association between TG 
and an increased risk of the disease.  The association was not significant (p = 0.24) and the 
study suggested that this may be due to small sample size, but the similar distribution of TG 
haplotypes in both Afro-Caribbeans with T2D and Yoruba suggests that the association may be 
due  to  a  demographic  effect.    Since  a  high  frequency  of  TG  haplotypes  were  identified  in 
Yoruba (and may be identified in other West Africans), further studies are warranted to clarify 
whether the TG haplotype is significantly associated with an increased risk of the disease or 
not.  If the association is confirmed, the results from the study presented here suggest that 
TCF7L2 genotypes may confer the same T2D risk in both Afro-Caribbeans and Yoruba.   
 
It is important to note that while the Afro-Caribbeans in this study were not a random sample of 
the general Afro-Caribbean population, they were a random sample of Afro-Caribbeans with   133 
T2D.  The inclusion of this sample in the population level analyses performed throughout this 
study  consequently  obeys  the  ‘random  sampling’  assumption  of  some  population  genetics 
statistical tests, e.g. Fst and exact test of population differentiation (Schneider et al., 2000).  
Including a random sample of the general Afro-Caribbean population would however place data 
from this study into the context of Afro-Caribbeans without T2D.  The similarity of Yoruba to the 
type 2 diabetic  Afro-Caribbean cohort throughout  this study does not  necessarily mean that 
Yoruba may be more susceptible to T2D than the general Afro-Caribbean population.   
 
5.4.2  Placing the TCF7L2 data into the context of Ethiopia 
 
Genotypes for each of the seven TCF7L2 SNPs analysed in this study failed to differentiate the 
majority of African groups (Ethiopian ascertainment populations, Yoruba and Afro-Caribbeans 
with T2D).  Many differences were however observed among groups when haplotypes were 
considered.    Furthermore,  two  SNP  haplotypes  (based  on  rs7903146  and  rs12255372) 
captured the majority of the information on intra and inter-population diversity from haplotypes 
of all seven SNPs.  Given that LD between rs7903146 and rs12255372 varied among groups 
and was generally low in Africans, it is evident that more information is available from haplotype 
data than genotype data when analysing populations with low overall levels of LD between two 
markers.   
 
In this study, African populations were more diverse than non-Africans.  This is consistent with 
anatomically modern human originating  in  Africa.   Furthermore, all of the common variation 
observed  outside  Africa  was  observed  in  the  Ethiopian  ascertainment  populations.    This  is 
consistent with anatomically modern humans expanding out of Africa via Ethiopia ~ 70 thousand 
years ago (Wallace et al., 1999), and a more recent migration of Semitic speaking peoples from 
Arabia to Ethiopia.  
 
The  ‘at  risk’  TG  and  TT  haplotypes  were  common  throughout  Ethiopia  suggesting  that 
substantial numbers of Ethiopians might be prone to T2D (it is however noteworthy to mention 
that T2D is a complex disease and many factors, both genetic and environmental, contribute to 
an individual’s T2D susceptibility).  These findings  are not  only  of benefit to  the indigenous 
populations  of  Ethiopia,  but  are  also  of  increasing  importance  in  directing  public  healthcare 
policies in the developed world, where growing numbers of individuals with recent Ethiopian 
descent are adopting Western dietary habits which may exacerbate the onset of T2D.   
 
Inter-population variation was observed in Ethiopians, and the majority of Ethiopian populations 
were significantly different in terms of their rs7903146/rs12255372 haplotypes, suggesting that 
Ethiopians  should  not  be  treated  as  one  group,  but  as  several  different  groups.    In  most 
Ethiopian  populations,  the  TG  ‘at  risk’  haplotype  (known  to  be  common  in  Afro-Caribbeans 
(Humphries et al., 2006)) was generally observed at higher frequencies than the TT ‘at risk’ 
haplotype  (known  to  be  common  in  Europeans  (Humphries  et  al.,  2006)).    Furthermore,   134 
consistent with their assumed mixed ancestry from the Arabic north and sub-Saharan Africa 
(Cavalli-Sforza  et  al.,  1994),  Ethiopian  populations  lay  between  Yoruba  and  Europeans,  but 
closer to Yoruba, in PCO plots of genetic distance.  These results suggest that most populations 
may have more of a West African TCF7L2 risk for T2D, with few populations possibly having 
more of a European TCF7L2 risk.   
 
Consistent  with  the  isolation  by  distance  model  which  predicts  that  population  similarity  will 
decline with increasing geographical distance as a result of the limiting effect of geographic 
distance on rates of gene flow (Hardy and Vekemans, 1999), pairwise genetic distance (based 
on two SNP haplotypes) was correlated with geographic distance between multiple Ethiopian 
populations.    Given  this  correlation,  genetic  distance  was  also  correlated  with  linguistic 
differences.  It is apparent that, for these markers in this gene, genes do not travel according to 
group specific language or religion.  These results are largely consistent with Y chromsome 
data  which shows an inter-ethnic  division between the north  Semitic and south non-Semitic 
speaking groups in Ethiopia (unpublished data).  This study consequently highlights the power 
of using two SNP haplotypes when analysing populations with low overall levels of LD between 
the two markers.   
 
LD between rs7903146 and rs12255372 was generally higher in groups towards the north east 
of Ethiopia and lower in groups to the south west.  Populations with varying levels of LD may 
prove useful in T2D genotype/phenotype association studies in the future.  They may also be 
informative in association studies investigating the role of rs7903146 in the aetiology of T2D.   
 
In accordance with their hierarchical societies, Manja and Dawuro were significantly different as 
were Ari cultivators, Ari potters and Ari smiths.  Ari (dataset not considering Ari social structure 
and collected prior to the collection of Ari cultivators, potters and smiths) were not different from 
Ari cultivators or Ari potters but were different from Ari smiths, suggesting that the Ari collection 
may have excluded Ari smiths.  These results highlight the importance of considering group 
social structure when collecting samples from ethnic groups in Ethiopia, not least in southern 
Ethiopia where hierarchical societies are common place (Freeman and Pankhurst, 2003).   
 
5.5  Conclusion 
 
In the course of investigating whether a specific TG  rs7903146/rs12255372 haplotype might be 
a potential T2D risk haplotype in Afro-Caribbeans with T2D, this study found that TCF7L2 might 
confer the same risk of T2D in both Yoruba and Afro-Caribbeans.  Depending on variation in 
other genes and environmental factors, this in turn suggests that Yoruba, and potentially other 
West Africans, might be as prone to T2D as Afro-Caribbeans.  With particular relevance for 
healthcare in Ethiopia, appreciable numbers of Ethiopians might be susceptible to T2D, with 
most populations having more TG ‘at risk’ haplotypes, hence more of a West African TCF7L2 
risk for the disease, and some having more TT ‘at risk’ haplotypes, hence more of a European   135 
TCF7L2 risk.  Since LD between rs7903146 and rs12255372 varied among Ethiopians, studies 
involving Ethiopians might prove particularly informative in T2D genotype/phenotype association 
studies, and in association studies investigating the causal variant of the association of TCF7L2 
with predisposition to the disease.  With particular relevance for anthropological studies, this 
study  also  found  that  the  rs7903146/rs12255372  haplotypes  could  effectively  discriminate 
Ethiopian populations in accordance with geography and linguistics, providing insight into inter-
population relationships and population histories.  The haplotypes even had enough power to 
differentiate caste-like groups covered by the same self-identifying ethnic label.  Consistent with 
the  hypothesis  that  anatomically  modern  humans  expanded  out  of  Africa  and  into  the  New 
World via Ethiopia, all of the common TCF7L2 variation observed in non-African populations 
was observed in Ethiopia.   
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6  General discussion 
 
According to the Out of Africa model, anatomically modern humans originated in Africa ~ 200 
thousand years ago and colonised the rest of the world within the last ~ 100 thousand years 
(Stringer and Andrews, 1988; Tishkoff et al., 1996; Campbell and Tishkoff, 2008).  One theory 
suggests  that  anatomically  modern  humans  may  have  migrated  out  of  Africa  via  Ethiopia 
(Forster and Matsumura, 2005; Reed and Tishkoff, 2006; Campbell and Tishkoff, 2008; Tishkoff 
et al., 2009).  Genetic studies have also provided evidence of a more recent migration into 
Ethiopia,  of  Semitic  speaking  peoples  from  Arabia  (Campbell  and  Tishkoff,  2008).    As  a 
consequence, it is possible that more human genetic/phenotypic variation will be observed in 
Ethiopians  than  in  any  other  indigenous  group  of  peoples  of  similar  number  living  in  close 
geographical  proximity.    Characterising  human  genetic  variation  in  Ethiopians  may 
consequently be important for the better design and interpretation of disease association and 
pharmacogenetic studies and for assisting the reconstruction of human evolutionary history, not 
only in Ethiopian populations, but also in populations spanning the globe.   
 
Despite the potential importance of Ethiopian population genetics, at the outset of this thesis 
few studies had investigated the distribution of human genetic variation in Ethiopia, and even 
then, those that had been undertaken were limited to few populations and small sample sizes.  
This  thesis  has  contributed  to  correcting  this  imbalance  by  analysing  variation  in  two 
therapeutically important genes (CYP1A2 and TCF7L2), primarily in a sample set suitable for an 
initial evaluation of diversity among Ethiopian populations (762 chromosomes from five ethnic 
groups: Afar, Amhara, Anuak, Maale and Oromo collected from a roughly north east to south 
west transect across Ethiopia) but variation in TCF7L2 was also analysed in multiple Ethiopian 
groups.  Data from other populations from publicly available databases were incorporated in the 
analyses of this thesis to place the Ethiopian data in a worldwide context. 
 
The  most  striking  finding  from  resequencing  CYP1A2  was  that  a  substantial  amount  of 
previously  unreported  genetic  variation  was  observed  in  the  Ethiopian  sample  sets.    Of 
particular relevance for healthcare in Ethiopian populations, most individuals may, depending on 
variation in the promoter region, exhibit normal CYP1A2 profiles.  However, several novel rare 
CYP1A2 non-synonymous mutations, predicted to cause both conservative and radical changes 
to protein structure, were identified.  The most striking finding from the TCF7L2 study was that 
both rs7903146 and rs12255372 alleles, reported to be associated with an increased risk of 
T2D, are common throughout Ethiopia suggesting that substantial numbers of Ethiopians might 
be  prone  to  developing  T2D.    TCF7L2  haplotype  distribution  varied  among  populations 
suggesting that T2D susceptibility due to the effect of TCF7L2 may also vary, with most groups 
likely having a West African TCF7L2 risk for the disease and some having more of a European 
TCF7L2  risk.    Subject  to  associations  being  confirmed  in  genotype/phenotype  association 
studies, many CYP1A2 and TCF7L2 haplotypes are consequently of important predictive value 
in the planning and provision of healthcare.  These findings are not only of benefit to native   137 
Ethiopians, but are also of increasing importance in the planning of healthcare intervention in 
the developed world, where growing numbers of individuals with recent Ethiopian descent are 
living. 
 
Reduction of both intra-population gene diversity and inter-population genetic distance for non-
synonymous  mutations  in  comparison  to  silent  mutations  (which  have  no  effect  on  protein 
structure) in CYP1A2, was consistent with the hypothesis that purifying selection has acted at 
these  non-synonymous  SNP  sites.    Further  support  for  this  phenomenon  comes  from  the 
approximate  coalescence  date  boundaries  of  these  non-synonymous  mutations  being 
consistent with the following hypothesis: mutations evidenced to be under purifying selection 
may include variants which drifted to high frequencies in smaller ancestral populations prior to 
the expansion of anatomically modern humans ~ 100 thousand years ago (Hughes et al., 2003).  
Since the minor allele frequencies at CYP1A2 loci evidenced to be under purifying selection are 
substantially  higher  than  those  of  genes  causative  of  severe  Mendelian  diseases,  the  data 
suggests  that  the  selective  forces  acting  against  these  non-synonymous  SNPs  are  mild  in 
comparison to those at SNP sites causative of severe disease.  Since mutations associated with 
complex diseases are expected to be individually only slightly deleterious, as opposed to highly 
deleterious variants associated with Mendelian diseases, it has been claimed that evidence of 
mild  purifying  selection  may  be  used  to  identify  candidate  alleles  for  complex  disease-
association studies (Hughes et al., 2003).  As a consequence, it may be appropriate to include 
non-synonymous SNPs identified in this thesis in future studies investigating complex diseases 
which  have  been  linked  to  CYP1A2,  e.g.  several  cancers  (Gunes  and  Dahl,  2008)  and 
cardiovascular disease (Cornelis et al., 2004). 
 
Consistent with Africa being the birthplace of humankind, gene diversity for both CYP1A2 and 
TCF7L2  was always higher in African populations than non-African populations (populations 
with a recent West African ancestry tended to be the most diverse throughout the analyses, 
however  their  sample  sizes  were  often  small  and  this  observation  should  consequently  be 
interpreted with caution).  Given that currently most drug testing is undertaken on non-African 
populations, this thesis has demonstrated that more testing on non European/Asian populations 
is  warranted.   With  increasing  numbers  of  people  having  a  recent  African  descent  living  in 
Europe and the Americas, their pharmacogenetic profiles should be represented in clinical trials.  
In addition, there should be close  attention paid to  them in post-marketing surveillance  and 
greater awareness of variability amongst them.  Largely consistent with Y chromosome data, 
variation  in  both  CYP1A2  and  TCF7L2  showed  an  inter-ethnic  division  between  the  north 
Semitic  and  south  non-Semitic  speaking  groups  in  Ethiopia.    Statistically  significant  inter-
population  variation  was  also  observed  among  Ethiopian  populations  living  in  close 
geographical  proximity.  As a consequence, the general Ethiopian  population  should not  be 
treated as a single homogenous group, a finding which undoubtedly has implications for future 
healthcare policies in Ethiopia. 
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Serving as further support for the hypothesis that anatomically modern humans expanded out of 
Africa via Ethiopia, Ethiopian populations evidenced all of the common CYP1A2 and TCF7L2 
variation  observed  elsewhere.    This  thesis  demonstrated  that  CYP1A2  functional  variation 
cannot be predicted in Ethiopians based on known variation, the majority of which is derived 
from East Asians and Europeans.  It may however be possible to use Ethiopians not only as a 
population  for  the  development  of  diagnostic  tests  useful  in  pharmacogenetic  prediction  in 
populations worldwide, but also to ensure that such tests were suitable not only for developed 
countries. 
 
Consistent with anatomically modern humans having existed in Africa longer than in any other 
geographic region, much lower LD was observed between loci in each of CYP1A2 and TCF7L2 
in Africans than in non-Africans.   Varying levels of overall low LD between rs7903146 and 
rs12255372  were  also  observed  among  Ethiopian  populations  with  the  consequence  that 
rs7903146/rs12255372  haplotypes  could  effectively  discriminate  Ethiopian  groups  in 
accordance with geography and linguistics, providing insight into inter-population relationships 
and population histories.  The haplotypes even had enough power to differentiate caste-like 
groups covered by the same self-identifying ethnic label.  Ethiopian populations with varying 
levels of LD may prove particularly informative in T2D genotype/phenotype association studies, 
and in association studies investigating the causal variant of the association of TCF7L2 with 
predisposition to the disease.  Likewise, the plethora of variation identified in the CYP1A2 study 
should  prove  of  considerable  utility  in  designing  association  studies  investigating 
pharmacokinetic variation due to the cis promoter region, not least in CYP1A2 where it has not 
yet been identified.  Similarly, they should prove useful in investigating copy number variation 
and variability due to mutations in non coding regions e.g. splice sites and initiation sites. 
 
I have been very fortunate in the timing of my PhD research.  Ethiopia has increasingly opened 
up its doors to population genetic research.  I owe a special thanks to Dr Ayele Tarekegn, 
without whom this research would not be possible.  As a postdoctoral research fellow affiliated 
with Addis Ababa University, he has spent the past 12 years travelling far and wide in Ethiopia 
collecting  buccal  DNA  and  sociological  background  data  from  over  8000  Ethiopians  from 
multiple ethnic groups.  From personal fieldwork experience in Ethiopia, this is certainly not an 
easy task.  The studies included in this thesis also come at a time when the UK government is 
reporting steps which have to be taken to ensure that the NHS is able to exploit the benefits of 
genetic research (http://www.parliament.uk/hlscience/).  I hope future reports push forward the 
potential healthcare benefits of approaches discussed in this thesis. 
 
6.1  Future work 
 
The outcomes of the studies included in this thesis suggest a number of potential projects that 
are immediately apparent, some of which are listed below: 
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•  Sequence more CYP genes in the Ethiopian ascertainment populations (refer to discussion 
of chapter 4 for details of genes). 
 
•  Since the Ethiopian data could only be tentatively interpreted within the context of West 
Africa, due to small Yoruba sample sizes, extend the CYP1A2 study to a number of West 
African populations with larger sample sizes. 
 
•  Develop  a  diagnostic  test  for  predicting  CYP1A2  functional  variation  among  Ethiopian 
populations (refer to chapter 4 discussion for further details). 
 
•  Confirm whether the rs7903146/rs12255372 TG haplotype is significantly associated with 
an increased risk of T2D in Afro-Caribbeans by repeating the Humphries et al. (2006) study 
with larger sample sizes.  If the association is confirmed, establish whether typing additional 
SNPs to rs7903146 and rs12255372 increases the association of TCF7L2 with T2D in Afro-
Caribbeans, using Afro-Caribbeans without T2D as a control. 
 
•  Characterise  human  genetic  variation  in  Ethiopia  at  a  much  finer  scale  by  typing  the 
Ethiopian ascertainment populations  with the million SNP chip – a project which is now 
being planned. 
 
•  Whole genome sequencing of representative donors from the groups analysed in this thesis 
– a project which is also in the course of being planned.   
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Appendix 1 
 
From genotype to haplotype 
A haplotype is the combination of allelic states of a set of polymorphic markers lying on the 
same DNA molecule e.g. a chromosome or region of a chromosome (Jobling et al., 2004).  
Haplotypes  are  immediately  identified  from  haploid  loci  (mtDNA,  Y  chromosome  and  the  X 
chromosome in males) but are less readily obtained from diploid autosomal loci.  The traditional 
method  for  determining  haplotypes  is  by  pedigree  analysis,  but  this  may  be  uninformative 
depending  on  allele  frequencies  within  the  pedigree.    Haplotypes  can  be  obtained  from 
genotype data by physical separation of one allele from the other, but this approach can be 
expensive and laborious (Jobling et al., 2004).  As a consequence of this, statisticians have 
developed, and continue to do so, algorithms for haplotype reconstruction.  Common methods 
include Clark’s algorithm, the expectation-maximization (EM) algorithm, the ELB algorithm and a 
Bayesian  approach  implemented  in  PHASE.    A  newer  model  using  the  EM  algorithm  is 
implemented in fastPHASE.   
Clark’s algorithm 
 
One of the earliest algorithms for haplotype reconstruction, from genotype data, was described 
in Clark (1990).  The approach is based on the principle of maximum parsimony as it attempts 
to minimise the total number of steps required to resolve a haplotype. The rationale for Clark’s 
algorithm  is  that  an  ambiguous  pair  of  haplotypes is  likely  to  contain  at  least  one  common 
haplotype.    The  algorithm  starts  by  identifying  all  unambiguous  haplotypes  (from  all 
homozygotes and single-site heterozygotes) and considering them as resolved.  The next step 
determines whether any of the resolved haplotypes could be one of the underlying haplotypes in 
the remaining unphased genotypes.  If this is the case, the haplotype is assumed to be correct 
and the complementary haplotype is added to the set of resolved haplotypes.  The algorithm 
continues to analyse the data, increasing the pool of resolved haplotypes, until all genotypes 
are resolved or no further genotypes can be resolved in this way.   
 
When  manually  applying  Clark’s  algorithm  to  the  CYP1A2  genotype  data,  the  following 
extensions were applied in the Clark-ancestral approach:- 
 
1.  For each individual, if the unphased genotype data can be divided into two previously 
resolved haplotypes, then this is the pair of haplotypes to assign to that individual.   
 
2.  When none of the possible haplotypes are in the resolved set, refer to the chimpanzee’s 
combination of alleles for this locus.  If possible, assign the chimpanzee’s haplotype, 
plus  the  complementary  haplotype,  to  this  individual  and  add  them  to  the  resolved 
haplotype set.     141 
 
3.  When one of the possible haplotypes is that of the chimpanzee (which has already been 
added to the resolved haplotype set), always adopt this option, unless the unphased 
genotype data can be divided into two previously resolved haplotypes.   
 
4.  When one of the possible haplotypes can be a number of different haplotypes from the 
resolved set, and the status of the chimpanzee is unknown or not a possibility, assign 
the  individual  to  the  most  common  haplotype  in  the  sample  population,  plus  the 
complementary haplotype. 
 
5.  When none of the above apply and none of the possible haplotypes are in the resolved 
set, assign this individual as having two orphan haplotypes.   
 
Another  extension  of  Clark’s  algorithm  (Clark-common)  was  also  manually  applied  to  the 
CYP1A2 data.  It is a certain resolution approach and underestimates diversity by not resolving 
low frequency polymorphisms into haplotypes.  Unlike the Clark-ancestral approach described 
above, the Clark-common approach prioritises the common haplotype in the population over the 
ancestral haplotype.  Thus when one of the possible haplotypes can be a number of different 
haplotypes from the resolved set, the individual is assigned to the most common haplotype in 
the sample population (whether it is the ancestral haplotype or not), plus the complementary 
haplotype.  The Clark-ancestral and Clark-common approaches were applied to the CYP1A2 
data in a segmented fashion.  Haplotypes were deduced separately for each exon and intron, 
and for the 5’ upstream region of the gene and the 3’ UTR, and were then linked together to 
produce haplotypes for the entire CYP1A2 gene.   
 
The advantages of Clark’s algorithm are that it is a relatively simple procedure which can handle 
large numbers of loci when haplotype diversity is limited in the population.  The algorithm also 
performs well for short stretches of DNA and longer regions in complete LD.  Along with the 
possibility of “orphan” haplotypes remaining undeduced, disadvantages include the algorithm 
not starting (at least not without extra information or adhoc intervention) when there are no 
homozygotes  or  single-site  heterozygotes  in  the  population,  the  algorithm  not  giving  unique 
solutions  due  to  the  phased  haplotypes  being  dependant  on  the  order  of  the  unphased 
genotypes, missing data not being accounted for, and its performance is relatively sensitive to 
the  extent  of  deviation  from  Hardy-Weinberg  equilibrium,  although  the  approach  does  not 
explicitly assume Hardy-Weinberg equilibrium (Niu et al., 2002).  In addition, Clark’s algorithm 
cannot assess the uncertainty associated with each phase call.   
 
Expectation-Maximization (EM) algorithm 
 
The  maximum-likelihood  approach,  implemented  through  the  EM  algorithm  (Excoffier  and 
Slatkin, 1995), is an iterative procedure which attempts to find the set of unknown population 
haplotype frequencies that maximises the likelihood of observing the known sample genotype   142 
frequencies, under the assumption of Hardy-Weinberg equilibrium.  The estimate found by the 
EM algorithm can depend on the starting point, so in practice a number of different starting 
points are used.  The first starting point has, as an example, been computed by finding all the 
possible  haplotypes  which  could  occur  in  the  sample  population  given  the  genotypes,  and 
setting each of them to an equal frequency (Excoffier and Slatkin, 1995).  Once the matrices of 
estimated haplotype frequencies are obtained, the haplotypes are then reconstructed for each 
individual generally by choosing the most probable haplotype assignment, given the estimated 
haplotype frequencies and the genotype data.   
 
Although the EM method is more computationally intensive than Clark’s algorithm, it has the 
advantage of estimating haplotype frequencies from a solid statistical theory.  Other advantages 
of the EM approach include its performance not being too sensitive to departures from Hardy-
Weinberg  equilibrium,  despite  it  making  a patent assumption  of  Hardy-Weinberg  equilibrium 
(Niu et al., 2002).  Disadvantages include the standard EM algorithm not being able to handle a 
large number of loci due to the need to store haplotype frequency estimates for every possible 
haplotype in the sample.   
 
ELB algorithm 
 
The ELB algorithm (Excoffier et al., 2003), implemented in Arelquin software (Schneider et al., 
2000), reconstructs the gametic phase of multiple genotypes.  A window of neighbouring loci is 
used to create phase updates, and the size of the window changes according to the local level 
of linkage disequilibrium; the higher the linkage disequilibrium between pairs of loci, the larger 
the window and vice versa.  The ELB algorithm begins by arbitrarily assigning phase to each 
individual in the population and associating each heterozygous locus with a window containing 
the locus and neighboring loci.  At each iteration of the algorithm, an individual is randomly 
chosen,  and  one  by  one,  its  heterozygous  loci  are  randomly  visited.    For  each  locus,  the 
window is updated by accepting or rejecting, (a) an extra locus at one end of the window and 
(b) the withdrawal of a locus at the opposite end.  The locus being visited always remains 
inside  the  window  and  at  least  one  other  heterozygous  locus  is  always  included  in  each 
window.  The two proposed updates are made successively so that the window can either 
increase by one locus, decrease by one locus, increase by one locus in either direction (if both 
changes are accepted) or remain unchanged (if both changes are rejected).  Finally, phase 
updates  for  each  locus  being  visited  are  made  based  on  haplotypes  observed  in 
corresponding windows of other individuals in the sample population.   
 
The key advantage of the ELB algorithm is that it is suited to problems involving multiple loci 
and/or  large  genomic  regions,  including  those  with  recombination.    The  approach  also 
evidenced consistently better accuracy on a local scale than other methods, such as PHASE, 
while its accuracy over larger genomic regions was close to the best rates (Excoffier et al., 
2003).  Missing data can be handled and haplotypes are reconstructed quickly when small   143 
numbers of loci are considered but slowly when large datasets are used.  Probability estimates 
for each haplotype pair per sample are also calculated.   
 
PHASE 
 
The  program  PHASE  (Stephens  et  al.,  2001)  implements  a  Bayesian  statistical  method  for 
reconstructing haplotypes from population genotype data.  The algorithm begins by identifying 
all unambiguous haplotypes from homozygotes and single-site heterozygotes in the sample.  A 
posterior  distribution  (the  conditional  distribution  of  the  unobserved  haplotypes  given  the 
observed genotype data (Stephens and Donnelly, 2003)) is then constructed.  This is based on 
a prior that approximates the coalescent (Stephens and Donnelly, 2003), the rationale being 
that the difference in genetic sequence between the progenitor and mutant offspring will be 
small, often only by a single base change.  The prior will put substantial weight on the possibility 
of dividing unphased genotypes into two haplotypes, one or both of which are already known in 
the sample.  When unphased genotypes cannot be divided in this manner, the approximate 
coalescent prior will put substantial weight on the possibility of both haplotypes being similar to 
known  haplotypes.    Once  the  posterior  distribution  has  been  constructed,  the  Markov-chain 
Monte Carlo method makes an initial guess, from this distribution, at all haplotype pairs in the 
sample, except one.  This individual is then assigned a pair of haplotypes from the posterior 
distribution  on  the  assumption  that  all  other  haplotype  pairs  in  the  sample  are  correct  (on 
occasions where none of the haplotypes from the posterior distribution are complementary to 
the unphased genotype data, the algorithm randomly sprinkles mutations onto the haplotypes 
which it chooses).  The algorithm then estimates the probability of this reconstruction being 
correct  given  the  genotype  of  the  individual.    Sufficient  repetition  of  this  process  creates  a 
distribution,  per  individual,  of  the  probability  of  the  reconstructed  haplotypes  given  the 
genotypes.  At the end of the algorithm, individuals are assigned haplotypes which are the most 
probable given the genotype data.  The algorithm initially estimates haplotype frequencies in 
short blocks of consecutive SNPs.  Adjacent blocks are then combined and haplotype estimates 
are obtained for the entire region under consideration.   
 
The key advantage of the algorithm is that it integrates the coalescence theory into its prior, and 
performs well in simulations based on a coalescent model.  The algorithm can also impute 
missing data and experiments on both real and simulated data show that it can outperform other 
methods  when  reconstructing  haplotypes  (Stephens  et  al.,  2001).    It  is  not  however  clear 
whether the algorithm outperforms other methods for admixed or rapidly expanding populations 
when  the coalescent  theory  is  not supported.    PHASE  and  EM  based approaches  produce 
similar results in in such cases (Zhang et al., 2001; Xu et al., 2002).  Stephens and Donnelly 
(2003) suggest increasing PHASE run times to increase the accuracy of haplotypes in these 
circumstances.  The main disadvantage of the algorithm is its lack of speed.  The algorithm 
works slowly, as it adopts a “piece by piece” strategy when updating new haplotypes which 
resemble existing haplotypes.   
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fastPHASE 
 
The programme fastPHASE implements methods described in Scheet and Stephens (2006).  It 
is a statistical model for haplotype reconstruction from population genotype data on a large 
scale.  The model is based on the theory that haplotypes tend to cluster into groups of similar 
haplotypes in a population over short regions (~ 3 kb in humans), with each cluster representing 
a common haplotype across the entire region under consideration.  This clustering is local in 
nature  due  to  recombination,  such  that  as  one  moves  along  the  chromosome,  similar 
haplotypes  will  vary.    fastPHASE  allows  cluster  memberships  of  observed  haplotypes  to 
continuously  vary  along  the  chromosome  via  a  hidden  Markov  model.    Each  observed 
haplotype ends up as a mosaic of a limited number of common haplotypes in the population.  
Unlike  block  based  cluster  models,  which  separate  the  chromosome  into  segments  of  high 
linkage  disequilibrium  only  allowing  cluster  memberships  to  vary  across  block  boundaries, 
fastPHASE  is  flexible  and  captures  more  complex  patterns  of  linkage  disequilibrium  while 
continuing to pick up on any block based patterns that may be present.  As examples, the 
model can capture the immediate break down of linkage disequilibrium across recombination 
hotspots and the more moderate decline of linkage disequilibrium with distance.   
 
The algorithm starts by assigning each observed sample to n clusters of origin by weighted 
probability (eg. sample 1 is more likely to come from cluster x, because cluster x is high in 
frequency) and given the genotype data.  The EM algorithm is then implemented to construct a 
matrix  of  the  frequencies  of  each  SNP  in  each  cluster.    The  probability  of  the  observed 
haplotype  is estimated given  the  matrix  and  frequency  of  clusters.    Each  haplotype  is  then 
assigned  a  probability  of  which  cluster(s)  it  belongs  to.    The  algorithm  then  estimates  the 
probability of each SNP, in each haplotype, originating from each cluster.  At this point, the 
hidden Markov model is used to take neighbouring SNPs into account as well as the distance 
between markers.  The algorithm then calculates probabilities of specific genotypes originating 
from specific  clusters.   For  each  individual,  the  EM  algorithm  is  then  employed  to create a 
distribution of haplotype probabilities given the matrices, frequency of clusters and genotype 
data.  At the end of the process, the most probable haplotypes are assigned to each individual.   
 
The advantages of the model are that it is flexible, fast, computationally convenient and can 
handle large amounts of data (thousands of individuals with hundreds of thousands of SNPs).  It 
can  impute  missing  genotypes  as  accurately,  or  more  so,  than  existing  methods  such  as 
PHASE.    Disadvantages  of  the  model  include  its  haplotype  estimates  being  slightly  less 
accurate than those from PHASE, it not producing recombination rate estimates, and it only 
being a purely predictive model.  The algorithm only estimates haplotypes.  It does not relate 
genetic data to underlying models of demography or evolution.  In addition, despite imputing 
missing genotypes, the model is only suited to imputation of genotypes at SNPs where many 
individuals have been genotyped (Scheet and Stephens, 2006).     145 
Supplementary Data 
 
Supplementary  figure  S1    Population  pairwise  genetic  distances  (pink)  and  p  values  (upper  triangle)  for 
CYP1A2 haplotypes.  P values below the 5 % significance threshold are highlighted in grey.   
 
  CYP1A2 (entire gene) haplotypes 
  Afar  Amhara  Anuak  Maale  Oromo  African American  Yoruba  European  Hispanic  East Asian 
Afar  -0.01  0.34  < 0.01  < 0.01  0.25  0.14  0.02  < 0.01  0.04  0.05 
Amhara  0.00  -0.01  < 0.01  < 0.01  0.07  0.04  < 0.01  0.01  0.09  0.02 
Anuak  0.08  0.12  -0.01  < 0.01  < 0.01  0.08  0.43  < 0.01  < 0.01  < 0.01 
Maale  0.03  0.06  0.02  -0.01  < 0.01  0.16  0.12  < 0.01  < 0.01  < 0.01 
Oromo  0.00  0.01  0.08  0.02  -0.01  0.35  0.11  < 0.01  0.09  0.16 
African American  0.02  0.05  0.03  0.01  0.00  -0.08  0.63  < 0.01  0.02  0.73 
Yoruba  0.07  0.12  0.00  0.03  0.04  -0.02  -0.11  < 0.01  < 0.01  0.29 
European  0.11  0.08  0.34  0.21  0.13  0.27  0.39  -0.04  0.27  < 0.01 
Hispanic  0.05  0.04  0.27  0.15  0.05  0.13  0.23  0.01  -0.08  0.05 
East Asian  0.03  0.06  0.08  0.04  0.01  -0.03  0.03  0.26  0.11  -0.04 
                     
  CYP1A2 cds (non-synonymous variants) haplotypes 
  Afar  Amhara  Anuak  Maale  Oromo  African American  Yoruba  European  Hispanic  East Asian 
Afar  -0.01  0.04  0.11  0.05  0.79  0.75  0.32  0.24  0.27  0.26 
Amhara  0.02  -0.01  0.01  < 0.01  0.12  0.28  0.08  0.99  0.99  0.99 
Anuak  0.01  0.05  -0.01  0.17  0.15  0.77  0.77  0.03  0.13  0.06 
Maale  0.01  0.05  0.00  -0.01  0.03  0.45  0.58  0.05  0.10  0.05 
Oromo  0.00  0.01  0.01  0.01  -0.01  0.79  0.21  0.25  0.41  0.44 
African American  -0.02  0.03  -0.01  -0.01  -0.02  -0.05  0.77  0.17  0.50  0.51 
Yoruba  0.01  0.15  -0.03  -0.02  0.02  -0.03  -0.09  0.07  0.14  0.10 
European  0.01  -0.01  0.04  0.04  0.01  0.04  0.15  -0.03  0.99  0.99 
Hispanic  0.01  -0.02  0.03  0.03  0.00  0.02  0.11  0.00  -0.05  0.99 
East Asian  0.00  -0.01  0.03  0.03  0.00  0.01  0.08  -0.01  -0.01  -0.03 
 
Supplementary figure S2  Population pairwise genetic distances (Fst) (pink) and p values (upper triangle) for 
TCF7L2 haplotypes.  P values below the 5 % significance threshold are highlighted in grey.   
 
  Afro-Caribbeans with T2D  Yoruba  European  Chinese  Japanese 
Afro-Caribbeans with T2D  -0.006  0.796  p < 0.001  p < 0.001  p < 0.001 
Yoruba  -0.004  -0.008  p < 0.001  p < 0.001  p < 0.001 
European  0.136  0.145  -0.008  p < 0.001  p < 0.001 
Chinese  0.312  0.334  0.163  -0.011  0.707 
Japanese  0.299  0.319  0.148  -0.007  -0.011 
 
Supplementary figure S3  Population pairwise genetic distances (Fst) (pink) and p values (upper triangle) for 
TCF7L2 haplotypes.  P values below the 5 % significance threshold are highlighted in grey.   
 
a) Based on seven SNP haplotype 
  Afar  Amhara  Anuak  Maale  Oromo  Afro-Caribbeans  Yoruba  European  Chinese  Japanese 
Afar  -1.01  0.14  p<0.01  p<0.01  0.08  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01 
Amhara  0.01  -1.01  p<0.01  p<0.01  0.39  p<0.01  p<0.01  0.03  p<0.01  p<0.01 
Anuak  0.04  0.07  -1.01  0.05  p<0.01  0.02  0.16  p<0.01  p<0.01  p<0.01 
Maale  0.02  0.04  0.01  -1.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01 
Oromo  0.01  0.00  0.05  0.03  -1.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01 
Afro-Caribbeans  0.04  0.06  0.01  0.02  0.04  -1.01  0.82  p<0.01  p<0.01  p<0.01 
Yoruba  0.04  0.07  0.00  0.03  0.05  0.00  -1.01  p<0.01  p<0.01  p<0.01 
European  0.03  0.02  0.14  0.10  0.04  0.14  0.15  -1.01  p<0.01  p<0.01 
Chinese  0.19  0.21  0.30  0.25  0.25  0.31  0.33  0.16  -1.01  0.73 
Japanese  0.18  0.19  0.28  0.24  0.23  0.30  0.32  0.15  -0.01  -1.01 
 
b) Based on two SNP haplotype 
  Afar  Amhara  Anuak  Maale  Oromo  Afro-Caribbeans  Yoruba  European  Chinese  Japanese 
Afar  -1.01  0.19  0.11  0.04  0.07  0.03  0.02  p<0.01  p<0.01  p<0.01 
Amhara  0.01  -1.01  0.03  p<0.01  0.81  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01 
Anuak  0.01  0.02  -1.01  0.34  p<0.01  0.23  0.29  p<0.01  p<0.01  p<0.01 
Maale  0.02  0.02  0.00  -1.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01 
Oromo  0.01  0.00  0.02  0.03  -1.01  p<0.01  p<0.01  p<0.01  p<0.01  p<0.01 
Afro-Caribbeans  0.02  0.03  0.00  0.02  0.03  -1.01  0.76  p<0.01  p<0.01  p<0.01 
Yoruba  0.02  0.04  0.00  0.02  0.04  -0.01  -1.01  p<0.01  p<0.01  p<0.01 
European  0.05  0.04  0.10  0.10  0.05  0.12  0.13  -1.01  p<0.01  p<0.01 
Chinese  0.19  0.22  0.25  0.24  0.24  0.28  0.29  0.16  -1.01  0.76 
Japanese  0.17  0.20  0.24  0.23  0.23  0.27  0.28  0.14  -0.01  -1.01 Supplementary figure S4  Population pairwise genetic distances (Fst) for rs7903146/rs12255372 haplotypes.  Significant distances are highlighted in pink (p < 0.05).  Afro-Caribbeans have T2D.  Basketo are also known as Masketo and Bume are also known as Nyangagtom.  
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Afro-
Caribbean
Yoruba European Chinese Japanese
Ari 
-0.004
Ari Cultivator 
0.001 -0.002
Afar 
0.078 0.116 -0.004
Agew, Eastern 
0.086 0.123 0.000 -0.002
Alaba 
0.053 0.086 0.003 0.002 -0.004
Amhara 
0.076 0.110 0.004 0.000 0.000 -0.001
Anuak 
0.070 0.106 -0.003 0.005 0.005 0.010 -0.005
Ari Potter 
0.004 0.021 0.040 0.046 0.021 0.040 0.033 -0.004
Ari Smith 
0.040 0.067 0.034 0.047 0.030 0.047 0.020 0.016 -0.010
Bena 
-0.016 -0.009 0.062 0.067 0.035 0.056 0.059 -0.007 0.048 -0.034
Basketo
-0.002 0.010 0.052 0.059 0.032 0.052 0.045 -0.002 0.027 -0.014 -0.004
Bume
0.044 0.077 -0.002 0.003 0.000 0.004 0.001 0.020 0.040 0.018 0.023 -0.021
Bench 
-0.002 0.007 0.065 0.073 0.043 0.066 0.055 0.000 0.025 -0.011 -0.003 0.038 -0.004
Burji 
0.006 0.023 0.041 0.051 0.027 0.047 0.032 -0.002 0.009 -0.001 0.000 0.022 0.000 -0.004
Busa 
0.007 0.026 0.035 0.043 0.019 0.038 0.027 -0.003 0.010 -0.002 -0.001 0.017 0.001 -0.003 -0.004
Dizi 
0.009 0.028 0.032 0.041 0.018 0.036 0.025 -0.003 0.009 -0.001 0.000 0.015 0.002 -0.003 -0.004 -0.004
Dime 
0.001 0.018 0.032 0.038 0.014 0.031 0.027 -0.007 0.019 -0.014 -0.006 0.007 -0.002 -0.004 -0.006 -0.006 -0.012
Dirasha 
0.013 0.034 0.028 0.035 0.013 0.030 0.020 -0.002 0.007 0.004 0.003 0.014 0.005 -0.002 -0.004 -0.004 -0.005 -0.005
Dasenech 
0.123 0.165 0.009 0.015 0.023 0.023 0.006 0.072 0.037 0.130 0.092 0.041 0.103 0.071 0.064 0.061 0.073 0.052 -0.019
Dawuro 
0.046 0.076 0.004 0.005 -0.002 0.003 0.005 0.018 0.027 0.027 0.026 -0.004 0.037 0.022 0.016 0.015 0.010 0.011 0.027 -0.002
Dorze 
0.002 0.016 0.042 0.048 0.023 0.041 0.037 -0.003 0.026 -0.014 -0.004 0.014 0.000 0.000 -0.001 -0.001 -0.008 0.001 0.082 0.018 -0.005
Gobeze 
0.024 0.050 0.014 0.018 0.003 0.015 0.010 0.003 0.011 0.011 0.010 0.003 0.016 0.005 0.001 0.001 -0.002 -0.002 0.037 0.002 0.005 -0.004
Gedeo 
-0.001 0.012 0.051 0.060 0.033 0.053 0.044 -0.002 0.023 -0.012 -0.004 0.023 -0.003 -0.002 -0.001 0.000 -0.006 0.002 0.090 0.027 -0.003 0.010 -0.004
Gofa 
0.021 0.045 0.017 0.021 0.004 0.017 0.014 0.001 0.013 0.007 0.007 0.005 0.013 0.004 0.000 0.000 -0.004 -0.002 0.043 0.003 0.003 -0.004 0.008 -0.004
Ganjule 
0.011 0.032 0.031 0.038 0.016 0.033 0.023 -0.003 0.006 0.003 0.002 0.016 0.004 -0.003 -0.004 -0.004 -0.005 -0.005 0.056 0.013 0.001 -0.001 0.001 -0.001 -0.005
Gamo 
0.044 0.075 0.003 0.007 -0.001 0.007 0.001 0.015 0.017 0.030 0.025 -0.002 0.034 0.017 0.012 0.011 0.009 0.007 0.021 -0.001 0.018 0.000 0.025 0.001 0.009 -0.002
Genta 
0.012 0.032 0.024 0.029 0.010 0.024 0.020 -0.002 0.018 -0.004 0.001 0.004 0.007 0.001 -0.002 -0.002 -0.007 -0.002 0.057 0.007 -0.002 -0.002 0.002 -0.003 -0.002 0.006 -0.004
Gurage 
0.069 0.105 0.000 -0.001 -0.002 -0.001 0.002 0.033 0.034 0.052 0.045 0.001 0.057 0.037 0.029 0.028 0.025 0.022 0.015 0.000 0.035 0.009 0.046 0.011 0.025 0.001 0.018 -0.003
Gewada 
0.008 0.027 0.031 0.040 0.018 0.035 0.024 -0.003 0.012 -0.004 -0.001 0.011 0.002 -0.003 -0.004 -0.004 -0.007 -0.003 0.062 0.014 -0.002 0.001 -0.001 0.000 -0.003 0.010 -0.003 0.027 -0.004
Hadiya 
0.041 0.072 0.002 0.007 -0.001 0.007 0.001 0.014 0.017 0.026 0.022 -0.005 0.031 0.015 0.011 0.009 0.007 0.006 0.024 -0.001 0.015 -0.001 0.022 0.001 0.008 -0.003 0.004 0.001 0.009 -0.004
Hamer 
0.002 0.023 0.019 0.028 0.008 0.025 0.013 -0.011 0.003 -0.011 -0.008 -0.001 -0.005 -0.011 -0.012 -0.012 -0.015 -0.012 0.056 0.003 -0.010 -0.009 -0.009 -0.009 -0.012 0.000 -0.011 0.016 -0.013 -0.002 -0.022
Kefa 
0.040 0.068 0.017 0.013 0.002 0.006 0.021 0.018 0.046 0.016 0.024 0.000 0.036 0.028 0.019 0.019 0.008 0.016 0.052 0.002 0.015 0.006 0.026 0.006 0.018 0.007 0.007 0.007 0.017 0.006 0.008 -0.004
Kembata 
0.046 0.078 0.001 0.005 -0.002 0.006 -0.001 0.016 0.017 0.032 0.026 -0.003 0.035 0.018 0.013 0.011 0.010 0.008 0.019 -0.001 0.019 0.000 0.026 0.002 0.010 -0.003 0.006 0.000 0.011 -0.004 0.000 0.007 -0.004
Konta 
0.011 0.028 0.036 0.038 0.016 0.030 0.036 0.004 0.041 -0.011 0.003 0.007 0.012 0.011 0.007 0.007 -0.004 0.008 0.080 0.013 -0.001 0.007 0.005 0.004 0.009 0.016 0.000 0.027 0.005 0.014 -0.003 0.004 0.017 -0.005
Kore
0.010 0.029 0.032 0.040 0.017 0.035 0.025 -0.003 0.008 0.001 0.001 0.017 0.003 -0.003 -0.004 -0.004 -0.006 -0.004 0.059 0.014 0.000 0.000 0.001 -0.001 -0.004 0.010 -0.002 0.027 -0.003 0.009 -0.012 0.018 0.011 0.008 -0.004
Konso 
0.038 0.068 0.005 0.011 0.000 0.010 0.002 0.011 0.011 0.026 0.020 0.000 0.027 0.011 0.007 0.006 0.006 0.003 0.023 0.000 0.014 -0.002 0.019 -0.001 0.004 -0.003 0.003 0.003 0.006 -0.003 -0.004 0.009 -0.004 0.015 0.006 -0.004
Manja 
0.003 0.018 0.042 0.049 0.024 0.043 0.035 -0.003 0.020 -0.010 -0.003 0.017 0.000 -0.001 -0.002 -0.002 -0.007 0.000 0.077 0.020 -0.003 0.005 -0.003 0.003 -0.001 0.017 -0.001 0.035 -0.003 0.015 -0.010 0.019 0.018 0.003 -0.001 0.013 -0.003
Mejenger 
0.037 0.066 0.012 0.023 0.011 0.024 0.004 0.011 0.001 0.031 0.020 0.008 0.024 0.007 0.006 0.005 0.008 0.003 0.025 0.009 0.016 0.001 0.018 0.003 0.003 0.003 0.007 0.014 0.005 0.002 -0.005 0.023 0.002 0.024 0.005 -0.001 0.013 -0.004
Mashile 
0.044 0.074 0.009 0.016 0.005 0.017 0.003 0.014 0.004 0.037 0.025 0.010 0.030 0.013 0.009 0.008 0.011 0.004 0.018 0.006 0.020 0.000 0.024 0.002 0.005 0.000 0.008 0.008 0.009 0.000 -0.001 0.019 -0.001 0.025 0.007 -0.002 0.017 -0.002 -0.004
Maale 
0.017 0.040 0.021 0.029 0.012 0.027 0.014 0.000 0.007 0.006 0.005 0.006 0.009 -0.001 -0.002 -0.003 -0.004 -0.003 0.046 0.008 0.002 -0.002 0.004 -0.002 -0.003 0.004 -0.002 0.019 -0.003 0.003 -0.012 0.015 0.004 0.008 -0.002 0.001 0.001 0.000 0.003 -0.004
Nuer 
0.080 0.117 0.003 0.011 0.010 0.016 -0.002 0.039 0.015 0.077 0.054 0.016 0.062 0.037 0.032 0.030 0.037 0.024 -0.001 0.012 0.047 0.014 0.052 0.019 0.026 0.006 0.028 0.007 0.031 0.007 0.020 0.032 0.004 0.049 0.029 0.005 0.043 0.005 0.002 0.019 -0.004
Oromo 
0.083 0.120 0.003 -0.001 0.002 -0.002 0.011 0.046 0.056 0.060 0.058 0.002 0.074 0.054 0.044 0.042 0.036 0.037 0.025 0.005 0.045 0.019 0.059 0.021 0.040 0.009 0.028 0.000 0.041 0.009 0.029 0.007 0.008 0.032 0.041 0.013 0.048 0.029 0.021 0.032 0.019 -0.003
Shekecho 
0.024 0.047 0.019 0.020 0.005 0.015 0.020 0.008 0.036 0.001 0.010 -0.004 0.021 0.014 0.009 0.008 -0.001 0.008 0.058 0.003 0.004 0.002 0.012 0.002 0.009 0.006 0.000 0.013 0.006 0.004 -0.003 -0.001 0.007 -0.002 0.009 0.006 0.007 0.016 0.015 0.006 0.032 0.016 -0.004
Sidama 
0.032 0.059 0.010 0.011 -0.001 0.007 0.010 0.008 0.023 0.014 0.015 -0.001 0.024 0.013 0.007 0.007 0.001 0.004 0.037 -0.001 0.009 -0.002 0.017 -0.002 0.006 -0.001 0.000 0.004 0.006 -0.001 -0.003 0.000 -0.001 0.005 0.006 -0.001 0.010 0.007 0.004 0.003 0.017 0.010 -0.001 -0.004
Sheko 
-0.003 -0.002 0.097 0.104 0.069 0.093 0.088 0.012 0.055 -0.014 0.003 0.058 0.002 0.014 0.016 0.018 0.009 0.023 0.147 0.060 0.008 0.037 0.004 0.032 0.021 0.060 0.021 0.087 0.016 0.056 0.011 0.053 0.062 0.018 0.019 0.053 0.009 0.051 0.060 0.028 0.100 0.101 0.034 0.045 -0.004
Somali 
0.050 0.083 0.002 0.008 0.001 0.009 -0.002 0.018 0.011 0.039 0.029 0.003 0.037 0.018 0.013 0.012 0.013 0.008 0.013 0.001 0.022 0.001 0.028 0.003 0.009 -0.002 0.009 0.002 0.012 -0.003 0.002 0.013 -0.004 0.023 0.011 -0.003 0.021 -0.001 -0.003 0.005 0.000 0.012 0.012 0.002 0.067 -0.005
Tigrayan 
0.095 0.135 -0.003 -0.003 0.003 0.001 0.001 0.051 0.044 0.080 0.066 0.008 0.081 0.055 0.046 0.044 0.044 0.037 0.003 0.007 0.054 0.020 0.066 0.024 0.040 0.006 0.034 -0.002 0.043 0.007 0.032 0.019 0.004 0.046 0.043 0.010 0.054 0.021 0.013 0.031 0.004 0.000 0.026 0.014 0.115 0.005 -0.007
Wolayta 
0.014 0.035 0.022 0.027 0.008 0.022 0.018 -0.001 0.016 -0.001 0.002 0.004 0.008 0.001 -0.002 -0.002 -0.007 -0.003 0.053 0.006 -0.001 -0.003 0.003 -0.004 -0.002 0.004 -0.004 0.016 -0.002 0.003 -0.011 0.007 0.005 0.001 -0.002 0.002 0.000 0.005 0.006 -0.002 0.025 0.026 0.000 -0.001 0.024 0.007 0.031 -0.004
Yem 
0.007 0.025 0.032 0.037 0.015 0.031 0.027 -0.003 0.019 -0.007 -0.001 0.011 0.003 -0.001 -0.003 -0.003 -0.008 -0.002 0.066 0.012 -0.004 0.000 -0.001 -0.002 -0.002 0.010 -0.004 0.025 -0.003 0.009 -0.011 0.011 0.011 0.000 -0.003 0.007 -0.003 0.010 0.011 -0.001 0.035 0.036 0.002 0.003 0.015 0.014 0.042 -0.004 -0.005
Zayse 
0.002 0.018 0.040 0.046 0.021 0.040 0.034 -0.004 0.021 -0.011 -0.003 0.016 0.000 -0.001 -0.003 -0.002 -0.008 -0.001 0.076 0.017 -0.004 0.003 -0.003 0.001 -0.001 0.016 -0.002 0.033 -0.003 0.014 -0.011 0.016 0.017 0.001 -0.002 0.012 -0.004 0.013 0.016 0.001 0.042 0.045 0.005 0.008 0.009 0.019 0.052 -0.002 -0.004 -0.005
Afro-Caribbean
0.051 0.078 0.026 0.035 0.030 0.038 0.028 0.037 0.060 0.024 0.034 -0.007 0.049 0.037 0.035 0.032 0.023 0.035 0.075 0.023 0.028 0.028 0.034 0.029 0.037 0.025 0.023 0.034 0.027 0.020 0.014 0.025 0.024 0.022 0.037 0.026 0.032 0.030 0.039 0.024 0.048 0.034 0.015 0.025 0.061 0.031 0.042 0.024 0.029 0.032 -0.006
Yoruba
0.051 0.078 0.026 0.035 0.030 0.038 0.028 0.037 0.060 0.024 0.034 -0.007 0.049 0.037 0.035 0.032 0.023 0.035 0.075 0.023 0.028 0.028 0.034 0.029 0.037 0.025 0.023 0.034 0.027 0.020 0.014 0.025 0.024 0.022 0.037 0.026 0.032 0.030 0.039 0.024 0.048 0.034 0.015 0.025 0.061 0.031 0.042 0.024 0.029 0.032 -0.006 -0.008
European
0.199 0.241 0.039 0.031 0.053 0.037 0.049 0.138 0.124 0.211 0.162 0.086 0.180 0.145 0.132 0.128 0.142 0.118 0.016 0.060 0.145 0.089 0.162 0.096 0.123 0.062 0.114 0.039 0.129 0.067 0.133 0.080 0.061 0.130 0.127 0.072 0.141 0.090 0.073 0.110 0.046 0.036 0.099 0.078 0.225 0.060 0.022 0.109 0.127 0.141 0.124 0.124 -0.008
Chinese
0.340 0.359 0.170 0.161 0.205 0.170 0.168 0.272 0.261 0.553 0.303 0.349 0.311 0.270 0.261 0.255 0.353 0.253 0.167 0.183 0.295 0.227 0.295 0.239 0.257 0.183 0.258 0.178 0.262 0.199 0.392 0.247 0.196 0.293 0.260 0.202 0.266 0.202 0.187 0.236 0.150 0.190 0.253 0.225 0.368 0.189 0.182 0.253 0.272 0.285 0.279 0.279 0.158 -0.011
Japanese
0.334 0.355 0.160 0.152 0.195 0.162 0.159 0.266 0.252 0.524 0.296 0.323 0.305 0.264 0.255 0.248 0.338 0.246 0.146 0.176 0.287 0.219 0.288 0.231 0.250 0.175 0.250 0.169 0.255 0.191 0.369 0.237 0.187 0.284 0.253 0.193 0.260 0.195 0.180 0.229 0.142 0.180 0.244 0.216 0.362 0.180 0.168 0.245 0.265 0.278 0.266 0.266 0.138 -0.007 -0.011
 146 Supplementary figure S5  Pairwise geographic distances (km) among multiple Ethiopian populations.  Basketo are also known as Masketo and Bume are also known as Nyangagtom.  
Ari
Ari 
Cultivator 
Afar 
Agew, 
Eastern 
Alaba  Amhara  Anuak  Ari Potter  Ari Smith  Bena  Basketo Bume Bench  Burji  Busa  Dizi  Dime  Dirasha  Dasenech  Dawuro  Dorze  Gobeze  Gedeo  Gofa  Ganjule  Gamo  Genta  Gurage  Gewada  Hadiya  Hamer  Kefa  Kembata  Konta  Kore  Konso  Manja  Mejenger  Mashile  Maale  Nuer  Oromo  Shekecho  Sidama  Sheko  Somali  Tigrayan  Wolayta  Yem 
Ari Cultivator 
26.38
Afar 
833.86 826.95
Agew, Eastern 
660.20 642.89 373.61
Alaba 
236.63 231.89 597.55 465.69
Amhara 
515.68 503.52 349.57 196.48 294.02
Anuak 
356.86 330.81 863.72 552.48 411.33 516.69
Ari Potter 
26.38 0.00 826.95 642.89 231.89 503.52 330.81
Ari Smith 
26.38 0.00 826.95 642.89 231.89 503.52 330.81 0.00
Bena 
7.47 28.14 841.21 666.25 244.04 522.57 356.56 28.14 28.14
Basketo
82.85 64.77 766.81 578.38 177.40 439.70 308.12 64.77 64.77 88.33
Bume
5.67 31.97 836.44 664.72 239.03 519.32 362.21 31.97 31.97 7.98 87.86
Bench 
195.94 169.66 817.40 563.19 282.62 470.42 162.08 169.66 169.66 196.25 148.23 201.41
Burji 
116.54 134.08 769.45 647.86 185.76 479.73 447.75 134.08 134.08 122.12 139.83 114.15 286.79
Busa 
71.92 90.56 793.71 651.33 199.90 491.69 412.14 90.56 90.56 77.49 108.07 69.52 250.18 44.64
Dizi 
135.31 113.19 875.92 645.61 303.79 535.55 235.70 113.19 113.19 132.45 131.59 139.66 93.62 246.75 203.71
Dime 
6.93 27.16 840.48 665.30 243.35 521.71 355.76 27.16 27.16 1.01 87.35 8.16 195.40 122.21 77.56 131.90
Dirasha 
85.38 100.34 774.27 635.23 181.16 473.67 413.15 100.34 100.34 91.71 105.77 83.92 251.89 35.23 19.56 212.28 91.62
Dasenech 
2.67 29.02 834.21 661.67 236.88 516.61 359.53 29.02 29.02 8.05 84.65 3.28 198.60 114.65 70.01 137.81 7.82 83.83
Dawuro 
151.39 139.38 689.21 511.93 104.00 364.56 328.94 139.38 139.38 158.15 77.61 155.28 185.13 153.76 143.14 199.85 157.27 130.25 152.46
Dorze 
113.74 118.13 727.35 585.23 131.70 423.32 396.08 118.13 118.13 121.13 92.57 114.65 239.21 67.23 68.45 219.02 120.67 50.49 113.23 86.86
Gobeze 
66.87 86.91 801.07 657.09 206.90 498.31 411.17 86.91 86.91 72.04 109.08 64.07 249.11 50.40 7.54 200.08 72.19 27.06 64.81 147.91 75.29
Gedeo 
189.86 197.76 675.52 574.43 110.02 396.72 463.66 197.76 197.76 196.92 170.65 189.67 312.49 94.86 127.78 299.53 196.63 108.93 188.87 136.09 80.80 135.25
Gofa 
89.18 97.96 756.01 611.34 160.43 451.45 396.76 97.96 97.96 96.33 88.71 89.28 236.76 52.50 40.36 205.51 95.99 24.49 88.29 105.84 28.78 46.87 100.79
Ganjule 
83.41 96.23 769.32 627.12 174.89 466.66 405.20 96.23 96.23 90.11 97.43 82.56 244.21 42.59 25.07 207.04 89.93 9.26 82.11 121.20 43.39 32.03 107.80 15.81
Gamo 
99.53 104.77 741.20 595.31 144.92 435.41 391.15 104.77 104.77 106.90 84.72 100.36 232.67 63.35 56.48 207.96 106.45 40.07 98.98 91.41 14.33 62.91 93.20 16.13 31.82
Genta 
92.01 102.12 756.63 614.92 161.99 453.85 402.93 102.12 102.12 99.02 94.86 91.76 242.85 46.34 37.95 210.63 98.74 20.31 90.97 110.88 30.54 44.92 97.91 6.22 12.90 19.88
Gurage 
302.80 291.21 541.77 372.64 95.55 212.91 382.75 291.21 291.21 309.71 228.12 306.41 286.67 275.31 281.64 334.88 308.86 264.51 303.71 151.91 214.07 287.92 205.54 241.30 256.88 225.17 244.31
Gewada 
66.46 90.71 823.50 679.99 230.06 521.64 420.39 90.71 90.71 69.54 124.88 62.09 258.51 63.58 30.17 201.73 70.00 49.29 63.93 169.89 98.56 23.33 154.69 70.20 55.20 86.24 68.09 311.18
Hadiya 
246.55 237.62 589.65 434.91 39.91 271.76 381.57 237.62 237.62 253.71 177.37 249.73 262.72 213.01 220.39 295.59 252.91 202.87 247.22 99.80 152.37 226.85 146.41 180.05 195.47 163.95 182.78 62.30 250.17
Hamer 
1.64 27.87 833.60 660.67 236.31 515.79 358.43 27.87 27.87 8.16 83.56 4.45 197.47 115.09 70.46 136.95 7.79 84.08 1.20 151.58 112.97 65.36 188.84 88.21 82.23 98.74 90.96 302.89 64.82 246.48
Kefa 
192.68 167.01 761.07 516.17 230.81 415.04 190.21 167.01 167.01 195.15 124.95 198.35 57.21 263.46 232.93 129.67 194.18 230.27 195.18 139.66 207.30 233.57 273.48 211.22 221.64 203.70 217.44 229.57 247.50 208.06 193.98
Kembata 
210.52 203.74 623.57 474.56 32.28 310.91 382.63 203.74 203.74 217.82 146.92 213.35 250.84 173.30 180.85 271.89 217.07 163.13 211.00 72.04 112.65 187.41 112.29 140.56 155.87 124.51 143.12 102.09 210.75 39.89 210.33 199.81
Konta 
164.12 144.73 704.63 498.55 144.53 368.30 276.09 144.73 144.73 169.51 81.27 169.11 138.09 197.11 177.39 171.92 168.52 168.60 165.91 53.24 133.07 180.51 189.27 145.60 159.34 133.84 151.44 163.07 199.88 127.04 164.82 88.10 112.81
Kore 
98.10 113.15 767.28 634.31 176.70 470.20 423.67 113.15 113.15 104.34 115.73 96.51 262.80 24.10 29.48 224.88 104.28 12.85 96.51 133.53 49.35 36.86 98.46 29.16 18.64 42.12 23.25 262.58 56.88 200.54 96.78 239.49 160.66 174.69
Konso 
78.62 99.10 799.04 660.88 207.03 499.71 422.95 99.10 99.10 83.51 119.61 75.56 260.92 40.33 11.65 212.24 83.71 26.05 76.48 153.89 76.52 12.21 129.58 49.54 33.75 65.57 46.15 290.46 25.14 228.89 77.07 244.40 189.17 188.91 31.90
Manja 
159.72 145.88 685.61 501.66 107.47 357.69 317.79 145.88 145.88 166.24 82.21 163.89 177.25 167.55 155.71 198.33 165.33 143.39 160.96 14.02 100.77 160.22 148.73 119.08 134.27 104.95 124.26 145.91 181.84 97.89 160.03 129.51 75.19 41.72 147.05 166.62
Mejenger 
214.75 188.39 808.43 547.44 285.69 460.31 145.88 188.39 188.39 215.39 162.33 220.29 21.03 301.87 266.60 114.37 214.52 267.27 217.40 191.79 251.57 265.91 322.53 251.03 259.31 245.92 257.18 282.68 276.26 263.20 216.25 55.17 254.46 142.00 277.80 277.55 182.68
Mashile 
68.22 90.31 809.92 667.33 216.47 508.24 417.30 90.31 90.31 72.56 117.39 64.69 255.22 53.11 16.59 202.98 72.85 35.67 65.93 158.10 85.04 10.26 141.99 56.83 41.65 72.93 54.54 298.03 13.63 236.88 66.63 241.37 197.38 190.08 43.74 12.90 170.35 272.40
Maale 
6.73 21.09 835.89 659.24 239.01 516.27 350.75 21.09 21.09 7.39 81.15 11.50 190.07 122.90 78.33 128.60 6.38 91.32 9.22 151.75 117.87 73.42 194.85 94.06 89.00 103.77 97.16 303.47 73.16 247.89 8.36 188.05 212.37 162.26 104.09 85.23 159.58 209.04 74.93
Nuer 
436.38 411.41 955.02 628.09 513.09 611.25 102.86 411.41 411.41 434.84 398.54 441.35 250.35 536.23 497.73 305.06 434.16 501.11 439.02 427.40 489.29 495.82 560.31 486.92 493.77 483.01 492.97 485.42 502.12 484.06 438.01 287.75 483.86 375.26 512.41 507.92 416.94 238.05 500.83 429.89
Oromo 
244.66 229.19 614.69 416.23 104.15 277.57 317.18 229.19 229.19 250.99 164.48 248.99 211.50 243.12 238.22 261.23 250.05 223.95 246.00 96.04 176.42 243.35 197.06 199.48 215.21 184.05 203.92 75.41 265.65 67.29 245.04 154.54 86.07 90.89 225.43 248.57 85.43 208.29 253.58 244.16 419.98
Shekecho 
205.46 179.12 791.62 536.02 266.28 444.11 160.83 179.12 179.12 206.71 147.80 211.08 27.27 287.62 253.78 116.98 205.80 253.38 208.08 173.13 235.35 253.51 304.92 236.20 245.19 230.33 242.40 263.84 265.08 243.72 206.91 35.67 235.11 122.81 263.52 264.94 163.72 19.50 260.46 200.07 255.39 189.22
Sidama 
216.08 219.82 636.42 535.15 74.51 355.93 458.08 219.82 219.82 223.43 181.78 216.76 314.09 133.03 160.83 313.29 222.99 141.34 215.48 130.02 102.44 168.36 41.06 128.00 138.28 116.56 126.68 169.28 189.45 113.51 215.27 269.60 85.58 182.10 132.58 164.43 140.38 321.67 176.20 220.30 557.25 171.48 303.11
Sheko 
202.47 176.15 789.37 535.29 262.57 442.07 164.64 176.15 176.15 203.82 144.13 208.10 28.59 283.95 250.28 116.26 202.90 249.76 205.08 169.23 231.51 250.07 301.01 232.48 241.54 226.53 238.68 260.82 261.79 240.21 203.91 32.15 231.36 119.00 259.85 261.46 159.87 23.13 257.07 197.13 259.31 186.10 3.92 299.22
Somali 
742.71 744.97 287.27 550.26 521.77 415.29 891.36 744.97 744.97 750.07 697.55 743.41 795.35 648.17 684.27 825.56 749.62 665.36 742.13 625.73 628.98 691.73 556.50 654.44 663.62 643.17 652.69 512.60 710.54 533.80 741.91 739.23 553.72 660.81 654.91 685.59 628.13 793.64 698.21 746.81 992.78 585.53 774.42 526.65 771.16
Tigrayan 
393.26 379.40 472.88 277.51 188.52 127.58 406.23 379.40 379.40 399.90 314.96 397.23 344.59 370.63 376.37 407.97 399.00 359.52 394.38 241.97 309.17 382.49 298.01 336.08 351.75 319.96 339.28 95.35 405.67 157.63 393.49 288.56 197.44 241.37 357.85 385.41 233.78 335.62 392.66 393.32 505.35 151.15 318.74 259.75 316.50 490.96
Wolayta 
109.90 109.51 725.28 572.53 127.76 414.95 375.15 109.51 109.51 117.37 74.39 111.84 219.17 86.44 78.81 203.87 116.75 63.67 109.90 67.58 21.47 84.66 96.32 39.23 55.01 23.95 43.72 203.58 107.77 143.19 109.42 186.05 104.49 111.90 66.00 88.62 81.22 231.02 94.87 112.98 468.93 160.27 214.54 111.33 210.68 635.47 297.91
Yem 
255.84 242.38 594.28 409.03 86.55 261.41 341.91 242.38 242.38 262.49 178.31 259.82 235.81 242.70 242.44 282.13 261.60 226.82 256.97 104.60 177.53 248.10 187.49 202.67 218.48 186.76 206.53 52.76 270.96 47.19 256.08 179.06 75.26 110.38 226.88 252.20 96.53 233.12 258.35 255.95 444.74 25.19 213.97 158.08 210.78 560.57 137.41 163.65
Zayse 
89.69 100.40 759.74 617.82 165.12 456.94 403.25 100.40 100.40 96.64 95.14 89.31 242.92 45.30 34.83 209.51 96.38 17.48 88.59 113.22 33.63 41.78 100.38 7.56 9.77 22.60 3.13 247.31 64.97 185.82 88.61 218.21 146.18 153.14 21.69 43.17 126.51 257.45 51.42 94.93 492.94 206.54 242.82 129.56 239.12 655.44 342.25 46.28 209.34
 147Supplementary figure S6  Population pairwise distances (Fst) based on counts of donor's first language.  Significant distances are highlighted in pink (p < 0.05).  Basketo are also known as Masketo and Bume are also known as Nyangagtom.  
Ari 
Ari 
Cultivator 
Afar 
Agew, 
Eastern 
Alaba  Amhara  Anuak  Ari Potter  Ari Smith  Bena  Basketo  Bume Bench  Burji  Busa  Dizi  Dime  Dirasha  Dasenech  Dawuro  Dorze  Gobeze  Gedeo  Gofa  Ganjule  Gamo  Genta  Gurage  Gewada  Hadiya  Hamer  Kefa  Kembata  Konta  Kore Konso  Manja  Mejenger  Mashile  Maale  Nuer  Oromo  Shekecho  Sidama  Sheko  Somali  Tigrayan  Wolayta  Yem  Zayse 
Ari 
0.00
Ari Cultivator 
0.05 0.00
Afar 
0.88 0.94 0.00
Agew, Eastern 
0.58 0.69 0.68 0.00
Alaba 
0.82 0.90 0.93 0.63 0.00
Amhara 
0.92 0.96 0.98 0.60 0.95 0.00
Anuak 
0.88 0.94 0.99 0.68 0.93 0.98 0.00
Ari Potter 
0.13 0.03 0.99 0.69 0.94 0.99 1.00 0.00
Ari Smith 
0.09 0.02 0.99 0.64 0.91 0.98 1.00 0.00 0.00
Bena 
0.76 0.90 0.95 0.54 0.85 0.97 0.97 0.97 0.94 0.00
Basketo
0.85 0.92 0.96 0.65 0.90 0.97 0.96 0.97 0.95 0.91 0.00
Bume 
0.80 0.92 0.97 0.60 0.88 0.98 0.98 0.99 0.97 0.85 0.93 0.00
Bench 
0.88 0.94 0.98 0.68 0.92 0.98 0.98 0.98 0.98 0.94 0.95 0.96 0.00
Burji 
0.68 0.79 0.78 0.53 0.72 0.88 0.78 0.80 0.73 0.62 0.75 0.67 0.78 0.00
Busa 
0.74 0.84 0.84 0.59 0.79 0.91 0.85 0.86 0.81 0.72 0.82 0.76 0.84 0.65 0.00
Dizi 
0.78 0.87 0.88 0.59 0.82 0.92 0.88 0.89 0.85 0.78 0.85 0.81 0.88 0.69 0.75 0.00
Dime 
0.80 0.91 0.95 0.59 0.87 0.97 0.96 0.97 0.94 0.83 0.91 0.88 0.94 0.67 0.76 0.81 0.00
Dirasha 
0.62 0.76 0.74 0.43 0.68 0.80 0.75 0.76 0.68 0.55 0.71 0.61 0.74 0.53 0.60 0.64 0.61 0.00
Dasenech 
0.78 0.90 0.94 0.56 0.85 0.96 0.96 0.96 0.93 0.78 0.90 0.85 0.94 0.64 0.73 0.78 0.83 0.57 0.00
Dawuro 
0.90 0.94 0.96 0.74 0.93 0.97 0.96 0.97 0.96 0.94 0.95 0.95 0.96 0.84 0.88 0.90 0.94 0.81 0.93 0.00
Dorze 
0.84 0.91 0.95 0.64 0.89 0.96 0.95 0.96 0.94 0.88 0.92 0.91 0.94 0.73 0.80 0.84 0.89 0.69 0.88 0.94 0.00
Gobeze 
0.71 0.82 0.82 0.56 0.76 0.90 0.82 0.84 0.78 0.68 0.79 0.72 0.82 0.61 0.68 0.72 0.72 0.57 0.70 0.86 0.77 0.00
Gedeo 
0.88 0.94 0.98 0.68 0.93 0.98 0.99 0.99 0.99 0.96 0.96 0.97 0.98 0.78 0.85 0.88 0.95 0.75 0.95 0.96 0.95 0.82 0.00
Gofa 
0.57 0.73 0.71 0.30 0.64 0.52 0.71 0.73 0.65 0.49 0.68 0.57 0.71 0.51 0.58 0.59 0.57 0.37 0.52 0.79 0.66 0.55 0.72 0.00
Ganjule 
0.88 0.94 0.99 0.68 0.93 0.98 1.00 1.00 1.00 0.97 0.97 0.99 0.98 0.78 0.85 0.88 0.96 0.75 0.96 0.96 0.95 0.82 0.99 0.71 0.00
Gamo 
0.61 0.73 0.72 0.33 0.67 0.40 0.72 0.74 0.68 0.56 0.70 0.63 0.72 0.56 0.61 0.62 0.62 0.42 0.58 0.78 0.68 0.59 0.73 0.15 0.72 0.00
Genta 
0.65 0.78 0.77 0.48 0.71 0.84 0.77 0.79 0.71 0.59 0.74 0.65 0.77 0.56 0.63 0.67 0.65 0.49 0.61 0.83 0.72 0.60 0.77 0.43 0.77 0.47 0.00
Gurage 
0.50 0.65 0.62 0.25 0.56 0.41 0.63 0.64 0.57 0.42 0.59 0.50 0.63 0.45 0.51 0.52 0.49 0.31 0.45 0.71 0.58 0.48 0.63 0.12 0.63 0.14 0.37 0.00
Gewada 
0.88 0.94 0.98 0.68 0.93 0.98 0.99 0.99 0.99 0.95 0.96 0.97 0.98 0.78 0.84 0.88 0.95 0.74 0.94 0.96 0.95 0.82 0.98 0.71 0.99 0.72 0.77 0.62 0.00
Hadiya 
0.73 0.83 0.83 0.55 0.78 0.89 0.84 0.85 0.80 0.70 0.81 0.75 0.83 0.64 0.71 0.74 0.75 0.58 0.72 0.87 0.79 0.68 0.84 0.53 0.84 0.57 0.62 0.46 0.83 0.00
Hamer 
0.73 0.88 0.92 0.49 0.82 0.94 0.93 0.94 0.89 0.68 0.87 0.78 0.91 0.60 0.70 0.75 0.77 0.51 0.72 0.92 0.85 0.65 0.92 0.43 0.93 0.50 0.56 0.37 0.92 0.67 0.00
Kefa 
0.79 0.88 0.89 0.60 0.83 0.93 0.90 0.90 0.87 0.79 0.86 0.83 0.89 0.69 0.76 0.79 0.82 0.64 0.80 0.91 0.85 0.73 0.89 0.60 0.90 0.63 0.67 0.53 0.89 0.75 0.76 0.00
Kembata 
0.79 0.88 0.90 0.60 0.84 0.93 0.90 0.91 0.87 0.80 0.87 0.83 0.89 0.69 0.76 0.79 0.82 0.65 0.80 0.91 0.86 0.73 0.90 0.60 0.90 0.63 0.67 0.53 0.90 0.75 0.77 0.80 0.00
Konta 
0.88 0.94 0.99 0.68 0.93 0.98 1.00 1.00 1.00 0.97 0.96 0.98 0.98 0.78 0.85 0.88 0.96 0.74 0.96 0.96 0.95 0.82 0.99 0.71 1.00 0.72 0.77 0.62 0.99 0.84 0.93 0.89 0.90 0.00
Kore
0.64 0.77 0.75 0.47 0.69 0.83 0.75 0.77 0.69 0.57 0.72 0.63 0.75 0.52 0.61 0.65 0.63 0.47 0.59 0.82 0.70 0.58 0.75 0.43 0.75 0.48 0.52 0.37 0.75 0.60 0.54 0.65 0.66 0.75 0.00
Konso 
0.68 0.80 0.80 0.50 0.74 0.85 0.80 0.81 0.75 0.64 0.77 0.69 0.80 0.59 0.66 0.70 0.69 0.53 0.66 0.85 0.75 0.64 0.80 0.47 0.80 0.51 0.57 0.40 0.80 0.65 0.61 0.70 0.71 0.80 0.55 0.00
Manja 
0.90 0.95 0.99 0.71 0.94 0.98 0.99 0.99 0.99 0.97 0.97 0.98 0.98 0.81 0.87 0.90 0.96 0.78 0.96 0.96 0.96 0.85 0.99 0.76 0.99 0.75 0.80 0.67 0.99 0.86 0.94 0.91 0.92 0.99 0.79 0.83 0.00
Mejenger 
0.89 0.95 0.99 0.68 0.93 0.98 1.00 1.00 1.00 0.97 0.97 0.99 0.98 0.79 0.85 0.89 0.96 0.75 0.96 0.96 0.96 0.83 0.99 0.72 1.00 0.73 0.78 0.63 0.99 0.84 0.94 0.90 0.90 1.00 0.76 0.80 0.99 0.00
Mashile 
0.77 0.86 0.87 0.61 0.82 0.92 0.87 0.88 0.84 0.77 0.84 0.80 0.87 0.67 0.74 0.78 0.80 0.64 0.78 0.89 0.83 0.69 0.87 0.61 0.87 0.64 0.67 0.54 0.87 0.74 0.74 0.78 0.79 0.87 0.64 0.70 0.89 0.88 0.00
Maale 
0.81 0.90 0.92 0.63 0.86 0.95 0.93 0.93 0.90 0.84 0.89 0.87 0.92 0.72 0.79 0.82 0.86 0.68 0.84 0.92 0.88 0.76 0.92 0.64 0.93 0.67 0.70 0.56 0.92 0.78 0.81 0.83 0.83 0.92 0.69 0.74 0.93 0.93 0.81 0.00
Nuer 
0.89 0.95 0.99 0.68 0.94 0.99 1.00 1.00 1.00 0.97 0.97 0.99 0.98 0.79 0.85 0.89 0.96 0.75 0.96 0.96 0.96 0.83 0.99 0.72 1.00 0.73 0.78 0.63 0.99 0.84 0.94 0.90 0.91 1.00 0.76 0.81 0.99 1.00 0.88 0.93 0.00
Oromo 
0.67 0.78 0.77 0.48 0.72 0.81 0.77 0.79 0.73 0.62 0.75 0.67 0.77 0.49 0.65 0.68 0.67 0.48 0.64 0.82 0.73 0.58 0.77 0.43 0.77 0.48 0.55 0.37 0.77 0.63 0.59 0.68 0.68 0.77 0.47 0.58 0.80 0.78 0.65 0.72 0.78 0.00
Shekecho 
0.83 0.91 0.94 0.64 0.88 0.96 0.94 0.95 0.93 0.87 0.91 0.90 0.93 0.74 0.80 0.84 0.88 0.70 0.87 0.93 0.90 0.78 0.94 0.66 0.94 0.68 0.72 0.58 0.94 0.79 0.84 0.85 0.85 0.94 0.70 0.75 0.95 0.94 0.83 0.88 0.94 0.73 0.00
Sidama 
0.77 0.86 0.88 0.59 0.82 0.92 0.88 0.89 0.85 0.77 0.85 0.81 0.87 0.68 0.75 0.78 0.80 0.63 0.78 0.90 0.84 0.72 0.88 0.58 0.88 0.61 0.66 0.51 0.88 0.73 0.74 0.79 0.79 0.88 0.64 0.69 0.90 0.88 0.77 0.82 0.89 0.67 0.83 0.00
Sheko 
0.88 0.94 0.98 0.67 0.93 0.98 0.99 0.99 0.99 0.95 0.96 0.97 0.98 0.78 0.84 0.88 0.95 0.74 0.94 0.96 0.95 0.82 0.98 0.71 0.99 0.72 0.76 0.62 0.98 0.83 0.92 0.89 0.89 0.99 0.75 0.79 0.99 0.99 0.87 0.92 0.99 0.77 0.93 0.87 0.00
Somali 
0.81 0.89 0.92 0.62 0.86 0.95 0.92 0.93 0.90 0.83 0.89 0.86 0.91 0.71 0.78 0.81 0.85 0.66 0.83 0.92 0.87 0.75 0.92 0.62 0.92 0.65 0.69 0.54 0.92 0.76 0.79 0.82 0.83 0.92 0.67 0.72 0.93 0.92 0.80 0.85 0.93 0.70 0.87 0.81 0.91 0.00
Tigrayan 
0.62 0.79 0.78 0.34 0.70 0.72 0.78 0.80 0.71 0.53 0.74 0.62 0.78 0.54 0.62 0.64 0.62 0.41 0.57 0.84 0.72 0.58 0.79 0.24 0.79 0.28 0.47 0.18 0.78 0.58 0.48 0.66 0.66 0.78 0.46 0.51 0.82 0.79 0.66 0.70 0.79 0.48 0.72 0.63 0.78 0.68 0.00
Wolayta 
0.59 0.74 0.71 0.39 0.65 0.75 0.72 0.74 0.65 0.51 0.69 0.58 0.72 0.51 0.58 0.61 0.58 0.42 0.54 0.79 0.67 0.55 0.72 0.31 0.72 0.34 0.46 0.26 0.71 0.55 0.47 0.62 0.62 0.71 0.45 0.49 0.76 0.72 0.62 0.65 0.73 0.48 0.67 0.60 0.71 0.63 0.35 0.00
Yem 
0.87 0.94 0.98 0.67 0.92 0.98 0.99 0.99 0.99 0.95 0.96 0.97 0.97 0.77 0.84 0.88 0.95 0.74 0.94 0.96 0.94 0.81 0.98 0.70 0.99 0.72 0.76 0.62 0.98 0.83 0.92 0.89 0.89 0.99 0.74 0.79 0.99 0.99 0.86 0.92 0.99 0.76 0.93 0.87 0.98 0.91 0.77 0.71 0.00
Zayse 
0.79 0.88 0.89 0.60 0.84 0.93 0.90 0.91 0.87 0.79 0.87 0.83 0.89 0.69 0.75 0.79 0.82 0.64 0.80 0.91 0.85 0.73 0.90 0.60 0.90 0.63 0.67 0.52 0.89 0.74 0.76 0.80 0.81 0.90 0.65 0.70 0.91 0.90 0.79 0.83 0.90 0.68 0.85 0.79 0.89 0.82 0.65 0.61 0.89 0.00
   148 Supplementary figure S7  Population pairwise distances (Fst) based on counts of donor's first language (linguistic group).  Significant distances are highlighted in pink (p < 0.05).  Basketo are also known as Masketo and Bume are also known as Nyangagtom.  
Ari 
Ari 
Cultivator 
Afar 
Agew, 
Eastern 
Alaba  Amhara  Anuak  Ari Potter  Ari Smith  Bena  Basketo  Bume Bench  Burji  Busa  Dizi  Dime  Dirasha  Dasenech  Dawuro  Dorze  Gobeze  Gedeo  Gofa  Ganjule  Gamo  Genta  Gurage  Gewada  Hadiya  Hamer  Kefa  Kembata  Konta  Kore  Konso  Manja  Mejenger  Mashile  Maale  Nuer  Oromo  Shekecho  Sidama  Sheko  Somali  Tigrayan  Wolayta  Yem  Zayse 
Ari 
-1.00
Ari Cultivator 
0.05 -1.00
Afar 
0.88 0.94 -1.00
Agew, Eastern 
0.58 0.69 0.34 -1.00
Alaba 
0.82 0.90 0.04 0.26 -1.00
Amhara 
0.92 0.96 0.98 0.59 0.95 -1.00
Anuak 
0.88 0.94 0.99 0.68 0.93 0.98 -1.00
Ari Potter 
0.13 0.03 0.99 0.69 0.94 0.99 1.00 -1.00
Ari Smith 
0.09 0.02 0.99 0.64 0.91 0.98 1.00 0.00 -1.01
Bena 
-0.04 0.05 0.95 0.54 0.85 0.97 0.97 0.41 0.23 -1.03
Basketo
0.06 0.00 0.97 0.66 0.91 0.97 0.97 0.02 0.01 0.11 -1.00
Bume
0.80 0.92 0.97 0.60 0.88 0.98 0.09 0.99 0.97 0.85 0.94 -1.02
Bench 
0.11 0.01 0.98 0.68 0.93 0.98 0.99 0.00 -0.01 0.27 0.00 0.97 -1.00
Burji 
0.88 0.94 0.00 0.35 0.05 0.98 0.99 0.99 0.99 0.96 0.97 0.97 0.98 -1.00
Busa 
0.78 0.87 0.07 0.29 0.04 0.94 0.91 0.91 0.87 0.80 0.87 0.85 0.90 0.06 -1.00
Dizi 
-0.01 0.04 0.88 0.59 0.82 0.92 0.88 0.11 0.08 -0.04 0.05 0.81 0.09 0.88 0.79 -1.00
Dime 
0.00 0.00 0.95 0.59 0.87 0.97 0.96 0.13 0.06 -0.02 0.01 0.88 0.07 0.95 0.82 0.00 -1.01
Dirasha 
0.67 0.80 0.24 0.06 0.12 0.84 0.80 0.81 0.74 0.62 0.77 0.68 0.80 0.25 0.15 0.69 0.68 -1.00
Dasenech 
0.78 0.90 0.15 0.17 -0.01 0.96 0.96 0.96 0.93 0.78 0.92 0.85 0.95 0.17 0.04 0.78 0.83 0.04 -1.02
Dawuro 
0.12 0.01 0.97 0.75 0.94 0.97 0.97 0.01 0.00 0.20 0.00 0.96 0.00 0.97 0.91 0.10 0.04 0.86 0.95 -1.00
Dorze 
0.05 -0.01 0.95 0.65 0.90 0.97 0.96 0.03 0.01 0.06 -0.01 0.92 0.01 0.96 0.86 0.04 0.00 0.75 0.89 0.00 -1.00
Gobeze 
0.89 0.95 0.00 0.36 0.06 0.98 1.00 1.00 1.00 0.97 0.97 0.99 0.99 0.00 0.08 0.89 0.96 0.26 0.24 0.97 0.96 -1.00
Gedeo 
0.89 0.95 0.00 0.36 0.06 0.99 1.00 1.00 1.00 0.97 0.98 0.99 0.99 0.00 0.09 0.89 0.96 0.27 0.24 0.97 0.97 0.00 -1.00
Gofa 
0.35 0.57 0.75 0.34 0.68 0.59 0.75 0.59 0.49 0.28 0.52 0.62 0.57 0.75 0.66 0.37 0.38 0.47 0.57 0.66 0.50 0.76 0.76 -1.00
Ganjule 
0.12 0.03 0.99 0.68 0.93 0.98 1.00 0.00 0.00 0.37 0.02 0.99 0.00 0.99 0.90 0.10 0.11 0.80 0.96 0.01 0.02 1.00 1.00 0.57 -1.00
Gamo 
0.43 0.60 0.72 0.33 0.67 0.40 0.73 0.62 0.55 0.38 0.57 0.63 0.60 0.73 0.66 0.45 0.46 0.48 0.59 0.68 0.55 0.73 0.73 0.01 0.60 -1.00
Genta 
0.00 0.11 0.83 0.53 0.77 0.89 0.84 0.18 0.13 -0.03 0.11 0.74 0.16 0.83 0.73 0.01 0.03 0.61 0.70 0.20 0.09 0.84 0.84 0.27 0.17 0.36 -1.00
Gurage 
0.87 0.94 0.98 0.48 0.92 0.00 0.98 0.99 0.98 0.94 0.96 0.96 0.98 0.98 0.91 0.87 0.94 0.74 0.94 0.97 0.95 0.99 0.99 0.44 0.98 0.29 0.81 -1.00
Gewada 
0.88 0.94 -0.01 0.34 0.04 0.98 0.99 0.99 0.99 0.95 0.97 0.97 0.98 0.00 0.07 0.88 0.95 0.24 0.15 0.97 0.95 0.00 0.00 0.75 0.99 0.72 0.83 0.98 -1.00
Hadiya 
0.74 0.84 0.13 0.15 0.03 0.90 0.85 0.86 0.82 0.73 0.83 0.77 0.85 0.14 0.07 0.75 0.76 0.02 -0.01 0.89 0.81 0.15 0.15 0.58 0.85 0.58 0.69 0.83 0.13 -1.00
Hamer 
0.01 0.21 0.92 0.50 0.82 0.94 0.93 0.47 0.29 -0.03 0.25 0.78 0.39 0.92 0.77 0.01 0.06 0.59 0.72 0.40 0.20 0.94 0.94 0.20 0.43 0.30 -0.02 0.90 0.92 0.70 -1.02
Kefa 
0.00 0.02 0.89 0.60 0.83 0.93 0.90 0.08 0.05 -0.03 0.03 0.83 0.07 0.89 0.79 0.00 -0.01 0.69 0.79 0.07 0.02 0.90 0.90 0.40 0.08 0.47 0.02 0.89 0.89 0.76 0.04 -1.00
Kembata 
0.80 0.88 0.06 0.23 -0.01 0.94 0.91 0.92 0.88 0.81 0.89 0.84 0.91 0.07 0.03 0.80 0.83 0.09 -0.02 0.92 0.87 0.08 0.08 0.65 0.91 0.64 0.74 0.90 0.06 0.01 0.78 0.81 -1.00
Konta 
0.86 0.94 0.99 0.47 0.93 0.00 1.00 1.00 1.00 0.96 0.97 0.98 0.99 0.99 0.91 0.87 0.96 0.73 0.95 0.97 0.96 1.00 1.00 0.41 1.00 0.27 0.80 0.00 0.99 0.82 0.91 0.89 0.90 -1.00
Kore 
0.07 0.20 0.71 0.42 0.64 0.84 0.76 0.24 0.17 0.03 0.18 0.63 0.22 0.71 0.59 0.08 0.09 0.47 0.54 0.29 0.15 0.72 0.72 0.22 0.22 0.32 0.04 0.74 0.71 0.56 0.02 0.08 0.61 0.71 -1.00
Konso 
0.69 0.81 0.17 0.10 0.07 0.86 0.81 0.82 0.76 0.65 0.78 0.71 0.81 0.18 0.10 0.70 0.70 0.00 0.01 0.86 0.77 0.19 0.20 0.51 0.81 0.52 0.63 0.78 0.17 0.00 0.62 0.70 0.04 0.76 0.49 -1.00
Manja 
0.15 0.03 0.99 0.71 0.95 0.99 1.00 0.00 0.00 0.48 0.03 0.99 0.00 0.99 0.92 0.13 0.16 0.84 0.97 0.01 0.03 1.00 1.00 0.63 0.00 0.64 0.21 0.99 0.99 0.88 0.53 0.10 0.93 1.00 0.27 0.84 -1.00
Mejenger 
0.89 0.95 0.99 0.68 0.94 0.98 0.00 1.00 1.00 0.97 0.97 0.09 0.99 0.99 0.91 0.89 0.96 0.81 0.96 0.97 0.96 1.00 1.00 0.76 1.00 0.73 0.84 0.99 0.99 0.86 0.94 0.90 0.91 1.00 0.76 0.82 1.00 -1.00
Mashile 
0.90 0.95 0.00 0.37 0.07 0.99 1.00 1.00 1.00 0.97 0.98 0.99 0.99 0.00 0.09 0.90 0.97 0.28 0.26 0.97 0.97 0.00 0.00 0.77 1.00 0.74 0.85 0.99 0.00 0.16 0.94 0.91 0.09 1.00 0.74 0.21 1.00 1.00 -1.00
Maale 
0.04 -0.01 0.95 0.65 0.90 0.97 0.96 0.03 0.02 0.05 -0.01 0.92 0.02 0.95 0.86 0.03 -0.01 0.76 0.89 0.00 -0.01 0.96 0.96 0.50 0.03 0.55 0.09 0.95 0.95 0.82 0.19 0.02 0.87 0.96 0.16 0.77 0.04 0.96 0.96 -1.00
Nuer 
0.89 0.95 0.99 0.69 0.94 0.99 0.00 1.00 1.00 0.97 0.97 0.09 0.99 0.99 0.91 0.89 0.96 0.81 0.96 0.97 0.96 1.00 1.00 0.76 1.00 0.73 0.84 0.99 0.99 0.86 0.94 0.90 0.91 1.00 0.77 0.82 1.00 0.00 1.00 0.96 -1.00
Oromo 
0.67 0.78 0.23 0.05 0.12 0.81 0.77 0.79 0.73 0.62 0.75 0.67 0.78 0.24 0.16 0.68 0.67 -0.01 0.05 0.83 0.73 0.25 0.25 0.47 0.77 0.48 0.61 0.70 0.23 0.03 0.59 0.68 0.09 0.69 0.48 0.00 0.81 0.78 0.26 0.74 0.78 -1.00
Shekecho 
0.03 0.00 0.93 0.64 0.88 0.96 0.94 0.04 0.02 0.02 0.00 0.90 0.02 0.94 0.84 0.03 -0.01 0.74 0.87 0.01 -0.01 0.94 0.94 0.49 0.03 0.54 0.08 0.93 0.93 0.80 0.15 0.01 0.86 0.94 0.14 0.76 0.05 0.94 0.95 -0.01 0.94 0.73 -1.00
Sidama 
0.77 0.86 0.09 0.19 0.01 0.92 0.88 0.89 0.85 0.77 0.86 0.81 0.88 0.10 0.05 0.78 0.80 0.05 -0.02 0.91 0.84 0.12 0.12 0.62 0.88 0.62 0.72 0.87 0.09 0.00 0.74 0.78 0.00 0.86 0.59 0.02 0.90 0.88 0.12 0.85 0.89 0.06 0.83 -1.00
Sheko 
0.10 0.01 0.98 0.68 0.93 0.98 0.99 0.00 -0.01 0.24 0.00 0.97 -0.01 0.98 0.89 0.09 0.06 0.79 0.94 0.00 0.01 0.99 0.99 0.56 0.00 0.59 0.15 0.98 0.98 0.85 0.36 0.06 0.90 0.99 0.21 0.80 0.00 0.99 0.99 0.01 0.99 0.77 0.02 0.87 -1.00
Somali 
0.81 0.90 0.04 0.25 -0.01 0.95 0.93 0.94 0.91 0.84 0.91 0.87 0.93 0.05 0.04 0.82 0.86 0.11 -0.01 0.94 0.89 0.07 0.07 0.67 0.93 0.66 0.76 0.92 0.04 0.03 0.81 0.83 -0.01 0.92 0.63 0.06 0.95 0.93 0.08 0.89 0.93 0.12 0.88 0.01 0.92 -1.00
Tigrayan 
0.83 0.93 0.98 0.42 0.90 -0.01 0.99 0.99 0.98 0.92 0.96 0.96 0.98 0.98 0.88 0.83 0.92 0.67 0.91 0.96 0.94 0.99 0.99 0.35 0.99 0.24 0.75 -0.01 0.98 0.78 0.85 0.86 0.87 0.01 0.66 0.71 0.99 0.99 0.99 0.94 0.99 0.64 0.92 0.83 0.98 0.90 -1.01
Wolayta 
0.10 0.29 0.76 0.44 0.70 0.79 0.77 0.34 0.26 0.05 0.27 0.64 0.32 0.77 0.67 0.12 0.14 0.52 0.60 0.40 0.24 0.77 0.78 0.10 0.32 0.19 0.05 0.68 0.76 0.62 0.01 0.15 0.67 0.65 0.05 0.55 0.38 0.77 0.79 0.24 0.78 0.53 0.23 0.65 0.31 0.69 0.59 -1.00
Yem 
0.10 0.01 0.98 0.67 0.92 0.98 0.99 0.00 -0.01 0.24 0.00 0.97 -0.01 0.98 0.89 0.08 0.06 0.79 0.94 0.00 0.01 0.99 0.99 0.55 0.00 0.59 0.15 0.98 0.98 0.84 0.35 0.06 0.90 0.99 0.20 0.80 0.00 0.99 0.99 0.01 0.99 0.76 0.02 0.87 -0.01 0.92 0.98 0.30 -1.00
Zayse 
0.00 0.02 0.90 0.61 0.84 0.94 0.91 0.10 0.06 -0.03 0.04 0.84 0.08 0.90 0.81 -0.01 -0.01 0.70 0.81 0.07 0.02 0.91 0.91 0.40 0.09 0.47 0.02 0.90 0.90 0.77 0.04 -0.01 0.82 0.90 0.09 0.72 0.12 0.91 0.92 0.02 0.91 0.69 0.01 0.80 0.07 0.84 0.87 0.14 0.07 -1.00
 149Supplementary figure S8  Population pairwise distances (Fst) based on counts of donor's religion.  Significant distances are highlighted in pink (p < 0.05).  Basketo are also known as Masketo and Bume are also known as Nyangagtom.  
Ari  Ari 
Cultivator 
Afar  Agew, 
Eastern 
Alaba  Amhara  Anuak  Ari Potter  Ari Smith  Bena  Basketo Bume Bench  Burji  Busa  Dizi  Dime  Dirasha  Dasenech  Dawuro  Dorze  Gobeze  Gedeo  Gofa  Ganjule  Gamo  Genta  Gurage  Gewada  Hadiya  Hamer  Kefa  Kembata  Konta  Kore  Konso  Manja  Mejenger  Mashile  Maale  Nuer  Oromo  Shekecho  Sidama  Sheko  Somali  Tigrayan  Wolayta  Yem  Zayse 
Ari 
-1.00
Ari 
Cultivator  0.04 -1.00
Afar 
1.00 0.92 -1.00
Agew, 
Eastern  0.02 0.02 0.96 -1.00
Alaba 
0.98 0.91 0.01 0.95 -1.00
Amhara 
0.10 0.08 0.77 0.08 0.76 -1.00
Anuak 
0.00 0.04 1.00 0.01 0.98 0.10 -1.00
Ari Potter 
0.35 0.28 0.76 0.39 0.74 0.24 0.34 -1.00
Ari Smith 
0.36 0.20 0.87 0.35 0.84 0.15 0.35 0.01 -1.01
Bena 
0.00 0.00 1.00 -0.02 0.97 0.06 0.00 0.22 0.15 -1.03
Basketo
0.00 0.04 1.00 0.02 0.98 0.10 0.00 0.35 0.35 0.00 -1.00
Bume
0.09 -0.02 0.99 0.00 0.96 0.05 0.09 0.19 0.12 -0.02 0.09 -1.02
Bench 
0.00 0.04 1.00 0.02 0.98 0.11 0.00 0.36 0.37 0.00 0.00 0.10 -1.00
Burji 
0.02 0.02 0.97 -0.01 0.95 0.06 0.02 0.31 0.27 -0.02 0.02 0.00 0.03 -1.00
Busa 
0.00 0.04 1.00 0.02 0.98 0.11 0.00 0.36 0.37 0.00 0.00 0.10 0.00 0.03 -1.00
Dizi 
0.00 0.04 1.00 0.02 0.98 0.11 0.00 0.36 0.38 0.00 0.00 0.10 0.00 0.03 0.00 -1.00
Dime 
0.00 0.02 1.00 0.00 0.97 0.08 0.00 0.26 0.22 0.00 0.00 0.02 0.00 0.01 0.00 0.00 -1.01
Dirasha 
0.00 0.04 1.00 0.01 0.98 0.10 0.00 0.34 0.34 0.00 0.00 0.08 0.00 0.02 0.00 0.00 0.00 -1.00
Dasenech 
0.00 0.01 1.00 0.00 0.97 0.08 0.00 0.24 0.19 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 -1.02
Dawuro 
0.00 0.06 1.00 0.03 0.99 0.14 0.00 0.49 0.55 0.00 0.00 0.22 0.00 0.05 0.00 0.00 0.00 0.00 0.00 -1.00
Dorze 
0.00 0.03 1.00 0.01 0.98 0.10 0.00 0.34 0.34 0.00 0.00 0.08 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 -1.00
Gobeze 
0.00 0.04 1.00 0.02 0.98 0.11 0.00 0.35 0.36 0.00 0.00 0.09 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.00
Gedeo 
0.16 0.11 0.82 0.13 0.80 0.00 0.16 0.20 0.13 0.07 0.16 0.06 0.17 0.09 0.17 0.17 0.11 0.15 0.09 0.27 0.15 0.16 -1.00
Gofa 
0.00 0.04 1.00 0.01 0.98 0.10 0.00 0.34 0.35 0.00 0.00 0.09 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16 -1.00
Ganjule 
0.00 0.04 1.00 0.01 0.98 0.10 0.00 0.34 0.35 0.00 0.00 0.09 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16 0.00 -1.00
Gamo 
0.00 0.04 0.99 0.01 0.97 0.11 0.00 0.40 0.41 -0.03 0.00 0.03 0.00 0.01 0.00 0.00 -0.01 0.00 -0.02 0.01 0.00 0.00 0.17 0.00 0.00 -1.00
Genta 
0.00 0.04 1.00 0.01 0.98 0.10 0.00 0.34 0.35 0.00 0.00 0.09 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16 0.00 0.00 0.00 -1.00
Gurage 
0.03 0.02 0.95 0.00 0.93 0.05 0.03 0.31 0.26 -0.01 0.03 0.00 0.03 -0.01 0.03 0.04 0.01 0.03 0.01 0.06 0.03 0.03 0.08 0.03 0.03 0.02 0.03 -1.00
Gewada 
0.13 0.07 0.84 0.10 0.81 0.00 0.13 0.18 0.11 0.05 0.13 0.04 0.14 0.07 0.14 0.14 0.09 0.13 0.07 0.23 0.13 0.14 -0.01 0.13 0.13 0.15 0.13 0.06 -1.00
Hadiya 
0.00 0.04 1.00 0.02 0.98 0.11 0.00 0.36 0.37 0.00 0.00 0.10 0.00 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.17 0.00 0.00 0.00 0.00 0.04 0.14 -1.00
Hamer 
0.00 0.01 1.00 -0.01 0.97 0.07 0.00 0.24 0.18 0.00 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.09 0.00 0.00 -0.02 0.00 0.00 0.07 0.00 -1.02
Kefa 
0.00 0.04 1.00 0.02 0.98 0.11 0.00 0.35 0.36 0.00 0.00 0.09 0.00 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16 0.00 0.00 0.00 0.00 0.03 0.14 0.00 0.00 -1.00
Kembata 
0.00 0.04 1.00 0.02 0.98 0.10 0.00 0.35 0.36 0.00 0.00 0.09 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16 0.00 0.00 0.00 0.00 0.03 0.13 0.00 0.00 0.00 -1.00
Konta 
0.00 0.03 1.00 0.01 0.98 0.10 0.00 0.34 0.34 0.00 0.00 0.08 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.15 0.00 0.00 0.00 0.00 0.03 0.13 0.00 0.00 0.00 0.00 -1.00
Kore 
0.00 0.04 1.00 0.02 0.98 0.10 0.00 0.35 0.35 0.00 0.00 0.09 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16 0.00 0.00 0.00 0.00 0.03 0.13 0.00 0.00 0.00 0.00 0.00 -1.00
Konso 
0.03 0.02 0.96 0.00 0.94 0.05 0.03 0.30 0.25 -0.01 0.03 0.00 0.03 -0.01 0.03 0.04 0.01 0.03 0.00 0.07 0.03 0.03 0.08 0.03 0.03 0.02 0.03 -0.01 0.06 0.04 0.00 0.03 0.03 0.03 0.03 -1.00
Manja 
0.85 0.80 0.87 0.86 0.85 0.72 0.85 0.43 0.58 0.78 0.85 0.77 0.86 0.82 0.85 0.86 0.81 0.85 0.80 0.91 0.84 0.85 0.72 0.85 0.85 0.87 0.85 0.82 0.71 0.86 0.79 0.85 0.85 0.84 0.85 0.81 -1.00
Mejenger 
0.00 0.04 1.00 0.02 0.98 0.10 0.00 0.35 0.36 0.00 0.00 0.09 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16 0.00 0.00 0.00 0.00 0.03 0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.85 -1.00
Mashile 
0.00 0.04 1.00 0.02 0.98 0.11 0.00 0.37 0.39 0.00 0.00 0.11 0.00 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.17 0.00 0.00 0.00 0.00 0.04 0.15 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.86 0.00 -1.00
Maale 
0.00 0.04 1.00 0.02 0.98 0.11 0.00 0.35 0.36 0.00 0.00 0.10 0.00 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16 0.00 0.00 0.00 0.00 0.03 0.14 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.85 0.00 0.00 -1.00
Nuer 
0.00 0.04 1.00 0.02 0.98 0.11 0.00 0.35 0.36 0.00 0.00 0.09 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16 0.00 0.00 0.00 0.00 0.03 0.14 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.85 0.00 0.00 0.00 -1.00
Oromo 
0.14 0.09 0.82 0.11 0.80 0.00 0.14 0.21 0.14 0.06 0.14 0.06 0.15 0.08 0.15 0.15 0.10 0.14 0.08 0.23 0.13 0.14 -0.01 0.14 0.14 0.15 0.14 0.07 -0.01 0.15 0.08 0.14 0.14 0.13 0.14 0.07 0.72 0.14 0.15 0.14 0.14 -1.00
Shekecho 
0.00 0.04 1.00 0.02 0.98 0.11 0.00 0.36 0.37 0.00 0.00 0.10 0.00 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16 0.00 0.00 0.00 0.00 0.03 0.14 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.85 0.00 0.00 0.00 0.00 0.14 -1.00
Sidama 
0.10 0.05 0.88 0.05 0.86 0.00 0.10 0.24 0.16 0.03 0.10 0.03 0.10 0.04 0.10 0.11 0.06 0.10 0.05 0.17 0.09 0.10 0.01 0.10 0.10 0.10 0.10 0.02 0.00 0.10 0.04 0.10 0.10 0.09 0.10 0.03 0.76 0.10 0.11 0.10 0.10 0.00 0.10 -1.00
Sheko 
0.00 0.04 1.00 0.01 0.98 0.10 0.00 0.34 0.35 0.00 0.00 0.09 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16 0.00 0.00 0.00 0.00 0.03 0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.85 0.00 0.00 0.00 0.00 0.14 0.00 0.10 -1.00
Somali 
0.97 0.90 0.02 0.94 -0.01 0.75 0.97 0.72 0.82 0.95 0.97 0.94 0.97 0.94 0.97 0.97 0.96 0.97 0.96 0.99 0.97 0.97 0.78 0.97 0.97 0.97 0.97 0.92 0.80 0.97 0.95 0.97 0.97 0.97 0.97 0.93 0.84 0.97 0.98 0.97 0.97 0.78 0.97 0.85 0.97 -1.00
Tigrayan 
0.19 0.10 0.88 0.13 0.85 -0.01 0.18 0.20 0.13 0.07 0.19 0.06 0.20 0.09 0.20 0.20 0.11 0.18 0.09 0.34 0.18 0.19 -0.01 0.19 0.18 0.20 0.19 0.07 -0.01 0.20 0.08 0.19 0.19 0.18 0.19 0.07 0.73 0.19 0.21 0.19 0.19 -0.01 0.20 0.00 0.19 0.83 -1.01
Wolayta 
0.00 0.04 1.00 0.01 0.98 0.10 0.00 0.34 0.35 0.00 0.00 0.09 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16 0.00 0.00 0.00 0.00 0.03 0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.85 0.00 0.00 0.00 0.00 0.14 0.00 0.10 0.00 0.97 0.19 -1.00
Yem 
0.00 0.04 1.00 0.01 0.98 0.10 0.00 0.34 0.35 0.00 0.00 0.09 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16 0.00 0.00 0.00 0.00 0.03 0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.85 0.00 0.00 0.00 0.00 0.14 0.00 0.10 0.00 0.97 0.18 0.00 -1.00
Zayse 
0.00 0.04 1.00 0.01 0.98 0.10 0.00 0.34 0.35 0.00 0.00 0.09 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16 0.00 0.00 0.00 0.00 0.03 0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.85 0.00 0.00 0.00 0.00 0.14 0.00 0.10 0.00 0.97 0.18 0.00 0.00 -1.00
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